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ABSTRACT 
Cardiovascular disease, diabetes mellitus and obesity are the leading causes of 
death, disability and reduced quality of life globally. Hyperglycaemia and 
hyperlipidaemia are the two major causational risk factors for the metabolic and 
vascular complications of Type 1 and 2 diabetes, accumulation of excess body weight 
and atherosclerosis. The research reported in this thesis investigates some of the 
molecular mechanisms linking diabetes with atherosclerosis, as well examining 
potential anti-glycative and antioxidant compounds, which may improve 
cardiovascular related diseases induced by hyperglycaemia and hyperlipidaemia. 
 
People with diabetes have an elevated risk of atherosclerosis. The 
accumulation of lipid within macrophage cells in the artery wall is believed to arise 
via the uptake and subsequent processing of modified low-density lipoproteins (LDL) 
via the endolysosomal system. Chapter 3 explores the effects of prolonged exposure to 
elevated glucose upon macrophage lysosomal function to determine whether this 
contributes to modulated LDL and protein catabolism. Exposure to elevated glucose, 
but not mannitol (to control for osmotic effects), was found to result in a 
concentration-dependent decrease in the activity, and to a lesser extent protein levels, 
of four lysosomal cathepsins. Lysosomal acid lipase (LAL) activity, the major 
hydrolase for cholesteryl esters, was also significantly reduced. Arysulfatase activity, 
lysosomal associated marker protein-1 (LAMP-1) levels (commonly used markers of 
lysosomal numbers) and lysosomal dye accumulation were also decreased at the 
highest glucose concentrations, though to a lesser extent.  
 
Chapter 4 extended this work by monitoring the effects of high glucose upon 
lysosomes during the maturation of human monocytes to monocyte-derived 
macrophages (HMDM) under normal 5.5 mM and high 20 mM glucose conditions. 
High glucose concentrations were shown to have an inhibitory effect on lysosomal 
function in monocytes within two days of culturing and the magnitude of the glucose-
induced changes increased as the cells matured into macrophages. Thus high glucose 
modulated the activity of the lysosomal cathepsin B, L and LAL enzymes, their 
proteins levels and also lysosomal numbers during monocyte maturation with these 
effects becoming more pronounced over time except in the case of LAL. This 
xiii 
 
inhibition of lysosomal function may lead to cellular cholesterol accumulation and 
contribute to the generation of macrophage foam cells and atherosclerotic plaque 
development in people with diabetes. 
 
Carnosine has been shown previously to modulate triglyceride and glycation 
levels in both cell and whole animal systems. In Chapter 5 investigations were 
undertaken to determine whether prolonged supplementation with carnosine inhibits 
atherosclerosis in hyperglycaemic and hyperlipidaemic mice. To assess the possible 
anti-atherogenic properties of carnosine, streptozotocin-induced diabetic apo E
-/- 
mice 
were maintained for twenty weeks, post-induction of diabetes. Half of the animals 
received carnosine (2 g/L) in their drinking water. Diabetes was confirmed by 
significant increases in blood glucose and glycated haemoglobin, plasma triglyceride 
and total cholesterol levels, brachiocephalic artery and aortic sinus plaque area; and a 
significantly lower body mass. Supplementation with carnosine was shown to increase 
plasma carnosine levels. Although this did not result in smaller plaque areas in the 
diabetic mice, carnosine supplementation significantly reduced triglyceride levels and 
the area of plaque occupied by extracellular lipid, and increased the number of 
macrophages, α-actin-positive for smooth muscle cells and plaque collagen content. 
These findings indicate that in a well-established model of diabetes-associated 
atherosclerosis, prolonged carnosine supplementation has a significant impact on 
markers of atherosclerotic plaque stability. Carnosine supplementation may therefore 
be of benefit in lowering triglyceride levels and suppressing plaque instability in 
diabetes-associated atherosclerosis at least in this animal model.  
 
The nitroxide compound TEMPOL has been shown to prevent obesity-induced 
changes in adipokine secretion in both cell and whole animal systems. Chapter 6 
investigated whether TEMPOL supplementation inhibits inflammation and 
atherosclerosis in mice that were fed a high fat diet. Adult male C57BL/6 and apo E
-/-
 
mice were fed for 7 weeks either on a standard chow diet or a high-fat diet. Half the 
mice were supplemented with 10 mg/g TEMPOL in their food. High fat feeding 
resulted in a substantial increase in body mass and hyperlipidaemia. Dietary TEMPOL 
resulted in a marked reduction in weight gain and plasma lipid levels. In the 
hyperlipidaemic and obese mice, a significant elevation in plasma lipid levels and the 
inflammatory markers IL-6, MCP-1, MPO, SAA were observed, along with an 
xiv 
 
increase in leptin and decrease in adiponectin. TEMPOL supplementation reversed 
these effects. No significant differences were detected in plaque area. These data 
indicate that in a well-established model of obesity-associated hyperlipidaemia, 
TEMPOL had a significant impact on weight gain, hyperlipidaemia and inflammation. 
TEMPOL supplementation may therefore be of potential value in suppressing obesity 
and metabolic disorders. However whether TEMPOL inhibits atherosclerosis requires 
further investigation.  
 
Chapter 7 extended these in vivo studies by examining the impact of TEMPOL 
supplementation upon macrophage lysosomal function and the potential anti-
inflammatory and anti-glycaemic properties of TEMPOL on cytokine expression in 
hyperglycaemic macrophages.  TEMPOL did not affect the inhibition of lysosomal 
cathepsin B, L and LAL activities observed between the different concentrations of 
glucose. Levels of MCP-1, IL-6, MIF, CRP, TNF-α and MIP-1α were increased with 
LPS stimulation, and a dose dependent increase in TNF-α and MIP-1α expression was 
only seen with increasing concentrations of glucose. TEMPOL supplementation 
inhibited this elevation of TNF-α and MIP-1α induced by high glucose. These 
findings indicate that TEMPOL had a significant suppressive impact upon the pro-
inflammatory cytokines TNF-α and MIP-1α in human macrophages that were matured 
in high glucose conditions. These data support the hypothesis that TEMPOL 
supplementation may be of therapeutic benefit in alleviating inflammation and 
oxidative stress induced by hyperglycaemia.  
 
Overall, the data presented in this thesis are consistent with the hypothesis that 
the chronic elevated blood glucose levels detected in people with diabetes may have a 
detrimental impact upon macrophage lysosomal function, and that this may promote 
atherosclerosis. Long term exposure of human and murine macrophage cells to 
elevated glucose levels resulted in a depression of lysosomal proteolytic and lipase 
activities, their proteins levels and also lysosomal numbers in both maturing 
monocytes and macrophages. These functional changes may affect the capacity of 
macrophages to catabolise modified (lipo)proteins and enhance lipid accumulation in 
people with diabetes. Lysosomal damage may therefore contribute to the increased 
incidence, and rate of development of atherosclerosis in people with diabetes. The 
endogenous agent carnosine was examined in a murine model of diabetes-induced 
xv 
 
atherosclerosis. The effect of carnosine supplementation was shown to have anti-
hyperlipidaemic effects and properties that may enhance plaque stability which may 
be of therapeutic value in the treatment of diabetes-accelerated atherosclerosis. The 
nitroxide TEMPOL was investigated in two well-established obesity murine models 
by a high fat feeding. The intervention of TEMPOL was shown to effectively block 
weight gain in mice and relieve the associated hyperlipidaemia induced by a high fat 
diet. Further mechanistic studies showed that TEMPOL was able to reduce systemic 
inflammation and reverse the changed adipokine profile of obesity. TEMPOL was 
also shown to have an impact upon inflammation induced by high glucose in human 
macrophages. TEMPOL therefore appears to be a promising novel therapeutic target 
for chronic metabolic disorders such as diabetes, obesity, cardiovascular diseases.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xvi 
 
LIST OF ABBREVIATIONS 
 
α-SM-actin alpha-smooth muscle-actin 
4-HE  4-hydroxy-2-nonenal 
4-MU  4-methylumbelliferone 
4-MUO 4-methylumbelliferyl oleate 
Ang II  angiotensin II 
Apo   apolipoprotein 
Apo A  apolipoprotein A 
Apo B  apolipoprotein B 
Apo C  apolipoprotein C 
Apo E  apolipoprotein E 
Apo E
-/-
 apolipoprotein E knockout 
ACAT  acetyl-coenzyme A cholesterol-acetyl transferase 
ACE  angiotension-converting enzyme 
AGE  advanced glycation end products 
AGT  angiotension 
AHA  American Heart Association 
AP  alkaline phosphatase 
ANOVA analysis of variance 
AR  aldose reductase 
AZA  azaserine 
ADP  adensine diphosphate 
ATP  adenosine triphosphate 
Brig 35 polyoxyethylene-23-lauryl ether 
BIA  bioelectrical impedance analysis 
BCA  Bicinchoninic assay 
BHA  butylated hydroxyanisole 
BMI  body mass index 
xvii 
 
BSA  bovine serum albumin 
BVI  body volume index 
conc.  concentration 
CCL  chemokine (C-C motif) ligand 
CD 36   Cluster of differentiation 36 
CEL  carboxyethyllysine 
CHAOS Coronary artery disease, Hypertension, Atherosclerosis, Obesity and 
Stroke 
CML  carboxylmethyl lysine 
CN  carnosine 
CRP  C-reative protein 
CSF-1  colony stimulating factor-1 
CTL  control 
CVD  cardiovascular disease 
DAG  diacylglycerol 
DHAP  dihydroxy acetone phosphate 
db/db A model for diabetic dyslipidaemia induced by a point mutation in the 
Lepr gene which causes Type 2 diabetes, dyslipidaemia and obesity.   
DIAB  diabetes 
DM  diabetes mellitus 
DMEM Dulbecco’s modified Eagle’s medium 
DMSO  dimethyl sulfoxide 
DNA  deoxyribonucleic acid 
DOLD  3-deoxyglucosone lysine dimer 
DPX  di-N-butyl phthalate in xylene 
DTT  dithiothreitol 
eNOS  endothelial nitric oxide synthase 
E64  N-[N-(L-3-trans-carboxyirane-2-carbonyl)-L-leucul]-agmatine 
EC  endothelial cell 
ECL  enhanced chemiluminescence 
ECM  extracellular matrix 
xviii 
 
EDTA  ethylendiaminetetraacetic acid 
EEA1  early endosome antigen 1 
EGIR  European Group of Insulin Resistance 
ELISA  enzyme-linked immunosorbent assay 
FCS   fetal calf serum 
FDA  Food and Drug Administration 
Fruc-6-P fructose-6-phosphate 
g  gram 
G1cNac N-acetylglucosamine 
GAPDH  glyceraldehyde-3-phosphate dehydrogenase 
GFAT  glutamine: fructose-6-phosphate amidotransferase 
GFR   glomerular filtration rate 
GOLD  glyoxal-lysine dimer 
GSH  glutathione 
hr  hour 
H&E  Haematoxylin and Eosin 
HbA1c  glycated haemoglobin 
HCl  hydrochloric acid 
HDL  high-density lipoprotein 
HDL-C high-density liporprotein 
HFD  high fat diet 
HMDM human monocyte-derived macrophages 
HMG-CoA 3-hydroxy-3-methylglutaryl-coenzyme A 
HOSCN hypothiocyanous acid 
HPLC  high-performance liquid chromatography 
HRP  horseradish peroxidase 
HBSS  Hank’s balanced salt solution 
HS  human serum 
iNOS  inducible nitric oxide synthase 
IgG  Immunoglobulin G 
xix 
 
ICAM-1 intracellular adhesion molecule-1 
IDF  International Diabetes Federation 
IDL  intermediate-density lipoprotein 
IFN  interferon 
IL  interleukin 
JNK  c-jun-N-terminal kinase 
kDa  kiloDalton 
kcal  kilocalorie 
L  litre 
LAL  lysosomal acid lipase 
LAMP-1 lysosomal associated marker protein-1 
LCAT  lecithin cholesterol acyltransferase 
LDH  lactate dehydrogenase 
LDL  low-density lipoprotein 
LDL-C  low-density lipoprotein-cholesterol 
LDL-R low-density lipoprotein receptor 
Lepr  leptin receptor 
LOX-1  lectin-type oxidised LDL receptor 1 
LPS  lipopolysaccharide 
LZR  lean Zucker rats 
mg  milligram 
min  minute 
mL  millilitre 
mM  mmoles/L 
mRNA  messenger ribonucleic acid 
M  macrophage 
MCP-1 monocyte / macrophage chemotactic protein-1 
MDA  malondialdehyde 
MGO  methylgloxal 
MIF   macrophage migration inhibitory factor 
xx 
 
MIP  macrophage inflammatory protein 
MOLD methylgloxal-lysine dimer 
MPO  myeloperoxidase 
MTT  3-(4,5-dimethylthiazol-2-yl)-2,5-diphenltetrazolium bromide 
ng  nanogram 
NaCl  Sodium chloride 
NAD  nicotinamide adenine 
NADP  nicotinamide adenine dinucleotide 
NCEH  neutral cholesterol-ester hydrolase 
NADPH nicotinamide adenine dinucleotide phosphate 
NECP  National Cholesterol Education Program 
NHNES National Health and Nutrition Examination Survey 
NO  nitric oxide 
ob/ob A mutant mouse that is unable to produce leptin, its food intake is 
uncontrolled and therefore eats excessively which causes obesity and 
Type 2 diabetes.   
oxLDL oxidized low-density lipoprotein 
OGT   O- N-acetylglucosamine (G1cNAc) 
OZR  obese Zucker rats 
pg  picogram 
PAGE  polyacrylamide gel electrophoresis 
PAI-1  plasminogen activator inhibitor-1 
PKD  protein kinase D 
PARP  poly (ADP-ribose) polymerase 
PBS  phosphate-buffered saline 
PEG  polyethylene glycol 
PERK  protein kinase RNA-like endoplasmic reticulum kinase 
PKC  protein kinase C 
PPAR-γ peroxisome proliferator activated receptor-γ activation 
rpm  revolution per minute 
RAAS  renin-angiotensin aldosterone system 
xxi 
 
RAGE  receptor for advanced glycation end products 
RBC  red blood cell 
RNA  ribonucleic acid 
ROI  reactive oxygen intermediates 
ROS  reactive oxygen species 
RPMI  Roswell Park Memorial Institute 
RT-PCR reverse transcription- polymerase chain reaction 
s  second 
Sp1  specificity protein-1 
SAA  serum amyloid A 
SDS  sodium dodecyl sulfate 
SEM  standard error of mean 
SHR  spontaneous hypertensive rats 
SHHR  spontaneously hypertensive heart-failure rats 
SMC  smooth muscle cell 
SR-A1  steroid receptor RNA activator-1 
SR-B1  scavenger receptor class B member 1 
SREBP sterol regulatory element-binding protein 
STZ  streptozotocin 
T1D  Type 1 diabetes 
T2D  Type 2 diabetes 
TEMPOL 4-hydroxyl-2,2,6,6-tetramethylpiperidine-N-oyl 
TBS  Tris-buffered saline 
TBST  Tris-buffered saline and Tween 20 
TC  total cholesterol 
TG  triglyceride 
TGF  transforming growth factor 
TNF-α  tumour necrosis factor- alpha 
TZD  thiazolidinedones 
UDP  uridine diphosphate 
xxii 
 
UPR  unfolding protein response 
UPS  ubiquitin-proteasome system 
UV  ultraviolet 
v  version 
v/v  volume per volume 
VAT  visceral adipose tissue 
VLDL  very low-density lipoprotein 
VSMC  vascular smooth muscle cells 
w/v  weight per volume 
WBC  white blood cell 
WC  waist circumference 
WHO  World Health Organisation 
WKY  Wistar-Kyoto (rats) 
ZDF  Zucker Diabetic Fatty (rat) 
ZSF  strain of ZDF crossed with SHHR 
 
 
 
 
 
 
 
 
 
 
 
xxiii 
 
LIST OF FIGURES 
 
Figure 1.1:  Schematic diagram of the structure of LDL and                                          
apo B-100 on the surface of LDL particle.     8 
Figure 1.2:  Schematic diagram of atherosclerotic plaque formation.   11 
Figure 1.3:  Pathological classification of atherosclerotic lesions.  13 
Figure 1.4:  Global trends in obesity from 1980 and 2008.   20 
Figure 1.5:  Polyol (sorbitol) pathway; glucose-6-P, glucose 6-phosate.   25 
Figure 1.6:  The hexosamine pathway.      27 
Figure 1.7:  Reaction scheme for reactive carbonyl biogenesis.   31 
Figure 1.8:  Schematic representation of the complex Maillard reaction                          
and formation of some advanced glycation end products.   32 
Figure 1.9:  The structure of proteasomes and the protein degradation                      
pathway.         37 
Figure 1.10:  Overview of cathepsin expression and activity in                            
atherosclerotic plaque.       39 
Figure 2.1:  Animal model for the carnosine project.    60 
Figure 2.2a:   Dissection and tissue sectioning of the brachiocephalic artery. 63 
Figure 2.2b:  Dissection of the aortic sinus.      63 
Figure 2.3:  Aortic sinus dissections.      64 
Figure 2.4:  Estimation of extracellular lipid content of atherosclerotic               
plaques.        69 
Figure 2.5:  Animal model for TEMPOL study.      71 
Figure 2.6:  Representative images of 3 cross-sections (A - C) taken from                        
the aortic sinus.        72 
Figure 3.1:  Cell viability of J774A.1 and HMDM cells incubated in normal                   
(5.5 mM) and high (30 mM) glucose conditions for 11 days.  80 
xxiv 
 
Figure 3.2:  Protein levels in J774A.1 and HMDM cells incubated in various 
concentrations of glucose (5.5, 10, 20 and 30 mM) for 11 days.  81 
Figure 3.3:  Changes in fluorescence in cell lysate fractions of HMDM               
matured in normal 5.5 mM or 10, 20 and 30 mM glucose             
concentrations followed by addition of cathepsin B substrate. 83 
Figure 3.4:  Lysosomal cysteine and aspartic cathepsin activities in                            
J774A.1 cells incubated in various concentrations of                              
glucose (5.5, 10, 20 and 30 mM) for 11 days.   85 
Figure 3.5:  Lysosomal cysteine and aspartic enzyme activities in HMDM                    
cells matured in various concentrations of glucose (5.5, 10, 20                 
and 30 mM) for 11 days.      87 
Figure 3.6:  Lysosomal acid lipase (LAL) activity in J774A.1 and HMDM                     
cells incubated in various concentrations of glucose (5.5, 10, 20                      
and 30 mM) for 11 days.       89 
Figure 3.7:  Lysosomal enzymatic activities in J774A.1 and HMDM cells               
incubated in the normal (5.5 mM), high (30 mM) glucose and                         
5.5 mM glucose + 24.5 mM mannitol (osmotic control)                    
conditions for 11 days.       91 
Figure 3.8:  Quantification of LAMP-1 levels by Western blotting for                      
J774A.1 and HMDM cells incubated in various concentrations                        
of glucose (5.5, 10, 20 and 30 mM) for 11 days.   93 
Figure 3.9:  Protein levels of cathepsins B, L, S and D in HMDM cells               
exposed to 5 or 30 mM glucose as determined by Western                     
blotting.        95 
Figure 3.10:  Effect upon lysosomal aryl sulfatase activity of maturation of                  
human monocytes to macrophages (HMDM) (Panel A) or               
incubation of murine macrophage-like J774A.1 cells (Panel B)                      
in 5 versus 30 mM glucose.      96 
Figure 3.11:  Representative photomicrographs of HMDM (Panels A to F)                        
and J774A.1 (Panels G to L) cells incubated under normal or               
high glucose concentrations and stained with LysoTracker
®
                            
Red DND-99.        97 
Figure 4.1:  Measurement of cellular protein levels during maturation of                    
human monocytes in normal versus high glucose concentrations.  104 
xxv 
 
Figure 4.2:  Maturation of human monocytes in high glucose decreases                       
the activity of cathepsin B (Panel A) and L (Panel B)                           
compared to normal glucose concentrations.    105 
Figure 4.3:  LAL activity during monocyte maturation at different time                      
points.         106 
Figure 4.4:  Procathepsin and activated cathepsin B over the total cathepsin               
protein levels during monocyte maturation at different time                       
points.         108 
Figure 4.5:  Cathepsin B protein levels during monocyte maturation at                       
different time points.       109 
Figure 4.6:  Activated cathepsin B protein levels and cathepsin B activity                    
versus protein levels during monocyte maturation at different                          
time points.           110 
Figure 4.7:  Procathepsin and activated cathepsin L over the total cathepsin               
protein levels during monocyte maturation at different time               
points.         112 
Figure 4.8:  Cathepsin L protein levels during monocyte maturation at                
different time points.       113 
Figure 4.9:  Mature cathepsin L protein levels and cathepin L activity                           
versus protein levels during monocyte maturation at                       
different time points.        114 
Figure 4.10:  LAL protein levels during monocyte maturation at different                                 
time points.        116 
Figure 4.11:  LAL activity relative to protein levels during monocyte                      
maturation at different time points.      117 
Figure 4.12:  LAMP-1 protein levels during monocyte maturation.  118 
Figure 5.1:  Experimental Plan.       126 
Figure 5.2:  Blood glucose levels (A) and glycated haemoglobin levels (B),                                   
at the time of sacrifice, for control (CTL) and diabetic (DIAB)                            
apo E
-/-
 mice with (+CN) or without carnosine supplementation.  127 
Figure 5.3:  Plasma carnosine levels (μmoles/L), at the time of sacrifice, for                  
control (CTL) and diabetic (DIAB) apo E
-/-
 mice with (+CN) or             
without carnosine supplementation.      129 
xxvi 
 
Figure 5.4:  Representative images of 6 cross sections (A - F) taken from the 
brachiocephalic artery.      130 
Figure 5.5:  Calculation of plaque morphometry in the brachiocephalic artery. 131 
Figure 5.6:  Plaque morphometry in brachiocephalic artery for plaque area                    
(Panel A), total area (Panel B) and  percentage of plaque compared                 
to total arterial cross-sectional area (Panel C) in control (CTL) and 
diabetic (DIAB) apo E
-/-
 mice with or without carnosine (+/- CN) 
supplementation.         133 
Figure 5.7:  Ratio of lumen (Panel A) and internal elastic intima areas                     
(Panel B) over the total cross-sectional area of the brachiocephalic                 
artery in control (CTL) and diabetic (DIAB) apo E
-/-
 mice with or 
without carnosine (+/- CN) supplementation.     134 
Figure 5.8:  Representative images of 6 cross-sections (A - F) taken from                   
the aortic sinus.       136 
Figure 5.9:  Calculation of plaque morphometry in the aortic sinus.  137 
Figure 5.10:  Plaque morphometry in the aortic sinus for plaque area (Panel A),              
total area (Panel B) and percentage of plaque on total area                         
(Panel C) in control (CTL) and diabetic (DIAB) apo E
-/-
 mice                         
with or without carnosine (+/- CN) supplementation.    138 
Figure 5.11:  Representative sections showing α-SM-actin staining in the            
brachiocephalic artery in control (CTL) and diabetic (DIAB)                        
apo E
-/-
 mice with or without carnosine (+/- CN)                        
supplementation.         140 
Figure 5.12:  α-SM-actin staining of fibrous cap in the brachiocephalic artery                       
for α-actin area (Panel A), plaque area (Panel B) and percentage                        
of α-actin on total area (Panel C) in control (CTL) and diabetic                
(DIAB) apo E
-/-
 mice with or without carnosine (+/- CN) 
supplementation.         141 
Figure 5.13:  Representative sections showing α-SM-actin staining in the                       
aortic sinus in control (CTL) and diabetic (DIAB) apo E
-/-
                            
mice with or without carnosine (+/- CN) supplementation.    143 
Figure: 5.14:  α-SM-actin staining of the fibrous cap in the aortic sinus for                     
α-actin area (Panel A), plaque area (Panel B) and percentage of                 
α-actin on total area  (Panel C) in control (CTL) and diabetic                      
xxvii 
 
(DIAB) apo E
-/-
 mice with or without carnosine (+/- CN) 
supplementation.         144 
Figure 5.15:  Representative sections showing F4/80 staining in the                   
brachiocephalic artery in control (CTL) and diabetic (DIAB)                         
apo E
-/-
 mice with or without carnosine (+/- CN)                         
supplementation.         146 
Figure 5.16:  F4/80 staining for macrophages in the brachiocephalic artery                  
for F4/80 area (Panel A), plaque area (Panel B) and percentage                              
of F4/80 on total area (Panel C) in control (CTL) and diabetic                 
(DIAB) apo E
-/-
 mice with or without carnosine (+/- CN) 
supplementation.         147 
Figure 5.17:  Representative sections showing F4/80 staining in the aortic                        
sinus in control (CTL) and diabetic (DIAB) apo E
-/-
 mice with                          
or without carnosine (+/- CN) supplementation.     149 
Figure 5.18:  F4/80 staining for macrophages in the aortic sinus for F4/80 area                   
(Panel A), plaque area (Panel B) and percentage of F4/80 on total                  
area (Panel C) in control (CTL) and diabetic (DIAB) apo E
-/-
 mice                   
with or without carnosine (+/- CN) supplementation.    150 
Figure 5.19:  Comparison of extracellular lipid pools in the brachiocephalic                   
artery determined as absolute lipid area (Panel A) and percentage                
area occupied by lipid compared to total plaque area (Panel B)                           
in control (CTL) and diabetic (DIAB) apo E
-/-
 mice with or                       
without carnosine (+/- CN) supplementation.     152 
Figure 5.20:  Comparison of extracellular lipid pools in the aortic sinus.                   
Absolute lipid area (Panel A), plaque area (Panel B) and                        
percentage of area occupied by extracellular lipid when                         
compared to the total lesion area (Panel C) in control (CTL)                              
and diabetic (DIAB) apo E
-/-
 mice with or without carnosine                              
(+/- CN) supplementation.        154 
Figure 5.21:  Representative images of atherosclerotic plaques stained with              
picrosirius red in the brachiocephalic artery cross sections of                        
control (CTL), control + carnosine (CTL + CN), diabetes (DIAB)                  
and diabetes + carnosine (DIAB + CN) mice.    156 
Figure 5.22:  Comparison of collagen content within plaques in the                  
brachiocephalic artery. Absolute collagen area (Panel A),                         
plaque area (Panel B) and percentage of collagen expressed                       
relative to the total plaque area (Panel C) in control (CTL)                                
xxviii 
 
and diabetic (DIAB) apo E
-/-
 mice with or without carnosine                               
(+/- CN) supplementation.        157 
Figure 5.23:  Representative images of atherosclerotic plaques stained with                  
picrosirius red in the aortic sinus cross sections of control (CTL),               
control + carnosine (CTL + CN), diabetes (DIAB) and diabetes                         
+ carnosine (DIAB + CN) mice.      159 
Figure 5.24:  Comparison of collagen within plaques in the aortic sinus.                     
Absolute collagen area (Panel A), plaque area (Panel B) and                
percentage of collagen expressed relative to the total plaque area                
(Panel C) in control (CTL) and diabetic (DIAB) apo E
-/-
 mice                       
with or without carnosine (+/- CN) supplementation.    160 
Figure 6.1:  Chemical structure of TEMPOL.     168 
Figure 6.2:  Animal model for TEMPOL study.     171 
Figure 6.3:  Average body mass of apo E
-/-
 (Panel A) and C57BL/6 (Panel B)                 
mice during the intervention phase during which the mice were                      
fed normal chow or HFD with or without TEMPOL                  
supplementation.         173 
Figure 6.4:  Representative sections of the aortic sinus stained with H & E                     
from chow and high fat diet (HFD) fed apo E
-/-
 mice with or                   
without TEMPOL supplementation.      175 
Figure 6.5:  Plaque morphometry in the aortic sinus for plaque area (Panel A),               
total area (Panel B) and percentage of plaque on total area                    
(Panel C) in apo E
-/-
 mice that were fed either a chow or HFD,                        
with or without TEMPOL supplementation.     176 
Figure 6.6:  Plasma triglyceride levels for apo E
-/-
 (Panel A) and C57BL/6                      
(Panel B) mice.       178 
Figure 6.7:  Plasma total cholesterol levels for apo E
-/-
 (Panel A) and                       
C57BL/6 (Panel B) mice.                       180 
Figure 6.8:  Plasma HDL-C levels for apo E
-/-
 (Panel A) and C57BL/6                       
(Panel B) mice.       182 
Figure 6.9:  Plasma LDL levels for apo E
-/-
 (Panel A) and C57BL/6                                          
(Panel B) mice.        184 
Figure 6.10:  Plasma TNF-α levels for apo E-/- (Panel A) and C57BL/6                                 
(Panel B) mice.         186 
xxix 
 
Figure 6.11:  Plasma MCP-1 levels for apo E
-/-
 (Panel A) and C57BL/6                                 
(Panel B) mice.       188 
Figure 6.12:  Plasma IL-6 levels for apo E
-/-
 (Panel A) and C57BL/6                                     
(Panel B) mice.       190 
Figure 6.13:  Plasma SAA levels for apo E
-/-
 (Panel A) and C57BL/6                                            
(Panel B) mice.        192 
Figure 6.14:  Plasma MPO levels for apo E
-/-
 (Panel A) and C57BL/6                                 
(Panel B) mice.       194 
Figure 6.15:  Plasma adiponectin levels for apo E
-/-
 (Panel A) and C57BL/6                         
(Panel B) mice.       196 
Figure 6.16: Plasma leptin levels for apo E
-/-
 (Panel A) and C57BL/6                                       
(Panel B) mice.       198 
Figure 6.17  Plasma resistin levels for apo E
-/-
 (Panel A) and C57BL/6                                 
(Panel B) mice.       200 
Figure 6.18:  Chemical structure of TEMPO.     202 
Figure 7.1:  Lysosomal enzymatic activities in human monocytes matured                     
under normal 5.5 mM or high 20 mM glucose concentrations                        
with or without 100 μM TEMPOL supplementation for 10 days.  214 
Figure 7.2:  Protein levels for HMDM cells subject to LPS stimulation                                       
(0, 50 and 200 ng/mL) for 24 or 48 hrs after maturation for                            
10 days in normal 5.5 mM (blue) and high 20 mM (orange)                        
glucose concentrations.        215 
Figure 7.3:  Fold increase in MCP-1 (Panel A), IL-6 (B), MIF (C), CRP (D),               
TNF-α (E) and MIP-1α (F) expression compared to control                              
(5.5 mM glucose) for 24 (clear bars) and 48 hrs (hatched bars)                              
of LPS stimulation (0, 50 and 200 ng/mL) in HMDM that were                   
matured for 10 days in normal 5.5 mM (blue) and high 20 mM                  
(orange) glucose concentrations.        219 
Figure 7.4:  Protein levels for HMDM cells after LPS stimulation (0, 25                           
and 50 ng/mL) for 24 hrs after maturation for 10 days in normal                
5.5 mM (blue) and high 20 mM (orange) glucose concentrations                    
with and without 100 μM TEMPOL supplementation.    220 
Figure 7.5:  Fold increase in CRP expression compared to control (5.5 mM                  
glucose) after 24 hrs of LPS stimulation (0, 25 and 50 ng/mL)                       
xxx 
 
for HMDM that had been matured for 10 days in normal 5.5 mM                 
(blue) or high 20 mM (orange) glucose concentrations with and                    
without 100 μM TEMPOL supplementation.     221                                      
Figure 7.6:  Fold increase in TNF-α expression compared to control (5.5 mM                 
glucose) after 24 hrs of LPS stimulation (0, 25 and 50 ng/mL) for                  
HMDM that were matured for 10 days in normal 5.5 mM (blue)                      
and high 20 mM (orange) glucose concentrations with and                      
without 100 μM TEMPOL supplementation.     223 
Figure 7.7:  Fold increase in MIP-1α expression compared to control (5.5 mM                 
glucose) after 24 hrs of LPS stimulation (0, 25 and 50 ng/mL) for                   
HMDM that were matured for 10 days in normal 5.5 mM (blue)                     
and high 20 mM (orange) glucose concentrations with and                                
without 100 μM TEMPOL supplementation.     225 
Figure 8.1:  Proposed mechanisms for macrophage lysosomal dysfunction                            
caused by high glucose in monocytes and macrophages.   241 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xxxi 
 
LIST OF TABLES 
 
Table 1.1:  Current diagnostic criteria for the Metabolic Syndrome.   4 
Table 1.2:  Health risk according to body mass index (BMI).    18 
Table 2.1:  Caloric profile between chow and high fat diet in terms of                    
protein, fat and carbohydrate in kcal/g.    70 
Table 5.1:  Mean body mass, total cholesterol and triglyceride plasma                         
levels, estimated at the time of sacrifice, for non-diabetic               
(control) and diabetic apo E
-/-
 mice with or without                     
carnosine (CN) supplementation.      128 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xxxii 
 
PUBLICATIONS ARISING FROM THIS THESIS 
 
Research Papers 
1) Christine H. J. Kim, Fatemeh Moheimani, Aldwin Suryo Rahmanto, David M. van 
Reyk, Michael J. Davies. (2010) Inhibition of lysosomal function in macrophages 
incubated with elevated glucose concentrations: a potential contributory factor in 
diabetes-associated atherosclerosis. Atherosclerosis, 223 (1): 144-151. 
2) Christine H. J. Kim, Bronwyn E. Brown, Fraser R. Torpy, Christina A. Bursill, 
Lucinda S. McRobb, Alison K. Heather, Michael J. Davies, David M. van Reyk. 
“Supplementation with carnosine decreases plasma triglycerides and modulates 
atherosclerotic plaque development in diabetic apo E
-/-
 mice.” Manuscript submitted 
to Atherosclerosis (23
rd
 April 2013). 
3) Christine H. J. Kim, David M. van Reyk, Michael J. Davies. “Development of 
lysosomal dysfunction during the maturation of human monocytes to macrophages in 
the presence of elevated glucose concentrations” Manuscript under preparation for 
Atherosclerosis. 
4) Christine H. J. Kim, James Mitchell, David M. van Reyk, Michael J. Davies. 
“TEMPOL prevents obesity, decreases plasma hyperlipidaemia and inflammatory 
cytokines, and modulates atherosclerotic plaque composition in obese C57BL/6 and 
apo E
-/- mice.” Manuscript under preparation for Atherosclerosis, Thrombosis, and 
Vascular Biology (ATVB). 
 
Conference Presentation (presenting author underlined) 
1) Christine H. J. Kim, Bronwyn, E. Brown, Christina, A., Bursill, Fraser R. Torpy, 
Lucinda S. McRobb, Alison K. Heather, Michael J. Davies, David M. van Reyk. 
“Supplementation with carnosine decreases plasma triglycerides and modulates 
atherosclerotic plaque composition in diabetic mice.” World Diabetes Congress 2013, 
Dec 2 - 6 2013, Melbourne, Victoria (poster). 
2) Christine H. J. Kim, David M. van Reyk, Michael J. Davies. “Lysosomal disruption 
in monocyte development to macrophages: a potential contributory factor in diabetes-
associated atherosclerosis.” World Diabetes Congress 2013, Dec2 - 6 2013, 
Melbourne, Victoria (poster). 
3) Christine H. J. Kim, David M. van Reyk, Michael J. Davies. “TEMPOL prevents 
obesity, decreases plasma hyperlipidaemia and inflammatory cytokines, and 
modulates atherosclerotic plaque composition in obese mice.” World Diabetes 
Congress 2013, Dec2 - 6 2013, Melbourne, Victoria (poster). 
xxxiii 
 
4) Christine H. J. Kim, David M. van Reyk, Michael J. Davies. “Inhibition of 
lysosomal function in macrophages incubated with elevated glucose concentrations: a 
potential contributory factor in diabetes-associated atherosclerosis.” 80th European 
Atherosclerosis Society Congress on May 25 – 28th May 2012, Milan, Italy (poster). 
5) Christine H. J. Kim, David M. van Reyk, Michael J. Davies.“Lysosomal disruption 
during maturation of human monocytes to macrophages in presence of elevated 
glucose: potential mechanistic insights into diabetes-associated atherosclerosis.” 80th 
European Atherosclerosis Society Congress on May 25 – 28th May 2012, Milan, Italy 
(poster). 
6) Christine H. J. Kim, David M. van Reyk, Michael J. Davies. “Perturbation of 
lysosomal function in macrophages exposed to elevated glucose concentrations: 
potential role in diabetes-associated atherosclerosis.” XVI International Symposium 
on Atherosclerosis hosted by The Australian Atherosclerosis Society (AAS) and The 
International Atherosclerosis Society, 25 – 29th March 2012, Sydney, NSW (oral). 
7) Christine H. J. Kim, Fatemeh Moheimani, Aldwin Suryo Rahmanto, David M. van 
Reyk, Michael J. Davies. “Perturbation of lysosomal function in macrophages 
exposed to elevated glucose concentrations: potential role in diabetes-associated 
atherosclerosis.”Australian Diabetes Society (ADS) and Australian Diabetes 
Education Association (ADEA) Annual Scientific Meeting 2011, Perth, WA (poster). 
8) Christine H. J. Kim, David M. van Reyk, Michael J. Davies. “Perturbation of 
lysosomal function in macrophages exposed to elevated glucose concentrations: 
potential role in diabetes-associated atherosclerosis.”Australian Diabetes Society 
(ADS) and Australian Diabetes Education Association (ADEA) Annual Scientific 
Meeting 2010, Sydney, NSW (poster). 
9) David M. van Reyk, Bronwyn, E. Brown, Christine H. J. Kim, Fraser R. Torpy, 
Lucinda S. McRobb, Alison K. Heather, Michael J. Davies. “Prolonged 
supplementation with carnosine decreases plasma triglycerides, but does not 
modulate diabetes status or atherosclerotic plaque development in streptozotocin-
induced diabetic apo E
 -/-
 mice.”ADS and ADEA Annual Scientific Meeting 2010, 
Sydney, NSW (poster). 
10) Christine H. J. Kim, David M. van Reyk, Michael J. Davies. “Perturbation of 
lysosomal function in macrophages exposed to elevated glucose concentrations: 
potential role in diabetes-associated atherosclerosis.”Australian Society for Medical 
Research meeting 2010, Sydney, NSW (poster). 
11) Bronwyn, E. Brown, Christine H. J. Kim, Michael J. Davies, David M. van Reyk. 
“Prolonged supplementation with carnosine decreases plasma triglycerides, but does 
not modulate diabetes status or atherosclerotic plaque development in streptozotocin-
induced diabetic apo E
-/-
 mice.” 7th Congress of the Asian Pacific Society of 
Atherosclerosis and Vascular Diseases and the 2010 Annual Scientific Meeting of the 
Australian Atherosclerosis Society in Cairns, QLD (poster). 
1 
 
    
 
 
CHAPTER 1: 
INTRODUCTION 
  
2 
 
1.1 Metabolic syndrome 
The metabolic syndrome embodies a cluster of metabolic and haemodynamic 
disorders the prevalence of which are associated with lifestyle and other risk factors [1]. 
Factors characteristic of the metabolic syndrome include varying degrees of insulin 
resistance and glucose intolerance, central abdominal visceral obesity, abnormal lipid 
levels in the blood (elevated triglycerides, total cholesterol, and low density lipoprotein 
(LDL) cholesterol; and low high density lipoprotein (HDL) cholesterol), raised blood 
pressure, and prothrombotic and proinflammatory states [2,3,4]. The diagnostic criteria 
of metabolic syndrome, as determined by several major health authorities are shown in 
Table 1.1. 
The metabolic syndrome is becoming a major global health crisis as it affects all 
ages, from children to adults and all racial / ethnic groups [2,5]. The prevalence has 
been reported to be as high as 50% in the United States and 34% in Australia. It is 
predicted to continue increasing in developed countries with continuing global 
modernisation [2,6,7,8,9]. The rising prevalence of obesity is a major contributor to the 
incidence of metabolic syndrome worldwide [2]. A direct association between high 
body mass index (BMI) and disease is observed for both genders across all racial or 
ethnic groups [2]. The prevalence of metabolic syndrome is the highest in obese 
children and adolescents, and the severity of this syndrome worsens as BMI increases, 
leading to obesity-related morbidity and premature deaths [2,5].  
Several studies have indicated that the metabolic syndrome is a strong predictor 
of cardiovascular morbidity and mortality, diabetes and all-cause mortality in a number 
of populations worldwide [3,10,11,12,13]. Thus, the metabolic syndrome is referred to 
as the inducing factor for a “new cardiovascular epidemic,” as it triples the risk of a 
heart attack and doubles the risk of early mortality [14]. Furthermore those affected by 
the metabolic syndrome have a fivefold greater possibility of developing Type 2 
diabetes [2]. 
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1.1.1 Diagnostic criteria of the metabolic syndrome 
The constellation of metabolic disorders which is now defined as the metabolic 
syndrome was first observed by the anatomist Morgagni in 1765, where he identified 
the close correlation between abdominal obesity and the occurrence of hypertension, 
atherosclerosis, dyslipidaemia, sleep apnea and hyperuricaemia. This syndrome became 
well established in the 20
th
 century [15] when Kylin proposed that hypertension, 
atherosclerosis, dyslipidaemia and gout tended to appear together [16].  Subsequently, 
central obesity was noted as a key feature, by Vogue, in predisposing patients to 
diabetes, atherosclerosis, gout and uric calculi [17]. The definition of the metabolic 
syndrome was further refined by Reaven, as referring to a combination of hypertension, 
abdominal obesity, insulin resistance and hyperlipidaemia [18,19,20]. In 1988, Reaven 
established the clinical importance of this syndrome by proposing a conceptual 
framework connecting these independent biological events into a single 
pathophysiological paradigm [21].  
The diagnostic criteria of the metabolic syndrome have yet to be standardised 
worldwide. The metabolic syndrome has also been known under different names 
including metabolic syndrome X, syndrome X, insulin resistance syndrome, 
cardiometabolic syndrome and Reaven’s syndrome. In Australia it has been termed 
CHAOS, which stands for Coronary artery disease, Hypertension, Atherosclerosis, 
Obesity, and Stroke, to explicitly delineate the manifestations and complications that are 
associated with the elevated risk of cardiovascular disease, obesity  and Type 2 diabetes 
[22,23,24]. 
Diagnostic criteria for the metabolic syndrome have been proposed by the World 
Health Organisation (WHO), the International Diabetes Federation (IDF), the United 
States National Cholesterol Education Program Adult Treatment Panel III (NECP) and 
the European Group for the Study of Insulin Resistance (EGIR) [2,14,16,25,26,27]. 
These criteria are given in Table 1.1. 
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 WHO  IDF  EGIR  NCEP ATP 
III  
Criterion  Diabetes or impaired 
glucose tolerance or 
insulin resistance 
plus 2 or more of the 
following: 
Central obesity  
Waist 
circumference  
Plus any 2 of the 
following: 
Insulin resistance 
or 
hyperinsulinaemia 
(only non-diabetic 
subjects) plus two 
or more of the 
following: 
Three or more of 
the following: 
Blood Pressure 
or controlled 
by Medication  
≥ 140/90 mmHg  ≥130/85 mmHg  ≥ 140/90 mmHg  ≥130/85 mmHg  
Triglyceride 
(TG) level 
≥ 1.695 mmol/L ≥ 1.7 mmol/L ≥ 2.0 mmol/L ≥1.695 mmol/L 
HDL-C level ≤ 0.9 mmol/L (M) 
≤ 1.0 mmol/L (F) 
 
1.03 mmol/L (M) 
≤1.29 mmol/L (F) 
≤1.0 mg/dL ≤40 mg/dL (M) 
≤ 50 mg/dL (F) 
Waist 
circumference 
≥ 0.90 (M) 
≥ 0.85 (F) 
(Waist: Hip Ratio) 
Ethnicity Specific ≥ 94 cm (M) 
≥ 80 cm (F) 
≥ 102 cm (M) 
≥ 88 cm (F) 
Other features Obesity: BMI ≥ 30 
kg/m
2
 
Microalbuminuria: 
Urinary albumin 
excretion ratio > 20 
μg/min or albumin: 
creatinine ratio >30 
mg/g 
Fasting plasma 
glucose ≥          
5.6 mmol/L or 
previously 
diagnosed Type 2 
Diabetes 
Fasting plasma 
glucose ≥          
6.1 mmol/L 
Fasting plasma 
glucose ≥        
6.1 mmol/L 
(1100 mg/dL) 
 
Table 1.1: Current diagnostic criteria for the Metabolic Syndrome  
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1.2 Cardiovascular disease 
Cardiovascular disease (CVD) is a general term reflecting the dysfunction of the 
heart and the blood vessels (specifically the arteries and veins) subsequently affecting 
the circulation of the body system and as such affecting the supply of oxygen and 
nutrients to, and removal of waste from, the cells and tissues of the body [28]. Common 
cardiovascular conditions include rheumatic heart disease, peripheral arterial disease, 
hypertensive heart disease, heart failure, ischemic heart disease, cerebrovascular 
disease, inflammatory heart disease, congenital heart disease, deep vein thrombosis and 
pulmonary embolism [28]. 
CVD is the number one cause of death in developed countries [29] and 
worldwide total mortality approaches 17.5 million a year, representing a third of all 
global deaths [28]. One in every three adult men and women suffer from some form of 
CVD. It affects all age and ethnic groups and its prevalence is increasing as nations 
develop commercially and industrially, resulting in changes in diet and lifestyle that 
greatly increase CVD risk [29]. The increase in associated morbidities and the number 
of people dying prematurely is a substantial economic burden to developed and 
developing nations. For instance it is predicted that between 2006 and 2015 that the cost 
of China will be $558 billion from heart disease, stroke and diabetes [28]. 
CVD remains the leading cause of death in Australia and continues to be a 
heavy burden on the Australian population in terms of illness and disability and affects 
the health system economically. In 2004 - 2005, the total health care expenditure for 
cardiovascular diseases in Australia was approximately $6 billion, representing 11% of 
the total health care expenditure and was higher than for any other disease sector 
[30,31]. Health expenditure for CVD is estimated to rise to $16.2 billion in 2032-2033 
[32]. In 2009, CVD was the cause of approximately 46 100 deaths, representing almost 
a third (32.8%) of all total deaths in Australia [31].  The onset of cardiovascular disease 
increases with age, with 13% aged between 35 and 44, 23% between the ages of 45 and 
54, and 63% aged 75 years or over having been as reported as having a cardiovascular 
condition [33]. 
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1.3 Atherosclerosis  
Atherosclerosis is a chronic inflammatory disease characterised by the 
thickening and loss of elasticity in the walls of large and medium arteries leading to 
narrowing and constriction of the blood vessels that can give rise to severe 
complications such as myocardial infarction, stroke and limb amputation [34]. The 
accumulation of fat (cholesterol, cholesteryl esters and triglycerides derived from 
apolipoprotein B-100 containing lipid-protein particles) combined with vascular 
inflammation give rise to lesions in the vessel intima known as plaques.  
Atheroma (‘lump of gruel’ in Greek) is characterised by three main 
compartments: the nodular build up of a soft flaky yellow substance consisting of large 
plaques rich in lipid-laden macrophages; cholesterol crystals; and calcification in 
chronic and advanced lesions.  ‘Sclerosis’ refers to the hardening of the arteries due to 
fibrotic changes in the connective tissues of the walls.  This chronic disease ultimately 
produces two critical problems.  Firstly, lesion rupture, thrombus formation and the 
potential for thrombo-emboli to form that become lodged in smaller vessels leading to 
ischaemic damage. Though the clot can heal and contract, stenosis remains which 
results in narrowing of the artery causing reduced downstream blood supply to the 
tissues and organs.  The second problem that may arise is that after a long and excessive 
period of inflammation the vessel wall is weakened and results in an  aneurysm with an 
increased risk of vessel rupture and life-threatening haemorrhage [35].  
 
1.3.1 Cholesterol and lipoproteins  
The majority of cholesterol in the plasma is transported in protein-lipid particles, 
known as lipoproteins, including: very-low density lipoprotein (VLDL), low-density 
lipoprotein (LDL) and high-density lipoprotein (HDL). These lipoproteins are 
heterogeneous in size, density, composition and atherogenicity [36]. High levels of 
LDL, VLDL and remnant, intermediate-density lipoproteins (IDL), can promote 
atherosclerosis and thus high blood levels are major risk factors for coronary heart 
disease [37].   
LDL (approx. 2.5 MDa) is a spherical-shaped particle that is the major carrier of 
cholesterol to cells [38]. The LDL particle is much smaller in size (180-250 Å in 
diameter) than when originally secreted as VLDL (600 to 800 Å in diameter). LDL 
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consists of around 22% protein, with a single molecule of apoB-100, 22% 
phospholipids, 8% cholesterol, 42% cholesteryl esters and 6% triglycerides (w/w) [38].   
There are three LDL subclasses, L3-L1 (L1 as the smallest and L3 densest), and 
the differences between these subclasses are due to differences in lipid composition, 
density, size, chemical composition and apoB-100 structural changes [39].  Small and 
dense LDL particles have been associated with the development of coronary heart 
disease [39]. Different mechanisms have been proposed for the pro-atherogenic effects 
of LDL on the vasculature including; higher entrance and retention into the 
subendothelial space, greater affinity for binding to proteoglycans, and higher 
susceptibility to oxidation.  Other risk factors associated with vascular disease are 
hypertriglyceridaemia, low HDL cholesterol, obesity, hyperglycaemia and insulin 
resistance [36]. 
The density of HDL is between 1.063 and 1.210 g/mL, the molecular masses are 
in the range of 1.7 and 4.0 × 10
5
 g/mL and the protein content is between 45 and 55% 
[40].  HDL are heterogenous particles that are distinguished by their apolipoprotein 
composition including: only apo A-I (LP-A-I), both apo A-I and apo A-II (LP-A-I: A-
II), both apo A-I and apo A-IV (LP-A-I: A-IV), and both apo A-I and apo E (LP-A-I: E) 
[41].  The major protein components (~ 90%) are apo A-I and apo A-II, with apo A-I 
three times more abundant than apo A-II based on mass. The remaining proteins (10%) 
include apo C-I, apo C-II, apo C-III and apo D [41].  
HDL can be subdivided in to classes H5-H1 (with H5, H4 and H3 as the larger 
particles) as assessed by nuclear magnetic resonance [39]. HDL can also be divided into 
two major classes reported to possess different roles in protecting against 
atherosclerosis [42]. Apo A-I containing HDL particles (H5, H4 and H3 corresponding 
to HDL2, 1.063 < density < 1.125 g/mL) are negatively correlated with coronary artery 
disease. H2 and H1, that correspond to HDL3 (1.125 < density < 1.21 g/mL), are 
positively related with coronary artery disease [40]. HDL particles containing apoA-1 
appear to prevent or decrease atherogenesis [42,43].   
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Figure 1.1: Schematic diagram of the structure of LDL and apoB-100 on the 
surface of LDL particle.  
Spherical LDL (Panel A) and the proposed organisation of apoB-100 (Panel B) on the 
surface of LDL particle [41]. 
 
 
1.4 Pathogenesis of atherosclerosis 
Atheroma and atherosclerosis can be referred to as benign and malignant 
conditions, respectively. Atheroma denotes a benign wound healing in response to 
injury and fibrous change which can be resolved. Atherosclerosis denotes a malignant 
transformation and multifactorial progression of chronic inflammation, 
fibroproliferation and angiogenesis [44]. It involves a succession of responses which 
results in systemic damage to the endothelium and the arterial intima instigated by the 
retention of modified low-density lipoproteins, haemodynamic factors and reductive-
oxidative stress [44]. 
Atherosclerotic lesions develop and progress driven by an inflammatory 
response characterised by the release of numerous cytokines, increased proliferation of 
smooth muscle cells and their migration in to the intima, changes in connective tissue 
extracellular matrix and the accumulation of neutral lipid deposits principally in 
macrophages in the initial stages, but subsequently as large extracellular deposits [45].  
(A) (B) 
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Though the mechanism behind atherogenesis is not fully known, some 
hypotheses that are widely accepted are the ‘response to injury’ hypothesis, the 
‘response to retention’ hypothesis and the ‘oxidation’ hypothesis. These are outlined 
below.  Other hypotheses include: that platelets or fibrin are deposited on the intima in 
the initial stages of atherogenesis, and that the macroscopic gelatinous appearance may 
be an intimal thickening which may lead to the primary formation of atherosclerotic 
lesions [45,46]. 
The 'response to injury’ hypothesis, proposed by Russell Ross in 1973 focused 
on the notion that injury induced to the endothelial cells lining the artery walls caused 
endothelial dysfunction and disrupted the wall of the artery. This manifests in abnormal 
cellular interactions which are detailed below, chronic inflammation and plaque 
formation in the initial developmental stages of atherogenesis [47].  
The ‘response to retention’ hypothesis postulates that the sub-endothelial 
retention and successive accumulation of lipids by the extracellular matrix is main 
trigger for the initiation of atherogenesis [48]. This theory was later expanded in 1994 to 
incorporate the oxidation hypothesis which proposes that oxidatively-modified low-
density lipoproteins (ox-LDL) in the arterial wall generates a response that may be 
proinflammatory in terms of endothelial dysfunction as well as chemotactic, leading 
eventually to progression of atherosclerotic lesion formation [49].  
Common to all these hypotheses is the key event of endothelial damage or 
dysfunction and the subsequent triggering of downstream pro-inflammatory events. 
Damage to the endothelium leads to monocyte and platelet adhesion thought to be 
mediated, at least in part, by redox signalling pathways. These monocytes migrate into 
the subendothelial space and differentiate into pro-inflammatory macrophages which 
may contribute to the modifications to LDL as well as promoting foam cell and thus 
fatty streak formation.  
  
1.4.1 Stages of plaque formation 
The atherosclerotic plaque is identified by arterial intimal thickening and is 
characterised by increased populations of smooth muscle cells, macrophages and 
lymphocytes, cholesterol deposits and solid layers of connective tissue matrix (as shown 
in Figure 1.2).  
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In the developmental stages of atherosclerosis, the earliest discernible lesion of 
atherosclerosis is the fatty streak appearing as a yellow raised area in the lumen of the 
artery  arising from the accumulation of lipid-laden “foam cells” in the intimal layer of 
the artery [45]. These occur in medium and large-sized arteries and present as a fatty 
intramural thickening of the subintima that intrudes into the arterial lumen. This process 
may also affect the vascular network and the aetiology and clinical impact of 
atherosclerosis may differ from one vascular bed to another. The fatty streak comprises 
of three main segments. The first is the cellular segment predominately consisting of 
smooth muscle cells and macrophages. The second is the connective tissue matrix and 
extracellular lipid. The third segment is the intracellular lipid which accrues within 
macrophages and transforms them into foam cells [45].  
The inflammatory process is further exacerbated by the death of foam cells and 
is the stimulus for vascular smooth muscle cells (VSMC) migration into the intima. The 
affected sites are weakened and softened which result in the thickening of the intima by 
oedematous pads and an increase in extracellular matrix molecules and VSMC collagen. 
The continued uptake of accumulated LDL molecules by macrophages engenders the 
additional release of inflammatory cytokines and growth factors propagating a 
succession of inflammation, lipid deposition and lesion expansion, generating the 
“atheroma” which is the prelude to atherosclerotic plaque formation [48]. 
Advanced plaques can be segregated into two types; fibro-lipid and fibrous 
plaques. The fibrous plaques cause tension within the subendothelial wall and result in a 
compensatory extension of the muscular wall, as well as developing a fibrous cap 
concealing the atheromatous core. Necrosis due to tissue damage tends to occur in the 
atheromatous core generating more tissue debris, and accumulation of proteoglycans, 
collagen, and lipid laden cells [48]. In the advanced stages of coronary atherosclerosis, a 
great reduction in lumen diameter is observed due to increased thickening of the wall, 
loss of elasticity and hardening due to calcification [48]. Plaque rupture resulting in 
progressive or sudden occlusion of the lumen, as well as the formation of thrombo-
embolis, may lead to acute cardiovascular events and complications such as myocardial 
infarction, stroke and unstable angina.   
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Figure 1.2: Schematic diagram of atherosclerotic plaque formation.  
Adapted from reference [50].  
 
 
1.4.2 Classification of atherosclerosis  
There have been many attempts to establish and unify the developmental stages 
of atherosclerotic lesions.  There are slight differences and variations in definitions 
between systems, and the practical classification of human atherosclerotic lesions is still 
in the process of development [51]. The American Heart Association Committee on 
Vascular Lesions of the Council on Arteriosclerosis, has recommended dividing the 
progression of atherosclerotic lesions, with numbers corresponding to the chronological 
series of events as shown in Figure 1.3 [51]. The lesions are divided into three main 
forms; Early (Type I-II), Intermediate (III) and Advanced (IV-VIII) [46,51,52].  
Early lesions Type I and Type II represent small lipid deposits in the arterial 
intima, with Type II lesions often referred to as fatty streaks. Type I is known as the 
initial lesion consisting of macrophages, scattered foam cells and lipid deposits in the 
intima [52]. Type II lesions have thicker intracellular matrix mainly comprised of 
intimal macrophage foam cells in layers, and smooth muscle cells which also contain 
intracellular lipid droplets, with a lack of extracellular lipid. Type III lesions are known 
as the intermediate or transitional lesions between fatty streaks and more advanced 
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lesions. Type III lesions are also known as the preatheroma stage where some 
extracellular pools of lipid are observed which become confluent and pronounced in 
Type IV lesions [52]. 
The Type IV lesion is the first atheroma stage that may result in reportable 
symptoms, where the intimal structure and the arterial wall are deformed and 
disorganised. The earliest advanced lesion are characterised by the disruption of the 
well-defined intimal structure as the dense core of the lesion, consisting of accumulated 
extracellular lipid, forces the intima to protrude into the lumen of the artery. 
Macrophages, foam cells, lymphocytes become densely concentrated in the lesion 
leading to generation of a proteoglycan-rich layer within the intima. Smooth muscle cell 
migration and proliferation into the lesion may result in the lesion becoming fibrous, as 
these cells lay down extracellular matrix [46]. 
When the lipid core from Type IV becomes fibrous, this constitutes the 
transition to a Type V lesion, defined as fibroatheromas. In Type VI lesions, the arteries 
are considerably more narrowed than Type VI lesions, and may develop fissures, 
hematoma and thrombus.  In Type VII, calcified regions are seen within the fibrotic 
lipid core. [46]. The last lesion in this classification is Type VIII. The lumen of the 
artery is narrowed to a great degree obstructing the blood flow. These lesions are prone 
to unstable surface defects causing rupture leading to serious complications such as 
haemorrhage, thrombosis, unstable angina, myocardial infarction, stroke, and sudden 
death [46,51].  
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Figure 1.3: Pathological classification of atherosclerotic lesions 
Thick and thin arrows represent the relative progression with which lesions develop at 
specific sites, or they show the relative incidence and magnitude of a pathway segment. 
Image modified from [53]. 
 
 
1.4.3 Current hypolipidaemic-agents for cardiovascular diseases 
Statins are the most effective and widely used treatment for cardiovascular 
diseases accompanied with hypercholesterolaemia. Many forms of statins are available 
such as atorvastatin (Lipitor and Torvast), fluvastatin (Lesol), lovastatin (Mevacor, 
Altocor, Altoprev), pitavastin (Livalo, Pitava), pravastin (Pravachol, Selektin, Lipostat), 
rosuvastatin (Crestor) and simvastatin (Ezetimibe, Zocor, Lipex).  Statins reduce 
cholesterol levels by inhibiting the enzyme HMG-CoA reductase, which restricts 
cholesterol synthesis and increases cellular LDL uptake.  Statins have also shown to be 
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effective against atherosclerosis via enhancing endothelial function, sustaining 
inflammatory responses, preserving plaque stability and preventing thrombus formation. 
A major side effect is the increased risk of developing diabetes, with greater dosages 
leading to a more pronounced manifestation.  
Fibrates (bezafibrate, cipofibrate, clofibrate, gemfibrozil and fenofibrate) are a 
class of amphipathic carboxylic acids commonly administered to treat various 
hyperlipidaemic disorders, predominantly hypercholesterolaemia. They have also been 
shown to be effective in metabolic syndrome by counteracting dyslipidaemia, lowering 
LDL and triglyceride levels, increasing HDL, improve insulin sensitivity, and reducing 
the incidence of Type 2 diabetes (T2D) and hypertension. Fibrates activate peroxisome 
proliferator-activated receptors-α (PPAR), influencing carbohydrate and fat metabolism 
and adipose tissue differentiation. They are structurally closely related to the 
thiazolidinediones (TZDs) which specifically activate PPAR-γ. 
 
1.5 Diabetes mellitus  
Diabetes mellitus (DM) embodies a range of metabolic disorders characterised 
by hyperglycaemia occurring from defects and deficiency in the secretion and / or 
action, of the hormone insulin. This results in either an absolute deficiency in insulin or 
a failure of the target organs to respond to increased insulin secretion (“insulin 
resistance”).  
The word diabetes mellitus arises from two Greek words. The first part, 
diabainein meaning “siphon” or “passing through” refers to the characteristic polyuria 
(increase in the urinary frequency and volume) of this syndrome. The second part 
mellitus relates to honey referring to the high glucose levels in the urine. In addition to 
polyuria, other characteristic symptoms are a compensatory polydipsia (increased thirst) 
and polyphagia (increased hunger). Chronic hyperglycaemia in people with diabetes 
mellitus affects the function of many organs; in particular long-term damage to the eyes 
(causing potential blindness), kidneys, nerves, heart and blood vessels [54]. People with 
diabetes are at an elevated risk for cardiovascular, peripheral vascular and 
cerebrovascular disease [24].  
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1.5.1 Classification and prevalence of diabetes  
According to the World Health Organisation, 171 million people across the 
globe had diabetes in the year 2000 which accounts for 2.5% of the world population. It 
is estimated that by 2030 this number will almost double, to affect 366 million people 
corresponding to 4.4% of the world population [55]. In 2012, it was reported that 
approximately 4.8 million people died from diabetes, more than 371 million people 
were living with diabetes worldwide with approximately 50% of these people left 
undiagnosed [56,57].  The economic cost of diabetes in 2013 has been estimated at 
approximately 471 billion US dollars [56].   
The increase in incidence of diabetes in developing countries follows the trend 
of increasing urbanisation and the accompanying adoption of Western style diets and 
more sedentary lifestyles [57].  Indigenous populations have a higher prevalence than 
their corresponding non-indigenous populations in countries like Australia. The 
incidence of diabetes is four fold higher amongst indigenous Australians than non-
indigenous populations [33].  
There are three major types of diabetes: Type I, Type II and gestational diabetes 
[33]. Type I diabetes (T1DM), previously known as insulin-dependent diabetes, is an 
autoimmune disease where the immune system destroys the insulin-producing beta cells 
in the pancreas resulting in a failure to produce and secrete insulin. As a result, 
replacement insulin via injection is constantly required. T1DM accounts for 5 - 10% of 
total cases globally, and 10 - 15% in the Australian population, and may appear at any 
age but is commonly seen before 40 [33]. This type of diabetes may be activated by 
environmental factors such as viruses, diet or chemicals in people who are genetically 
susceptible [33,58].   
Type II diabetes (T2DM), previously termed as non-insulin dependent diabetes 
ranges from insulin resistance to an absolute insulin deficiency. It is the most common 
form of diabetes affecting 90 - 95% of people with diabetes worldwide and 85 - 90% 
[33] in Australia. This type of diabetes has also been previously termed as late-onset 
diabetes, however nowadays the occurrence of T2DM has become relatively common in 
young people [33]. Familial and genetic factors as well as lifestyle factors such as 
excess weight, inactivity, high blood pressure and poor diet are major risk factors for its 
occurrence and progression [33].  Thus modification of diet and pattern of physical 
activity are the principal components of the treatment of T2DM [33]. Pharmaceuticals 
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are commonly used to treat people with T2DM. The initial stage of T2DM is 
characterised by hyperinsulinaemia. However, the disease may progress to a stage 
where there is an absolute insulin deficiency, and where insulin injections may be 
needed.  
For some women, gestational diabetes mellitus occurs during pregnancy and 
these women are prone to develop type 2 diabetes.  It occurs in 1 - 14% of pregnancies 
depending on the population investigated, and in Australia 5.5 - 8.8% of pregnant 
women develop gestational diabetes [33]. Risk factors for gestational diabetes may 
include a family history of diabetes, increased maternal age, obesity and being a 
member of a socio-economic or ethnic group with an increased likelihood of developing 
T2DM. Complications from gestational diabetes include babies which are large for their 
gestational age making vaginal delivery more difficult, hypertension, pre-term birth, 
uterine bleeding, foetal distress, pre-eclampsia, neonatal hypoglycaemia, respiratory 
distress and jaundice [33]. The carbohydrate intolerance usually stabilises after giving 
birth, however the mother has a greater risk of developing T2DM later in life, and the 
baby is more prone to develop obesity and impaired glucose tolerance later in life [58].   
Other causes of diabetes, which are uncommon, include genetic mutations which 
lead to defects in beta cell function, insulin processing or actions; exocrine pancreatic 
defects; infections; drugs impairing insulin secretion and some toxins that damage 
pancreatic beta cells [33]. 
 
1.5.2 Pathophysiology and complications of hyperglycaemia leading to micro- 
and macrovascular disease 
Hyperglycaemia is a hallmark of DM and drives an array of changes in the cells 
of the vasculature, which may be linked to the development and progression of 
microvascular complications in the retina, renal glomeruli and peripheral nerves. Thus 
chronic complications may lead to retinopathy and loss of vision, nephropathy leading 
to renal failure, peripheral neuropathy problems such as ulcers and amputations, as well 
as autonomic neuropathy causing gastrointestinal, genitourinary, and cardiovascular 
problems. As well as these microvascular complications, the risk of macrovascular 
disease, including atherosclerosis in the heart, arms and leg, is higher for people with 
diabetes [58,59].  
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1.5.3 Current pharmaceutical agents for diabetes  
Anti-diabetic medications and anti-hyperglycaemic agents aim to treat diabetes 
mellitus by lowering blood glucose levels. Insulin injections used to treat the insulin 
deficiency of T1D. Oral hypoglycaemic agents such as insulin sensitisers are used to 
alleviate T2D in people that have insulin resistance. The main types of insulin 
sensitisers are biguanides (e.g. metformin, phenformin and buformin), the 
thiazolidinedones (TZD) (e.g. rosiglitazone, pioglitazone and troglitazone) and the 
sulfonylureas (tolbutamide, acetohexamide, tolazamide and chlorpropamide). 
Biguanides decrease hepatic glucose output and increase uptake of glucose by 
peripheral skeletal muscles [60]. TZD bind to PPARγ, a transcription factor mediating 
the transcription of genes regulating glucose and fat metabolism [61]. Sulfonylureas 
work by activating the endogenous release of insulin by pancreatic beta cells by 
inhibiting the potassium ATP channel [61]. Although the action of these compounds is 
fast, the main side effect is hypoglycaemia accompanied with weight gain and higher 
risk of death compared to biguanides and TZDs [62]. There are many reported side 
effects of these drugs including undesirable body weight gain, gastrointestinal 
discomfort, oedema, anaemia, cardio- and hepatotoxicity and as a result some 
medications like phenformin, buformin, rosiglitazone and troglitazone have been 
suspended or withdrawn from use [62]. Metformin is the most commonly prescribed 
anti-diabetic medication with this reducing the levels of LDL and triglycerides without 
effects on weight gain or blood pressure [63]. However there are contraindications for 
these species including renal disease or heart failure due to the risk of lactic acidosis, 
gastrointestinal disorders, and vitamin B12 deficiency [63,64].  
 
1.6 Obesity: definition 
Obesity is characterised by abnormal or excessive fat accumulation in adipose 
tissue and other organs leading to reduced life expectancy and detrimental health 
problems [65]. Obesity is related to multiple morbidities, including elevated risk of 
diabetes, cardiovascular disease, sleep apnoea, and cancer. The body fat level for 
healthy female is typically 20 - 27% of the total body mass, with the corresponding 
value healthy males being 15 - 22%. An overweight person generally has 10 - 20% 
more body mass than normal, with this comprised mostly of fat. Obesity is defined as 
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greater than 20% more than the normal body mass and morbid obesity is defined as 
greater than 40% above the ideal weight for one’s age and height.  
The body mass index (BMI) is a simple index that has been widely accepted by 
health organisations and health professionals to identify overweight and obese adults. It 
has been widely used in epidemiological investigations due to its simplicity and is 
advocated as a screening criterion in the initial clinical assessment of obesity [66]. The 
BMI is calculated by mass in kilograms divided by the square of the height in metres. 
A BMI value less than 18.5 is underweight and is associated with greater health 
risks with lower BMI readings. A higher BMI than 25 is overweight and increases the 
risk of health impairment and in particularly greater than 30 is classified obese and is 
associated with greater health risks with excess fat-related disorders [67]. The severity 
of obesity is graded into classes I to III, as presented in Table 1.2.  
 
Category BMI (kg/m2) Health Risk 
 
Very severely underweight < 15.0 Extremely high risk 
 
Severely underweight 15.0 – 16.0 High risk 
 
Underweight 16.0 – 18.5 Moderate risk 
 
Normal (healthy weight) 18.5 – 24.9 Most healthy weight 
 
Overweight 25 – 29.9 Moderate risk  
 
Obese Class I  
(Moderately obese) 
30 – 34.9 High risk 
 
 
Obese Class II  
(Severely obese) 
35 – 39.9 Very high risk  
 
 
Obese Class III  
(Morbidly obese) 
≥ 40 Extremely high risk 
 
 
 
Table 1.2: Health risk according to body mass index (BMI) 
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1.6.1 Prevalence and causes of obesity 
Obesity has become one of the core threats to global health and its  prevalence 
has doubled since 1980 [68]. This occurred in almost every continent is parallel with 
industrial and economic development that has occurred across the globe (Figure 1.4). In 
countries like Australia and the United States, the majority of adults now considered to 
be overweight [67,69], and more than 10% of the world’s adult population is obese. 
Being overweight and obesity now kills more people than undernourishment for the 
majority of populations [68]. The treatment of obesity continues to set a huge economic 
burden on the health care system [5].  
Childhood obesity is becoming a serious medical and social concern worldwide 
[70,71]. In 2011, about 40 million children aged five years and under were overweight 
with more than 30 million children that live in developing countries, along with 10 
million children in developed countries judged to be overweight [68]. Type 2 diabetes 
and cardiovascular diseases once thought to only appear in adults are now observed in 
obese children [68,70,71,72]. 
Obesity is the fifth leading risk factor for global deaths, and causes at least 2.8 
million deaths in adults annually. Of these, 44% are also burdened with diabetes, 23% 
with ischemic heart disease and approximately 7% and 41% of cancers are attributed to 
being overweight or obese respectively [68]. The largest growth in obesity since 1980 
has appeared in developing countries, particularly in urbanised groups in Oceania, Latin 
America and North Africa [65].  
The primary cause of obesity is an energy imbalance between the consumption 
and expenditure of calories. While body fat content can be significantly modulated by 
genetics and maternal as well as peri-natal factors, the current global rise in obesity is 
predominantly due to a change to a diet consisting of energy-dense foods. These foods 
tend to be rich in fat and sugars, low in vitamins and other micronutrients, relatively low 
cost and widely available [65,68]. Thus, over the past two decades, there has been a 
global escalation in total calorie intake. In addition to this, epidemiological studies show 
that chronic consumption of high fat diets, high fructose levels (particularly from soft 
drinks) and regular consumption of fast food elevates the risk and severity of obesity, 
along with diabetes mellitus and cardiovascular disease [73,74,75]. The impact is 
particularly seen in indigenous populations as traditionally, indigenous diets are 
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abundant in vegetables, fruits and fish in contrast to the cheaper, easily accessible and 
energy-dense Western-style diets [76,77].  
 
 
Figure 1.4: Global trends in obesity from 1980 and 2008. 
Worldwide obesity prevalence between 1980 (blue) and 2008 (red) in men (A) and 
women (B). Adapted from reference [65]. 
 
 
1.6.2 Pathogenesis of obesity 
Adipose tissue is an active endocrine organ, which primarily consists of cells 
(adipocytes) that are filled with triglycerides, adipocyte precursors and other stromal 
cells and resident and infiltrating immune cells, all embedded in collagen network with 
a rich blood supply [78,79]. The increase in body fat characteristic of obesity may be 
due to either increases in adipocyte number or cell size. In adipogenesis, mesenchymal 
stem cells commit to the formation of preadipocytes which undergo a series of cell 
divisions before proceeding to terminal differentiation and mature adipocytes. Turnover 
of adipocytes continues into adult life. However, in adult obesity the increase in fat 
mass is principally attributed to adipocyte hypertrophy rather than hyperplasia (the latter 
is more typical of pre-pubescent obesity). Adipokines are proteins that are secreted by 
adipocytes, which work closely to regulate adipose tissue growth and signal other 
organs to control feeding, energy balance, and other functions.  
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Lipid droplets are intracellular organelles covered with proteins of the perilipin 
family, which store neutral lipids in cells [80]. Excess accumulation of intracellular 
lipids within these organelles has been associated with obesity, diabetes, atherosclerosis 
and other organ dysfunction [80]. Dysfunction of adiposity in obesity is accompanied 
with ectopic fat deposition (steatosis), hyperlipidaemia, insulin resistance, diabetes, 
endothelial dysfunction, cardiovascular complications and other metabolic diseases 
[78,81]. 
Monogenic syndromes, rare chromosomal abnormalities, complex molecular 
interactions between the brain and other organs, and eating disorders have all been 
proposed as causal agents of obesity [82]. In addition to these, the discovery of leptin 
was a significant breakthrough in understanding energy homeostasis and its 
dysregulation in obesity [83].  Leptin is an adipokine which acts on the hypothalamus to 
inhibit food intake, increases energy expenditure and decreases body fat. Leptin can also 
modulate blood pressure, heart rate, immunity, sympathetic activities, intermediary 
metabolism, reproduction, and bone biology. In addition it is considered to be pro-
inflammatory agent [83]. Obesity is associated with elevated serum leptin 
concentrations but also leptin resistance. Conversely, voluntary weight loss, in 
particularly where this leads to a decrease in adipose tissue mass, results in reduced 
circulating leptin levels [84]. When secretion of leptin increases, secretion of another 
adipokine, adiponectin declines. This suppression of adiponectin is believed to result in 
metabolic impairment. Reduced levels of adiponectin have been shown to contribute to 
insulin resistance, as adiponectin receptors in hepatocytes and muscle cells help control 
β-oxidation of fatty acids, glucose uptake, gluconeogenesis and peroxisome proliferator 
activated  receptor (PPAR)-γ activation [85,86]. Further, a decrease in adiponectin 
production may provide a mechanistic link between obesity and hypertension. 
Adiponectin stimulates the activity of endothelial nitric oxide synthase (eNOS), the 
product of which, nitric oxide (NO˙), is a key mediator of vascular tone, inflammation 
and smooth muscle cell proliferation. The activation of eNOS by adiponectin stabilizes 
eNOS mRNA and eNOS phosphorylation. Plasma adiponectin supplementation in 
adiponectin-deficient mice has been reported to restore endothelial NO˙ production and 
vascular wall tone, enhance smooth muscle cell proliferation and decrease leukocyte 
adhesion [86]. 
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Obesity can lead to a state of systemic, low-grade inflammation. Pro-
inflammatory mediators are able to interfere with insulin signalling pathways, thereby 
reducing responsiveness in insulin sensitive tissues, a key indication of Type 2 diabetes. 
The inflammatory responses are likely to  mediate: (i) infiltration of adipose tissue by 
inflammatory cells (including monocyte/macrophages and lymphocytes); (ii) the 
expansion of adipose tissue itself as this is a source of cytokines in addition to 
adipokines, and (iii) inflammation of the liver in response to either pro-inflammatory 
signals delivered by portal circulation or hepatic fat accumulation [87,88,89,90,91]. 
Adipose tissue macrophages are believed to be the major mediators of the 
chronic systemic inflammation of obesity as these cells are sources of cytokines (such 
as IL-6) and reactive oxygen species (ROS). Visceral adipose tissue typically contains 
greater macrophage numbers than subcutaneous adipose tissue, with this being of 
potential importance because of the key role accumulation of abdominal fat has upon 
metabolic dysfunction. A number of cytokines have been shown to invoke insulin 
resistance [85], and in addition cytokine IL-6 stimulates vascular smooth muscle cell 
production and secretion of angiotensin (AngII) which is as a potent vasoconstrictor, 
growth factor and stimulant for the generation of reactive oxygen species (ROS) and 
inflammatory cytokines [92,93]. Production of TNF-α and ROS can be further provoked 
by free fatty acids, the levels of which are increased during obesity [85,92]. The 
increase in vascular ROS and cytokine levels may cause endothelial dysfunction (for 
example by reducing NO˙ bioavailability) thereby exacerbating vascular inflammation. 
Furthermore adipokines (including resistin and possibly lowered levels of adiponectin) 
have been shown to activate the expression of monocyte adhesion molecules (e.g. 
intracellular adhesion molecule-1, ICAM-1) by the vascular endothelium, as well as 
monocyte / macrophage chemotactic protein-1 (MCP-1) and colony stimulating factor-1 
(CSF-1) which regulates monocyte-to-macrophage differentiation [85,94]. Oxidative 
stress in turn, suppresses adiponectin secretion and free fatty acid storage by adipocytes 
and augments the production of MCP-1 [92], thereby creating a vicious cycle of pro-
inflammatory changes.  
Resistin is a relatively recently discovered adipokine, the molecular properties of 
which are still in the process of elucidation [95]. The consequences of increased resistin 
levels in human obesity remain unclear. Resistin has been reported in in vitro studies, to 
impair endothelial function by reducing the expression of eNOS and enhancing the 
release of the potent vasoconstrictor endothelin-1 [96,97]. Elevated resistin levels, have 
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also been shown to induce insulin resistance in mice, with this accompanied by elevated 
blood pressure and hypertension [95]. Resistin is believed to be secreted mainly by 
adipose tissue macrophages with higher levels detected in obese humans [98,99]. 
However, the pathophysiological role of circulating resistin in metabolic disturbances in 
glucose and lipid metabolism its contribution to the progression of obesity-related 
hypertension is not well established [95].  
 
1.6.3 Current therapeutic agents and interventions for obesity 
Anti-obesity medications are used to decrease mass or reduce the rate of mass 
gain by suppressing appetite, increasing basal metabolism or reducing caloric 
absorption.  The main pharmaceutical drugs for treating obesity are orlistat, lorcaserin, 
sibutramine, rimonabant, exantide and pramlintide. These are not usually suitable for 
long term use due to life-threatening side effects such as elevated blood pressure and 
heart rate, palpitations, glaucoma, drug addiction, restlessness, depression and insomnia. 
Although orlistat (Xenical) has been recently authorised by FDA for long term use, it 
has reported side effects of steatorrhea, stomach pain, and flatulence. 
Persistent body mass management via lifestyle modifications (i.e. dietary and 
physical activity) are logical targets for preventing and treating obesity. However, many 
overweight or obese individuals report that it is very easy to gain but difficult to lose 
mass and it is known that anti-obesity drugs are not very effective [100]. Bariatric 
surgery and laparoscopic banding, initially deliver great and rapid weight reduction 
however many subjects are confronted with substantial weight regain over time. There 
is therefore a pressing need for a clearer understanding of the molecular pathways 
behind energy homeostasis and how obesity affects diabetes, atherosclerosis and other 
complications.  
 
1.7 Causational and mechanistic links (pathogenesis and manifestations) 
between obesity, diabetes and atherosclerosis 
The growing problem of obesity is linked with multiple morbidities, capable of 
impairing every body system. Obesity is presently the most prevalent cardiovascular 
risk factor in individuals with confirmed coronary heart disease [101]. Obese people 
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have a poor quality of life as well as a shorter life expectancy than individuals of 
healthy body mass [100,101].  
Epidemiological studies have revealed that obesity is a major risk factor for 
coronary heart disease, atherosclerosis, heart failure, atrial fibrillation, ventricular 
arrhythmias and sudden death [102,103,104]. It is also considered a predisposing causal 
factor in hypertension, diabetes mellitus type 2, osteoarthritis, obstruction sleep apnoea, 
dyslipidaemia, gastroesophageal reflux, non-alcoholic fatty liver disease, renal failure 
and various types of cancers [100,104].  
The association between obesity and different forms of cardiovascular disease is 
complex, due to the presence of a large cascade of interacting factors. Obesity can 
induce coronary atherosclerosis through well-established mechanisms, such as 
dyslipidaemia, hypertension, and diabetes [105,106,107]. However, recent evidence has 
shown that the association between obesity and cardiovascular disease may also include 
other factors including subclinical inflammation, neuro-hormonal activation with 
increased sympathetic tone, high leptin and insulin concentrations, obstructive sleep 
apnoea, increased release of saturated free fatty acids in addition to increases in the 
volume/mass of subepicardial and abdominal fat deposits. [107,108,109,110]. 
The mechanisms by which excess fat causes insulin resistance are complex, and 
are likely to involve several pathways encompassing cytokines, other inflammatory 
mediators and adipokines. Insulin resistance precedes type 2 diabetes mellitus which 
can initiate or accelerate atherosclerotic progression. People with diabetes have a 
substantially greater risk of atherosclerosis and this is true for both genders [111], the 
increased occurrence also manifests as an acceleration of the rate of disease progression, 
as well as increasing size and complexity of atherosclerotic plaques [59,112,113]. It is 
now accepted that this increase in the prevalence and severity of atherosclerosis in 
people with diabetes includes mechanisms that involve hyperglycaemia [111,112,114]. 
Four main mechanisms have been proposed to explain how hyperglycaemia invokes or 
accelerates diabetic vascular complications: increased glucose flux through polyol-
sorbital pathway; the hexosamine pathway; formation of advanced glycation end 
products (AGE); and activation of protein kinase C (PKC) [115]. Conceivably the four 
pathways may act together in response to common upstream events, most notably 
oxidative stress. 
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1.7.1 The poly-sorbitol pathway  
Aldose reductases (AR) catalyse the metabolism of glucose to sorbitol, which is 
then converted to fructose by sorbitol dehydrogenase in the polyol-sorbitol pathway. 
These reactions are accompanied by the oxidation of nicotinamide adenine dinucleotide 
phosphate (NADPH) to NADP
+
, and reduction of nicotinamide adenide dinucleotide 
(NAD
+
) to hydrogenated NAD (NADH) [48].  
 
 
Figure 1.5: Polyol (sorbitol) pathway; glucose-6-P, glucose 6-phosate.  
Adapted from reference [116]. 
 
High fluxes of glucose through this pathway lead to greater osmotic stress due to 
increased sorbitol accumulation and reduced radical scavenging capacity due to reduced 
production of NADPH (an essential co-factor of the antioxidant glutathione peroxidase / 
reductase system) but also an increase in the cytosolic NADH / NAD
+
 ratio and 
potentially an increase in reductive stress [117,118]. In support of this hypothesis 
sorbitol and fructose concentrations have been reported to be approximately 9-fold, and 
the NADH / NAD
+
 ratio nearly 4-fold, greater in diabetic hearts [119]. Increased polyol 
pathway flux may also decrease the production of the antioxidant glutathione by 
inhibiting glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and elevate triose 
phosphate concentrations which may leave the cells more prone to oxidative stress and 
thus promote vascular damage [117].  An in vivo study on LDL receptor-deficient 
diabetic mice showed increased atherosclerotic lesion size when human AR was over 
expressed in these mice [120]. Inhibition of AR in transgenic rats with over expressed 
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AR was shown to improve altered glucose metabolism and protect against the 
progression of long-term diabetic complications [121]. However at this current stage, 
there is no clinical evidence to support the hypothesis that AR inhibition ameliorates 
atherosclerosis in people with diabetes, and further studies are required to determine the 
pathological role of polyol pathway in diabetic atherosclerosis.  
 
1.7.2 The hexosamine pathway 
In the hexosamine pathway, fructose-6-phosphate is transformed to 
glucosamine-6-phosphate and then to uridine diphosphate (UDP)-N-acetyl glucosamine 
via the activity of L-glutamine: D-fructose-6-phophate amidotransferase (GFAT) [122], 
as shown below. Many substrates for the synthesis of proteoglycans and glycoproteins 
are generated subsequently.  
 
Fructose-6-phosphate    Glucosamine-6-phosphate+UDP-N-acetyl glucosamine 
          O-linked protein glycosylation 
             Altered enzyme function 
  
Metabolism of excess glucose via this pathway results in disruption in transcriptional 
activity and enzyme function. In bovine aortic endothelial cells, increased flux through 
the hexosamine pathway was found to increase N-acetyl glucosamine levels and 
transcription of pro-inflammatory cytokines, such as transforming growth factor-α 
(TGF-α), TGF-β1 and plasminogen activator inhibitor-1 (PAI-1) [123]. Although this is 
one pathway through which hyperglycaemia can initiate and promote atherosclerosis, 
intraperitoneal administration of glucosamine for 12 weeks to apo E
-/-
 mice was shown 
to lower atherosclerotic lesion size in the aortic root [124]. Thus the hexosamine 
pathway may be associated with microvascular diabetic complications but may not have 
a strong correlation with the development of atherosclerosis. Further studies may clarify 
the possible mechanistic link between diabetes and atherosclerosis through the 
hexamine pathway. 
GFAT 
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Figure 1.6: The hexosamine pathway.  
The glycolytic intermediate fructose-6-phosphate (Fruc-6-P) is converted to 
glucosamine-6-phosphate by the enzyme glutamine: fructose-6-phosphate 
amidotransferase (GFAT). Intracellular glycosylation by the addition of N-
acetylglucosamine (GlcNAc) to serine and threonine is catalysed by the enzyme O-
GlcNAc transferase (OGT). Increased donation of GlcNAc products to serine and 
threonine residues of transcription factors such as Sp1, often at phosphorylation sites, 
increases the production of factors as PAI-1 and TGF-β1. AZA, azaserine; AS-GFAT, 
antisense to GFAT. Adapted from reference [117]. 
 
 
1.7.3 Protein Kinase C Activation 
The protein kinases C (PKC) are a group of enzymes consisting of 12 isozymes. 
They are important in a variety of cellular activities such as proliferation, contractility, 
hypertrophy, signal transduction, growth factor transcription and apoptosis [125]. 
Activation of PKC in diabetes has been implicated in cardiovascular dysfunction by 
promoting extracellular matrix production, activation of an inflammatory response by 
cytokine expression and leukocyte adhesion, loss of vascular reactivity, increased 
endothelial permeability, vascular membrane thickening and angiogenesis [125]. The 
level of the PKC activator diacylglycerol (DAG) is increased by hyperglycaemia in 
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endothelial cells by de novo synthesis from dihydroxyacetone phosphate (DHAP) and 
glyceraldehyde-3-phosphate.  
 
    DHAP                                                    DAG                                                     PKC 
 
 
DAG may also be indirectly synthesised by the receptor for advanced glycation 
end products (RAGE) or via the polyol pathway. The activation of the PKCs may lead 
to numerous proatherogenic effects of these enzymes, such as dysfunction of vascular 
reactivity and fibrinolysis via elevated plasminogen activated inhibitor-1 (PAI-1) 
expression and increased redox stress by effects on NADPH oxidases [125]. In 
hyperglycaemic conditions, PKC also up-regulates adhesion molecules on endothelial 
cells which would stimulate an inflammatory response. PKC activation in VSMC has 
been shown to affect mitogenesis, DNA synthesis, and growth factor receptor turnover 
[126]. PKC activation increases the concentration of transforming growth factor-β 
which regulates extracellular matrix formation [126]. Inhibition of PKC has been shown 
to impede or stabilise many vascular abnormalities in diabetes in particularly 
endothelial dysfunction, a primary initiating factor in atherosclerosis [126]. 
 
1.7.4 Oxidative stress   
Ninety five percent of oxygen consumption occurs via tetravalent reduction by 
the cytochrome oxidase system of mitochondria, producing water and ATP. The 
remaining 5% oxygen is reduced univalently, with electrons added one at a time. This 
process results in a production of a range of reactive oxygen species (ROS) [48]. ROS 
consists of free radicals including superoxide, hydroxyl, peroxyl and hydroperoxyl 
radicals as well as non-radical species such as hydrogen peroxide and hypochlorous 
acid. Under physiological conditions, any increase in oxidant concentration brings about 
a compensatory response mediated by several antioxidant enzymes (e.g. superoxide 
dismutase, catalase, glutathione (GSH) peroxidases, GSH-S-transferases), thiols (e.g. 
GSH, cysteine, as well as protein-bound thiols) as well as a number of low molecular 
mass antioxidant compounds including urate, ubiquinol, tocopherol, ascorbate and 
carotenoids [45, 147].  
NADH               NAD+ α-Glycerol-phosphate 
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Oxidative stress can lead to damage to proteins, lipids, carbohydrates and 
nucleotides including DNA [125] leading to cell dysfunction. ROS may alter 
endothelial function by peroxidation of membrane lipids, modulated gene expression 
and by decreasing the bioavailability of NO˙. The latter may occur as superoxide can 
react with NO˙ (at rates comparable to the spontaneous dismutation of superoxide to 
hydrogen peroxide) and yield the potent oxidant peroxynitrous acid and consequently 
augmented peroxidation, oxidation of other molecules and protein nitration [127]. ROS 
are also capable of oxidising LDL [49,128,129,130].  Superoxide and peroxynitrous 
acid may be critical mediators of pancreatic cell death, potentially leading to 
atherosclerosis and heart failure [131]. In the context of diabetes, Brownlee has argued 
that increased mitochondrial production of superoxide under conditions of 
hyperglycaemia may represent a common underlying mechanism for increased activity 
of the aldose reductase, hexosamine and PKC pathways [115,117,132]. Thus if 
oxidative stress does play a key role in the diabetes-induced atherogenesis it would be 
expected that development and progression of the disease would be inhibited by 
antioxidant therapies. However, supplementation studies with vitamin C and E and β-
carotene have been unsuccessful in confirming the potential retardation of 
cardiovascular disease progression [133,134].  
 
1.7.5 Glycation, glycoxidation reactions and the formation of advanced glycation 
end products (AGE)   
One of the potentially most important effects of diabetes-induced 
hyperglycaemia is the non-enzymatic reaction between glucose and proteins leading to 
the production of advanced glycation end products (AGE) [120]. AGE are adducts that 
are formed on proteins, lipids or DNA bases after exposure to glucose or reactive 
aldehydes [135]. The non-enzymatic chemical reaction between glucose and proteins is 
known as the Maillard or browning reaction, and generates Schiff’s base (early 
glycation products), Amadori products and eventually AGE. Reactive aldehydes such as 
methylglyoxal, 3-deoxyglucosone and glyoxal, the levels of which are increased in 
people with diabetes, are key intermediates in the development of “carbonyl stress” and 
AGE formation [117].  
Wolff and Dean have shown that the non enzymatic reaction of sugars with protein 
entails three processes as follows [136]: 
30 
 
1) Glycation- the non-oxidative, covalent, addition of sugar to the protein; 
2) Auto-oxidative glycosylation- free radicals, arising from glucose auto-oxidation, 
interacting with proteins; and 
3) Auto-oxidation of protein-bound sugars produced as a consequence of glycation.  
The two auto-oxidative processes are known as glycoxidation and these processes lead 
to formation of AGE [115]. There is increasing evidence that AGE formation plays a 
major role in diabetes associated cardiovascular disease and particularly atherosclerosis.  
The accumulation of AGE is not just a hallmark of hyperglycaemia, as it also entails a 
combination of metabolic burden (both hyperglycaemia and hyperlipidaemia), oxidative 
stress and inflammation resulting in detrimental effects on vascular tissue [137]. 
Alteration of extracellular and intracellular proteins due to AGE formation may 
distort their role and function by a number of mechanisms including cross-linking of 
molecules (including these of the extracellular matrix, ECM) structural modifications or 
adduct formation which leads to a loss of enzyme activity and by binding to the 
receptors present on various cell types, such as endothelial cells, macrophages and 
vascular smooth muscle cells which are critical in atherogenesis [120].  
Accumulation of AGE has been demonstrated in both the microvascular and 
macrovascular complications of diabetes, and thus may contribute to progression of 
atherosclerosis [135]. AGE accumulate with increasing age of the vessel wall and have 
been noted to accelerate the development of DM, potentially engendering plaque 
formation by interfering with the function of endothelial cells which line the artery 
walls [125]. AGE formation can interrupt molecular communication and may modify 
enzymatic activity and may lead to damaging effects in accelerating atherosclerosis via 
both non-receptor mediated and receptor-mediated mechanisms [120].  
Cross-links may be formed between molecules in the basement membrane of the 
extracellular matrix and with the receptor for advanced glycation end products (RAGE) 
[135]. Activation of RAGE by AGE causes up-regulation of the pro-inflammatory 
transcription factor nuclear factor-κB and thus its target genes [135]. Soluble AGE 
activates monocytes, and AGE in the basement membrane may disrupt monocyte 
function and exacerbate the production of reactive oxygen species [132,138,139]. 
Because of the emerging evidence implicating AGE in damage to the vasculature of 
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patients with diabetes, a number of different therapies to inhibit AGE are under 
investigation [135,139].  
 
Figure 1.7: Reaction scheme for reactive carbonyl biogenesis. 
Adapted from reference [140]. 
 
 
1.7.5.1 Nature and mechanism of formation of AGE  
The rate of turnover of glycated or glycoxidised proteins, the extent of 
hyperglycaemia, the degree of oxidative stress and duration of exposure to these various 
stimuli, are all critical factors in the formation and accumulation of AGE 
[115,135,141,142].   
The initial step in AGE formation is the reduction of a carbonyl group on (or 
from a) sugar molecule with protein (or nucleic acid) amino groups, resulting in the 
formation of chemically-reversible, Schiff base adducts [135]. These Schiff bases can 
undergo a slow chemical reorganisation (Amadori rearrangement) into a chemically 
reversible, 1-amino-1-deoxy-2-ketose or ketamine (e.g. fructosyl-lysine or 
fructosamine). During the Amadori rearrangement, highly reactive species known as α-
carbonyls or oxoaldehyde products, such as 3-deoxyglycosone and methylglyoxal 
(MGO), are generated [143]. Similar reactive carbonyls can be generated as a result of 
lipid oxidation. The build up of these products is termed carbonyl stress. These α-
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dicarbonyls are also capable of reacting with amine, sulfhydryl, and guanidine, 
functional groups on proteins. Amino acid side chains that react with carbonyls include 
Lys, Arg, His, Trp and Cys with these reactions contributing to the functional 
impairment of proteins [144]. Collectively, these reactions lead to denaturation, 
browning and cross-linking of targeted proteins [141,145]. The reactions between α-
dicarbonyls with Lys and Arg functional groups on proteins, result in the production of 
stable fluorescent and non fluorescent AGE compounds such as N
ɛ
-(carboxymethyl) 
lysine (CML), pentosidine, hydroimidazolones, N
ɛ
-(carboxymethyl) lysine, a 
homologue of CML; and methylglyoxal lysine dimer (MOLD) [135,145,146]. AGE 
formation is poorly or non-irreversible due to the highly stable AGE-based crosslinks 
which are resistant to enzymatic degradation [135,141]. Crosslinking and denaturation 
of proteins triggered by glycation are common features implicated in aging linked with 
diabetic, vascular, renal, respiratory, rheumatoid and other chronic disorders 
[143,147,148]. 
 
Figure 1.8: Schematic representation of the complex Maillard reaction and 
formation of some advanced glycation end products.  
CEL = carboxyethyllysine; MOLD = methylgloxal lysine dimer; DOLD = 3-
deoxyglucosone lysine dimer; CML = carboxymethyllysine; GOLD = glyoxal lysine 
dimer. Adapted from reference [137]. 
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1.7.5.2 LDL glycation / glycoxidation 
Glycation of apolipoprotein component of LDL occurs via Lys, Arg and other 
residues [149]. The initial reactions result in the formation of  Schiff’s bases, that may 
react further to give a more stable fructosamine that is characteristic of early-stage 
glycated proteins [150]. Chemical modification of Lys residues of apolipoprotein B-100 
by the related process of acetylation is known to cause poor recognition by lipoprotein 
receptors including the native LDL receptor (LDL-R). In contrast these modified 
species are readily recognised by macrophage scavenger receptors resulting in rapid 
internalisation of glycated / glycoxidised LDL may further initiate various other 
processes that are involved in atherogenesis. Glycation of LDL may favour oxidative 
modifications as glycated LDL can augment inflammatory cell chemotaxis and 
formation of superoxide radicals by macrophages [150]. In endothelial cells, glycated 
LDL inhibits shear stress-mediated L-arginine uptake and NO˙ production, and 
stimulates secretion of plasminogen-activator inhibitor-1 and prostaglandins, whilst 
preventing the expression of tissue plasminogen activator [149,150].  
There is increasing evidence that AGE play a pivotal role in atherosclerosis and 
increased AGE accumulation is closely associated with the development of 
cardiovascular complications of diabetes [137]. AGE-forming reactions can cause 
modifications to the structure of LDL that are recognised by the scavenger receptors of 
macrophages. These processes can contribute to a build up of cholesterol and 
cholesteryl esters within macrophages and foam cell formation [151]. The LDL 
modifications required for cellular recognition and unregulated uptake are not 
completely understood and carbonyl stress may play a significant role in facilitating the 
formation of foam cells and vascular complications of diabetes.  
 
1.7.5.3 Inhibition of glycation and glycoxidation reactions  
A number of inhibitors of AGE formation have been identified and more are 
being developed, which act through preventing glycation / glycoxidation reactions, 
scavenging the reactive 1,2-dicarbonyls or reversing AGE modifications [135]. Some of 
these are in advanced clinical trials [152,153,154]. These potential AGE inhibiting 
drugs include: aminoguanidine, metformin, carnosine, homocarnosine, pyridoxamine, 
N-[2-(hydrazinoiminomethyl)amino)ethyl] acetamide monohydrochloride (ALT-946), 
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4-oxo-N-phenyl-4,5-dihydro-2-[(1-methylethylidene)hydrazino]-5-thiazoleactamide 
(OBP-9195), alagebrium chloride, and N-phenacylthiazolium bromide [155]. Anti-
inflammatory drugs such as tenilsetam and aspirin also exhibit AGE-inhibiting 
properties [154,156]. Antioxidants may also operate as AGE inhibitors, via metal-ion 
chelation and direct scavenging of free radical species. 
Inhibition of glycation and glycoxidation reactions can occur via multiple 
different modes of action such as: blocking free amino groups on proteins; blocking 
carbonyl groups on reducing sugars, Amadori products and dicarbonyl intermediates 
such as methylglyoxal; blocking Amadori products by antibodies with high specificity; 
chelation of transition metals to prevent glycoxidation; scavenging of free radicals 
derived from autoxidative glycoxidation; deglycation of Amadori products; reversing 
AGE accumulation by AGE-cross-link breakers; and inhibiting AGE interaction with 
RAGE by RAGE blockers [157,158].  In order to carry out such actions, these 
compounds would require long plasma or tissue half-lives, and minimal side effects, to 
be of therapeutic use as they would need to be prescribed for long periods due to the 
slow and chronic progression of the targeted reactions [157]. Inhibition of AGE may be 
therapeutic significance in numerous diseases and attempts to block the deleterious 
effects of AGE are still in an experimental phase. Some of the current drugs have 
harmful side effects as well as beneficial actions [158,159,160,161]; these actions are 
discussed in greater detail below. 
 
1.7.5.3.1 Aminoguanidine  
Aminoguanidine (Pimagedine) has been investigated as a potential therapeutic 
therapy for the  treatment of microvascular complications of diabetes and also as an 
effective scavenger of methylglyoxal [157].  It removes toxic 1,2 dicarbonyl compounds 
via conversion to their respective 1,2,4-triazines, which are less toxic compounds. 
Aminoguanidine has other potential effects in suppressing oxidative stress, via 
peroxynitrite scavenging and transition metal ion chelation [156]. Several clinical trials 
have demonstrated the capacity of aminoguanidine to reduce AGE accumulation and the 
development of the complications of diabetes [158,162]. However the drug has a 
relatively short half life of four hours which restricts its effectiveness and requires 
administration in multiple doses over a day. Severe toxicity and adverse reactions were 
reported in Phase III clinical trials in diabetic recipients, and this material is therefore 
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unlikely to undergo further trials [163]. A small percentage of the patients developed flu 
like symptoms, headaches and nausea in human trials.  However after a longer duration, 
macrocytic anaemic was observed in a significant proportion of the patients and 
antinuclear cytoplasmic antibodies were developed with high doses of aminoguanidine 
[158].   
 
1.7.5.3.2 Carnosine   
Carnosine (β-alanyl-L- histidine) is a naturally occurring dipeptide that contains 
the β-isomer of alanine (3-aminopropanoic acid) and histidine (2-amino-3-(1H-
imidazol-4-yl)propanoic acid). A number of in vitro studies have suggested that 
carnosine has anti-oxidant, anti-ageing, buffering and immune regulation properties 
[164]. It is synthesised endogenously and is present in high concentrations in skeletal 
muscle at approximately 5 - 8 mM [165]. Carnosine and associated dipeptides are 
highly expressed in skeletal muscle, and are detectable in cardiac muscle and brain 
(particularly in the olfactory lobe). However, it has not been found in the lung, spleen, 
kidney, adrenal, prostate and thyroid glands, colon or pancreas [166]. In humans  
intestinal hydrolysis is readily saturated so that a significant proportion of the intact 
dipeptide is absorbed [167]. Plasma levels of the intact dipeptide are however low or 
undetectable due to its rapid degradation by the plasma enzyme carnosinase [166]. 
Carnosine has been proposed to have a number of actions. It is an effective 
physiological buffer, neuroprotective and neuromodulatory agent, regulates Ca
2+
 
sensitivity, has antioxidant activity, and may prevent and or reverse Malliard reaction-
type modifications to cell and tissue proteins [168,169,170]. Carnosine has been also 
detected in the eye lens [171] and potential carnosine-supplementing strategies, via 
lubricant eye drops containing N-acetylcarnosine (NAC), have been reported to 
alleviate vision impairment due to Type 1 and 2 diabetes [172,173,174]. NAC eye drops 
are currently available commercially [175], however the evidence as to whether 
carnosine delays or attenuates cataractogenesis is preliminary.  
 
1.8 Removal of glycation and glycoxidation products 
The maintenance of cellular homeostasis requires cellular organelles to be 
synthesised and assembled when required, but it is especially critical for these cellular 
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components to be degraded when they are in excess or damaged. Autophagy is a 
lysosomal process involved in sustaining cellular homeostasis and it is responsible for 
the turnover of long lived proteins and organelles that are functionally redundant or 
damaged. Consequently if the degradation process does not occur efficiently, cellular 
metabolism may be perturbed and cells may die or transform into a cancerous cell in 
which growth progresses uncontrollably. Chaperone-mediated autophagy is another 
lysosomal protein degradation system which is responsible for eliminating cytosolic 
proteins holding a lysosomal targeting code. This involves detection by a specific 
chaperone in the cytosol that transports the cytosolic proteins to the lysosomes to be 
engulfed and degraded [176]. Research on macro autophagy is beginning to highlight 
the significance of this process in cellular homeostasis in many diseases such as cancer; 
infectious, neurodegenerative, metabolic and cardiovascular diseases [176].   
 
1.8.1 Proteasomes 
The ubiquitin-proteasome pathway is involved in the degradation of short-lived 
proteins. Proteasomes are very large protein complexes which can be observed in the 
nucleus and the cytoplasm of eukaryotes [177]. The major role of the proteosome is to 
degrade unrequired or damaged proteins by proteolysis, with a particular role in 
degrading short-lived proteins. Proteasomal degradation is the main mechanism by 
which cells regulate the concentration of specific proteins and degrade misfolded 
proteins.  Proteins targeted for degradation are tagged with ubiquitin, a small protein. A 
polyubiquitin chain is formed as the initial bound ubiquitin recruits other ligases to 
append additional ubiquitin molecules [178]. Proteasomes generate peptides of 
approximately seven to eight amino acids in length, which are further degraded by other 
peptidases into single amino acids that are utilised in producing new proteins.  
The structure of the proteasome is a large complex tube consisting of four 
stacked rings around a central axis, with each ring comprised of seven separate proteins. 
The inner two rings are composed of seven β subunits which contain six protease active 
sites, directed towards the central axis [178].  The outer top and bottom two rings 
consist of seven α subunits which control the gate by which proteins enter the tube. The 
regulatory components on the α subunits identify the polyubiquitin tags connected to the 
protein substrates and initiate the degradation progress [178]. The ubiquitination and 
proteolytic degradation is known as the ubiquitin-proteasome system (UPS) which is 
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responsible for the regulation of many essential cellular processes, such as the cell 
cycle, regulation of gene expression and responses to oxidative stress [178]. 
 
 
Figure 1.9: The structure of proteasomes and the protein degradation pathway.  
In the ubiquitin-proteasome pathway, energy from ATP is used to tag an unwanted 
protein with a chain of ubiquitins marking it for destruction. The protein is then 
hydrolyzed into small peptide fragments by the proteasome. Adapted from reference 
[179]. 
 
 
1.8.2 Lysosomes 
Lysosomes are single membrane-bound organelles synthesised by the Golgi 
apparatus that contain, amongst other agents, a large range of hydrolases that degrade 
endocytosed materials and cellular debris. The approximate size of the lysosome is 
between 0.1 and 1.2 μm. The name lysosome is derived from the Greek word ‘lysis’ 
means to separate and ‘soma’ defining to the body, indicating this organelles’ 
proficiency in degrading a number of biological macromolecules and particles.  
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The core role of the lysosome is in autophagy as they digest excess or exhausted 
organelles, food particles, engulfed viruses and bacteria. This occurs as lysosomes fuse 
with particle-containing vacuoles and discharge their contents into the vacuoles. The 
digestive enzymes of the lysosomes are optimal at a pH of ~4.5 which is considerably 
more acidic than the cytosol (pH 7.2). This shift in pH is brought about by the activation 
of proton pumps that acidify the enclosed compartment leading to the generation of 
secondary lysosome that degrade the particles. The membrane of the lysosomes protects 
the cytosol from leakage of hydrolases, peptidases (such as the cathepsin family) and 
other degradative enzymes as these enzymes are pH sensitive and do not function 
properly in neutral to alkaline environment. 
Cathepsins are lysosomal peptidases categorised in four main classes; aspartic, 
metalloprotease, serine, and cysteine proteases [180]. Cathepsin D and E are aspartyl 
proteases, cathepsin III is a metalloprotease, cathepsins A and G are serine proteases, 
and cathepsin B, C, F, H, I, J, K, L, M, O, P, Q, R, S, T, U, V, W, X, Y and Z are 
cysteine proteases [181,182,183,184]. Cathepsin B, L and the aspartyl protease cathepin 
D are the most abundant lysosomal proteases with lysosomal concentrations as high as 1 
mM [140].  
The main mechanism of action of these proteases involves nucleophilic reaction 
at the carbonyl-carbon of the amide bond. In the serine and cysteine proteases HO- and 
HS- side chains, respectively behave as nucleophiles. While in aspartic and metallo-
proteases, aspartate residues or metal ions, bind and polarise a water molecule in which 
the oxygen atom functions as the nucleophile [140,182,185]. 
 
1.8.2.1 Lysosomal cysteine proteases 
Cysteine-dependent cathepsins have been reported to play a major role in the 
development and progression of cardiovascular disease. They are implicated as having 
major roles in ECM remodelling and lipid metabolism [180,181]. Cathepsins have the 
capability to degrade LDL and decrease cholesterol efflux from macrophages, 
exacerbating foam cell formation. In vitro studies have shown that cathepsins V, K, S, 
K, L and B possess high elastolytic activity [180,186,187]. Human macrophages secrete 
cathepsins B, L and S which are found to be localised in macrophage-, smooth muscle 
cell- and lipid-rich areas in advanced stages of atherosclerosis [180,188]. Cathepsin L 
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and S were also highly expressed in both human and murine atheroma 
[187,188,189,190]. Cathepsin B protein levels were increased in atherosclerotic lesions 
of apo E
-/-
  mice [190], and in vivo cathepsin-knockout studies has shown that 
deficiency of cathepsin K or S reduces atherosclerosis [180,187,191,192,193]. A 
suppression of cathepsin S was shown to arrest and stabilise atherosclerotic plaque in 
apo E
-/-
 and LDL-R
-/-
 mice that were fed a high fat diet [192,193,194]. Cathepsin K has 
been shown to be heavily involved in the turnover of ECM proteins in organs, and this 
enzyme has been reported to play a significant role in cardiovascular disease, 
inflammation and obesity [195]. Although the data is still preliminary, cathepsins B, L 
and S may serve as important biomarkers or imaging tools in the diagnosis of 
atherosclerosis [180,182].  
 
 
Figure 1.10: Overview of cathepsin expression and activity in atherosclerotic 
plaque.  
Cathepsins are observed in endothelial cells (EC), smooth muscle cells (SMC) and 
macrophages (M). The ECM consisting of elastin and collagen, is degraded by 
cathepsin L, K, S and V. Cathepsin S may engender plaque rupture. Cathepsin F and S 
may influence macrophage foam cell formation by decreasing cholesterol efflux which 
is counteracted by cathepsin K due to elevation of lipid uptake. Adapted from reference 
[180]. 
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1.8.2.2 Lysosomal aspartic proteases  
The lysosomal aspartic protease Cathepsin D is the major endopeptidase of the 
lysosomal compartment [184,196]. Cathepsin D has been postulated to play a role in 
many diseases such as cancer, Alzheimer’s disease, and atherosclerosis [197]. A number 
of studies have found that cathepsin D levels represent an independent prognostic factor 
in many forms of cancers, and this enzyme is a potential target of anti-cancer therapy 
[197,198].  It has been shown that expression of cathepsin D is decreased in 
macrophages of low HDL cholesterol subjects, and thus it may be associated with 
intracellular metabolism and transport of phospholipids and cholesterol [199]. 
Cathepsin D may also be significant in LDL degradation. Smooth muscle cells and 
macrophages generate cathepsins that are able to degrade native but not modified LDL 
resulting in an accumulation of modified LDL in the vessel wall, engendering foam cell 
formation and accelerated atherosclerosis [200]. 
Macrophage lysosomal dysfunction may result from the inactivation of 
lysosomal cysteine and aspartic proteases with this resulting in impaired degradation of 
modified proteins and LDL. Hyperglycaemia may also inhibit lipases, rendering these 
unable to degrade cholesterol esters from the lipoproteins causing accumulation of LDL 
derived material within the lysosomes. This could lead to cellular cholesterol 
accumulation generating macrophage foam cells and thus contributing to plaque 
development due to hyperglycaemia.  
 
1.9 Animal models of macrovascular complications of diabetes and obesity   
While T1DM accounts for only around 5% of all DM cases, many of the animal 
models of diabetes associated atherosclerosis resemble this condition. These animals are 
produced either by treatment with drugs such as streptozotocin (STZ) or a genetic 
modification to induce T1DM [201]. T2DM is the main form of DM as it accounts for 
approximately 95% of DM cases. Most of these T2DM mice have been generated by 
either a genetic approach or via the use of high fat / sucrose diets [201].  
Hyperglycaemia and hyperinsulinaemia are two hallmarks arising from insulin 
resistance commonly seen in T2DM animal models. Another important manifestation of 
insulin resistance is dyslipidaemia, marked by an elevation of VLDL, triglyceride levels 
and a reduction of HDL cholesterol levels, collectively known as the metabolic 
41 
 
syndrome. T1DM have very similar hyperglycaemic complications to T2DM. Therefore 
a suitable mouse model that closely resembles both types of diabetes in humans and 
atherosclerosis are required to study mechanistic links and allow the development of 
strategies to prevent and effectively treat hyperglycaemic complications.  
 
1.9.1 The apolipoprotein E knockout mice   
Apolipoprotein E (apo E) is one of several lipoprotein transfer proteins. The 
main role of this protein is the mediation of receptor-mediated lipoprotein elimination 
from the blood. Human apo E consist of 317 amino acids, with an 18-amino acid signal 
peptide arrangement that when cleaved produces the 299-amino acid mature apo E 
detected in plasma [202].  Apo E is a glycoprotein with a molecular size of around 34 
kD that is synthesised in the liver, brain and other tissues in both humans and mice.  It 
serves as the principal ligand for the LDL receptor mediated removal of lipoprotein 
remnants from the circulation [203]. Apo E was the first lipoprotein transport gene to be 
deleted via gene targeting in mice. The apo E
-/-
 mouse is amongst the most intensely-
expressed phenotypes seen in lipoprotein transport transgenic and gene knockout mice, 
providing 100% viability of animals lacking apo E [202]. 
Many studies have used apo E
-/-
 mice to study the pathogenesis and anti-
atherogenesis potential of pharmacological interventions. The lesions seen in these mice 
when fed a high fat Western style diet mimic morphologically the atherosclerotic 
lesions observed in humans [204,205,206]. Other mouse models of atherosclerosis fail 
to show the progression of atherogenic stages seen in humans. Significant 
hypercholesterolaemia develops in apo E
-/-
  mice when fed a low fat chow diet [203]. 
This finding implies that apo E
-/-
 results in increased sensitivity to dietary fat and 
cholesterol. Atherosclerosis in the murine aorta was reported to almost have a linear 
relationship with growth of plaque area and time [207]. Hence the apo E
-/-
 mouse offers 
many desirable attributes for studying genetic diseases and currently is one of the most 
appropriate models for atherogenesis. 
Many studies have shown that the apo E
-/-
  mice treated with STZ have aortic 
lesions that are increased in area by greater than fivefold due to the presence of diabetes, 
which increases serum glucose and cholesterol by up to three fold 
[205,208,209,210,211]. Similarly, STZ treatment of apo E
-/-
 mice has been shown to 
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increase the occurrence of premature calcified cartilaginous areas [212].  The use of 
STZ treatment in apo E
-/-
 mice has also been reported to accelerate atherosclerosis and 
macrophage-derived foam cell formation via a glucose-dependent mechanism [213]. 
The STZ-induced atherosclerotic apo E
-/-
 mouse model displays three common 
features which serve as a useful model in diabetes-associated atherosclerosis.  These 
include the maintenance of hyperglycaemic condition, the presence of accelerated 
atherosclerosis with increased atherosclerotic regions, and dyslipidaemia with elevated 
levels of lipoproteins LDL, VLDL, and triglycerides irrespective of feeding chow or a 
high fat diet. 
 
1.9.2 Animal models of obesity and related metabolic disorders 
T2D and insulin resistance are one of the most predominant forms of metabolic 
disease, and many animal models have been used to examine the pathogenesis of insulin 
resistance and diabetes-associated metabolic complications.  
Models of obesity with T2D are mainly divided into two groups; a mutation in 
the leptin or leptin receptor gene and polygenic models. Rodents with a mutation, in or 
deficiency of, the leptin receptor such as the Zucker rats, ob/ob mice, and db/db mice 
are widely used for T2D research [214]. Db/db mice are the most widely used mice for 
T2DM research. These mice have a leptin receptor mutation (Lepr (+/+ C57BL/KsJ) 
that develop T2D, along with increased systolic blood pressure, obesity and 
hyperlipidaemia, which are also manifested in humans. The db/db mice tend to over 
consume and do not develop T2D until approximately weeks 9 - 10 and develop more 
advanced T2D by week 14 with severe hyperglycaemia, requiring insulin injections for 
survival [215]. By week 20, these mice develop advanced renal dysfunction with 
declining glomerular filtration rate (GFR) and proteinuria.  
The leptin-deficient (ob/ob) or obese mouse develops even more severe renal 
structural damage and function [216]. However, the db/db mice do not develop 
atherosclerotic lesions regardless of the manifestations of obesity, hyperlipidaemia, 
hyperglycaemia, advanced kidney disease and cardiomyopathy [210]. These mice are 
relatively resistant to the development of atherosclerosis unless they are cross-bred with 
a vulnerable genetic background, such as the apolipoprotein E-deficient (apo E
-/-
) and 
LDL receptor (LDL-R) deficient mouse strains [209,210]. Hence, the db/db and ob/ob 
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leptin deficient mouse models may be more appropriate models for diabetic 
nephropathy disorders and obesity resulting from T2D.  
Obesity models due to leptin signalling abnormalities display microvascular 
complications that are commonly observed in humans, such as diabetic retinopathy and 
nephropathy [215,216].  However the major problem with leptin insufficiency or 
dysfunction, is that this corresponds to only a minority of the obese / diabetic 
population. This model does not therefore provide the same conditions or circumstances 
that occur in the majority of T2D [217,218] and obesity cases, and is therefore unable to 
adequately model obesity-related metabolic disorders.  
Polygenic models of obesity with diabetes present a much clearer perspective to 
the human condition [219]. Particular inbred strains of mice when fed a high fat diet 
(HFD) show significant obesity, while others experience gene-diet interactions and stay 
lean [220]. Some strains develop obesity with severe insulin resistance and glucose 
intolerance, whilst some are obese and resistant to the onset of diabetes. In contrast, 
some are very susceptible to T2D but do not become morbidly obese [221,222,223]. 
Polygenic models in rodents fed on a HFD or crossed with other obesity strains, allow 
access to various diabetic phenotypes, similarly to those detected in humans 
[219,221,222,223].  
The use of a HFD is the most common approach in inducing obesity as it 
provides a non-leptin-deficient model, a better representation of the current worldwide 
obesity epidemic [219,224]. Amongst the range of C57 strains, C57/BL/6 mice are the 
most extensively used to study HFD-induced obesity [220,225,226,227]. This is due to 
metabolic manifestations which closely resemble the human metabolic syndrome 
caused by a high HFD consumption [220,221,225]. Sprague Dawley rats are also widely 
used as a rodent model of HFD-induced obesity, which also mimics the metabolic 
disorders observed in humans [221].  
 
1.10 Summary and concluding remarks   
Cardiovascular-related metabolic disorders are a substantial economic and 
personal burden in the developing world. Atherosclerosis is the most prevalent type of 
cardiovascular disease, with a risk of plaque rupture and life-threatening cardiovascular 
events. Obesity and diabetes exacerbate this risk with perturbations in glucose and lipid 
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metabolism causing deleterious manifestations in cell and vascular function. The role of 
hyperglycaemia and hyperlipidaemia in diabetic- and obesity-exacerbated 
cardiovascular diseases are not yet completely elucidated.  Most of the anti-diabetic, 
anti-lipidaemic and anti-obesity drugs have severe side effects, particularly when these 
medications are prescribed concurrently over long periods in patients who suffer from a 
cluster of metabolic disorders. These medications may be effective initially but may 
cause other effects or lose responsiveness with long term use. Therefore a better 
understanding and knowledge of the processes which may be occurring in cell culture 
and animal models are required in order to improve clinical interventions, treatment 
outcomes and develop suitable pharmaceutical compounds.  
 
1.11 Thesis aims and outline    
The research undertaken in this project attempts to investigate some of the 
molecular mechanisms linking diabetes with atherosclerosis, as well examining 
potential anti-glycative and antioxidant compounds, which may improve cardiovascular 
related diseases induced by hyperglycaemia and hyperlipidaemia.  
Therefore the aims of this project are: 
1) To investigate the impact of high glucose concentrations on macrophage 
lysosomal function and populations, in a murine macrophage-like cell line 
(J774A.1) and human monocyte-derived macrophages (HMDM).   
2) To examine the potential impairment of lysosomal enzymatic activity and 
protein levels induced by high glucose during the maturation of human 
monocytes to HMDM. 
3) To assess the possible anti-atherogenic properties of carnosine in a murine type 
1 model of diabetes-accelerated atherosclerosis using streptozotocin-treated apo 
E
-/-
 mice. 
4) To examine the potential anti-atherogenic, anti-lipidaemic and anti-
inflammatory properties of the stable nitroxide radical TEMPOL in a murine 
model of obesity and hyperlipidaemia using high fat fed apo E
-/-
 and C57BL/6 
mice.  
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5) To assess the impact of TEMPOL upon macrophage lysosomal function under 
normal and high glucose concentrations, and assess the potential anti-
inflammatory and anti-glycaemic properties of TEMPOL on cytokine expression 
in hyperglycaemic macrophages.  
Chapter 2 describes the experimental materials and methods used in this project. 
In Chapter 3, the effect of high glucose concentrations upon lysosomes from cell lysates 
of J774A.1 murine macrophage-like cells and HMDM cell is examined. Chapter 4 
extends this work by monitoring the effects of high glucose upon lysosomes during the 
monocyte to macrophage development in the HMDM cells. The potential anti-
atherogenic properties of carnosine and TEMPOL were assessed in in vivo animal 
models in Chapters 5 and 6, respectively. In Chapter 7 the potential protective effects of 
TEMPOL were examined in hyperglycaemic HMDM cells with lysosomal dysfunction. 
Finally, a general discussion of the key findings and the prospective future directions 
for the studies reported in Chapters 3 - 7 is presented in Chapter 8. 
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CHAPTER 2: 
MATERIALS AND METHODS 
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This chapter describes the overall material and methods used throughout the 
studies. Each results chapter describes methods relevant to its individual content.  
 
2.1 Materials 
Fatty acid free bovine serum albumin (BSA), ethylendiaminetetraacetic acid 
(EDTA), sodium pyruvate, dimethyl sulfoxide (DMSO), polyoxyethylene 23 lauryl 
ether (Brig 35), benzamidine, pepstatin A, sodium acetate, triton X-100, E64, sodium 
dodecyl sulfate (SDS), β-mercaptoethanol, D-mannitol, Tween 20 were from Sigma-
Aldrich Pty. Ltd. (Castle Hill, NSW, Australia). Diploma Instant skim milk powder for 
blocking buffer was purchased from Coles (Parramatta, NSW, Australia). D-(+)-glucose 
and bromophenol blue sodium salts were obtained from ICN Biomedicals (Aurora, OH, 
USA).  Copper sulfate was purchased from ICN (Seven Hills, NSW, Australia).  
Sodium chloride, Tris hydrochloride, Tris base, sodium carbonate, glycerol, phosphate 
buffered saline (20x concentrate, pH 7.5) and glacial acetic acid were from Amresco 
(Solon, OH, USA).  NADH and complete Mini protease inhibitor tablets were 
purchased from Roche Pty. Ltd (Castle Hill, NSW, Australia).  Dithiothreitol (DTT) 
was purchased from Astral Scientific Pty. Ltd. (Gymea, NSW, Australia).  
The substrates used for lysosomal enzyme activities included: Z-Arg-Arg-AMC 
(for cathepsin B), Z-Phe-Arg-AMC (for cathepsin L) and Z-Val-Val-Arg-AMC (for 
cathepsin S) which were obtained from Bachem AG, Bubendorf, Switzerland; 7-
methoxycoumarin-4-Acetyl-Gly-Lys-Pro-Ile-Leu-Phe-Phe-Arg-Leu-Lys-DNP-D-Arg-
amide (for cathepsin D) was purchased from Sigma-Aldrich.  Substrates for cathepsins 
B, L and S were prepared at a concentration of 40 mM in DMSO; while cathepsin D 
was made up at 8 mM concentration, also in DMSO. These were all stored at -20 ºC. 
Agarose gels (1% (w/v) were purchased from Helena laboratories (Mt. Waverly, 
VIC, Australia). 
All solutions were prepared using nanopure water from a Milli Q system 
(Millipore-Waters, Lane Cove, NSW, Australia) and if necessary treated with washed 
Chelex-100 resin (Bio-Rad, Reagent Park, NSW, Australia). 
All other chemicals were of analytical grade and all solvents were HPLC grade.  
Methanol, and isopropanol are purchased from EM Science (Gibbstown, NJ, USA) and 
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hexane was from Sigma-Aldrich. Hydrochloric acid was Analar® grade and purchased 
from Merck Pty. Ltd. (Kilsyth, Vic, Australia). 
 
2.2 Tissue culture materials 
RPMI-1640 medium (with L-glutamine, without glucose and sodium 
bicarbonate), Dulbecco’s phosphate-buffered saline (PBS) pH 7.4 and Dulbecco's 
modified Eagle's medium (DMEM) were purchased from Sigma-Aldrich.  Two mM 
glutamine was obtained from Thermo Electron (Melbourne, VIC, Australia), 1% (v/v) 
PenStrep containing 100 units/mL penicillin and 0.1 mg/mL streptomycin from 
BioWhittaker (Radnor, PA, USA), and 10% (v/v) heat activated (30 min at 60 ºC) 
human serum (HS) from the Australian Red Cross (Clarence St Blood Bank, Sydney, 
NSW, Australia) or fetal calf serum (FCS) from JRH Biosciences (Lenexa, Kansas, 
USA) were added to all media where appropriate.  To prepare normal to high glucose 
conditions, D-glucose (molecular mass = 180.16 g/mol) was added to (glucose-free) 
media at 5.5, 10, 20 or 30 mM concentrations and then the medium was  filter-sterilised 
by the Bottle Top Vacuum Filter; 0.2 µm pore size, PES Membrane (Corning, NY, 
USA).   
 
2.2.1 Cell culture 
All cells were cultured in 12 well (22 mm diameter wells) or 6 well (35 mm 
diameter wells) tissue culture plates (Corning, NY, USA), or in Falcon (Becton 
Dickinson, Franklin Lakes, NJ, USA) 175 or 75 cm
2
 tissue culture flasks, in humidified 
incubators at 37 ºC and 5% (v/v) CO2. 
 
2.2.2 J774A.1 Mouse macrophage cells grown under normal to high glucose 
conditions 
J774A.1 mouse macrophages (ATCC # TIB-67 and purchased from ATCC™, 
Manassas, VA, USA) were grown in normal DMEM media (with 5.5 mM glucose 
content) and used as the control (or normal) glucose condition. Alternatively they were 
grown in DMEM (with 10% v/v FCS) supplemented with extra 4.5 mmol/L (thus final 
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glucose concentration was 10 mM), 14.5 mmol/L (20 mM glucose) and 24.5 mmol/L 
glucose (30 mM glucose) for high glucose conditions.  J774A.1 mouse macrophages 
were incubated in these conditions for 11 days and cells were split every 2 - 3 days.  
Cell morphology was checked under the microscope then cell pellets were prepared and 
treated as required. 
 
2.2.3 J774A.1 Mouse macrophage cells for investigation of lysosomal activity  
J774A.1 mouse macrophages were grown in 175 cm
2
 flasks and supplemented 
with glucose as previously described.  Cells were harvested by scraping using a 
disposable cell scraper (Greiner Bio-One; Frickenhausen, Germany) and the cell 
suspension was replated at 1:15 dilution every 2 - 3 days.  In order to prepare the cell 
extracts for lysosomal activity measurements, J774A.1 cells were scraped at confluency 
and replated into 75 cm
2
 Falcon flasks at 0.5 × 10
6
 cell/mL (1 mL/ well) and incubated 
overnight (16 hr). Cells were washed three times with PBS. Cells were scraped and 
transferred into a 15 mL Falcon tube. Cell pellets were obtained by centrifugation 
(Beckman Coulter™, Allegra® X-15R Centrifuge; Palo Alto, CA, USA) at 524 g for 5 
min at 4 ºC.  The supernatant was discarded and the undisturbed cell pellets were snap 
frozen in liquid nitrogen and stored at -80 ºC for subsequent determination of lysosomal 
acid lipase (LAL), lysosomal cathepsin B, L, S and D activities.  
 
2.2.4 Human monocyte-derived macrophages (HMDM) 
Monocytes were isolated by Mr Pat Pisansarakit from white cell concentrates 
(provided by the Australian Red Cross), within 24 hrs of collection. The elutriation 
system consisted of a Beckman Avanti J20-XPI centrifuge equipped with a JE-5.0 
elutriation rotor and a 4.2 mL elutriation chamber with a Masterflex (Barrington, IL, 
USA) peristaltic pump.  The elutriation media was pyrogen-free HBSS (Sigma-Aldrich) 
with phenol red and 0.01% (v/v) EDTA but without Ca
2+
 and Mg
2+
.  First of all the 
system was rinsed with about 250 mL 70% (v/v) ethanol followed by water, 30% (w/w) 
H2O2, water and finally HBSS.  The white cell concentrates were diluted 1:2 in HBSS.  
Next 30 mL aliquots of diluted white cell concentrate was underlaid with 15 mL 
Lymphoprep (Fresenius Kabi Norway) and centrifuged at 1900 rpm (2060 g), with the 
brake off, at 21 °C for 40 min.  Thereafter, peripheral blood mononuclear cells were 
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isolated from the Lymphoprep interface, washed once with HBSS and resuspended in 
30 mL HBSS.  The mononuclear cell suspension was loaded at a rotor speed of 2020 
rpm with an initial flow rate of 9 mL/min at room temperature.  The flow rate was 
increased by 1 mL/min every 10 min and the cell fractions from 15, 16, 17, 18 and then 
a final flow rate of 40 mL/min were collected.  The purity of each fraction was routinely 
determined on smears of the cell suspension prepared using the Cytospin
®
 system 
(Shandon; Astmoor, Runcorn, England).  Cells were stained using Diff Quick staining 
kits (LabAids Pty. Ltd.; Narrabeen, NSW) according to the manufacturer’s instruction.  
Fractions that were largely pure monocytes were pooled.  A viable cell count was 
subsequently performed using Trypan blue 0.4% (w/v) (Sigma-Aldrich).  Cells were 
diluted to 1×10
6
 cells/mL in X-VIVO 10 media (without phenol red or gentamicin; 
Lonza Australia Pty. Ltd., Mount Waverley VIC, Australia) with no serum and 1 mL 
was added to each well of 12 well, or 2 mL per well was added to 6 well tissue culture 
plates.  After 1 - 2 hr incubation, the media was replaced with 1 or 2 mL RPMI at the 
required glucose concentration with 10% v/v HS as previously mentioned.  The media 
was changed 3 days after the elutriation and then every second day afterwards.  The 
health of cells was always checked under the microscope after each media change. 
 
2.2.5 Preparation of human monocyte-derived macrophages (HMDM) matured 
in normal to high glucose conditions for determination of lysosomal enzyme 
activities 
Monocytes were prepared as previously noted and incubated for 10 - 11 days in 
RPMI containing normal (5.5 mM) to high (10, 20 and 30 mM) glucose concentrations.  
This time period results in differentiation into human monocyte-derived macrophages 
(HMDM) [228]. The health of cells was checked under the microscope before cell 
harvesting.  
Cells were washed three times with PBS. Cells were scraped using the cell 
scraper and transferred into a 15 mL Falcon tube. Cell pellets were obtained by 
centrifugation (Beckman Coulter™, Allegra® X-15R Centrifuge) at 931 g for 15 min at 
4 ºC.  The supernatant was discarded and the undisturbed cell pellets were snap frozen 
in liquid nitrogen and stored at -80 ºC for the determination of LAL, lysosomal 
cathepsin B, L, S and D activities.  
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2.3 Lysosomal enzyme activity 
2.3.1 Lysosome isolation 
Cell pellets (J774A.1 cells or HMDM incubated in normal to high glucose 
concentrations as previously noted) were resuspended and lysed in 250 µL of nanopure 
water.  The lysate was centrifuged 13.4 x 1000 g for 5 min at 4 °C to remove unlysed 
cells and membrane fractions that may interfere with the assay [229]. The supernatant 
was transferred to fresh Eppendorf tubes, placed on ice and used immediately for 
quantification of LAL, cathepsin B, L, S and D activities followed a protein assay.   
 
2.3.2 Determination of cathepsin B and L activity 
Cathepsin B activity was measured by continuously monitoring the release of 
AMC from the peptide substrate Z-Arg-Arg-AMC. Cathepsin L activity was measured 
by the initial linear increase in fluorescence following the cleavage of AMC from the 
peptide substrates Z-Phe-Arg-AMC (10 μM). Prior to running the assay, the stock 
solution was diluted 1000-fold with nanopure water.   
20 μL of the lysate was combined with 180 μL of 0.1 M phosphate buffer (NaH2PO4 / 
Na2HPO4: pH 5.5) containing 0.005 % (w/v) Brij 35, 2.5 mM EDTA, 2.5 mM DTT, 1 
μM pepstatin and 5 mM benzamidine and the cathepsin substrate (10 μM).  
The plate was shaken for 30 s prior to analysis to ensure a homogenous mix of the 
components. Assays were performed in triplicate on 96-well plates at 21 °C with 
fluorescence changes measured using  λexcitation 360 nm and λemission 460 nm.  
The change in fluorescence was monitored over 10 cycles, with changes in cathepsin B 
activity monitored every 2 min for 20 min and cathepsin L monitored every minute for 
10 min. Fluorescence changes were monitored on either a Cytofluor II fluorescence 
plate reader or a M2e spectroflurometer. 
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2.3.3 Determination of cathepsin S activity 
To measure cathepsin S activity, a similar procedure to that used for cathepsins 
B and L was employed except that Z-Val-Val-Arg-AMC was used as the substrate.  
Before running the assay, the substrate was diluted 50-fold in nanopure water  
Cell lysate (50 μL) was added to wells containing 100 μL of 0.2 M phosphate 
buffer (NaH2PO4 / Na2HPO4: pH 5.5) containing 5 mM EDTA, 5 mM DDT, 1 μM 
pepstatin A, 5 mM benzamidine and incubated for 1 hr at 40 ºC in an incubator to 
inactivate other cathepsins.  The plate was then placed on the plate shaker for 5 min at 
21 °C. Fluorescence changes were measured immediately after addition of 50 μL of 
substrate (0.2 mM) using a M2e spectrometer, with measurements made every 5 min for 
50 min  with λexcitation 360 nm and λemission 460 nm at 21 °C [229]. 
 
2.3.4 Determination of cathepsin D activity 
To measure cathepsin D activity, cell lysate (25 μL) was added to wells 
containing 100 μL of 0.1 M acetate buffer (CH3CO2Na / CH3COOH, pH 4.2) containing 
2.5 mM EDTA, 0.005% (w/v) Brij 35, 5 mM benzamidine and 10 μM E64 (irreversible 
inhibitor of cysteine proteases) in a 96 well plate.  After 5 min activation at room 
temperature of 21 °C, 50 μL of 7-methoxycoumarin-4-acetyl-Gly-Lys-Pro-IIe-Leu-Phe-
Phe-Arg-Leu-Lys-DNP-D-Arg-amide (stock solution 8 mM in DMS0 stored at -20 ºC) 
at 2 μM was added.  Changes in fluorescence were monitored using a M2e Plate Reader 
spectrometer with λexcitation 328 nm and λemission 393 nm with measurements made every 
30 s for 6 min. 
 
2.3.5 Analysis of lysosomal cathepsin activity data 
Activity of cathepsins was quantified by the initial linear change in fluorescence 
over time.  Nanopure water was used for dilutions, and as negative control (no cell 
lysate fraction) as this did not result in any change in fluorescence over time. The 
protein concentrations were determined with other aliquots of the same samples using 
the Bio-Rad protein assay as described in Section 2.4.1, thereby allowing the lysosomal 
activity to be expressed relative to the protein concentration. 
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2.3.6 Determination of lysosomal acid lipase (LAL) activity 
LAL activity was quantified using a procedure based on a previously method 
published [230]. 4-Methylumbelliferone (4-MU) and 4-methylumbelliferyl oleate (4-
MUO) were purchased from Sigma-Aldrich. A stock concentration was constituted by 
dissolving 4-MU (5.676 μM) in hexane and this was further diluted in 4% (w/v) Triton 
X in order to generate a standard curve from 0 - 2.8 μM of 4-MU. 4-MUO (2.3 μM) was 
similarly dissolved in hexane and further diluted in 4% (w/v) Triton X (1:100). 
 In order to determine LAL activity in the J774A.1 cells and HMDM, 25 μL of 
cell lysate was added to each well followed by 50 μL of prepared 4-MUO in each well. 
One hundred and twenty five microlitres of prepared assay buffer (0.2 M Na₂Ac, 0.01% 
v/v Tween 80, pH 5.5) was added to both the standard and cell lysate wells and 
incubated for 30 min at 37 °C, covered in foil to protect from light. The reaction was 
stopped with 100 μL of stop buffer (0.75 M Tris, pH 8.0). The fluorescence signal was 
detected using an M2e plate reader spectrometer with λexcitation 360 nm and λemission 460 
nm. Fluorescence readings were converted to 4-MU concentrations using the standard 
curve and expressed as µM of 4-MU formed per min. The 4-MU concentrations were 
corrected for the protein concentration present in each sample.  
 
2.3.7 Osmotic control 
D-Mannitol was used as a control to account for any osmotic effects when cells 
were exposed to higher glucose levels during the incubation period. J774A.1 cells and 
HMDM were cultured for 11 days in their media containing 5.5 mM glucose plus 24.5 
mM D-Mannitol. Lysosomal activity of cathepsins B, L and LAL activities were 
determined as described above.  
 
2.4 Protein and enzyme assays 
2.4.1 Protein determination 
To determine the protein concentration of the cell lysates, the Pierce (Thermo 
Fisher Scientific, North Ryde, NSW) Bicinchoninic Acid (BCA) Protein Assay was 
used.  One part of Reagent B (4% (w/v) CuSO4) was mixed with 49 parts Reagent A 
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(sodium carbonate, sodium bicarbonate, BCA and sodium tartrate in 0.1 N NaOH).  
This method quantifies the reduction of Cu
2+
 by protein to Cu
1+
 under alkaline 
conditions (Biuret reaction) with colorimetric detection of the Cu
1+
: BCA complex.  Ten 
µL of sample along with 190 µL BCA working reagent was added in each well of a 96 
well plate and incubated  at 60 ºC for 30 min. The plate was cooled for 5 min before the 
absorbance was read at 562 nm on a Tecan Sunrise plate reader (Grödig, Austria).  A 
standard curve obtained using 0 - 50 µg BSA prepared in the same buffer as the 
samples, was used to calculate the protein concentration, with this expressed as µg/µL. 
   
2.4.2 Cell viability 
Lactate dehydrogenase (LDH) is a cytosolic enzyme that is released into the 
culture medium when plasma membranes are compromised. LDH catalyses the 
reversible reduction of pyruvate, with NADH as the cofactor. 
NAD
+
 + lactate ↔ NADH + pyruvate 
In this assay, excess substrate is added to ensure that the enzyme is the limiting 
factor.  NADH loss, which is the proportional to the amount of enzyme present either 
intracellularly (cell lysate) or extracellularly (cell media), was quantified at 340 nm.  
Two hundred microlitres of working reagent (0.15 mg/mL NADH and 2.5 mM sodium 
pyruvate in PBS) was added to 10 µL samples of cell lysate or cell media (after 
spinning at 353 g for 5 min at 4 ºC to remove cellular debris) in each well of a 96-well 
plate.  The absorbance was read every 5 min for 7 cycles on a Tecan Sunrise plate 
reader.  The linear change of absorbance per min was used in the following equation to 
determine cell viability: 
Viability (%) = [Δ340 nm cell lysate / (Δ340 nm cell lysate + Δ340 nm cell media)] × 
100 
Cells were considered viable if the percentage was > 80% and there was no decrease in 
the total activity (Δ340 nm cell lysate + Δ340 nm cell media). 
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2.5 Western blotting to determine protein levels of lysosomal cathepsins B, L, 
LAL and lysosomal associated marker glycoprotein-1 (LAMP-1) 
2.5.1 Antibodies for Western blotting 
Mouse polyclonal to LAL, mouse polyclonal antibodies to cathepsin L, rabbit 
polyclonal to LAMP-1 and rabbit polyclonal to β-tubulin (loading control) were 
purchased from Abcam (Cambridge, UK) and goat anti-cathepsin B was purchased from 
Santa Cruz Biotechnology (Santa Cruz, CA, USA).  Secondary antibodies of donkey 
anti-goat IgG-HRP and goat anti-mouse IgG-HRP was purchased from Santa Cruz 
Biotechnology; donkey anti-rabbit IgG-HRP was purchased from GE Healthcare, Life 
Sciences, Amersham Biosciences UK Ltd. (Buckinghamshire, UK). 
 
2.5.2 Cell lysis buffer 
Cell lysis buffer was premade containing 150 mM NaCl, 50 mM Tris pH 8.0. On 
the day of the experiment, 0.1% (v/v) Triton-X 100 was added and one mini protease 
inhibitor cocktail tablet was dissolved into the 7 mL of cell lysis buffer.  
Gel loading dye stock 5x was constituted with nanopure water (42.5%), 0.5M 
Tris pH 6.8 (12.5%), glycerol (20%), 10% w/v SDS (20%) and 0.5% w/v Bromophenol 
Blue (5%). The premade loading buffer (8 mL) was aliquoted into Eppendorf tubes and 
stored at -20 °C. 
 
2.5.3 Sample preparation for loading gels 
J774A.1 cells or HMDM were washed with PBS and lysed with 1 mL of cell 
lysis buffer and placed on ice for 15min. The protein concentration of the cell lysates 
was determined using the BCA protein assay using the cell lysis buffer to dilute the 
standards. The pre-prepared 5x gel loading dye stock was reconstituted with 5% (v/v) β-
mercaptoethanol. Then 5 × complete sample buffer was added to each cell lysate sample 
to give 1 × final concentration, mixed well and centrifuged briefly to remove particulate 
matter.  Samples were then heated at 95 °C for 5 min, centrifuged briefly to remove 
precipitated material and placed on ice until loaded onto gels.  For investigation of 
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protein levels of different lysosomal markers, 15 - 30 μL of cell lysate containing 20 - 
40 μg protein was loaded into each well. 
 
2.5.4 Gel loading and running to separate proteins by electrophoresis 
Four to fifteen percent Tris-HCl gradient SDS-PAGE gels or 4 - 20% mini 
protean TGX precast gels were purchased from Biorad (Gladesville, NSW, Australia). 
Two to four gels were assembled into the gel cassettes with these then firmly clamped 
and placed into a Mini-Protean 3 electrophoresis cell (2 gels) or Mini-Protean Tetra 
System (4 gels) tank (Biorad). Approximately 1 L of 1 × running buffer prepared from 5 
× running buffer (3% w/v Tris base, 14.4% w/v glycine and 0.5% w/v SDS) was 
inserted into tank and the tank was checked for leaks before filling up the entire tank 
with running buffer. Five μL of Precision plus protein Kaleidoscope molecular mass 
standards (Bio-Rad) were included in the first or last lane in each gel.  The loaded gels 
were then run at 125 V for at least 1 hr until the loading bands reached the bottom of the 
gel.  The gels were then separated from the glass and spacer plates, briefly washed in 
water and then processed further by transferring to nitrocellulose membranes. 
 
2.5.5 Protein transfer to nitrocellulose membranes 
Protein transfer from the gels to nitrocellulose membranes was achieved using 
an iBlot™ Dry Blotting System (Invitrogen Australia Pty Ltd, Mount Waverley, VIC, 
Australia) with a blotting area of 14 × 8.5 cm suitable for two mini gels.  The excess 
water was removed from gels by gentle shaking of gels and carefully holding the edge.  
Then two mini gels were placed on the nitrocellulose of an iBlot NC anode stack.  
Excess water and air bubbles between gel and membrane were carefully removed with a 
wet roller.  A wet filter paper was placed on the gels and excess water and air bubbles 
were removed as before.  On top of this was laid the iBlot cathode stack.  The complete 
apparatus was pressed together by rolling a few times with a dry roller.  An iBlot 
disposable sponge was placed on the lid of the iBlot apparatus and the sandwich 
assembly was then firmly closed.  The transferring of proteins from gels to 
nitrocellulose membrane was accomplished in 7 min. The sponge, top cathode stack and 
the wet filter paper were carefully removed and discarded.  Any excess of nitrocellulose 
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membrane around the gels was trimmed and membrane was placed in Tris-buffered 
saline containing Tween 20 buffer (TBST) with tweezers until Western blotting.  
 
2.5.6 Western blotting 
Nitrocellulose membranes with transferred proteins were initially blocked for 
one hour, using 5% w/v skim milk powder in TBST. This was followed by overnight 
incubation with the primary antibody (LAMP-1, LAL, cathepsin B or L).  For J774A.1 
cells the antibodies were used at 1:500 dilution. For HMDM the dilutions for LAMP-1, 
LAL, cathepin B or L were 1:1000, 1:500, 1:250 or 1:500, respectively.  
On the following morning, the membranes were then washed with TBST (5 × 5 
min) followed by incubation with the appropriate secondary antibody at 1:2000 dilution 
in blocking buffer for 1 hr.  The membrane was then washed with TBST (4 × 5 min). 
Donkey anti-rabbit IgG-HRP was used for LAMP-1, goat anti-mouse IgG-HRP was 
used for LAL or cathepsin L, and donkey anti-goat IgG-HRP was used for cathepsin B. 
Freshly prepared ECL Western blotting detection reagent (0.125 mL/cm
2
) was added to 
the membrane and incubated for 1 min at 21 °C.  Surface tension holds the reagent on 
the membrane.  The excess of reagent was removed by gentle shaking of the membrane 
and holding it with tweezers touching the edge against a Kimwipe.  Then the membrane 
was wrapped in polyethylene wrap (Glad wrap™) with bubbles carefully removed.  The 
chemiluminescence was acquired using a Molecular Imager ChemiDoc XRS System 
(Bio-Rad laboratories, Segrate, Milan, Italy) and Quantity One software, with the 
focused recorded frozen when a satisfactory image was acquired.  The raw images were 
saved as TIFF files. A blank image was also taken using normal white light exposure. 
The acquired images of the scanned membrane were opened using Photoshop 
and the image adjusted (brightness and contrast) to visualise the bands. LAMP-1 (120 
kDa), LAL (45 kDa), procathepsin L (55 kDa), mature cathepsin L (25 kDa), 
procathepsin B (25 kDa) and mature cathepsin B (20 kDa) were identified by 
comparison with the manufacturer’s guidelines. 
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2.5.7 Stripping of membrane 
The membrane was stripped for 10 min using a Restore PLUS Western Blot 
Stripping buffer (Thermo Fisher Scientific), and subsequently washed with TBST (4 × 5 
min). The stripped membrane was then blocked with blocking buffer for 1 min then 
probed for β-tubulin (1:1000 in blocking buffer) for 3 hrs. The membrane was then 
washed with TBST (5 × 5 min), and probed with donkey anti-rabbit IgG-HRP (1:2000 
dilution in blocking buffer) for 1 hr. This was followed by washing with TBST (4 × 5 
min), addition of the ECL reagent and recording of the membrane image reading as 
described previously.  β-Tubulin was detected by mass at 51 kDa based on the 
manufacturer’s guidelines.  
 
2.5.8 Molecular band analysis 
The intensity of each band was quantified using Image J Software (NIH, USA). 
Briefly, a box was plotted around each band and the same box was copied and pasted 
for relevant bands on each raw scan of the membrane.  For each band the adjusted 
volume (intensity × mm
2
) was calculated.  This was the volume (sum of the intensities 
of the pixels inside the volume boundary × area of a single pixel) minus the local 
background volume. LAMP-1, LAL, cathepsin B and L levels were expressed relative 
to β-tubulin. 
 
2.6 In vivo animal studies 
Histology was conducted on three animal models reported in Chapters 5 and 6. 
 
2.6.1 Materials and solutions for histology 
Xylene, Harris’ Haematoxylin solution, Eosin Alcoholic 1%, Histolene (100%), 
and Scott’s Blueing Solution were purchased from Fronine Lab Supplies (Riverstone, 
N.S.W., Australia). DPX Mountant for cover-slipping was purchased from Sigma-
Aldrich. Formaldehyde was purchased from Analar
®
 Merk Pty. Ltd. (Kilsyth, Vic, 
Australia).   
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2.7 Preparation of tissue samples from diabetic mice 
Samples of aortae and brachiocephalic arteries were provided by Dr David van 
Reyk. The animals were supplied by the Biological Facility of the Heart Research 
Institute and were maintained and monitored in accordance with the guidelines of 
Sydney South West Area Health Service Animal Welfare Committee (Protocol number: 
2007/002B). Animal housing and care were carried out by Drs. van Reyk, Bronwyn 
Brown and the staff of the Biological Facility. 
Diabetes was induced in male apo E
-/-
 mice at six to seven weeks of age by 
intraperitoneal injection of streptozotocin dissolved in citrate buffer (pH 4.5) with daily 
injections of 55 mg/kg for 5 days. Control mice were injected with citrate buffer. These 
procedures were modified from a previously published method [231].  
 
2.7.1 Animal groups 
Mice (n = 80) were maintained for twenty weeks, post-induction of diabetes, 
with half of the animals receiving carnosine (2 g/L) in their drinking water. Food and 
water were available ad libitum. The groups comprised of control-non supplemented, 
control-carnosine (β-alanyl-L-histidine) supplemented, diabetic and diabetic-carnosine 
supplemented as shown in the figure below.   
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Figure 2.1: Animal model for the carnosine project. 
The animal study consisted of 80 apo E
-/-
 mice. The first two comprised of control mice 
groups (outlined in blue) with and without carnosine in the water. The third and fourth 
groups comprised of diabetic mice (outlined in orange) that were induced by 
streptozotocin with and without carnosine in the water.   
 
 
2.7.2 Sample collection 
The mice were sacrificed at approximately 20 weeks after the induction of 
diabetes by exsanguination via cardiac puncture following anaesthesia using 
methoxyflurane.  
The heart and entire arterial tree were collected for histological analysis based 
on a method previously published [232]. The arterial tree was flushed by perfusion 
through the left ventricle, at physiological pressure, with PBS, containing 2 mM EDTA 
and 20 µM butylated hydroxytoluene, for 4 min followed by fixation by perfusion with 
4 % (w/v) paraformaldehyde (pH 7.5) for 6 min. The heart and arterial tree were 
carefully dissected out and stored in paraformaldehyde. The samples were rinsed in PBS 
and stored in 70% v/v ethanol. The tissues was then analysed for the plaque areas in the 
brachiocephalic and the aortic sinus regions with the identity of the samples being 
coded, to avoid bias by another researcher.  
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Blood obtained by cardiac puncture was immediately transferred to Eppendorf 
tubes containing a cocktail of protease inhibitors to prevent clotting and sample 
degradation (1 μL/mL aprotinin, 0.04 μM D-phenylalanyl-L-prolyl-L-arginine 
chloromethyl ketone [PPACK; a rapid thrombin inhibitor], 20 μg/mL soybean trypsin 
inhibitor and 2mM EDTA). Blood glucose concentration were determined using a True 
Track™ Smart System glycometer (Nipro Diagnostics Inc., Fort Lauderdale, FL, USA), 
and HbA1c (as a measure of glycated haemoglobin) was determined using AlcNow+ 
kits (Metrika Inc., Sunnyvale, CA, USA). The remaining blood was spun at 800 g for 10 
min at 4 °C. The recovered plasma was snap-frozen in liquid N₂ and stored at -80 °C for 
further analyses, as were the resultant and remaining cell pellets. 
 
2.7.3 Preparation of formalin fixed, paraffin-embedded mouse tissue  
The aortic sinus was dissected making a cut perpendicular to the aorta halfway 
through the heart. The brachiocephalic artery was separated from the aortic arch by 
dissecting diagonally across the vessel where the artery meets the arch, and embedded 
in agarose gel. The dissected samples were enclosed in Tissue TEK cassettes and placed 
in 70% v/v ethanol and taken over the Pathology Department at the University of 
Sydney for tissue processing overnight through a Tissue-TEK VIP automatic tissue 
processor (Miles Scientific, Naperville, IL, U.S.A) to dehydrate samples before infusing 
with paraffin wax. Samples were embedded in paraffin blocks in the desired orientation 
using a stainless steel mould (Tissue-TEK Dispensing Console, Miles Scientific). These 
paraffin blocks were taken back to the Heart Research Institute. 
 
2.7.4 Dissection and paraffin embedding of the aortic sinus and the 
brachiocephalic artery 
The whole aortic tree with the heart was carefully removed for morphological 
and immunohistochemical analyses of the aortic sinus and the brachiocephlic artery. 
The brachiocephalic artery was separated from the aortic arch dissecting diagonally 
across the vessel where the artery meets the aortic arch, embedded in agarose gel and 
cut in a pentagonal shape as shown in Figure 2.2a. The embedded sample in agarose 
was carefully positioned in between two sponges that were inserted within the top and 
bottom of the cassette. The dissected samples that were enclosed in cassettes were 
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labelled with pencil and immersed in 70% ethanol for overnight tissue processing. On 
the following day the artery was embedded in paraffin blocks with the beginning of the 
brachiocephalic artery facing the bottom and the right common carotid artery and the 
right subclavian artery facing the top.   
For the aortic sinus, the arterial tree along with the aorta was removed, leaving 
behind the two atriums attached on top of the whole heart. The second cut was made 
perpendicular to the aortic root, approximately halfway through the heart and parallel to 
the two atriums as illustrated in Figure 2.3. The dissected top half of the heart was 
processed and embedded in paraffin blocks the next day with the aortic opening and the 
atrium facing the top and the cut end of the heart facing the bottom.  
 
2.7.5 Tissue Sectioning 
Plaque area was estimated for the brachiocephalic artery and the aortic sinus. 
Five micrometer sections of tissue were initially cut on a rotary microtome and floated 
on a 42 °C water bath. Sections were lifted on to a Superfrost Plus positively-charged 
glass slides (Menzel-Glaser, Braunschweig, Germany) and air dried before placing in 
racks to dry overnight at 37 °C. 
The first cross section slide of the brachiocephalic artery was taken from the 
appearance of a complete circular section at the region proximal to the arch. The first 
section of the aortic slide was taken at the first appearance of the three valve leaflets. 
A set of six duplicate (A - F) cross sections were counted and taken at every 100 
µm along the brachiocephalic artery and the aortic sinus (refer to Figures 2.2 and 2.3). 
One set of six duplicate sections (A - F) were stained with Haematoxylin and Eosin (H 
& E) and photographed using the appropriate magnification (10x for brachiocephalic 
and 4x magnification for sinus) for plaque area. Total plaque area was calculated across 
the six sections using Adobe Photoshop CS5 (v12.0). 
The other replicate sections were used for immunohistological analysis for α-
actin for smooth muscle cells (Slide B), F4/80 for macrophages (Slide C) and 
picrosirius red for collagen (Slide D).  
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Figure 2.2a: Dissection and tissue sectioning of the brachiocephalic artery. 
The brachiocephalic artery was incised from the aorta, fixed in an agarose gel.  After the 
agarose gel had cooled, the sample was cut around the sample in a pentagonal outline as 
shown in the middle diagram. Two triangular cuts are made on top of the right common 
carotid artery and the right subclavian artery whilst two parallel cuts are made along the 
brachiocephalic artery. This allowed the starting point for tissue sectioning to 
commence from the base of the pentagon. The far right diagram indicates where the 
duplicate slides of A to F were taken. Slide A was taken where the first full 
circumference of the artery appeared.  
 
 
 
Figure 2.2b: Dissection of the aortic sinus. 
The arterial tree was removed and separated from the heart. The second cut was parallel 
to the first cut and also perpendicular from the aortic opening. The tissues were 
processed and embedded with the larger cross-section facing the bottom. The sample 
within the block was sectioned until the leaflets were detected. The first duplicate slide 
of A was taken at the appearance of all three leaflets of the sinus.  
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Figure 2.3: Aortic sinus dissections. 
This is an anatomical position of the heart in 2D, where two imaginary lines meet 
perpendicularly from the aortic opening and between the left and the right atriums. The 
critical dissection (indicated by the broken blue line) takes place midway into the heart, 
perpendicular to the aortic opening and parallel to the left and right atriums. The first 
cross section is taken at appearance of three valve leaflets, as outlined in green.  
 
 
2.7.6 Dewaxing and re-hydration of paraffin-embedded sections 
Dewaxing of slides was performed by immersing slides in two changes of 
xylene for at least 10 min each. Sections were progressively re-hydrated through two 
changes of 100% ethanol for 2 min each, followed by two changes in 95% v/v ethanol 
(2 min each) and finally 2 min in 70% v/v ethanol. Sections were then washed in 
running tap water for at least 2 min. 
 
2.7.7 Haematoxylin and eosin staining (H&E) 
Sections were stained in Harris’ Haematoxylin for 2 - 3 min. Sections were then 
washed well under tap water until the water colour was clear. The sections were 
subsequently dipped three times quickly in an acid alcohol differentiator (conc. HCl 
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diluted at 1:400 in 70% v/v ethanol) to remove excess blue colouration. After washing 
in tap water sections were submerged in Scott’s Blueing Solution for 30 s. Sections 
were then checked under the microscope, to determine whether the nuclei were clearly 
differentiated. If not, the sections were rinsed with water, and re-stained with Harris’s 
Haematoxylin for 30 s, washed under tap water until the water colour was clear, and 
then submerged in Scott’s Blueing Solution for 20 s, washed with water and re-checked 
under the microscope.   
When staining was such that the nuclei were clearly differentiated, the sections 
were then stained with eosin. Sections were washed in tap water then dipped in 70% v/v 
ethanol for 30 s and subsequently in two changes of eosin (30 s each). The sections 
were then washed in two changes of 95% v/v alcohol (30 s each) followed by two more 
washes in 100% alcohol (30 s each). Slides were then submerged in two changes of 
histolene (at least 10 min each) before they were mounted with DPX and coverslipped. 
 
2.8 Immunohistochemistry materials and methods 
Alkaline phosphatase substrate was purchased from Vector Laboratories Inc. (CA, 
U.S.A.) One drop from Reagent 1, 2 and 3 were added to 2.5 mL of 100 mM Tris-HCl 
(pH 8.2 - 8.5) prior to use. PBS 20x conc. (Amresco) was re-constituted to 1x PBS with 
nanopure water to which PBST 0.1% v/v Tween 20 was added (PBST).  
Normal rabbit serum was purchased from Abacus (East Brisbane, Qld, Australia) 
The powder was reconstituted with 5 mL of nanopure water (as suggested by the 
product information) in order to yield 100% normal rabbit serum and aliquoted and 
stored at -20°C.  Normal rabbit serum working solution (10% v/v in PBS) was made 
fresh on the day of experiment.  
For the antigen retrieval buffer 5.46 g of sodium citrate tribasic dihydrate (Sigma-
Aldrich) was dissolved in 1.5 L of nanopure water. The pH of the solution was 
measured using a pH meter (PHM 220, Meter Lab®) and adjusted to 6 with 37% w/v 
HCl (Astral Scientific). The solution was then topped up to 2 L with nanopure water. 
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2.8.1 Antibodies for immunohistochemistry 
Mouse monoclonal α-SM-actin was purchased from Sigma-Aldrich. Rat 
monoclonal Anti-F4/80 antibody [Cl:A3-1],  mouse polyclonal (Alkaline Phosphatase)- 
IgG isotype control  and rat IgG2b, kappa monoclonal [RTK4530]- isotype control were 
purchased from Abcam.  
 
2.8.2 Plaque composition 
Macrophages (Anti-F4/80), smooth muscle cells (α-SM-actin), and collagen 
(Picrosirius Stain) were identified in paraffin-embedded sections of the brachiocephalic 
artery and the aortic sinus (refer to Section 2.7.5) taken at 100 μm, 200 μm and 300 μm, 
from the first complete cross-section of the brachiocephalic and the appearance of three 
valve leaflets of the sinus. Negative controls without the primary antibody were used for 
each staining to screen for nonspecific binding which was not evident.  
 
2.8.3 Smooth muscle-α-actin staining 
Sections were embedded and deparaffinised as described above. The sections 
were then rinsed in PBS. Antigen retrieval was achieved by placing the slides in citrate 
buffer and heating them in the microwave on high power for 15 min. The slides were 
then rapidly cooled in running tap water and immersed in PBST for 4 min. Sections 
were encircled with a ImmEdge™ hydrophobic barrier pen (Vector Laboratories Inc., 
Burlingane, CA, U.S.A.) to reduce the volume of reagents required. Normal rabbit 
serum working solution was added to the samples which were incubated for 4 hr at 21 
°C in a closed slide sorter. The slides were then briefly rinsed in PBST. The alkaline 
phosphatase-conjugated anti-α-SM-actin monoclonal antibody (1/100 dilution in TBS, 
Sigma-Aldrich) was applied overnight at 4 °C with damp paper towels inside the slide 
sorter.  
The following day samples were rinsed in Tris-HCl (200 mM Tris, pH 8.3) for 5 
min. The samples were recircled with the hydrophobic barrier pen. The Vector Red 
Substrate (Alkaline Phosphatase Substrate Kit, Vector Laboratories Inc.) was freshly 
prepared in Tris-HCl buffer at room temperature as previously described. The prepared 
substrate was added to the samples and incubated for 10 min. The colour development 
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was halted by immersing the slides in Tris-HCl buffer for 5 min. Sections were rinsed 
briefly in water before counterstaining in Harris’ Haematoxylin and Scott’s blueing 
solution as previously described.  
 
2.8.4 De-hydration of paraffin-embedded sections for immunohistochemistry 
After the completion of counterstaining with Harris’s Haematoxylin and Scott’s 
blueing solution, the sections were then taken through two changes of 70% v/v ethanol 
(30 s each), followed by 95% v/v (2 min each) and 100% absolute alcohol (5 min each) 
and submerged in histolene for at least 10 min each. Slides that were cleared with 
histolene and mounted with aqueous mounting medium (Aquamount, BDH Laboratory 
Supplies, Poole, England, U.K.). 
 
2.8.5 F4/80 macrophage staining 
Paraffin embedded sections were prepared as described above, however no 
antigen retrieval was performed. Normal rabbit serum working solution was added to 
the samples which were incubated for 4 hrs at 21 °C with the slide sorter closed. The 
samples were then briefly rinsed in PBST. The anti-F4/80 antibody [Cl:A3-1] (1:100 
dilution in PBS, Abcam) was applied overnight at 4 °C with damp paper towels inside 
the slide sorter.  
The following day the samples were rinsed with TBS for 1 min. The samples 
were then recircled with the PAP-pen and incubated for 1 hr at 21 °C with goat anti-Rat 
H & L (AP) secondary antibody (Abcam) diluted 1:200 in PBS. The slides were then 
immersed in Tris-HCl buffer for 5 min.  
The Vector Red Substrate was freshly prepared in Tris-HCl buffer at room 
temperature 21 °C as described above. The prepared substrate was added to the samples 
and incubated for 20 min. The colour development was halted by immersing the slides 
in Tris-HCl buffer for 5 min. The sections were then rinsed briefly in water before 
counterstaining, dehydration and mounting as described. 
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2.8.6 Cholesterol clefts 
Lipid filled areas appeared white as a result of the sample delipidation. These 
delipidated areas were clearly differentiated from macrophages that were stained pink. 
The quantification of these areas was carried out using a modification of previously 
published methods [233,234]. 
 
2.8.7 Determination of plaque lipid  
The lipid content was measured from the F4/80 stain (Slide C), which were used 
to quantify the area occupied by macrophages. The lipid content was assessed as 
extracellular lipid pools which appeared as white areas within atherosclerotic plaque 
sections following the F4/80 staining with graded ethanol concentration, which 
solubilises the lipid. These delipidated white areas were clearly differentiated from 
macrophages that were stained pink as shown in Panel A in Figure 2.4. The images for 
the aortic sinus were retaken one valve leaflet at a time, at a higher magnification of 10x 
as the program could not accurately detect the specific areas of interest. 
All the images were colour deconvoluted and filtered, as previously described. 
The area of interest was saturated with red as indicated in Panel B in Figure 2.4. The 
total area of interest within the plaque was outlined and calculated as displayed in Panel 
C in Figure 2.4. The amount of red marked within the plaque equates to the extracellular 
lipid pool quantified.  
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Figure 2.4: Estimation of extracellular lipid content of atherosclerotic plaques. 
Extracellular lipid content of atherosclerotic plaques was estimated by measuring the 
white area on a section stained with F4/80 as shown on Panel A. The image was filtered 
via the Image J program in order to quantify the lipid areas. The white areas were 
selected and saturated with red, leaving the remaining segments white as seen in Panel 
B. The plaque area was carefully outlined as shown in Panel C.  The amount of red 
corresponds to the original extracellular lipid pool, which was calculated and expressed 
as a percentage of total plaque area.  
 
 
2.9 Materials for picrosirius staining 
2.9.1 Picrosirius for collagen staining 
Paraffin embedded sections were dewaxed and taken through rehydration as 
previously described. The sections were stained using picrosirius red solution (0.5 g of 
Sirius Red (Sigma-Aldrich) dissolved in 500 mL of saturated aqueous solution of picric 
acid (Sigma-Aldrich) for 1 hr). The slides were then washed in two changes of acidified 
water (glacial acetic acid 1:400 in nanopure water; Astral Scientific) by vigorous 
shaking to remove any excess red dye from the sections. The slides were dehydrated in 
three changes of 100% ethanol (2 min each). The sections were cleared with histolene 
and coverslipped as previously described. 
 
2.9.2 Compositional analysis of atherosclerotic plaques 
Duplicate images obtained from each slide were captured digitally using an 
IX71 Olympus microscope (North Ryde, NSW, Australia).  Measurements of smooth 
muscle cell, macrophage, lipid and collagen areas were quantified using the Image J 
program (NIH, Bethesda, MD, USA).  
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All the images that were taken for smooth muscle cells, macrophages and 
collagen, were initially separated into three colours (blue, green and pink) using the 
“Colour Devolution” function within the Image J program. The pink deconvoluted 
image was then filtered by the “Multi-thresholder” function in order to detect the 
specific stain of interest, which was marked with red. The amount of red marked 
equates to the area of interest that was quantified.  The α-actin, F4/80, lipid or collagen 
content were expressed as a percentage of total plaque area for each image produced.  
 
2.10 Preparation of tissue and plasma samples from high fat diet fed mice for the 
4-hydroxy-2,2,6,6-tetramethylpiperidin-1-oxyl (TEMPOL) study 
Heart and plasma samples were obtained from Prof. Jim Mitchell (Radiation 
Biology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MS, 
U.S.A.) from C57/B6 (n = 28) and apo E
-/-
 (n = 38) mice. The two animal types each 
comprised of four groups. In each case two groups were fed a chow diet with or without 
TEMPOL (10 μg/g) supplemented into the food. The remaining two groups were fed a 
high fat diet (refer to Figure 2.4) with and without TEMPOL placed into the food. The 
chow diet consisted of 5% kcal of fat whilst the high fat diet consisted of 60% kcal from 
fat (refer to Table 2.1 below).  
 
 Chow High Fat Diet 
Protein 0.936 0.82 
Fat 0.405 3.28 
Carbohydrate 1.96 1.43 
Total (kcal/g): 3.301 5.49 
Table 2.1: Caloric profile between chow and high fat diet in terms of protein, fat 
and carbohydrate in kcal/g. 
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Figure 2.5: Animal model for TEMPOL study.  
C57B/6 wild type and the apo E
-/-
 mice were each divided into four groups comprising 
of Chow control mice with and without TEMPOL included in the food or high fat diet 
fed mice with and without TEMPOL included in the food.   
 
 
2.10.1 Tissue processing and dissection for TEMPOL project 
The heart was sampled for histological analysis based on a previously method 
published [233]. The heart was dissected out and stored in paraformaldehyde. The 
samples were rinsed in PBS and stored in 70% v/v ethanol. The aortic sinus was 
dissected as described above by making a cut perpendicular to the aorta halfway 
through the heart. The dissected samples were enclosed in cassettes and placed in 70% 
ethanol and then processed at the Pathology Department, University of Sydney, where 
the tissues were embedded in paraffin blocks. These paraffin blocks were then sectioned 
and stained with haematoxylin and eosin as previously described for plaque area.  
 
2.10.2 Histological sectioning for TEMPOL project 
The glass slides were pre-labelled from 1 - 25 for each sample. The sections for 
slide 1 were taken at the appearance of the first valve leaflet, and the rest of the 
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remaining sections were taken in sequentially labelled 2 - 25. Each slide consisted of 
three sections.  
 
2.10.3  Analysis of plaque for TEMPOL project 
Three slides arbitrarily labelled A, B and C were taken for plaque analysis. The 
first appearance of all three leaflets was chosen for Slide A and the first disappearance 
of all three leaflets were taken for Slide C. Slide B was taken in the middle of Slide A 
and C.  
Figure 2.6: Representative images of 3 cross-sections (A - C) taken from the aortic 
sinus.  
The first appearance of three leaflets was chosen for Slide A. The first disappearance of 
all three leaflets was taken for Slide C. Slide B was taken in the middle of Slide A and 
C.  
 
 
2.11 Lipid analysis in plasma for TEMPOL animal work 
The frozen plasma samples were obtained by the National Cancer Institute and 
stored at -80°C until analysis at the Heart Research Institute. Plasma samples were then 
given to a blinded observer for determination of triglycerides (TG), total cholesterol 
(TC), low-density lipoprotein-cholesterol (LDL-C) and high-density lipoprotein 
cholesterol (HDL-C).  
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2.11.1 Triglyceride determination 
A standard curve (0 to 300 mg/mL) was generated using materials supplied with 
the Triglyceride kit from Wako Diagnostics (Osaka, Japan). The plasma was diluted in 
1 in 5 with TBS. Initially 10 μL of prepared standards, along with 190 μL of colour 
reagent was applied to a 96-well plate in triplicate. The plate was incubated at 37 °C for 
5 min in the M2e Spectrometer, shaken for 5 s before reading the absorbance at 600 nm. 
Values were read from the standard curve for each sample and converted to mmol/L.  
 
2.11.2 Cholesterol determination 
A standard curve for cholesterol (0 to 200 mg/mL) was generated using the 
materials supplied with the Total Cholesterol kit (Wako Diagnostics). The standards and 
the samples (1 in 5 dilutions in TBS) were prepared as described in the previous section 
with the absorbance measured at 505 nm. Values were calculated from the standard 
curve generated for each sample.  
For HDL analysis, low density lipoproteins were precipitated from the plasma 
prior to analysis. Specifically 25 μL of undiluted serum from each mouse to be tested 
along with 25 μL of polyethylene glycol (PEG) solution (200 mg/mL in nanopure 
water; Sigma-Aldrich) were added to each Eppendorf tube and vortexed. The solution 
was allowed to stand for 20 min to allow the apolipoprotein B protein to precipitate then 
centrifuged at 13 000 rpm (15 700 g) for 20 min in a microcentrifuge. The supernatant, 
which contained the HDL-C, was quickly transferred to a fresh tube. The precipitate 
(LDL-C) was discarded. The HDL-C was measured for total cholesterol and then 
corrected for the dilution by the PEG solution.  
LDL-C (mmol/L) levels were determined as shown in the formula below. 
LDL-C = Total Cholesterol - {HDL-C + (Triglycerides/5)} 
 
2.11.3 Materials for mouse cytokine, chemokine and adipokine measurements 
Mouse Quantikine ELISA kits were purchased from R & D systems 
(Mineapolis, MN, U.S.A) for determining tumour necrosis factor-alpha (TNF-α), 
monocyte chemostatic protein-1 (MCP-1), leptin and resistin levels in mouse serum. 
74 
 
The murine MPO ELISA kit was purchased from Hycult Biotech, Inc. (Uden, 
Netherlands). The mouse IL-6 ELISA kit was purchased from Ray Biotech, Inc. 
(Norcross, GA, U.S.A.). The AssayMax mouse Adiponectin Kit was purchased from 
AssayPro (St. Charles, MO, U.S.A.). The mouse serum amyloid A (SAA) ELISA kit 
was purchased from Tridelta Development Ltd. (County Kildare, Ireland). Reagents 
supplied by the manufacture were brought to 21 °C before the commencement of the 
specified procedure. 
For the Quantikine ELISA kits, mouse plasma was diluted as required by the 
assays: TNF-α (no dilution), MCP-1 (1:2), leptin (1:10), resistin (1:30) with the 
Calibrator Diluent specific to serum/ plasma samples. Standards were also prepared 
according the manufacturer’s guidelines; TNF-α (0 - 700 pg/mL), MCP-1 (0 - 1000 
pg/mL), leptin (0 - 4000 pg/mL) and resistin (0 - 2000 pg/mL).  
Initially 50 μL of assay diluent was inserted in each well with 50 μL of the 
prepared samples / standards and incubated for 2 hrs at 21 °C, on the plate shaker. Each 
well was then manually aspirated and washed 4 - 5 times with 400 μL of washing 
buffer. 100 μL of conjugate was added and incubated for 1 to 2 hrs at 21 °C.  The wells 
were washed again 4 - 5 times and 100 μL of substrate solution prepared by mixing 
equal volumes of Colour Reagent A and B from the kit. The plate was mixed and 
incubated for 30 min in darkness. The appearance of the blue-green colour reaction was 
stopped by adding 100 μL of Stop Solution. The optical density of each well was read 
by the spectrometer at 450 nm and 570 nm. The subtraction of the two measurements 
corrected for optical imperfections in the plate.  
For the determination of MPO, IL-6, adiponectin and SAA levels in the plasma, 
enzyme linked immunosorbent assays were used in a similar manner to the Quantikine 
ELISA kits. The cytokine of interest within the standards and mouse plasma was 
determined using a sandwich ELISA in which the material was immobilized antibody 
and biotinylated polyclonal antibody of interest, which in turn is recognised by a 
streptavidin-peroxidase conjugate. The unbound material was then washed away and the 
peroxidase enzyme substrate tetramethylbenzidine (TMB) added. Colour development 
was stopped by the addition of oxalic acid. The absorbance was then measured with a 
spectrometer at 450 nm and 570 nm. The subtraction of the two measurements corrected 
for optical imperfections in the plate.  
75 
 
A standard curve was generated by plotting the absorbance (linear) versus the 
corresponding concentrations of the mouse MPO standards. The mouse plasma was 
diluted as required (MPO (1:4), IL-6 (1:6), Adiponectin (1:400), SAA (1:200)) with the 
supplied Diluent Buffer in Eppendorf tubes and vortexed. 50 – 100 μL of reconstituted 
standard, plasma samples and controls were transferred into appropriate wells and 
incubated for 1 to 2.5 hrs at 21 °C. After the first incubation, the wells were washed 4 to 
5 times in a similar manner as previously described. 50 – 100 μL of Biotinylated Tracer 
Antibody was added to each well and further incubated for 1 hr at 21 °C. After the 
washing step, streptavidin-peroxidase conjugate (50 – 100 μL) was added to each well 
and incubated for 30 – 60 min at 21 °C. The solution was then discarded from the wells 
and washed, then 50 – 100 μL of TMB was added to each well and incubated for 10 – 
30 min at 21 °C protected from light. The stop solution (50 – 100 μL) was then added to 
stop colour development.  The absorbance was then read at 450 nm and 570 nm to 
correct for optical imperfections.  
 
2.12 TEMPOL in vitro work  
Human monocytes were matured into macrophages in media containing 5.5 or 20 
mM glucose as previously described with and without the addition of 100 μM 4-
hydroxy-2,2,6,6-tetramethylpiperidin-1-oxyl (Sigma-Aldrich). Lysosomal acid lipase 
(LAL) and cathepsin B and L activities enzymatic assays were assessed as described in 
Sections 2.2 and 2.3. 
 
2.12.1 Cytokine expression 
To examine cytokine expression by normal and hyperglycaemic cells, HMDM 
was stimulated with lipopolysaccharide (LPS; Sigma-Aldrich) from Escherichia coli in 
order to induce cytokine secretion. On day 10 of the maturation period, the cells were 
stimulated with 0, 25 and 50 ng/mL of LPS and further incubated for 24 hrs. On the 
following day cell media was collected and transferred to Eppendorf tubes and 
centrifuged at 2000 rpm (400 g) for 5 min at 4 °C to remove cell debris. The supernatant 
was then transferred to fresh Eppendorf tubes, aliquoted and stored at -80 °C. Each well 
was washed 3 times with PBS and 1 mL of nanopure water was added to each well and 
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the plate placed on ice to induce cell lysis.  The cells were then scraped and transferred 
to Eppendorf tubes and stored at -20 °C before protein analysis.  
 
2.12.2 ELISA for human C-Reactive Protein (CRP), TNF-α and Macrophage 
Inhibitory Protein (MIP-1α) 
The levels of C-Reactive Protein (CRP), TNF-α and Macrophage Inhibitory 
Protein (MIP-1α) secreted into the media were determined by using Quantikine Human 
ELISA sandwich kits (R and D systems). Media samples were diluted with the supplied 
Calibrator Diluent specific for cell culture; 1:100 for MIP-1α, 1:200 for CRP and 1:10 
for TNF-α.   
Standards were prepared according to the manufacturer’s guidelines. 50 – 100 
μL of assay diluent was added to each well, then 50 – 100 μL of the reconstituted 
samples and standards was added and incubated for 1 – 2 hrs at 21 °C. Each well was 
then manually aspirated and washed 4-5 times with 400 μL of washing buffer. 200 μL 
of conjugate was added and incubated for 1 – 2 hrs at 21 °C.  The wells were then 
washed 4 to 5 times and 200 μL of substrate solution prepared by mixing equal volumes 
of Solution A and Solution B from the kit. The plate was mixed and incubated for 20 – 
30 min in darkness. The colour reaction was stopped by adding 50 μL of stop solution.  
The optical density of each well was read by the spectrometer at 450 nm and 570 nm, 
with subtraction used to correct for optical imperfections in the plate.  
  
2.13 Statistical analyses  
Data are expressed as mean ± standard error of the mean (SEM) in this thesis 
and results are from at least 4 - 6 separate experiments, consisting of samples assayed in 
triplicate.  
Statistical analyses were undertaken using Prism 5.03 (GraphPad software, San 
Diego, CA, USA).  For pair comparisons, paired or unpaired t tests were employed.  For 
multiple comparisons, one way analysis of variance (ANOVA) with Tukey’s Multiple 
Comparison test was used to assess differences. Two-way ANOVA with Bonferroni’s 
post hoc test was applied when two different conditions were applied such as glucose 
and time intervals. Differences were considered statistically significant when p < 0.05. 
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CHAPTER 3: 
INHIBITION OF LYSOSOMAL FUNCTION IN MACROPHAGES 
INCUBATED WITH ELEVATED GLUCOSE CONCENTRATIONS 
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3.1 Introduction 
 Atherosclerosis is a progressive vascular disorder leading to cerebro- and 
cardiovascular diseases and still remains the principal cause of mortality and morbidity 
in the world [235]. People with diabetes have a 2 to 4 fold elevated risk of 
cardiovascular disease compared to people without diabetes. Multiple studies indicate 
that this enhanced disease incidence cannot be solely explained by well-established 
cardiovascular risk factors, and are consistent with chronically elevated blood glucose 
levels contributing to an increased incidence of atherosclerosis [236].  
 In atherosclerosis macrophages are present within the inflamed artery wall and 
utilise multiple pathways including scavenger receptor mediated endocytosis, to remove 
damaged cells and tissue components, including modified low-density lipoproteins 
[237]. These materials are trafficked through the endo-lysosomal system for 
degradation, but under circumstances where the LDL are resistant to degradation, and / 
or lysosomal degradative function is impaired, they could accumulate with pathological 
consequences [238]. Thus altered lysosomal function is a potential route to lipoprotein-
derived intracellular accumulation of lipid and protein, and the generation of lipid-laden 
(“foam”) cells. Foam-cells are a major contributor to atherogenesis and atherosclerotic 
progression. Earlier onset and the rate of atherosclerotic progression are enhanced in 
DM along with chronically elevated level of AGE, glycated proteins and glucose.  
 Evidence from both cellular and in vivo studies, is consistent with lysosomal 
lipid accumulation [239,240]. Modified and native proteins are catabolised by the 
proteasomal and lysosomal systems, with the former primarily responsible for 
degradation of intracellular species, whereas the latter handles both extra- and intra-
cellular materials [241]. The lysosomal system of human monocyte-derived 
macrophages utilises multiple proteases including cysteine- (e.g. cathepsins B, L and S) 
and aspartate dependent (e.g. cathepsin D) enzymes. Both proteasomal [242] and 
lysosomal [243] enzyme activities can be modulated by in vitro incubation of cell 
lysates or proteasomal fractions with reactive aldehydes or pre-glycated proteins. For 
the lysosomal enzymes, the cysteine proteases were most markedly affected with this 
attributed to modification of the active site cysteine [243].  
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In the light of this data, we hypothesised that maturation of human monocytes 
into macrophages in, or exposure of a murine macrophage-like cell line to, elevated 
glucose would result in altered lysosomal function.  
 
3.2   Aims 
The aim of the studies reported here was to investigate whether high glucose 
concentrations alter enzymatic activities associated with lysosomal protein and lipid 
metabolism.  The impact of high glucose concentrations upon macrophage lysosomal 
function and population was examined in murine macrophage-like cell line J774A.1, 
and human monocyte derived macrophage (HMDM) cells incubated in normal (5.5 
mM) and higher (10, 20 and 30 mM) glucose concentrations, with the activities of 
lysosomal cathepsin enzymes (cathepsins B, L, S and D), lysosomal acid lipase activity 
(LAL) and lysosomal number quantified. 
 
3.3 Methods 
Murine J774A.1 macrophage-like cells were incubated, and primary human 
monocytes were matured into macrophages in the presence of 5.5, 10, 20 or 30 mM 
glucose for 11 days as detailed in Section 2.2. The activity of lysosomal cysteine 
proteases B, L and S, and the aspartic protease cathepsin D, along with lysosomal acid 
lipase (LAL) were quantified by fluorescence spectroscopy as described in Section 2.3 
to 2.4. Lysosomal numbers were quantified by Western blotting for LAMP-1 protein 
(relative to tubulin) levels as detailed in Section 2.5 to 2.5.8. 
The lysosomal activities were corrected for the protein concentration in the 
lysates for each sample.  The data (mean ± SEM, from 5 to 6 independent experiments 
each with triplicate samples) for the lysosomal activities from higher glucose treatments 
(10 to 30 mM) was expressed as a percentage of the 5.5 mM glucose condition.  
For multiple comparisons one-way ANOVA with Tukey’s multiple comparison 
tests were used. Gel analysis was carried out using Image J analysis software. 
Significance was assumed at p < 0.05.  
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3.4   Results 
3.4.1  Effects of incubation of J774A.1 and HMDM in high glucose concentrations 
for 11 days on cell viability 
The cell viability was measured as a marker for potential cytotoxicity in the 
J774A.1 and HMDM cells incubated in the normal 5.5 mM and 30 mM glucose 
conditions as outlined in Section 2.4.2, as elevated glucose levels might cause damage 
to the cells.  
Initial experiments examined the minimum and maximum concentrations of 
glucose used: 5.5 mM and high 30 mM. The overall cell viability observed was greater 
than 90% in both the J774A.1 (90.6 ± 0.9%) and HMDM (98 ± 0.8%) cells as shown in 
Figure 3.1. There were no statistical differences noted between the two glucose 
treatment groups for the J774A.1 or HMDM cells using Student’s t- tests. These results 
indicated the absence of cytotoxicity in either case. In the light of these data 
intermediate concentrations of glucose were not investigated.  
 
 
Figure 3.1: Cell viability of J774A.1 and HMDM cells incubated in normal (5.5 
mM) and high (30 mM) glucose conditions for 11 days.  
Measurement of cell viability for J774A.1 cells (Panel A) and human monocyte-derived 
macrophages (HMDM) (Panel B) in the normal 5.5 and high 30 mM glucose 
concentrations of glucose.  Data (mean ± SEM) are expressed as a percentage from 6 
independent experiments using separate cell donors (HMDM) or separate cultures of 
J774A.1 cells.  
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3.4.2  Protein content of J774A.1 and HMDM cells incubated in varying glucose 
concentrations for 11 days 
Protein levels were assessed to confirm the cell viability results and to establish 
that high glucose levels did not affect cell confluency in the case of the J774A.1 and 
HMDM cells. The protein levels of the cells incubated in the normal (5.5 mM) to high 
(10 to 30 mM) glucose concentrations were determined by the BCA protein assay by 
use of a standard curve generated using BSA as discussed in Section 2.4.1.   
There were no statistical differences in protein content observed across the 
glucose treatments for either J774A.1 or HMDM cells using a repeated measures one-
way ANOVA with Tukey’s post hoc multiple comparison’s test (Figure 3.2). These 
results suggest that high glucose conditions do not affect the protein levels or cell 
confluency in the J77A.1 or HMDM cells.  
 
 
 
 
Figure 3.2: Protein levels in J774A.1 and HMDM cells incubated in various 
concentrations of glucose (5.5, 10, 20 and 30 mM) for 11 days.  
Measurement of protein levels in J774A.1 cells incubated (Panel A), and maturation of 
human monocytes to macrophages (HMDM) (Panel B), in various concentrations of 
glucose (5.5, 10, 20 and 30 mM glucose). Data (mean ± SEM) are expressed in μg/μL 
equivalent of BSA protein from 6 independent experiments using separate cell donors 
(HMDM) or separate cultures of J774A.1 cells.  
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3.4.3 Effect of high glucose concentrations on activity and level of lysosomal 
cathepsin enzymes 
Lysosomal activity was determined in cell lysates prepared from J774A.1 cells 
and HMDM cells that were incubated in normal 5.5 mM and higher glucose 
concentrations (10, 20 and 30 mM) for 11 days (see Sections 2.2.2, 2.2.4, 2.2.5). The 
cell extracts for lysosomal activity measurements were collected and snap frozen in 
liquid nitrogen and stored at -80°C as described in Section 2.2.3 for J774A.1 cells and 
Section 2.2.5 for HMDM cells.   
The cell lysates obtained were then resuspended in nanopure water followed by 
centrifugation at 13 400 g for 5 min at 4°C to remove unlysed cells and membrane 
fractions that may interfere with the assay as described in Sections 2.2.3 and 2.3.1. The 
supernatant was then transferred to fresh tubes to measure the activity of lysosomal 
enzymes, and protein content by use for the BCA protein assay (see Section 2.4.1). 
To determine the activity of lysosomal cathepsin enzymes, release of AMC from 
the peptide substrates was monitored using a fluorescence plate reader (λexcitation 360 nm 
and λemission 460 nm) as discussed in Sections 2.3.2 to 2.3.5. The substrates for cathepsin 
B, L, S and D were Z-Arg-Arg-AMC, Z-Phe-Arg-AMC, Z- Val-Val-Arg-AMC and 7-
methoxycoumarin-4-acetyl-Gly-Lys-Pro-IIe-Leu-Phe-Phe-Arg-Leu-Lys-DNP-D-Arg-
amide, respectively.  The buffer pH used to achieve maximum activity for each 
cathepsin was 6, 5.5, 7.5 and 4.2 for cathepsin B, L, S and D, respectively. To ensure 
that the activities measured were specific to particular enzymes, specific assay inhibitors 
were included in the buffer to suppress the activities of other cathepsins. For example, 
in buffers for assessment of cysteine protease activity, pepstatin A was added to inhibit 
aspartate proteases such as cathepsin D, and in buffers for determination of cathepsin D 
activity, E64 was added to inhibit cysteine proteases.  
In order to determine lysosomal cathepsin activities, the initial linear region of 
plots of florescence against time were used as shown in Figure 3.3a and b. Nanopure 
water was used for dilutions, and served as the negative control (no cell lysate fraction) 
in each case. In these cases there was no change in fluorescence over time as shown by 
the black squares in Figure 3.3a and b.  
The protein concentration was determined in remaining portions of the same cell 
lysate samples as described in Section 2.4.1, thereby allowing the lysosomal activity to 
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be corrected for the protein concentration (μg/μL) of the cell lysate used for each 
measurement. The corrected data were expressed as a percentage of the lysosomal 
activities determined for the normal (5.5 mM) glucose condition. 
 
 
 
 
 
Figure 3.3: Changes in fluorescence in cell lysate fractions of HMDM matured in 
normal 5.5 mM or 10, 20 and 30 mM glucose concentrations followed by addition 
of cathepsin B substrate.  
Representative data are presented for cells matured in normal 5.5 mM and higher (10 - 
30 mM) glucose concentrations.  The changes in fluorescence emission followed a 
linear relationship as shown on the bottom graph.  The black squares represent the 
negative control (no cell lysate) which showed no change in fluorescence over time. 
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3.4.3.1  Effects of lysosomal cathepsin activity in J774A.1 cells incubated in 
normal and high glucose concentrations 
The lysosomal cathespsin B, L, S and D enzymatic activities were investigated 
in the J774A.1 cells to examine the impact of high glucose concentrations upon 
lysosomal function. Incubation of J774A.1 cells in high glucose concentrations for 11 
days modulated the activities of all of the lysosomal cathepsin enzymes examined 
(Figure 3.4).  Cells incubated in elevated glucose concentrations showed significantly 
less cathepsin B activity for the 10 mM condition (73.2 ± 6.6%, p < 0.01), the 20 mM 
condition (58.2 ± 8.5%, p < 0.001) and the 30 mM condition (50 ± 6.4%, p < 0.001) 
than cells incubated in 5.5 mM glucose (activity taken as 100%) using repeated 
measures one-way ANOVA with Tukey’s post hoc multiple comparison’s test. A 
statistical significance was also observed between the 10 and 30 mM glucose conditions 
(p < 0.05). 
  Cathepsin L activity also showed a significant decrease in cells incubated in 10 
mM (68.6 ± 7.6%, p < 0.05), 20 mM (53.9 ± 7.6%, p < 0.01) and 30 mM (37.1 ± 6.7, p 
< 0.001) glucose as compared to the 5.5 mM glucose concentration (values taken as 
100%). A statistical significance was also observed between the 10 and 30 mM glucose 
conditions (p < 0.05). 
Cathepsin S activity was significantly decreased in cells incubated in 10 mM (67 
± 4.3%, p < 0.001), 20 mM (47.8 ± 5.8%, p < 0.001) and 30 mM (23.4 ± 2.5%, p < 
0.001) glucose when compared to the 5.5 mM glucose condition (100%). Differences 
were also observed for the 20 and 30 mM glucose conditions (p < 0.001) versus the 10 
mM glucose condition, and also between the 20 and 30 mM glucose conditions (p < 
0.01). 
Cathepsin D activity was significantly lower in cells incubated in 10 mM (75.1 ± 
4.1%, p < 0.01), 20 mM (64.6 ± 3%, p < 0.001), 30 mM (42.5 ± 5.6%, p < 0.001) 
glucose compared to the 5.5 mM glucose concentrations (100%). Lower cathepsin D 
activity was detected for the 30 mM when compared with 10 mM (p < 0.01) and 20 mM 
(p < 0.05) glucose conditions.  
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In summary the results showed decreased cathepsin B, L, S and D activities in 
the J774A.1 cells incubated in high concentrations of glucose when compared to the 
normal glucose concentration.  
 
 
 
Figure 3.4: Lysosomal cysteine and aspartic cathepsin activities in J774A.1 cells 
incubated in various concentrations of glucose (5.5, 10, 20 and 30 mM) for 11 days. 
Data (mean ± SEM, from n = 5 independent experiments using different passages) are 
reported  as the linear change in fluorescence intensity with time, as a percentage of the 
5.5 mM glucose condition, corrected for protein levels. Panels A, B, C and D represent 
cathepsin B, L S and S activities, respectively. Statistical significant differences were 
carried out by one-way ANOVA followed by Tukey’s post-hoc test.  * p < 0.05, ** p < 
0.01 and *** p < 0.001 when compared to the 5.5 mM glucose condition.  # p < 0.05, ## 
p < 0.01 and ### p < 0.001when compared to the 10 mM glucose condition. + p < 0.05 
and +++ p < 0.001 when compared to the 20 mM glucose condition.  
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3.4.3.2 Effects of lysosomal cathepsin activity in HMDM incubated in normal and 
high glucose concentrations  
As inhibition of lysosomal cathepsin activities was observed in the murine 
J774A.1 cells that were treated with high glucose levels, the potential detrimental 
impact of high glucose levels upon lysosomal cathepsin activity was also investigated in 
the HMDM cells that were matured in the normal (5.5 mM) and high 10, 20 and 30 mM 
glucose conditions.   
HMDM incubated with elevated glucose concentrations showed significantly  
less cathepsin B activity  in the 10 mM (49 ± 3.4%, p < 0.001), 20 mM (43.1 ± 8.9%, p 
< 0.001)  and 30 mM (36.9 ± 9.5, p < 0.001) glucose conditions, than cells incubated in 
5.5 mM glucose (100%) using repeated measures  one-way ANOVA with Tukey’s post 
hoc multiple comparison’s test.  
Cathepsin L activity also showed a significant decrease in cells matured in 10 
mM (71 ± 4.1%, p < 0.05), 20 mM (50.5 ± 11.1%, p < 0.01) and 30 mM (35.5 ± 9.3%, p 
< 0.001) glucose concentrations as compared with 5.5 mM glucose (100%). A statistical 
significance was also observed between the 10 and 30 mM glucose conditions (p < 
0.05). 
Cathepsin S activity was decreased significantly in cells matured in 10 mM 
(61.3 ± 9.9%, p < 0.01), 20 mM (31.6 ± 8.6%, p < 0.001) and 30 mM (27.5 ± 8.8%, p < 
0.001) glucose when compared to the 5.5 mM glucose concentration (100%). Statistical 
significance were also observed between the 20 (p < 0.05) and 30 mM (p < 0.01) 
glucose conditions versus the 10 mM condition.  
Cathepsin D activity showed a significant decrease in cells matured in 20 mM 
(55.2 ± 11.3%, p < 0.01) and 30 mM (47.5 ± 8.6%, p < 0.01) glucose concentrations as 
compared with normal glucose concentrations (100%). Although there was lower 
cathepsin D activity in the 10 mM glucose (80.1 ± 7%) condition, this was not 
statistically significant when compared to the 5.5 mM condition. 
Overall, maturation of HMDM in high glucose concentrations for 11 days 
suppressed the activity of lysosomal cathepsin B, L, S and D enzymes (Figure 3.5) 
when compared to the normal glucose concentrations with this effect seen even at 10 
mM glucose for cathepsins B, L and S.  
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Figure 3.5: Lysosomal cysteine and aspartic enzyme activities in HMDM cells 
matured in various concentrations of glucose (5.5, 10, 20 and 30 mM) for 11 days. 
Data (mean ± SEM, from n = 5 independent experiments using different donors) are 
reported  as a percentage of the 5.5 mM glucose condition, corrected for protein levels. 
After incubation for 11 days the cells were lysed and cathepsin activity quantified using 
specific pro-fluorescent substrates as described in Section 3.4. Panels A, B, C and D 
represent cathepsin B, L S and S activities, respectively. Statistical significant 
differences were carried out by one-way ANOVA followed by Tukey’s post-hoc test.  * 
p < 0.05, ** p < 0.01 and *** p < 0.001 when compared to the 5.5 mM glucose 
condition.  # p < 0.05 and  ## p < 0.01 when compared to the 10 mM glucose condition.  
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3.4.4  Effects of normal and high glucose concentrations on lysosomal acid lipase 
activity (LAL) in J774A.1 and HMDM cells 
LAL is the sole lysosomal hydrolase for endocytosed cholesteryl esters and 
triglycerides [230]. Given the role of lipoprotein-derived cholesterol and triglycerides in 
foam cell formation it was therefore of interest to determine whether cells incubated in 
high glucose concentrations also demonstrated impaired LAL activity. Using cell 
lysates from HMDM and J774A.1 cells that were exposed to varying glucose levels, 
LAL activity was assessed by using the pro-fluorescent probe, 4-methylumbelliferyl 
oleate (4-MUO) which is cleaved to the fluorescent species 4-methylumbelliferone (4-
MU); this material was subsequently quantified as described in Section 2.3.6.  
Incubation of J774A.1 and HMDM cells in high glucose concentrations for 
11days modulated the activities of the lysosomal acid lipase (LAL) activities within the 
macrophages examined (Figure 3.6). J774A.1 cells incubated in high glucose 
concentrations for 11 days showed significantly lower levels of LAL activity for the 10 
mM (77.1 ± 4.3%, p < 0.05), 20 mM (63.3 ± 7.9%, p < 0.001) and 30 mM conditions 
(51.6 ± 8%, p < 0.001) than cells incubated in 5.5 mM glucose (activity set as 100%) 
using repeated measures one-way ANOVA with Tukey’s post hoc multiple 
comparison’s test. A statistical significance was also observed between the 10 and 30 
mM glucose conditions (p < 0.01). 
Maturation of HMDM in elevated glucose concentrations also suppressed LAL 
activity (Figure 3.6) when compared to the 5.5 mM glucose concentrations. Thus 
HMDM incubated in high glucose concentrations showed significantly less LAL 
activity  in the 10 mM (54.3 ± 5.6%, p < 0.001), 20 mM (49.9 ± 5.3%, p < 0.001)  and 
30 mM glucose condition (41.7 ± 5.7%, p < 0.001)  than cells incubated in 5.5 mM 
glucose (100%) using repeated measures  one-way ANOVA with Tukey’s post hoc 
multiple comparison’s test. A statistically significant difference was also observed 
between the 10 and 30 mM glucose conditions (p < 0.05). 
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Figure 3.6: Lysosomal acid lipase (LAL) activity in J774A.1 and HMDM cells 
incubated in various concentrations of glucose (5.5, 10, 20 and 30 mM) for 11 days.  
The effect of incubation of murine macrophage-like J774A.1 cells (Panel A) and 
maturation of human monocytes to macrophages (HMDM) (Panel B) in various 
concentrations of glucose (5.5, 10, 20 and 30 mM glucose) on the activity of LAL is 
presented. Data (mean ± SEM) are reported as a percentage of the 5.5 mM glucose 
condition, corrected for protein levels from 6 independent experiments using separate 
cell donors (HMDM) or separate cultures (J774A.1 cells). Statistically significant 
differences were assessed by one-way ANOVA followed by Tukey’s post-hoc test.  * p 
< 0.05 and *** p < 0.001 when compared to the 5.5 mM glucose condition.  # p < 0.05 
and  ## p < 0.01 when compared to the 10 mM glucose condition.  
 
 
3.4.5  Effect of high concentrations of mannitol on J774A.1 and HMDM 
incubated for 11 days 
High levels of glucose may induce osmotic stress upon cultured cells and this 
may explain the results presented above. In order to differentiate between the effects of 
higher osmotic pressure and other effects of high glucose levels, J774A.1 or HMDM 
cells were exposed to the normal (5.5 mM) or high (30 mM) glucose conditions, or 5.5 
mM glucose with 24.5 mM mannitol (as a high osmotic pressure treatment) for 11 days 
as stated in Section 2.3.7. Cells were collected and lysed, and the activities of lysosomal 
cathepsins B, L and LAL were measured as described in Sections 2.3, 2.3.1, 2.3.2, 2.3.5 
and 2.3.6.  
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There was a significant reduction in cathepsin B (48.6 ± 4%, p < 0.001), L (67.6 
± 5.5%, p < 0.001) and LAL (75.5 ± 5.9%, p < 0.01) activities in the 30 mM glucose 
condition treated J774A.1 cells when compared to the 5.5 mM condition (100%) 
consistent with the data reported earlier. Significantly greater cathepsin B (90.1 ± 2.9%, 
p < 0.001), L (101.2 ± 4.5%, p < 0.01) and LAL (97.6 ± 4.1%, p < 0.01) activity was 
observed in the glucose + mannitol-treated cells when compared to the 30 mM glucose 
treated J774A.1 cells. There were no statistically significant changes in lysosomal 
activities observed between incubation with 5.5 mM versus the cotreatment with 5.5 
mM glucose and 24.5 mM mannitol (Figure 3.7).  
For the HMDM cells a reduction in cathepsin B (37 ± 10.3%, p < 0.001), L (35.7 
± 9.7%, p < 0.001) and LAL (38.4 ± 10.6%, p < 0.001) activities were observed in the 
HMDM that were incubated with high glucose conditions compared to cells matured in 
5.5 mM glucose consistent with the data reported in Figure 3.5. However, no significant 
difference in lysosomal enzyme activity was found for the glucose + mannitol treated 
cells when compared to the cells matured in 5.5 mM glucose. However, significantly 
greater cathepsin B (95.5 ± 1.4%, p < 0.001), L (93.1 ± 1.1%) and LAL (99.8 ± 7.5%, p 
< 0.001) activities were detected in the osmotic control when compared to the high 
glucose condition in the HMDM cells. 
The addition of mannitol at a concentration which gave an equivalent osmotic 
pressure to 30 mM glucose did not result in a reduction of lysosomal activities as there 
were no statistically significant changes in the lysosomal activities when compared with 
the cells incubated with 5.5 mM glucose. In contrast with this, cells exposed to 30 mM 
glucose (positive control) clearly showed the expected inhibition of lysosomal 
cathepsins B, L and acid lipase activities based upon the results presented earlier. 
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Figure 3.7: Lysosomal enzymatic activities in J774A.1 and HMDM cells incubated 
in the normal (5.5 mM), high (30 mM) glucose and 5.5 mM glucose + 24.5 mM 
mannitol (osmotic control) conditions for 11 days.  
Macrophages were exposed to 5.5 mM glucose, 30 mM glucose or 5.5 mM glucose + 
24.5 mM mannitol (osmotic control). Panel A) J774A.1 and Panel B) HMDM. Each 
panel displays the lysosomal enzymatic activities of cathepsins B, L and LAL. 
Statistical significant inhibition of lysosomal activities were observed for the 30 mM 
glucose conditions at ** p < 0.01, and *** p < 0.001 against the normal glucose 
conditions and ## p < 0.01, ### p < 0.001 versus the osmotic control. No differences 
were detected between the 5.5 mM and 5.5 mM glucose + 24.5 mM mannitol 
conditions.    
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3.4.6 Western blot analysis of lysosomal associated marker protein-1 (LAMP-1) 
levels  
Exposure to high glucose decreased the activity of multiple lysosomal enzymes 
critical for the metabolism of low-density lipoproteins (LDL). This decrease in 
lysosomal activities observed in the macrophages incubated with high glucose 
conditions could be due to (i) inhibition of enzyme function or inactivation of the 
enzymes; (ii) a reduction in lysosomal population; or (iii) changes in protein expression. 
To examine the potential differences in lysosomal number in cells incubated in high 
glucose concentrations, LAMP-1 expression was assessed in macrophages that were 
incubated/matured in the normal 5.5 mM or 10 - 30 mM high glucose conditions.  
Cell lysates were collected from J774A.1 and HMDM cells after 11 days and 
subjected to Western blotting for the determination of LAMP-1 levels under various 
glucose concentrations as detailed in Sections 2.5 - 2.5.8. The LAMP-1 protein was 
detected at 120 kDa and β-tubulin was used as a loading control (band detected at 51 
kDa) and the data was expressed relative to β-tubulin and as a percentage of the data for 
the 5.5 mM glucose condition.  
J774A.1 cells incubated in high glucose concentrations for 11 days showed 
significant decreases in LAMP-1 levels for the 20 mM (61.6 ± 7%, p < 0.05)  and 30 
mM glucose concentration (47.7 ± 7.5%, p < 0.01)  when compared to cells incubated in 
5.5 mM glucose (values taken as 100%) using repeated measures  one-way ANOVA 
with Tukey’s post hoc multiple comparison’s test. A statistical significance was also 
observed between the 10 (86.7 ± 9.3%, p < 0.05) and 30 mM glucose conditions. 
Maturation of HMDM in elevated glucose decreased LAMP-1 protein levels 
(Figure 3.8) when compared to the normal glucose concentrations. HMDM incubated 
with high glucose showed significantly less LAMP-1 protein in the 20 mM (66.2 ± 
10.9%, p < 0.05)  and 30 mM (48.8 ± 11.4, p < 0.001) glucose conditions when 
compared to cells incubated in 5.5 mM glucose concentrations (100%) using repeated 
measures  one-way ANOVA with Tukey’s post hoc multiple comparison’s test. A 
statistical difference was also observed between the 10 mM (79.9 ± 6.6 %, p < 0.05) and 
30 mM glucose conditions. 
LAMP-1 protein levels were significantly diminished in the 20 and 30 mM 
glucose conditions, for both the J774A.1 and HMDM cells (Figure 3.8). Decreased 
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LAMP-1 protein expression at higher glucose concentrations may be indicative of a 
decrease in lysosomal population which may be a potential contributing factor for the 
loss of lysosomal activity observed in macrophages incubated under the highest (20 and 
30 mM) glucose concentrations.   
 
 
 
Figure 3.8: Quantification of LAMP-1 levels by Western blotting for J774A.1 and 
HMDM cells incubated in various concentrations of glucose (5.5, 10, 20 and 30 
mM) for 11 days.  
The top panels represent representative Western blots of LAMP-1 and corresponding β-
tubulin (loading control) from Panel A) J774A.1 and, Panel B) HMDM cells, incubated 
in (left to right) 5.5, 10, 20 or 30 mM glucose. The lower panels display the ratio of the 
band intensities of LAMP-1 relative to β-tubulin for the different glucose conditions as 
a percentage of the 5.5 mM glucose control. Data in lower panels are mean ± SEM from 
5 passages of J774A.1 cells or 5 individual donors (HMDM). Statistical analyses were 
carried out using one-way repeated measures ANOVA with Tukey’s post-hoc test. * 
Indicates p < 0.05, ** p < 0.01 relative to the 5.5 mM glucose condition. # p < 0.05 
between the 10 and 30 mM glucose conditions. 
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3.4.7 Pilot studies on aryl sulfatase activity, visualisation of lysosomes with 
LysoTracker and cathepsins B, L, S and D protein levels in J774A.1 and 
HMDM that were incubated in 5 and 30 mM glucose.  
Freshly isolated human monocytes were incubated in 5 and 30 mM glucose for 
11 days to allow maturation into macrophages J774A.1 cells were cultured in a similar 
manner in order to determine: the aryl sulfatase activity levels, lysosomal numbers 
using LysoTracker® Red DND-99; and the protein levels of cathepsins B, L S and D. 
The studies reported in this section were carried out by Dr Fatemeh Moheimani as 
reported in her PhD thesis and the result were subsequently published in Atherosclerosis 
[244].  
Western blot analyses were carried out to examine potential differences in 
cathepsin B, L S and D protein levels, using the 5 and 30 mM conditions; intervening 
levels were not examined in these pilot studies. For cathepsin B from HMDM, two 
bands at 25 (mature single chain) and 21 kDa (two-chain active form) were detected 
(Figure 3.9). For the J774A.1 cells a single band was detected at 25 kDa. The 
proenzyme (45 kDa) was not detected in either case. No significant differences were 
detected between the two conditions for either the individual species, or the total 
protein.  
For cathepsin L from HMDM, three bands were detected at 24 kDa (two-chain 
form), 30 kDa (single chain form) and 42 kDa (procathepsin) (Figure 3.9). A significant 
decrease of approximately 50% in the 30 kDa band was detected for the 30 compared to 
5 mM glucose condition, but the intensities of the other two bands individually and the 
sum of all three forms, were not significantly different. No bands were detected for the 
J774A.1 cells, with a wide range of antibody dilutions, consistent with a low level of 
this enzyme being present.  
A single band was detected for cathepsin S with both cell types at 24 kDa (active 
single side chain). For the HMDM cells exposed to 30 mM glucose, the intensity of the 
band was significantly less (by around 90%) compared to the 5 mM condition. For the 
J774A.1 cells no significant differences were detected between the two conditions. 
For HMDM cells and cathepsin D, three bands were detected at 22 (light chain), 
29 (heavy chain) and 50 kDa (dimer). A significant decrease in band intensity of 
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approximately 50% was detected for the 50 kDa for the 30 mM condition, but no 
significant differences were detected for the other two bands, or the total protein. 
For the J774A.1 cells two bands were detected at 31 kDa and 25 kDa. The 
former was invariant whereas the much weaker 25 kDa band showed a significant 
increase (approx. 80%) for the 30 versus 5mM condition. The total protein was 
significantly lower for the 30 mM condition. 
 
 
Figure 3.9: Protein levels of cathepsins B, L, S and D in HMDM cells exposed to 5 
or 30 mM glucose as determined by Western blotting.  
For each cathepsin representative Western blots (Panel A) and image analysis of total 
protein levels (i.e. sum of all bands) (Panel B) are given. Data are mean ± SEM from 
three independent blots obtained from separate experiments. Silver stained gels (not 
shown) showed identical loading in each lane. For assignment of bands see text. 
Statistical analyses were carried out using Student’s t test, with * indicating significant 
differences at the p < 0.05 level. 
 
Aryl sulfatase activity is commonly used for monitoring lysosomal populations. 
The aryl sulfatase activity in lysates from HMDM and J774A.1 cells exposed to 30 mM 
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glucose was significantly decreased (p < 0.05) when compared to the 5 mM condition as 
shown in Figure 3.10, and this decrease is consistent with the LAMP-1 data reported 
earlier in Figure 3.8.  
LysoTracker Red is a weakly-basic cell-permeable fluorescent amine dye that 
accumulates in lysosomes; as such it can be used to assess lysosomal numbers. 
Fluorescent (λexcitation 577nm, λemission 590 nm) and bright field images of HMDM and 
J774A.1 cells stained with this dye under identical conditions, showed more intense red 
fluorescence in cells incubated in 5 versus 30 mM glucose (Figure 3.11). The reduction 
in arylsulfatase activity and visualisation of lysosomes by LysoTracker
®
 Red DND-99 
observed in the high glucose conditions in both cell types may indicate a decrease in 
lysosomal population.  
These preliminary data indicate that maturation of HMDM in high glucose 
concentrations results in a decrease of overall lysosomal number, a reproducible 
reduction in cathepsin (cysteine and aspartate) protein levels and a marked suppression 
of lysosomal cathepsin enzyme activities. These data complement and extend the results 
reported previously in Sections 3.4.3.2 and 3.4.4. 
 
Figure 3.10: Effect upon lysosomal aryl sulfatase activity of maturation of human 
monocytes to macrophages (HMDM) (Panel A) or incubation of murine 
macrophage-like J774A.1 cells (Panel B) in 5 versus 30 mM glucose.  
After incubation for 11 days in the stated level of glucose, the cells were lysed, and aryl 
sulfatase activity quantified. Data are mean + SEM, from n = 4 independent 
experiments using separate donors (for HMDM) or separate cultures (for J774A.1 cells), 
and are reported as the change in absorbance with time, arising from cleavage of the 
added substrate as a percentage of the value determined for the 5 mM glucose condition, 
corrected for protein levels in the lysates. Statistical analyses were carried out using 
paired Student’s t-test: ** p < 0.01 when compared to the 5 mM glucose condition. 
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Figure 3.11: Representative photomicrographs of HMDM (Panels A to F) and 
J774A.1 (Panels G to L) cells incubated under normal or high glucose 
concentrations and stained with LysoTracker
®
 Red DND-99.  
Photos A - C and G - I are of cells incubated in 5 mM glucose, and D - F and J - L cells 
incubated in 30 mM glucose for 9 to 11 days. DND-99 (50 nM) was added to cells for 
30 min and images were obtained using bright field (A, D, G, J), and a fluorescent filter 
(λ excitation 530 - 550 nm and λ emission 575IF) exposed for 1 - 2 s (B, E, H, K). The bright 
field and fluorescent images were used to generate the merged images in Panels C, F, I, 
and L. Data are representative of  3 independent experiments for each cell type, with 
~50 images captured from cells in 6-well plates. 
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3.5   Discussion 
This study shows that exposure of both HMDM and a murine macrophage-like 
cell line (J774A.1), to extended periods of high glucose concentrations results in 
significant reductions in lysosomal function as evidenced by changes in the activity of 
multiple cathepsin enzymes and lysosomal acid lipase. These enzymes play a critical 
role in protein catabolism (cathepsins) and hydrolysis of endocytosed neutral lipids 
(cholesteryl esters and triglycerides; LAL). Significant decreases in some of the enzyme 
activities were detected with 10 mM glucose, with a greater loss detected at higher 
levels. Glucose concentrations of this magnitude are commonly encountered in people 
with poorly controlled diabetes. Levels of up to 30 mM have been reported [245] but 
are not commonplace. Analogous changes were not detected in osmotic control 
experiments using a mixture of 5.5 mM glucose and 24.5 mM mannitol.  
The changes in enzyme activity that occurred at the highest glucose 
concentrations (20 and 30 mM) were accompanied by changes in LAMP-1 protein level 
as evidenced by Western blotting. These results confirm the earlier findings of 
Moheimani et al. [244] for 30 mM glucose as evidenced by reduced accumulation of 
LysoTracker® Red DND-99 and decreased arylsulfatase activity. Thus lysosomal 
enzyme activity was found to be sensitive to high glucose levels below those that lead to 
reductions in protein expression and lysosomal number. A previous study has also 
reported decreased cathepsin (but not D) activity in endothelial progenitor cells exposed 
to high glucose [246].  
Multiple mechanisms may act in parallel or synergistically to give these 
alterations. It has been reported that lysosomal cysteine protease activity can be 
decreased by exposure to reactive aldehydes and glycated proteins as a result of 
modification of the active site Cys of cathepsins B, L and S [243]. Reactive aldehydes, 
including methylglyoxal and glyoxal, are formed at elevated levels in cells exposed to 
high glucose, as a result of glucose autoxidation and increased triose phosphate pathway 
flux, with decomposition of the triose phosphates yielding methylglyoxal [247]. 
Oxidative stress and oxidised proteins arising from high glucose concentrations can also 
modulate lysosomal enzyme activities directly [229]. Although direct enzyme 
inactivation may explain the decreased activity of cathepsins B, L and S, this may be of 
lesser significance for cathepsin D, which has an active site Asp residue that is unlikely 
to be modified by glucose or reactive aldehydes. However, lysosomal protease activity 
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is dependent on a reaction cascade that generates the functional enzymes from 
proenyzmes, so alterations to cahtepsin B, L or S activity may subsequently modulate 
cathepsin D activation [229]. 
Exposure of cells to high glucose generates glycated proteins, advanced 
glycation end products (AGE) and protein aggregates [115]. The proteasome is the 
major complex that degrades most modified cytosolic proteins, and hence it might be 
expected that AGE-modified and aggregated proteins would be catabolised by this 
complex. However evidence exists for cross-talk between the proteasome and the endo-
lysosomal systems, as well as direct trafficking of modified proteins to lysosomes [241]. 
The presence of modified proteins in the lysosomes may affect enzyme function 
directly, and or lysosomal properties that result in changes in protein level and enzyme 
activities for example by increasing the fragility of lysosomal membranes [248], and 
changes in intra-lysosomal pH [249], as these enzymes typically require acidic pHs 
[250]. It is likely that multiple mechanisms are involved, as these processes may occur 
concurrently and be interdependent.  
Little previous data is available on changes in LAL activity.  Mononuclear 
leukocytes from newly-diagnosed subjects with Type 1 of Type 2 diabetes have been 
reported to have unchanged activity compared to controls [251]; LAL activity was 
decreased in the Type 1, but not Type 2, subjects after insulin therapy. An earlier study 
reported an increase in LAL activity in subjects with Type 2 diabetes after insulin 
treatment [252]. People with autosomal recessive genetic traits resulting in Wolman’s 
disease, and Cholesteryl Ester Storage Disease [253,254] have a deficit in LAL activity 
with this resulting in substantial cholesteryl ester (and to a lesser extent triglyceride) 
accumulation within cells [253], and accelerated atherosclerosis [255]. Whether this is 
due to the defect in lysosomal function, or associated hyperlipidaemia, is not known. 
Modified, including glycated, LDL particles may also directly modulate LAL activity 
and expression in human vascular endothelial and smooth muscle cells, with this 
occurring via the LXR signalling pathway [256]. 
Clinical studies have reported increased lysosomal activity in human 
atherosclerotic lesions. Thus subjects with atherosclerosis and diabetes have elevated 
levels of plasma cathepsin D and S [257], monocyte cathepsin D activity [258], 
neutrophilic lysosomal activity [259] and myocardial levels of cathepsin L [260]. 
However, these represent data from an expanded population of activated inflammatory 
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cells, and not lysosomal function on a per cell basis as examined here. Furthermore 
while increased intracellular levels of oxidised proteins can induce elevated lysosomal 
cathepsin expression and activity, this may not equate to an increase in modified protein 
degradation [241]. Increased cathepsin expression and activity may merely be (an 
unsuccessful) response to the accumulation of damaged materials.  
The changes in enzyme activity may result from a decreased clearance of both 
native and modified (glycated / glycoxidised / oxidised) proteins, including those 
internalised by endocytosis, or trafficked intracellularly. A previous study has reported 
that pyrraline-modified albumin is cleared by macrophage-like (P388D1) cells at a 
slower rate than unmodified protein [261], but no changes in lysosomal activity were 
detected. As cathepsin enzymes play a key role in the turnover of internalised LDL in 
arterial wall macrophages, the data obtained in the current study may be of significance 
in diabetes-induced atherosclerosis, with decreased cathepsin activity resulting in an 
accumulation of native or modified apolipoprotein B-100 protein [262] and cholesteryl 
esters and triglycerides. A decreased turnover may also result in a vicious cycle of 
increasing organelle dysfunction, as the level of modified material increases; the 
consequences of such accumulation have been reviewed [239,263]. 
 
3.6 Conclusions 
The studies reported in this chapter indicate that the maturation of human 
monocytes to macrophages over a period of 11 days in high glucose concentrations (20 
- 30 mM) resulted in a significant reduction in lysosomal number, as indicated by the 
LAMP-1, cathepsin protein levels and arylsulfatase activities. There was a marked 
inhibition of lysosomal cathepsin B, L S, D and an inhibition of acid lipase activities 
with increasing glucose concentrations (10 - 30 mM) versus the normal 5.5 mM glucose 
condition at the end of the maturation period. However it is not known when this 
disruption begins to impede lysosomal function during the maturation period, as only 
macrophages after complete maturation were assessed. Thus a major limitation to this 
study is the use of the single time point of 11 days. In the following chapter the time 
course of inhibition of lysosomal function in maturing monocytes incubated in 20 mM 
glucose was investigated at multiple time points.  
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CHAPTER 4: 
LYSOSOMAL DISRUPTION DURING MATURATION OF HUMAN 
MONOCYTES TO MACROPHAGES IN PRESENCE OF 
ELEVATED GLUCOSE 
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4.1   Introduction 
 A number of studies have detected elevated levels of oxidised LDL in 
atherosclerotic plaques [264,265,266], however the mechanism by which this 
accumulation occurs is unclear. Changes in protease and possibly lipase activity may 
alter or inhibit the activity of the removal systems for damaged lipoproteins which may 
play a role in diabetes-associated cardiovascular diseases. Such accumulation may arise 
as a result of impairment of proteolysis and lipolysis processes such as those mediated 
by lysosomes [242,244]. Lysosomal enzymes have been shown to be susceptible to 
modulation by in vitro incubation with reactive aldehydes or preglycated proteins, both 
of which would be elevated in diabetes [243]. In the previous chapter, elevated glucose 
levels were shown to have a dose dependent inhibitory effect on lysosomal number, 
multiple cathepsins and acid lipase activities in fully-differentiated macrophages. These 
lysosomal functional changes may affect the capacity of macrophages to catabolise 
modified (lipo) proteins and enhance accumulation of lipids seen in diabetes associated 
atherosclerosis. In the light of this data, the aim of the studies reported in this chapter 
was to explore at what point during the maturation of monocytes to macrophages in 20 
mM glucose this perturbation in lysosomal function occurs.  
 
4.2   Aims 
To examine the impairment of lysosomal cathepsins and acid lipase activity and 
protein levels during the in vitro maturation of human monocytes to HMDM under 
conditions of high and normal glucose.  
 
4.3   Methods 
Human monocytes isolated from buffy coats of healthy donors were matured 
into macrophages over 10 days as detailed in Section 2.2.4. Maturation in 5.5 mM 
glucose was compared to that in 20 mM glucose. The cell pellets were obtained on days 
2, 4, 6, 8 and 10 as described in Section 2.2.5, to determine the lysosomal activities of 
cathepsins B, L and LAL as detailed in Sections 2.3, 2.3.2 and 2.3.6. 
In separate experiments, the cells were harvested on days 2, 4, 6, 8 and 10 and 
lysates prepared for Western blotting in order to quantify cathepsins B and L and LAL 
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protein levels as detailed in Sections 2.5 - 2.8. Lysosome numbers was estimated using 
lysosomal-associated membrane glycoprotein-1 (LAMP-1) expression. Lysosomal 
protein levels were quantified relative to β-tubulin as loading control. 
 
4.3.1  Statistical Analysis 
  Lysosomal activities from the cells of different donors were determined. The 
values were adjusted to the protein content of the sample and the results were then 
expressed as a percentage of that determined for cells incubated in 5.5 mM glucose after 
two days in vitro. Two-way ANOVA analysis was used followed by a Bonferroni’s post 
hoc test (against time points and glucose concentrations). Differences were assumed to 
be statistically significant at p < 0.05. 
 
4.4   Results 
4.4.1  Protein content in monocytes that were matured in normal and high glucose 
conditions  
The protein content was measured in monocytes as they were developing into 
macrophages to determine the rate of cell growth and examine whether this was 
different between the two glucose conditions.  This was determined by the BCA protein 
assay as detailed in Section 2.4.1. There was an overall increase in protein content as the 
monocytes developed into macrophages in both the normal (p < 0.001) and high glucose 
(p < 0.001) treated monocytes, using two-way ANOVA followed by Bonferroni’s post-
hoc test. However, there were no statistical differences in the protein content observed 
in the monocytes matured to HMDM in the normal 5.5 mM and high 20 mM glucose 
conditions during the maturation period.  
 
4.4.2 Lysosomal cathepsin B and L activity during maturation 
The data presented in the previous chapter is consistent with the inhibition of 
cathepsin B and L activities in human monocytes matured for 10 - 12 days in medium 
containing 20 mM glucose [244]. Whether this inhibition was also present at earlier 
time points during the maturation process was investigated in the current study.  
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Figure 4.1: Measurement of cellular protein levels during maturation of human 
monocytes in normal versus high glucose concentrations.  
Monocytes were matured in media with either 5.5 mM (blue line) or 20 mM (red line) 
glucose. Data (mean ± SEM) is expressed in μg/μL from 5 independent experiments 
using separate cell donors. φ indicates a significance (p < 0.001) by two-way ANOVA 
followed by Bonferroni’s post-hoc test in protein levels between day 2 and day 10. 
 
Cathepsin B activity (assessed as described in Chapter 3) was found to increase 
during monocyte maturation to macrophages. There was an overall increase in 
lysosomal cathepsin B activity as the monocytes developed into macrophages in both 
the normal (p < 0.001) and high glucose (p < 0.001) conditions (Figure 4.2; Panel A). 
At each time point cathepsin B activity was significantly lower for the cells matured 
under the high glucose condition. 
Cathepsin L activity was observed to increase during monocyte maturation to 
macrophages. The activity of lysosomal cathepsin L increased as the monocytes 
developed into macrophages in both the normal (p < 0.001) and high glucose (p < 
0.001) concentrations (Figure 4.2; Panel B). The cathepin L activity was significantly 
lower in the cells matured under the high glucose condition compared to 5.5 mM 
glucose for each time point assessed.  
Overall the monocytes incubated in high glucose showed lower levels of 
lysosomal cathepsin B and L activity at all the time points examined during the 
maturation process to macrophages. 
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Figure 4.2: Maturation of human monocytes in high glucose decreases the activity 
of cathepsin B (Panel A) and L (Panel B) compared to normal glucose 
concentrations.  
Lysosomal cathepsin B and L activities were measured in human monocytes that were 
matured in media with either 5.5 mM (blue line) or 20 mM (red line) glucose for up to 
10 days. Data (mean ± SEM) are expressed relative to the 5.5 mM glucose condition on 
Day 2. Samples were collected from 5 independent experiments using separate cell 
donors. Asterisks indicate a significant decrease in enzyme activity compared to control 
(5.5 mM glucose condition) by two-way ANOVA followed by Bonferroni’s post-hoc 
test; * p < 0.05,  p < 0.01,  p < 0.001. φ indicates a  significance (p < 0.001) in 
activity between day 2 and day 10.  
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4.4.3 Lysosomal acid lipase (LAL) activity during maturation 
LAL is the sole lysosomal hydrolase for endocytosed cholesteryl esters and 
triglycerides [230]. In the previous chapter it was demonstrated that there was an 
impairment of LAL activity in human monocytes matured for 10 - 12 days in medium 
containing 20 mM glucose [244]. The current study examined whether this inhibition 
was also present at earlier time points during the maturation process.  
LAL activity was measured, as described in the previous chapter, in the normal 
and high glucose conditions in the monocytes during the maturation period from days 2 
to 10. There was no statistical increase in LAL activity as the monocytes developed into 
macrophages in either the normal or high glucose treated cells. In the case of the cells 
incubated in 5.5 mM glucose there was an increase in LAL activity between day 2 and 4 
although this did not reach significance (p > 0.05). Between days 4 and 10, the LAL 
activity remained unchanged. In contrast for the cells treated with 20 mM glucose no 
increase in LAL was seen, and at each time point from day 4 to day 10 the LAL activity 
was significantly lower for the high glucose treated cells. 
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Figure 4.3: LAL activity during monocyte maturation at different time points. 
Lysosomal acid lipase (LAL) activity measured in human monoctyes that were matured 
in media with either 5.5 mM (blue line) or 20 mM (red line) glucose for up to 10 days. 
Data (mean ± SEM) are expressed relative to the activity detected for the 5.5 mM 
glucose condition on Day 2. Data was obtained from 5 independent experiments using 
separate cell donors. Asterisks indicate a significant decrease in enzyme activity 
compared to control (5.5 mM glucose condition) by two-way ANOVA followed by 
Bonferroni’s post-hoc test; * p < 0.05, ** p < 0.01. 
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4.4.4 Protein levels of cathepsin B 
The protein levels of procathepsin and mature cathepsin B were assessed to 
determine whether the changes in activity detected during the maturation process arose 
from changes in protein synthesis or processing during the maturation process. This was 
determined for monocytes that were incubated in the normal 5.5 mM and high 20 mM 
glucose concentrations and collected on every second day, by Western blotting (as 
described in Section 2.5.1 - 2.5.8). The cathepsin B proenzyme was detected at 37 kDa 
and the activated cathepsin B was observed at 25 kDa via Western blotting. Cathepsin B 
protein levels were expressed relative to β-tubulin levels, which was detected at 51 kDa.  
The total cathepsin B protein levels were calculated by the addition of 
procathepsin B and activated cathepsin B protein levels that were expressed relative to 
β-tubulin levels. When the ratio of procathepsin to activated cathepsin B protein levels 
were analysed, it was observed that the ratio of procathepsin B declined as the activated 
cathepsin B progressively increased. The normal and high glucose treated monocytes 
followed the same trend and ratio as shown in Figure 4.4.  
When the protein levels were assessed relative to β-tubulin levels, procathepsin 
levels declined as activated cathepsin B protein levels increased during monocyte 
maturation to macrophages in the normal glucose conditions only. There were no 
significant changes observed in the procathepsin and activated cathepsin B protein 
levels from days 2 to 10 in the monocytes that were incubated with high glucose. 
Treatment with high glucose resulted in decreased levels of procathepsin (p < 0.05) and 
activated cathepsin B (p < 0.01) protein with this difference being significantly lower at 
day 10 only (as shown in Figures 4.5 and 4.6 respectively).  
The activity values for cathepsin B that were reported in Section 4.4.2 were also 
assessed relative to activated cathepsin B protein levels to determine whether there was 
a change in lysosomal activity compared to the amount of protein present in the 
monocytes. Overall, there was a decrease in lysosomal activity when compared to 
protein levels expressed from days 2 and 4, which continued throughout the maturation 
process (refer to Panel B in Figure 4.6) though this was not statistically significant. 
However there were no differences in ratio of cathepsin B activity over protein levels in 
the two glucose conditions. 
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Figure 4.4: Procathepsin and activated cathepsin B over the total cathepsin protein 
levels during monocyte maturation at different time points. 
Procathepsin B (Panel A) and activated cathepsin B (Panel B) protein levels were 
measured and quantified over the total cathepsin B protein levels in human monocytes 
that were matured in media with either normal (5.5 mM; blue line) or high (20 mM; red 
line) glucose for up to 10 days. Pooled data (mean ± SEM; from 5 independent 
experiments using separate cell donors) for procathepsin and activated cathepsin B 
protein levels are presented in Panels A and B, respectively. Statistical analysis was 
carried out using two-way ANOVA followed by Bonferroni’s post-hoc test; φ indicates 
a significance (p < 0.001) difference between the values obtained at days 2 and 10.  
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Figure 4.5: Cathepsin B protein levels during monocyte maturation at different 
time points. 
Procathepsin B (37 kDa) and activated cathepsin B (25 kDa) protein levels were 
measured in human monocytes that were matured in media with either normal (5.5 mM; 
blue line) or high (20 mM; red line) glucose for up to 10 days. Panel A shows the results 
from one representative Western blotting experiment at the indicated time points from a 
total of five. Pooled data (mean ± SEM; from 5 independent experiments using separate 
cell donors) for procathepsin B protein levels (expressed relative to β-tubulin) is 
presented in Panel B. Statistical analysis was carried out using two-way ANOVA 
followed by Bonferroni’s post-hoc test; * p < 0.05 between the two glucose 
concentrations. φ indicates a significant (p < 0.001) difference between the values 
obtained at days 2 and 10.  
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Figure 4.6: Activated cathepsin B protein levels and cathepsin B activity versus 
protein levels during monocyte maturation at different time points. 
Activated cathepsin B (25 kDa) protein levels were measured in human monocytes that 
were matured in media with either normal (5.5 mM; blue line) or high (20 mM; red line) 
glucose for up to 10 days (as shown in Panel A). In Panel B the activity of lysosomal 
cathepsin B was assessed over the activated cathepsin B protein levels. Pooled data 
(mean ± SEM; from 5 independent experiments using separate cell donors) for activated 
cathepsin B protein levels (expressed relative to β-tubulin) and activity versus protein 
levels are presented in Panels A and B, respectively. Statistical analysis was carried out 
using two-way ANOVA followed by Bonferroni’s post-hoc test; ** p < 0.01 between 
two glucose concentrations. φ indicates a  significance (p < 0.001) difference between 
the values obtained at days 2 and 10.  
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4.4.5 Protein levels of cathepsin L 
The protein levels of procathepsin and mature cathepsin L were assessed to 
determine whether changes in activity detected during the maturation process affected 
the synthesis of cathepsin L and the conversion of the pro to active forms. This was 
examined via Western blotting (as detailed in Sections 2.5.1 - 2.5.8) from monocytes 
that were incubated in the normal 5.5 mM and high 20 mM glucose conditions and 
collected on every second day throughout the maturation period. The procathepsin L 
protein was detected at 55 kDa and the mature cathepsin L was observed at 25 kDa via 
Western Blotting. These protein levels were expressed relative to β-tubulin levels which 
were detected at 51 kDa.  
The total cathepsin L protein levels were calculated by the addition of 
procathepsin L and mature cathepsin L protein levels that were expressed relative to the 
β-tubulin levels. When the ratio of procathepsin and activated cathepsin L protein levels 
was analysed, the ratio of procathepsin L declined as the mature cathepsin L 
progressively increased as monocytes developed into macrophages, regardless of the 
different glucose conditions, as shown in Figure 4.7.  
When the protein levels were assessed relative to β-tubulin levels, procathepsin 
levels declined as the mature cathepsin L protein levels increased during monocyte 
maturation to macrophages in the normal glucose conditions only (as shown in Figure 
4.8 and 4.9 respectively). There were no significant changes observed in the 
procathepsin and mature cathepsin L protein levels from days 2 to 10 in the monocytes 
that were incubated with high glucose. There were no statistical differences in 
procathepsin L levels between the two glucose concentrations during the maturation 
period; however treatment with high glucose significantly lowered mature cathepsin L 
(p < 0.05) protein levels at day 10. 
The activities of cathepsin L that were reported in Section 4.4.2 were also 
assessed relative to the level of mature cathepsin L protein to determine whether there 
was a change in lysosomal activity compared to the amount of protein in the monocytes 
exposed to high glucose conditions. Overall, there was reduction in lysosomal activity 
relative to protein levels expressed for days 2 and 4 (p < 0.001) in the two glucose 
conditions, which continued throughout the maturation process (refer to Panel B in 
Figure 4.9). However there were no differences in the ratio of cathepsin L activity over 
protein levels between the normal and high glucose concentrations for the cells. 
112 
 
A 
 
 
 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7: Procathepsin and activated cathepsin L over the total cathepsin protein 
levels during monocyte maturation at different time points. 
Procathepsin L (Panel A) and activated cathepsin L (Panel B) protein levels were 
measured and quantified over the total cathepsin L protein levels in human monocytes 
that were matured in media with either normal (5.5 mM; blue line) or high (20 mM; red 
line) glucose for up to 10 days. Pooled data (mean ± SEM; from 5 independent 
experiments using separate cell donors) for procathepsin and mature cathepsin L protein 
levels are presented in Panels A and B, respectively. Statistical analysis was carried out 
using two-way ANOVA followed by Bonferroni’s post-hoc test; φ indicates a 
significance (p < 0.001) difference between the values obtained at days 2 and 10.  
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Figure 4.8: Cathepsin L protein levels during monocyte maturation at different 
time points. 
Procathepsin L (55 kDa) and mature cathepsin L (25 kDa) levels were measured in 
human monocytes that were matured in media with either normal (5.5 mM; blue line) or 
high (20 mM; red line) glucose for up to 10 days. Panel A shows the results from one 
representative experiment from a total of five. Pooled data derived from procathepsin 
and mature cathepsin L (mean ± SEM; from 5 independent experiments using separate 
cell donors) are expressed relative to β-tubulin levels as presented in Panel B, 
respectively. Statistical analysis was carried out using two-way ANOVA followed by 
Bonferroni’s post-hoc test; φ indicates a significant difference (p < 0.001) between days 
2 and 10.  
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Figure 4.9: Mature cathepsin L protein levels and cathepin L activity versus 
protein levels during monocyte maturation at different time points.  
Mature cathepsin L (25 kDa) levels were measured in human monocytes that were 
matured in media with either normal (5.5 mM; blue line) or high (20 mM; red line) 
glucose for up to 10 days (as shown in Panel A). The activity of lysosomal cathepsin L 
was assessed over the activated cathepsin B protein level as shown in Panel B. Pooled 
data derived from procathepsin and mature cathepsin L (mean ± SEM; from 5 
independent experiments using separate cell donors) are expressed relative to β-tubulin 
levels as presented in Panels A and B, respectively. Statistical analysis was carried out 
using two-way ANOVA followed by Bonferroni’s post-hoc test; * p < 0.05 between the 
two glucose concentrations. φ indicates a significant difference (p < 0.001) between 
days 2 and 10. 
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4.4.6 Protein levels of LAL 
The protein levels of LAL were assessed to determine whether the changes in 
activity detected during the maturation process arose from changes in protein synthesis 
during the maturation process. Therefore LAL protein levels were assessed by Western 
blotting (as described in Sections 2.5.1 - 2.5.8) to determine whether high glucose 
affected synthesis of LAL during the maturation process. This was examined in 
monocytes that were incubated in the normal 5.5 mM and high 20 mM glucose 
concentrations, with samples collected every second day between days 2 to 10. The 
LAL protein was detected at 45 kDa and was expressed relative to β-tubulin levels 
which were detected at 51 kDa via Western Blotting.  
There were no changes in LAL protein levels during the maturation process for 
cells incubated in either 5.5 mM or 20 mM glucose. The protein levels of LAL were 
generally lower for cells matured under 20 mM glucose most notably at day 10 but this 
did not reach statistical significance (p > 0.05) (refer to Figure 4.10). 
The activity of LAL that was reported in Section 4.4.3 was also assessed relative 
to LAL protein expression to determine whether there was a change in lysosomal 
activity relative to the amount of protein that was present in the monocytes. Overall, 
there were no changes in the lysosomal activity relative to the protein levels during the 
maturation period (refer to Figure 4.11) and no differences between the two glucose 
treatments. 
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Figure 4.10: LAL protein levels during monocyte maturation at different time 
points. 
LAL (45 kDa) protein levels were measured in human monocytes that were matured in 
media with either normal (5.5 mM; blue line) or high (20 mM; red line) glucose for up 
to 10 days. Panel A shows the results from one representative experiment from a total of 
five. Pooled data (mean ± SEM; from 5 independent experiments using separate cell 
donors) for LAL protein levels (expressed relative to β-tubulin) derived from 5 
individual donors is presented in Panel B. Statistical analysis was carried out using    
two-way ANOVA followed by Bonferroni’s post-hoc test; no statistical differences 
were detected. 
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Figure 4.11: LAL activity relative to protein levels during monocyte maturation at 
different time points.  
The LAL activity and LAL (45 kDa) protein levels were measured in human monocytes 
that were matured in media with either normal (5.5 mM; blue line) or high (20 mM; red 
line) glucose for up to 10 days. Pooled data for LAL activity relative to protein 
expression (mean ± SEM; from 5 independent experiments using separate cell donors). 
Statistical analysis was carried out using two-way ANOVA followed by Bonferroni’s 
post-hoc test, and showed no statistical differences. 
 
 
4.4.7 Protein levels of LAMP-1 
The protein levels of LAMP-1 were assessed as a measure of any change in 
lysosomal number during the maturation process; the data presented in the previous 
chapter indicated that LAMP-1 levels were significantly reduced on treatment with high 
glucose (20 mM) for 11 days in HMDM [244]. The LAMP-1 protein band was detected 
at 120 kDa and expressed relative to β-tubulin which was detected at 51 kDa.  
There was an overall increase in LAMP-1 protein levels in both the normal 
glucose (p < 0.001) and high glucose conditions (p < 0.001) during the maturation 
period (Figure 4.8). There were no statistical differences in LAMP-1 levels between the 
two glucose concentrations during the maturation period from days 2 to 8, although the 
results for the high glucose-treated cells trended to lower values. However by day 10 the 
LAMP-1 levels were significantly lower for the high glucose-treated HMDM (p < 0.05). 
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Figure 4.12: LAMP-1 protein levels during monocyte maturation. 
LAMP-1 (120 kDa) protein levels were measured in human monocytes matured under 
normal (5.5 mM; blue line) or high (20 mM; red line) glucose concentrations for up to 
10 days. Panel A shows the results from one representative Western blotting experiment 
from a total of five. Pooled data (mean ± SEM; from 5 independent experiments using 
separate cell donors) for LAMP-1 levels (expressed relative to β-tubulin) are presented 
in Panel B.  Statistical analysis was carried out using two-way ANOVA followed by 
Bonferroni’s post-hoc test; * p < 0.05 between the two glucose concentrations. φ 
indicates a significant difference (p < 0.001) between the data obtained at days 2 and 10.  
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4.5  Discussion 
This study examined changes in lysosomal protease and lipase activity and 
protein levels as well as lysosomal number in human monocytes as these were matured 
in vitro to macrophages. It was found that exposure of human monocytes to chronic 
high glucose concentrations resulted in an impairment of protease activity as monocytes 
matured to macrophages. The magnitude of the glucose-induced changes was most 
pronounced at the final time point examined.  
The studies reported in the previous chapter showed a significant reduction in 
lysosomal cathepsin B, L and LAL activities in macrophages matured in 20 mM 
glucose compared to the 5.5 mM condition [244]. Significant reductions in cathepsin B 
and L enzymatic activities were detected for cells matured under the high glucose 
conditions from as early as two days in vitro. The high glucose condition also reduced 
the LAL enzymatic activity in the maturing monocytes from day six onwards.  
Independent of the glucose treatment, maturation in vitro was associated with a 
decline in pro-cathepsin enzyme levels, with a parallel increase in active enzyme levels 
for both cathepsins B and L both individually and when expressed relative to the total 
cathepsins. The impact of high glucose upon protein levels differed between the two 
cathepsins. With cathepsin B there was a trend towards lower levels from day 2 
although this was only statistically significant at day 10. In contrast to this a decline in 
cathepsin L protein levels in the high glucose-treated cells was discernible after day 6 
although it was also only statistically significant at day 10. When comparing these 
results with those for cathepsin activity, it would seem that impact of high glucose upon 
monocyte/macrophage proteolytic activity may involve both inactivation as well as a 
reduction in protein synthesis. However this was not seen in a previous study by 
Moheimani [244], where HMDM were incubated with 5 or 30 mM glucose 
concentrations and the differences were not statistically different. In the current study 
the procathepsin and the mature/ activated form of cathepsin B and L were investigated 
and were quantified relative to β-tubulin levels, commonly used as a loading control to 
account for differences in protein loading. This is important as the total protein levels 
steadily increased throughout the whole maturation process. 
In contrast to the cathepsins, there was no significant increase in LAL protein 
levels during the maturation process and exposure to high glucose did not have a 
statistically significant impact upon these levels. Here again these results are in contrast 
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to what was seen with the LAL activity levels where maturation under the high glucose 
condition had a significant inhibitory effect. These data therefore suggest that the major 
effect of high glucose levels is to inactivate LAL.  
There was reduction in activity relative to the amount of the protein expressed 
for cathepsin L, and to a lesser degree cathepsin B over the maturation period when the 
individual lysosomal activities were assessed relative to the corresponding protein 
levels in both glucose conditions. However the differing glucose treatments did not 
cause any changes in LAL activity when compared to protein expression during the 
maturation process. A similar loss in activity was detected on incubation of 
glyceraldehyde-3-phosphate dehydrogenase with reactive aldehydes and protein-bound 
carbonyls along with concurrent loss of thiol groups.  This loss in activity has been 
reported to be due to reaction of the free or protein-bound carbonyls with the thiol 
groups of the enzyme [267]. Reactive aldehydes and protein-bound carbonyls have also 
been shown to inhibit lysosomal cysteine proteases B, L and S due to the loss of the 
cysteine residue within the active site in a macrophage cell line [243]. Inactivation of 
these enzymes induced by oxidative/ carbonyl stress may contribute to the accumulation 
of modified proteins and lead to cellular dysfunction in a number of diseases. 
The significant increase in lysosomal number (as represented by a significant 
increase in LAMP-1 protein levels) during monocyte maturation paralleled the changes 
for the two cathepsins as well as the trend seen for LAL protein. Here again a 
significant impact upon LAMP-1 levels of the high glucose levels were only seen at day 
10. The decrease in LAMP-1 levels observed at the end of the maturation period was 
similar to that observed in the previous chapter for HMDM that were incubated in 20 
mM glucose [244].  
A number of previous studies have proposed a major role for lysosomes in 
diabetes-associated complications. A reduction in lysosomal proteolytic activity has 
been reported to be reduced by glycated proteins [229,242,243]. Lysosomal cathepsin B 
and L activity has also been reported to be impeded by proteins containing 
hydroperoxide groups with this ascribed to oxidation of the active site Cys residues of 
these enzymes [229,243]. Advanced glycation end products (AGEs) which are known to 
be elevated in diabetes have also been shown to have inhibitory effects on both 
proteasome activity [242] and on lysosomal cathepsin activities [268,269]. These 
deleterious effects of AGE products on proteasomal and lysosomal function may 
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influence the turnover of both intracellular and extracellular proteins [268]. A reduction 
in intracellular protein turnover was also shown by Xian et al [270]. Suppression of 
cathepsin mRNA expression may play a role in reduced lysosomal activities, with a 
previous study having reported time and dose dependent decreases in the activities of 
cathepsins B, L and H after incubation with AGEs [271]. The inhibitory effects of high 
glucose on mRNA levels were not assessed for the monocytes/ macrophages examined 
in the current studies. A study by Moheimani et al. has shown that macrophage 
scavenger receptor mRNA and protein levels can be perturbed by high glucose in 
HMDM, however these changes did not affect cholesterol and cholesteryl ester 
accumulation, or ester type in these human macrophages [272]. The studies reported 
above confirm that hyperglycaemia may be a contributory factor in the increased 
occurrence and the acceleration of atherosclerosis in people with diabetes. 
The degradation of a complex mixture of AGE-modified proteins might be a 
multifactorial process involving several proteases and peptidases and lysosomal 
activities [243,273]. In particular the proteasome and the endosomal lysosomal systems 
involved in the catabolism of modified and damaged proteins may act synergistically 
[243,269].  Lysosomal proteolytic enzymes appear to be essential for the survival of 
cells during the maturation of monocytes to macrophages which may provide insight 
into how accumulation of AGEs and their deleterious effects can be reduced by 
lysosomal enzymes [269]. In the circumstances of diabetes where the current studies 
have demonstrated impaired lysosomal function, and previous studies have shown the 
deleterious impact of AGE-modified proteins upon the same functions [243,269,274], 
one important contributor to the increased prevalence and rate of progression seen in 
people with diabetes could be impact of chronic hyperglycaemia upon macrophage 
function.  
Further investigations should be carried out to determine whether stimulation of 
lysosomal cathepsins or acid lipase activities modulates lipid cholesterol and cholesteryl 
ester accumulation, which may be a base for developing new pharmaceuticals for the 
prevention / alleviation of diabetes-associated cardiovascular diseases. Therefore, as to 
whether therapies designed to promote lysosomal function could have a synergistic 
effect to those that alleviate the hyperglycaemia of diabetes remains to be investigated.  
Given the current findings, agents that could reduce the hyperglycaemia and 
glycative damage that characterises diabetes mellitus may be protective of macrophage 
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degradative function and potentially anti-atherogenic in the case of diabetes-accelerated 
atherosclerosis. The following chapter presents an investigation as to whether carnosine 
(which has putative hypoglycaemic and anti-glycative activities) can prevent or inhibit 
atherosclerotic plaque development in a model of diabetes-accelerated atherosclerosis:  
apo E
-/- 
mice in which diabetes is induced by treatment with streptozotocin.  
 
4.6 Conclusion 
Increased lysosomal cathepsin and acid lipase activities, as well as protein levels 
and lysosomal number were observed during in vitro maturation of monocytes to 
macrophages. This has implications for clinical studies that generally rely on blood 
monocytes as a marker of tissue-dwelling macrophage function. Chronic exposures to 
high glucose during the maturation lead to impaired lysosomal proteolytic and lipase 
levels as well as total lysosome numbers. Shorter term exposure was found to inhibit 
lysosomal enzyme activity independent of any effect upon protein levels. These results 
suggest several mechanisms by which high glucose can lead to an impairment of 
macrophage degradative activity. These functional changes may affect the capacity of 
macrophages to catabolise modified (lipo) proteins during the maturation process and 
enhance the lipid accumulation seen in diabetes-associated atherosclerosis. 
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CHAPTER 5: 
INVESTIGATIONS OF THE POTENTIAL PROTECTIVE EFFECT 
OF CARNOSINE IN A MURINE APO E
-/-
 MODEL OF DIABETES-
INDUCED ATHEROSCLEROSIS 
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5.1  Introduction 
Cardiovascular disease is a major complication of diabetes and several studies 
have demonstrated that people with diabetes have 2 - 4 fold greater risk of 
cardiovascular disease compared to people without diabetes [111]. Diabetes has also 
been identified as an independent risk factor for cardiovascular- associated mortality 
[112]. Evidence suggests that the high incidence of cardiovascular disease amongst 
people with diabetes cannot be solely explained by well-established cardiovascular risk 
factors and that the chronically elevated blood glucose levels in diabetes contributes to 
the increased incidence of atherosclerosis [114,275]. 
The major impact of diabetes on cardiovascular health has led to extensive 
investigations of therapies designed to prevent, inhibit or reverse diabetes-associated 
atherosclerosis with many of these studies carried out in experimental animals such as 
mice.  Mouse models of this disease include the streptozotocin-treated apo E
-/-
 mouse 
[276,277]. Studies using this model, as well as clinical reports, are consistent with a role 
for increased production of AGE, mediated by protein glycation / glycoxidation and 
oxidative stress, in the development and progression of diabetes-accelerated 
atherosclerosis [278].  
Carnosine (β-alanyl-L-histidine dipeptide) is an endogenous dipeptide present at 
high concentrations in skeletal muscle [279]. A number of functions have been ascribed 
to carnosine including: as a buffer; as a regulator of Ca
2+  
sensitivity, as an antioxidant, 
or as an agent which could both prevent and reverse glycative and glycoxidative 
modifications to cell and tissue components [279,280]. Previous in vitro studies have 
shown that carnosine was effective at blocking pro-atherosclerotic AGE formation on 
low-density lipoproteins [281]. Recently Meini et al. [282] have demonstrated an anti-
atherosclerotic activity of  D-carnosine octylester in fat-fed apo E
-/-
 mice. Carnosine has 
also been shown to block increases in plasma triglycerides and cholesterol in fat-fed, 
non-diabetic, C57BL/6 mice [283]. As an endogenous peptide, carnosine has been 
shown to be safe and effective for oral delivery. It is absorbed as the intact dipeptide 
and hydrolysis in the intestinal mucosa is readily saturable [284]. However while it 
would be expected that intact dipeptide should be detectable in blood, plasma carnosine 
levels in humans are low or undetectable due to the rapid hydrolysis of carnosine in 
plasma induced by the enzyme carnosinase (e.g. [279,284] ).  Synthetic derivatives have 
however been developed that are much less susceptible to such hydrolysis (e.g. 
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[285,286,287]) and may therefore have therapeutic potential. By contrast, chronic 
supplementation of rodents with carnosine results in a persistent and significant 
elevation of plasma and tissue carnosine levels (e.g. [283,288,289]). Thus, chronic 
supplementation of rodents with carnosine provides an appropriate model to examine 
potential in vivo effects of carnosine (or its derivatives) as anti-oxidative / anti-glycative 
agents. The current study assesses, in vivo, the anti-atherogenic potential of chronic 
supplementation of streptozotocinF-treated apo E
-/-
 mice with carnosine. 
 
5.2 Aims 
To determine whether carnosine prevents or reverses atherosclerotic lesion 
formation and progression caused by prolonged periods of high blood glucose in vivo, 
using streptozotocin-treated diabetic apo E
-/-
 gene knock-out mice as a model of 
diabetes-associated atherosclerosis.  
 
5.3  Methods 
5.3.1 Animal model design 
Mice (n = 80) were maintained for 20 weeks, post-induction of diabetes, with 
the grouping as shown in Figure 5.1 that is; (i) control (vehicle-dosed); (ii) control mice 
receiving carnosine (2 g/L) in their drinking water; (iii) diabetic (streptozotocin-dosed) 
mice; and (iv) diabetic mice receiving carnosine in their drinking water. At the time of 
sacrifice, blood was collected for quantification of blood glucose and glycated 
haemoglobin, and plasma was prepared for assessment of carnosine, total cholesterol 
and triglyceride levels. The details and source of the animals used in this study are 
outlined in Sections 2.7 and 2.7.1. 
Induction of diabetes; care and monitoring of the animals; determination of body 
mass, blood glucose and glycated haemoglobin level; sample collection, fixation and 
store; and determination of plasma carnosine levels were undertaken by Dr David van 
Reyk and Dr Bronwyn Brown. Plasma cholesterol and triglyceride analyses were 
carried out by Ms Liming Hou of the Lipid Group of the Heart Research Institute. 
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Figure 5.1: Experimental Plan. 
The first two groups comprised of vehicle-dosed control mice groups (outlined in blue) 
with and without carnosine supplemented in their water. The third and fourth groups 
comprised of streptozotocin induced diabetic mice (outlined in orange) with and without 
carnosine supplemented in the water respectively.  
 
 
5.4 Results 
5.4.1 Induction of diabetes with STZ treatment 
Diabetes was confirmed by significant increases in blood glucose and glycated 
haemoglobin as shown in Figure 5.2 (reproduced with permission from Dr van Reyk). A 
wide range of blood glucose levels was observed amongst the mice, a blood glucose 
level of 18 mM was chosen to distinguish between those with and without diabetes. 
This cut-off was supported by glycated haemoglobin levels and body mass 
determinations. Thus mice with blood glucose levels < 18mM (for STZ-treated mice) or 
above this level (for vehicle-treated mice) were omitted from the data set. This cut-off is 
similar to that used previously for this model (19.2 mM; [276]). To ensure this decision 
did not have a major effect on the conclusions drawn, the data sets were also censored at 
20, 16, 14 and 12 mM blood glucose and reanalysed. Each cut-off gave broadly 
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consistent results, indicating that the choice of 18 mM did not affect the conclusions, 
nor was the level of blood glucose used as an indicator of diabetes induction, critical to 
the effects detected.  
Using this cut-off to distinguish between control mice (CTL) and those with 
diabetes (DIAB), the latter had a significantly lower body mass at time of sacrifice with 
a significant elevation of blood glucose, glycated haemoglobin, total cholesterol and 
triglycerides levels as presented in Table 5.1 (reproduced with permission from Dr van 
Reyk). These data are in accord with previous studies [276,290,291].  
 
 
 
Figure 5.2: Blood glucose levels (A) and glycated haemoglobin levels (B), at the 
time of sacrifice, for control (CTL) and diabetic (DIAB) apo E
-/-
 mice with (+CN) 
or without carnosine supplementation.  
Individual determinations (n = 12 - 18) are presented, together with the median value 
(horizontal bar). Out of range results (> 33 mmoles/L for blood glucose; and < 4% or 
>13% for glycated haemoglobin) are represented as markers placed on the dashed line 
that delimits the range of detection. A number of the animals with diabetes have 
superimposed data points. *: significantly different (p < 0.05) from the control group at 
the same level of carnosine supplementation using rank-transformed data. 
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Control 
Control 
with CN 
Diabetic 
Diabetic 
with CN 
Mass (g) 27.8 + 0.6 29.9 + 0.5 24.6 + 0.9* 24.2 + 0.5* 
Total cholesterol 
(mmoles/L) 
9.6 + 0.5 9.0 + 0.3 14.6 + 2.1* 15.2 + 0.7* 
Triglycerides (mmoles/L) 1.1 + 0.1 0.8 + 0.1
#
 1.7 + 0.2* 1.3 + 0.1*
#
 
 
Table 5.1: Mean body mass, total cholesterol and triglyceride plasma levels, 
estimated at the time of sacrifice, for non-diabetic (control) and diabetic apo E
-/-
 
mice with or without carnosine (CN) supplementation.  
Results are expressed as mean + standard error of the mean (SEM) for 12 - 19 mice per 
group. *: significantly different (p < 0.05) from control group at the same level of 
carnosine supplementation. 
#
: significantly different (p < 0.05) from the non-
supplemented group matched for glycaemic status using transformed data. 
 
 
5.4.2 Efficacy of carnosine supplementation 
Plasma-derived low molecular mass filtrates (< 3000 Da) were obtained by 
centrifugation (13 400 g, 30 min, 4°C) using Pall Nanosep 3000 MWCO filters (Ann 
Arbor, MI, USA) after. Carnosine was quantified by HPLC, after pre-column 
derivatisation with o-phthaldialdehyde (with 5% v/v 2-mercaptoethanol), against 
authentic standards [18].  
Low levels of plasma carnosine were detected reproducibly in the non-
supplemented mice, with supplementation significantly increasing this value as 
presented in Figure 5.3 (reproduced with permission from Dr van Reyk and Dr Brown). 
There was however substantial variation amongst individual mice in both supplemented 
groups.   
Supplementation with carnosine had no effect on blood glucose or glycated 
haemoglobin levels, final body mass or plasma total cholesterol levels (Table 5.1). 
However, for mice with the same glycaemic status (CTL or DIAB), triglycerides were 
significantly lower in the carnosine supplementation groups. 
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Figure 5.3: Plasma carnosine levels (μmoles/L), at the time of sacrifice, for control 
(CTL) and diabetic (DIAB) apo E
-/-
 mice with (+CN) or without carnosine 
supplementation.  
Data are presented as the 95% confidence interval together with the mean (n =12 - 18). 
#: significantly different (p < 0.05) from the non-supplemented group matched for 
glycaemic status using General Linear Model on the natural log-transformed data. 
 
 
5.4.3 Morphometry of atherosclerotic plaques in the brachiocephalic artery 
Six sections (A - F) were prepared for estimation for atherosclerotic lesion size 
in the brachiocephalic artery. One set of the six duplicate sections (A - F) was stained 
with Haematoxylin and Eosin (H & E) for general morphology in order to determine 
plaque areas, as described in Section 2.7.7 and displayed in Figure 5.4. The images were 
captured digitally with an IX71 Olympus microscope (North Ryde, NSW, Australia) for 
morphometric analysis for the following areas within the outlined boundaries of the 
brachiocephalic artery: total cross-sectional area, lumen, plaque and the cross-sectional 
area within the internal elastic intima as illustrated in Figure 5.5.  
 
 
# 
# 
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Figure 5.4: Representative images of 6 cross sections (A - F) taken from the 
brachiocephalic artery. 
5 μm sections were taken from the brachiocephalic artery commencing when the first 
entirely circular cross-section appeared for Slide A. Duplicate sections were taken every 
100 μm until six sections in total had been obtained from A to F. Sections were stained 
with H&E and photographed using a 20x objective.  
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Figure 5.5: Calculation of plaque morphometry in the brachiocephalic artery. 
Morphometry was performed on the cross-sections of the brachiocephalic artery. For the 
brachiocephalic artery the following measurements were made; internal area of lumen, 
plaque, internal elastic intima and total cross-sectional area.  
 
 
The arteries from the diabetic mice contained more plaque than the non-diabetic 
mice (p < 0.05) in both the non-carnosine and carnosine supplemented groups as shown 
in Figure 5.6 (Panel A).  There were significant increases in plaque area in the diabetic 
control (60.9 ± 4.8 (x10³) μm², p < 0.05) when compared to the non-diabetic control 
mice (44.9 ± 4.7 (x10³) μm²). Diabetic mice supplemented with carnosine (57.2 ± 3.6 
(x10³) μm², p < 0.05) also had more plaque than the control supplemented carnosine 
mice (40.4 ± 4.7 (x10³) μm²).  
 
 
132 
 
When the plaque areas are expressed relative to the total area there was a higher 
percentage observed in the diabetic control (41.8 ± 2.9 %, p < 0.05) than the non- 
diabetic control mice (33.5 ± 2.8 %) as shown in Figure 5.6 (Panel C). There was also a 
greater plaque percentage in the diabetic supplemented carnosine mice (41.6 ± 1.5 %, p 
< 0.05) when compared to the control supplemented carnosine mice (31 ± 3.5%). 
The area enclosed within the internal elastic intima and the area of the lumen 
were also measured in order to determine whether there were any differences between 
the morphological structure of the diabetic and non-diabetic mice with and without 
carnosine supplementation. There was a smaller ratio of lumen area over the total area 
observed in the diabetic mice supplemented with carnosine (30.9 ± 1.4, p < 0.05) than 
the non-diabetic mice supplemented with carnosine (39 ± 2.9) as presented in Figure 5.7 
(Panel A).  There were no statistical differences observed when the internal elastic 
intima areas were analysed over the total area as shown in Figure 5.7 (Panel B). 
Overall the diabetic mice had a greater extent of atherosclerotic plaque and a 
decreased lumen size as a percentage of total area in the brachiocephalic artery than the 
non-diabetic mice. Carnosine supplementation had no effect upon the increased plaques 
and smaller lumen sizes in these mice.  
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Figure 5.6: Plaque morphometry in brachiocephalic artery for plaque area 
(Panel A), total area (Panel B) and  percentage of plaque compared to total arterial 
cross-sectional area (Panel C) in control (CTL) and diabetic (DIAB) apo E
-/-
 mice 
with or without carnosine (+/- CN) supplementation.   
Plaque and total cross sectional areas of the artery were determined in the 
brachiocephalic artery are calculated as (x10³) μm² in Panels A and B. Plaque is 
expressed as a percentage over the total area in Panel C.  Statistical significance was 
achieved at * p < 0.05 versus control (CTL - CN), + p < 0.05 versus control 
supplemented with carnosine (CTL + CN) using two-way ANOVA followed by 
Bonferroni’s post-hoc test. Values are expressed as mean ± SEM.   
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Figure 5.7: Ratio of lumen (Panel A) and internal elastic intima areas (Panel B) 
over the total cross-sectional area of the brachiocephalic artery in control (CTL) 
and diabetic (DIAB) apo E
-/-
 mice with or without carnosine (+/- CN) 
supplementation.   
Lumen and internal elastic intima areas of the artery were determined in the 
brachiocephalic artery and the ratio was calculated over the total cross-sectional area.  
Statistical significance was achieved at + p < 0.05 versus control supplemented with 
carnosine (CTL + CN) using two-way ANOVA followed by Bonferroni’s post-hoc test. 
Values are expressed as mean ± SEM.   
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5.4.4 Plaque area in aortic sinus 
Six duplicate (A - F) cross-sections were taken along the aortic sinus and were 
imaged and morphometric measurements were performed with image analysis software 
as described in Section 5.3.3 to 5.3.4 and shown in Figure 5.8. The areas within the 
outlined boundaries of the aortic sinus were examined across the six duplicates (A - F) 
cross-sections in order to determine total plaque and cross-sectional area as illustrated in 
Figure 5.9.  
There were significant increases in plaque area in the diabetic supplemented 
carnosine group (43.3 ± 4.9 (x10³) μm², p < 0.01) when compared to the control 
supplemented carnosine mice (24.9 ± 3.2 (x10³) μm²) as shown in Figure 5.10 (Panel 
A). There were no statistical significant differences in the average cross-sectional total 
areas of the aortic sinus observed across the groups as shown in Figure 5.10 (Panel B).  
When plaque area was analysed over the total arterial cross-sectional area there 
was a higher percentage plaque area observed in the diabetic mice supplemented with 
carnosine (28.9 ± 2.4 %, p < 0.001) when compared to the control supplemented 
carnosine mice (18.1 ± 1.6%). There was a lower percentage of plaque seen in the 
control supplemented carnosine mice than the control mice (26.2 ± 1.5%, p < 0.05) as 
shown in Panel C of Figure 5.10. 
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Figure 5.8: Representative images of 6 cross-sections (A - F) taken from the aortic 
sinus. 
5 μm sections were taken from the appearance of the three valve leaflets for Slide A. 
Duplicate sections were taken every 100 μm until six sections in total had been 
obtained. Sections were stained with H&E and photographed using a 10x objective.  
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Figure 5.9: Calculation of plaque morphometry in the aortic sinus. 
Morphometry was performed on the cross-sections of the aortic sinus. For the aortic 
sinus, the total surface cross-sectional area and plaque areas were measured.  
 
 
 
Overall the diabetic mice had a greater extent of atherosclerotic plaque 
formation than the non-diabetic mice for groups on the same supplementation regime. 
Ingestion of carnosine did not result in a significant reduction in plaque size for the 
diabetic animals.  
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Figure 5.10: Plaque morphometry in the aortic sinus for plaque area (Panel A), 
total area (Panel B) and  percentage of plaque on total area (Panel C) in control 
(CTL) and diabetic (DIAB) apo E
-/-
 mice with or without carnosine (+/- CN) 
supplementation.   
Plaque and total cross sectional areas within the leaflets were determined for the aortic 
sinus are calculated as (x10³) μm² in Panels A and B. Plaque is expressed as a 
percentage over the total area in Panel C.  Statistical significance was achieved at ++ p 
< 0.01, +++ p < 0.001 versus control supplemented with carnosine (CTL + CN) and ^ p 
< 0.05 versus the control (CTL – CN) using two-way ANOVA followed by 
Bonferroni’s post-hoc test. Values are expressed as mean ± SEM.   
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5.4.5 Smooth muscle cells in fibrous cap in the brachiocephalic artery 
Immunostaining for α-actin was examined as a marker for the degree of smooth 
muscle cell infiltration of the plaque, to determine whether carnosine had any effect on 
plaque stability. The plaques were examined using the same sets of samples as 
described previously (refer to Sections 2.8.3 and 2.8.4). The fibrous caps of the 
atherosclerotic plaques were observed to contain α-actin expressing cells with these 
primarily detected in the regions of the cap directly beneath the endothelium as shown 
in Figure 5.11.   
As shown in Figure 5.12 (Panel A), there were no differences in absolute levels 
of α-actin staining between the diabetic and control mice in the absence of carnosine 
supplementation. However, there was a greater extent of α-actin staining in the 
carnosine-supplemented diabetic (1.5 ± 0.3 (x10³) μm², p < 0.05) than the carnosine-
supplemented control (0.7 ± 0.2 (x10³) μm²) mice.  Carnosine-supplemented diabetic 
mice had more levels of α-actin than the diabetic (0.5 ± 0.2 (x10³) μm², p < 0.05) mice.    
A higher plaque area was observed in the diabetic (47.2 ± 4.2 (x10³) μm², p < 
0.05) than the control mice (34 ± 3.2 (x10³) μm²) without carnosine supplementation as 
shown in Figure 5.12 (Panel B). No statistical differences were seen between the two 
carnosine supplemented groups. When the area of α-actin staining was analysed over 
the plaque area, there was a higher, statistically significant, percentage of α-actin 
staining observed in the carnosine-supplemented diabetic (4.2 ± 0.8 %, p < 0.05) than 
the diabetic mice (1.5 ± 0.6 %; and refer to Panel C in Figure 5.12).  
Although there were no statistical differences detected in α-actin levels between 
the control and diabetic mice, when comparing the two diabetic groups, carnosine 
supplementation was associated with higher absolute levels and percentage of α-actin 
immunostaining in the brachiocephalic artery.  
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Figure 5.11: Representative sections showing α-SM-actin staining in the 
brachiocephalic artery in control (CTL) and diabetic (DIAB) apo E
-/-
 mice with or 
without carnosine (+/- CN) supplementation.   
Representative image of sections from the brachiocephalic artery stained for α-actin (red 
staining) produced by smooth muscle cells. The red staining was quantified and 
expressed as a percentage of the total plaque area. For illustration purposes the slides 
were captured using a Carl Zeiss microscope and a 20x objective lens. 
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Figure 5.12: α-SM-actin staining of the fibrous cap in the brachiocephalic artery 
for α-actin area (Panel A), plaque area (Panel B) and percentage of α-actin on total 
area (Panel C) in control (CTL) and diabetic (DIAB) apo E
-/-
 mice with or without 
carnosine (+/- CN) supplementation.   
The area of α-actin staining and plaque area determined for the brachiocephalic artery 
sections are calculated as (x10³) μm² in Panels A and B. The area stained by α-actin is 
expressed as a percentage over the plaque area in Panel C.  Statistical significance was 
achieved at * p < 0.05 versus control (CTL - CN), + p < 0.05 versus control 
supplemented with carnosine (CTL + CN) # p < 0.05 versus the diabetic (DIAB) apo E
-
/-
 mice using two-way ANOVA followed by Bonferroni’s post-hoc test. Values are 
expressed as mean ± SEM.   
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5.4.6 Smooth muscle cells in the aortic sinus 
The fibrous caps were examined for α-actin staining arising for smooth muscle 
cells in the aortic sinus at 100 μm from the first appearance of the three valve leaflets as 
described in Sections 2.8.3 and 2.8.4. Representative images of the fibrous caps of the 
atherosclerotic plaques contained α-actin expressing cells which were stained red are 
shown in Figure 5.13.  
As shown in Figure 5.14 (Panel A), there were no statistical differences in 
absolute levels of α-actin staining between the control and the diabetic mice in the 
absence of carnosine supplementation. However there was a significant increase in α-
actin staining in the carnosine-supplemented diabetic mice (1.5 ± 0.3 (x10³) μm², p < 
0.05) when compared to the carnosine-supplemented control mice (0.6 ± 0.1 (x10³) 
μm²).  
A significant increase in plaque size was detected in the diabetic (21.6 ± 1.5 
(x10³) μm², p < 0.001) when compared to the control mice (14.5 ± 2.9 (x10³) μm²) as 
shown in Figure 5.14 (Panel B). A similar trend for plaque area was seen in the 
carnosine-supplemented diabetic (18.1 ± 1.2 (x10³) μm², p < 0.001) than the carnosine-
supplemented control mice (11.9 ± 1.2 (x10³) μm²). There were no statistical differences 
detected across the groups when the area of α-actin was expressed as a percentage of the 
plaque area as shown in Figure 5.14 (Panel C). When α-actin staining was expressed as 
a percentage of the total plaque area, carnosine-supplementation was associated with an 
increase in the percentage area positive for α-actin for both control and diabetic mice; 
however this increase did not reach statistical significance at this site.  
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Figure 5.13: Representative sections showing α-SM-actin staining in the aortic 
sinus in control (CTL) and diabetic (DIAB) apo E
-/-
 mice with or without carnosine 
(+/- CN) supplementation.   
Representative images of sections taken from the aortic sinus stained for α-actin to 
detect smooth muscle cells which appear as red staining. The area of red was calculated 
over the plaque area and expressed as a percentage of α-actin content within the plaques 
formed. For illustration purposes the slides were captured by use of a Carl Zeiss 
microscope. 
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Figure: 5.14: α-SM-actin staining of the fibrous cap in the aortic sinus for α-actin 
area (Panel A), plaque area (Panel B) and percentage of α-actin on total area 
(Panel C) in control (CTL) and diabetic (DIAB) apo E
-/-
 mice with or without 
carnosine (+/- CN) supplementation.   
The α-actin and plaque areas that were determined in the aortic sinus are calculated as 
(x10³) μm² in Panels A and B. The area stained by α-actin is expressed as a percentage 
over the plaque area in Panel C.  Statistical significance was achieved at *** p < 0.001 
versus control (CTL - CN) and + p < 0.05, +++ p < 0.01 versus control supplemented 
with carnosine (CTL + CN) apo E
-/-
 mice using two-way ANOVA followed by 
Bonferroni’s post-hoc test. Values are expressed as mean ± SEM.   
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5.4.7 Macrophages in plaque within the brachiocephalic artery sections 
In the brachiocephalic artery, the presence of macrophages in the plaques was 
assessed by probing for the murine macrophage marker F4/80 at 200 μm from the first 
complete circumference of the vessel as described in Sections 2.8.5. The macrophages 
were stained pink as shown in Figure 5.15 and the area occupied by these cells was 
quantified in order to investigate the composition of the atherosclerotic plaque formed 
in the diabetic and non-diabetic mice that were treated with and without carnosine.   
There was no increase in the areas that were stained for macrophages in the 
diabetic mice versus the non-diabetic mice regardless of carnosine supplementation as 
shown in Figure 5.16 (Panel A). There was a significant increase in plaque area in the 
vessels from the diabetic mice (38.1 ± 3.3 (x10³) μm², p < 0.01) than the control mice 
22.3 ± 3.5 (x10³) μm²) and higher plaque size in carnosine-supplemented diabetic (33.1 
± 3.6 (x10³) μm², p < 0.01) than carnosine-supplemented control mice (17.4 ± 3.1 (x10³) 
μm²) as presented in Figure 5.16 (Panel B). 
When F4/80 staining was expressed as percentage of total plaque area diabetic 
mice were associated with decrease in percentage positive for F4/80 than the control 
mice regardless of carnosine-supplementation, however this decrease did not reach 
statistical significance.  There were no statistical differences achieved when the area of 
F4/80 was analysed over the total plaque area as shown in Figure 5.16 (Panel C). 
Supplementation with carnosine did not therefore appear to affect the macrophage 
content within the plaques formed in the brachiocephalic artery.  
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Figure 5.15: Representative sections showing F4/80 staining in the brachiocephalic 
artery in control (CTL) and diabetic (DIAB) apo E
-/-
 mice with or without 
carnosine (+/- CN) supplementation.   
Representative sections taken from the brachiocephalic artery were stained with F4/80 
to detect for macrophages which appeared as pink colouration. The area of pink staining 
was calculated over the plaque area and expressed as a percentage of F4/80 staining 
within the total plaques formed. For illustration purposes the slides were captured by 
Carl Zeiss microscope using a 20x objective lens. 
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Figure 5.16: F4/80 staining for macrophages in the brachiocephalic artery for 
F4/80 area (Panel A), plaque area (Panel B) and percentage of F4/80 on total area 
(Panel C) in control (CTL) and diabetic (DIAB) apo E
-/-
 mice with or without 
carnosine (+/- CN) supplementation.   
The F4/80 and plaque areas that were determined in the brachiocephalic artery are 
calculated as (x10³) μm² in Panels A and B. The area stained by F4/80 is expressed as a 
percentage over the plaque area in Panel C.  Statistical significance was achieved at ** p 
< 0.01 versus control (CTL - CN) and ++ p < 0.01versus control supplemented with 
carnosine (CTL + CN) apo E
-/-
 mice using two-way ANOVA followed by Bonferroni’s 
post-hoc test. Values are expressed as mean ± SEM.   
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5.4.8 Macrophages in plaque within aortic sinus sections 
In order to examine the composition of the plaque generated in the diabetic and 
non-diabetic mice with and without carnosine-supplementation, the presence of 
macrophages within the plaques of the aortic sinus was examined by probing for the 
murine macrophage marker F4/80 at 200 μm from the first appearance of three valve 
leaflets as described in Sections 2.8.5. The macrophages were stained pink within the 
atherosclerotic plaques formed within the valve leaflets of the aortic sinus as shown in 
Figure 5.17. 
There were no statistical differences observed in the areas that were stained for 
macrophages in the diabetic mice versus the non-diabetic mice regardless of carnosine 
supplementation as shown in Figure 5.18 (Panel A). There were a significant increase in 
plaque size in the valve leaflets from the diabetic (21.8 ± 1.6 (x10³) μm²) than the 
control mice (15.3 ± 1.2 (x10³) μm², p < 0.01) as presented in Figure 5.18 (Panel B). 
There was a smaller area of plaque in the carnosine-supplemented control (11.5 ± 1 
(x10³) μm², p < 0.05) than the control mice. There was a significant decrease in plaque 
size observed in the carnosine-supplemented diabetic (15.1 ± 1.1 (x10³) μm², p < 0.001) 
than the diabetic mice. 
When the F4/80 was expressed as a percentage of total plaque area there was a 
higher percentage of F4/80 staining observed in the carnosine treated mice compared to 
its respective control as shown in Figure 5.18 (Panel C). The carnosine-supplemented 
control mice (44.4 ± 4.3 %, p < 0.05) possessed higher macrophage content than the 
control mice (31.8 ± 3.7%). There was an increased percentage of F4/80 staining 
observed in the carnosine-supplemented diabetic (41.3 ± 3.7 %, p < 0.05) than the 
diabetic mice (22.7 ± 3.1 %, p < 0.01).  
 Although diabetic mice had greater plaque areas, the absolute area stained for 
macrophages was not significantly different to the control mice. However there was a 
percentage increase of macrophages on total plaque areas observed in the aortic sinus 
for the carnosine-supplemented mice in both the diabetic and non-diabetic groups.   
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Figure 5.17: Representative sections showing F4/80 staining in the aortic sinus in 
control (CTL) and diabetic (DIAB) apo E
-/-
 mice with or without carnosine (+/- 
CN) supplementation.   
Representative sections taken from the aortic sinus were stained with F4/80 to detect for 
macrophages which appeared as pink colouration. The area of pink staining indicating 
the presence of F4/80 macrophages was expressed as a percentage over the total plaque 
formed. For illustration purposes the slides were captured by Carl Zeiss microscope 
using the 10x objective lens. 
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Figure 5.18: F4/80 staining for macrophages in the aortic sinus for F4/80 area 
(Panel A), plaque area (Panel B) and percentage of F4/80 on total area (Panel C) in 
control (CTL) and diabetic (DIAB) apo E
-/-
 mice with or without carnosine (+/- 
CN) supplementation.   
The F4/80 and plaque areas that were determined in the aortic sinus are calculated as 
(x10³) μm² in Panels A and B. The area stained by F4/80 is expressed as a percentage 
over the plaque area in Panel C.  Statistical significance was achieved at ** p < 0.01 
versus control (CTL - CN), ^ p < 0.05 versus control supplemented with carnosine 
(CTL + CN) and ## p <0.01, ### p < 0.001 versus diabetic (DIAB) apo E
-/-
 mice using 
two-way ANOVA followed by Bonferroni’s post-hoc test. Values are expressed as 
mean ± SEM.   
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5.4.9 Lipid content of plaque within the brachiocephalic artery 
The extracellular lipid content of the plaques was determined in the 
brachiocephalic artery as detailed in Sections 2.8.6 and 2.8.7.  The lipid content was 
examined to determine the nature and progression of the atherosclerotic plaque 
generated in the non-diabetic and diabetic mice with and without carnosine-
supplementation.  
Plaques from diabetic mice (7.5 ± 1.2 (x10³) μm², p < 0.001) contained 
significantly larger extracellular lipid pools than for the control mice (1.3 ± 0.3 (x10³) 
μm²). Most notably the extracellular lipid content from the carnosine-supplemented 
diabetic mice (2.8 ± 0.5 (x10³) μm², p < 0.001) was significantly lower than for the un-
supplemented diabetic mice as shown in Figure 5.19 (Panel A). 
When the lipid area was expressed as a percentage of total plaque area that was 
measured from the F4/80 stained lesion samples as shown in Figure 5.17 (Panel B), the 
plaques from the diabetic mice (20.5 ± 2.7%) contained a significantly greater lipid 
percentage than the control (6 ± 1.2%, p < 0.001) mice. However, a significant decrease 
in lipid percentage was detected for the carnosine-supplemented diabetic mice (8.2 ± 
1%, p < 0.001) when compared to the diabetic mice.  
Overall the lesions analysed from the diabetic mice had a higher area occupied 
by lipid pools and a greater percentage of extracellular lipid compared to control mice 
brachiocephalic artery samples. There was significantly greater lipid deposition 
observed in the diabetic than both the non-diabetic control and carnosine supplemented 
mice and this elevation was significantly attenuated in the diabetic mice that were 
supplemented with carnosine.   
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Figure 5.19: Comparison of extracellular lipid pools in the brachiocephalic artery 
determined as absolute lipid area (Panel A) and percentage area occupied by lipid 
compared to total plaque area (Panel B) in control (CTL) and diabetic (DIAB) apo 
E
-/-
 mice with or without carnosine (+/- CN) supplementation.   
The lipid area that was determined in the brachiocephalic artery is calculated as (x10³) 
μm² in Panel A. The area occupied by lipid is expressed as a percentage over the total 
plaque area in Panel B.  Statistical significance was achieved at *** p < 0.001 versus 
control (CTL – CN) and ### p < 0.01 versus diabetic (DIAB) apo E-/- mice using two-
way ANOVA followed by Bonferroni’s post-hoc test. Values are expressed as mean ± 
SEM.   
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5.4.10 Lipid content in plaque within aortic sinus 
The extracellular lipid content of the plaques was determined in the aortic sinus 
sections in an analogous manner to that described in the previous section. The diabetic 
mice (7.6 ± 0.7 (x10³) μm²) contained a significantly higher extracellular lipid content 
than the control mice (2.2 ± 0.3 (x10³) μm², p < 0.001) as shown in Figure 5.20 (Panel 
A). Most notably the extracellular lipid content for the carnosine-supplemented diabetic 
mice (2.4 ± 0.3 (x10³) μm², p < 0.001) was significantly less than the diabetic mice. 
The lesion area occupied by extracellular lipid was expressed as a percentage of 
total plaque area as displayed in Figure 5.20 (Panel C). The diabetic mice (30.2 ± 1.6%) 
contained greater percentage lipid content when compared to the control mice (14.5 ± 
1.7%, p < 0.001). The carnosine-supplemented diabetic mice (13.2 ± 1.6%, p < 0.001) 
contained significantly less percentage lipid content than the non-supplemented diabetic 
mice. Overall the diabetic mice had a greater extent of extracellular lipid and a higher 
percentage area occupied by extracellular lipid in the aortic sinus sections than the 
control mice. This elevation was however significantly attenuated in the diabetic mice 
that were supplemented with carnosine.   
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Figure 5.20: Comparison of extracellular lipid pools in the aortic sinus. Absolute 
lipid area (Panel A), plaque area (Panel B) and percentage of area occupied by 
extracellular lipid when compared to the total lesion area (Panel C) in control 
(CTL) and diabetic (DIAB) apo E
-/-
 mice with or without carnosine (+/- CN) 
supplementation.   
The lipid and plaque areas that were determined in the aortic sinus are calculated as 
(x10³) μm² in Panels A and B. The area quantitated for lipid is expressed as a percentage 
over the plaque area in Panel C.  Statistical significance was achieved at *** p < 0.001 
versus control (CTL - CN), +++ p < 0.001 versus control supplemented with carnosine 
(CTL + CN) and ### p < 0.01 versus diabetic (DIAB) apo E
-/- 
mice using a two-way 
ANOVA followed by Bonferroni’s post-hoc test. Values are expressed as mean ± SEM.   
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5.4.11 Collagen content of plaques within the brachiocephalic artery 
The collagen content of the plaques was examined to provide information on the 
potential stability of the plaques that were formed in the diabetic and non-diabetic mice 
that were treated with or without carnosine. The composition of collagen was examined 
at 300 μm from the first complete circumference of the brachiocephalic artery as 
described in Sections 2.91. The collagen was stained with picrosirius red as shown in 
Figure 5.21.   
Although, there were no differences observed in collagen content between the 
diabetic and the control mice, there was an increase in collagen content observed in the 
carnosine-supplemented diabetic mice (23.7 ± 1.7 (x10³) μm²) when compared to the 
carnosine-supplemented control mice (15.7 ± 2.3 (x10³) μm², p < 0.05). There was also 
significantly greater collagen content determined in the carnosine-supplemented 
diabetic than the diabetic mice (15.9 ± 1.2 (x10³) μm², p < 0.05). 
There was a higher absolute amount of plaque observed in the diabetic control 
(44 ± 3.4 (x10³) μm²) than the control mice (32.6 ± 3.1 (x10³) μm², p < 0.05). A greater 
extent of plaque was also detected in the diabetic mice supplemented with carnosine 
(39.2 ± 2.7 (x10³) μm²) than the control supplemented carnosine mice (27.3 ± 3.5 (x10³) 
μm², p < 0.05). When the collagen area was expressed as percentage of total plaque area 
there were no statistical differences between the diabetic and control groups. However, 
the carnosine-supplemented diabetic mice contained higher collagen content (60.3 ± 
3.4%) than the corresponding non-supplemented diabetic mice (37.5 ± 2.8%, p < 0.001) 
as shown in Figure 5.22.  
Overall the carnosine-supplemented diabetic mice contained greater absolute 
collagen content than the carnosine-supplemented control and diabetic mice. 
Furthermore the diabetic mice that were supplemented with carnosine contained a 
higher collagen percentage than the diabetic control in the brachiocephalic artery 
suggesting that these lesions might be of greater stability than those in the non-
supplemented animals.  
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Figure 5.21: Representative images of atherosclerotic plaques stained with 
picrosirius red in the brachiocephalic artery cross sections of control (CTL), 
control + carnosine (CTL + CN), diabetes (DIAB) and diabetes + carnosine (DIAB 
+ CN) mice.  
Positive staining for collagen is depicted in red. The area of red was calculated over the 
plaque area and expressed as a percentage of collagen content within the plaques 
formed. For illustration purposes the slides were captured by a Carl Zeiss microscope 
using the 20x objective lens.  
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Figure 5.22: Comparison of collagen content within plaques in the brachiocephalic 
artery. Absolute collagen area (Panel A), plaque area (Panel B) and percentage of 
collagen expressed relative to the total plaque area (Panel C) in control (CTL) and 
diabetic (DIAB) apo E
-/-
 mice with or without carnosine (+/- CN) supplementation.   
The collagen and plaque areas that were determined in the brachiocephalic artery are 
calculated as (x10³) μm² in Panels A and B. The area quantitated for collagen is 
expressed as a percentage over the plaque area in Panel C.  Statistical significance was 
achieved at *p < 0.05 versus control without carnosine (CTL - CN), + p < 0.05versus 
control supplemented with carnosine (CTL + CN) and # p < 0.05, ### p < 0.001 versus 
diabetic (DIAB) apo E
-/-
 mice using two-way ANOVA followed by Bonferroni’s post-
hoc test. Values are expressed as mean ± SEM.   
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5.4.12 Collagen in plaque within the aortic sinus 
The collagen content was also examined via picrosirius red stain at 300 μm from 
the first appearance of the three value leaflets in the aortic sinus as described in Section 
2.9.1 and shown in Figure 5.23. Although there were no statistical differences in 
collagen content between the diabetic and the control mice, a significantly greater 
absolute area of collagen staining was seen in the carnosine-supplemented diabetic (11 
± 0.9 (x10³) μm²) than the carnosine-supplemented control mice (7.9 ± 0.8 (x10³) μm², p 
< 0.05).  
There was higher plaque observed in the diabetic (22.8 ± 1.5 (x10³) μm²) than 
the control (13.8 ± 1 (x10³) μm², p < 0.001). This was also detected with the carnosine-
supplemented diabetic mice (17.2 ± 1.1 (x10³) μm²) when compared to the carnosine-
supplemented control mice (11.4 ± 1 (x10³) μm², p < 0.001). Less plaque was observed 
in the carnosine-supplemented diabetic mice (p < 0.01) than its respective control.  
When the collagen area was expressed as percentage of total plaque, a 
significantly lower percentage of collagen was observed in the diabetic mice (42.7 ± 
3.6%) than the control (67.7 ± 2.6%, p < 0.001) mice. This was also the case in the 
diabetic groups where the diabetic mice had significantly less percentage collagen 
content than the carnosine-supplemented diabetic mice (63.9 ± 3%, p < 0.001) as shown 
in Figure 5.24.  
Overall lesions from the carnosine-supplemented diabetic mice appear to have 
significantly higher collagen content than those of the diabetic mice. When the collagen 
content was examined over the plaque area, the diabetic mice had the lowest percentage 
of collagen in the aortic sinus. There was a lower percentage of collagen observed in the 
diabetic group than the non-diabetic control group, and this decrease in collagen content 
seen in the diabetic mice was significantly attenuated by carnosine.  
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Figure 5.23: Representative images of atherosclerotic plaques stained with 
picrosirius red in the aortic sinus cross sections of control (CTL), control + 
carnosine (CTL + CN), diabetes (DIAB) and diabetes + carnosine (DIAB + CN) 
mice.  
Positive staining for collagen is depicted in red. The area of red was calculated over the 
total plaque areas and expressed as a percentage of collagen content within the plaques 
formed. For illustration purposes the slides were captured using a Carl Zeiss microscope 
with a 10x objective lens. 
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Figure 5.24: Comparison of collagen within plaques in the aortic sinus. Absolute 
collagen area (Panel A), plaque area (Panel B) and percentage of collagen 
expressed relative to the total plaque area (Panel C) in control (CTL) and diabetic 
(DIAB) apo E
-/-
 mice with or without carnosine (+/- CN) supplementation.   
The collagen and plaque areas that were determined in the aortic sinus are calculated as 
(x10³) μm² in Panels A and B. The area quantitated for collagen is expressed as a 
percentage over the plaque area in Panel C.  Statistical significance was achieved at *** 
p < 0.001, + p < 0.05, +++ p < 0.001 versus control supplemented with carnosine (CTL 
+ CN) and ## p <0.01, ### p < 0.001 versus diabetic (DIAB) apo E
-/-
 mice using two-
way ANOVA followed by Bonferroni’s post-hoc test. Values are expressed as mean ± 
SEM.   
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5.5  Discussion 
The antioxidant / anti-glycative activity of carnosine has been investigated 
extensively given the therapeutic potential that such actions could have in diseases 
where oxidative and / or glycative damage contributes to pathogenesis and disease 
progression. As an endogenous product, carnosine can be administered safely. Rodents 
provide an ideal model to assess the effects of carnosine, as chronic supplementation 
results in a sustained elevation in blood carnosine levels. The hyperglycaemic 
component of atherosclerosis was investigated using a mouse model of diabetes that 
was induced by streptozotocin in apo E
-/-
 mice. This treatment increased blood glucose, 
haemoglobin Alc, total cholesterol and triglycerides in the mouse plasma, and the 
diabetic mice had a significantly greater plaque burden than the non-diabetic mice  
resulting in a smaller lumen size in the artery.  
Direct administration of carnosine to humans results in only transient increases 
in plasma levels [288]. However, previous studies (e.g. [288,289]) and the current study 
have demonstrated that there is a significant increase in plasma carnosine levels in 
rodents if the animals are continuously supplemented with carnosine via their drinking 
water. The levels achieved in the current study are higher than those reported by Lee et 
al. [288] (who used Balb/cA mice), probably due to the higher dose employed in the 
current study. In contrast to these findings, Aldini et al. [289] using Zucker rats, 
demonstrated significant increases in plasma and kidney carnosine levels with chronic 
supplementation with D- but not L- carnosine. Thus the capacity to establish and 
maintain significantly high circulating levels of L-carnosine varies from species to 
species. In our study, a wider range of plasma carnosine levels was detected amongst 
the diabetic animals when compared to those for the matched control group, with this 
likely to be due to the characteristic polydipsia of diabetes with a three-fold higher level 
of water consumption observed in the diabetic animals.  
In this study, prolonged carnosine administration did not significantly modulate 
multiple disease parameters in the mice with diabetes including blood glucose levels. 
Lee et al. [288] demonstrated a significant reduction in blood glucose levels after four 
weeks of carnosine supplementation in mice with diabetes. Transient hyperglycaemia 
induced by 2-deoxy-D-glucose in Wistar rats has also been shown to be inhibited by 
intravenous and intraperitoneal delivery of carnosine [292]. The effect of carnosine in 
the latter study was restricted to submicro- and in some circumstances subnanomolar 
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concentrations. Whilst it has been repeatedly demonstrated that plasma levels of 
reactive aldehydes (e.g. methylglyoxal and glyoxal) are elevated in people with 
diabetes, the determination of plasma aldehyde levels is problematic. Values for 
methylgloxal can range from 0.2 - 120 and 0.5 - 400 μM in normoglycaemic and people 
with diabetes, respectively [293,294,295,296]. As these aldehydes react rapidly with 
proteins [297] these low concentrations are not unexpected. Thus the levels of plasma 
carnosine achieved by supplementation in this study, and another [288], may be within 
the range that would lead to effective aldehyde scavenging in vivo. In contrast to these 
studies, we did not find any hypoglycaemic effect of carnosine supplementation in the 
animals with diabetes, and this is supported by the absence of a carnosine-associated 
decrease in glycated haemoglobin. We conclude that the chronic high dose 
supplementation of carnosine used here does not have the more transient and low dose 
effects of carnosine upon blood glucose previously demonstrated.  
Whilst carnosine supplementation had no effect upon diabetes-induced 
hypercholesterolaemia in the diabetic mice, supplementation significantly reduced 
plasma triglyceride levels. This effect was also seen with carnosine-supplemented 
control mice. This differential effect upon the two classes of lipids was also found by 
Lee et al. [288] where both doses of carnosine (0.5 and 1.0 g/L) blunted the increase in 
heart and liver triglyceride levels in diabetic mice, while for cholesterol levels a 
significant effect was only seen with the higher dose of carnosine. In contrast, 
supplementation of hyperlipidaemic (but not hyperglycaemic) Zucker rats with either L- 
or D-carnosine resulted in matched and significant decreases in both plasma cholesterol 
and triglyceride levels [289]. Similarly both carnosine and histidine  (at 1g/L of 
drinking water) blocked increases in plasma triglycerides and cholesterol in fat-fed, 
non-diabetic, C57BL/6 mice [283]. Thus while carnosine has been consistently 
demonstrated to have a cross-species hypotriglyceridaemic action this is not the case for 
modulation of blood cholesterol levels.  
Further port mortem studies were carried out to examine the anti-atherogenic 
potential of carnosine as plasma triglyceride levels were significantly decreased in the 
diabetic mice that were supplemented with carnosine. Analysis of atherosclerotic 
lesions and disease progression using this model of diabetes-associated atherosclerosis 
is commonly determined by en face analysis of total aortic plaque area. However we 
chose to restrict our analysis to a more detailed examination of the brachiocephalic 
artery and aortic sinus given the propensity of these sites for the development of 
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advanced, rupture-prone, lesions in this strain of mouse [277]. Induction of diabetes 
resulted in a significant increase in plaque area at both sites. The plaques in the diabetic 
mice was shown to consist of large pools of deposited lipids extracellularly in the 
subendothelial space with lower levels of macrophages and decreased level of collagen 
with this potentially weakening the structure of the lesion and heightening the risk of 
plaque rupture [50,298].  
Despite the triglyceride-lowering effects of carnosine, supplementation did not 
lead to a significant reduction in plaque area compared to the un-supplemented mice 
matched for glycaemic status. This data is in agreement with Nestel et al. [291] who 
showed that dietary supplementation of diabetic apo E
-/-
 mice with conjugated linoleic 
acid did not lead to a decrease in aortic plaque area although there was a substantial 
lowering of plasma triglycerides. Using the same model Levi et al. [299] have 
demonstrated a decrease in aortic sinus plaque area in mice treated with PPARγ-agonist 
rosiglitazone, while drug treatment resulted in an elevation of blood triglycerides and 
cholesterol levels. Thus the modulation of diabetes-induced hypertriglyceridaemia in 
this particular animal model does not appear to have a consistent impact on gross plaque 
characteristics. Our results are in contrast to the recent demonstration that 
supplementation of fat-fed apo E
-/-
 with D-carnosine octylester resulted in a reduction in 
plaque area [282]. In common with the study of Menini et al., carnosine 
supplementation did lead to changes in plaque composition, specifically a reduction in 
the area occupied by lipid matched by an increase in that occupied by collagen. 
Cholesterol cleft formation and lipid deposition in atherosclerotic plaque reflects the 
severity and progression of the arterial disease and such lipid-enriched lesions are prone 
to plaque rupture [298]. In particular lesion rupture has been associated with a thinning 
of the fibrous cap and decreased collagen formation [300,301,302]. This shift in plaque 
composition from a lipid rich environment to a collagen rich area is thought to reduce 
the risk of plaque rupture [303]. Given the increasing costs, both personal and 
economic, of the complications of diabetes mellitus there is a strong drive to develop 
treatments to alleviate, delay and hopefully prevent these complications.  
Carnosine and its analogues have recently been shown to have both anti-
hyperlipidaemic, anti-atherosclerotic, hepato- and renal-protective actions in models of 
obesity-associated complications [282,283,288,289]. Our current study is the first to 
demonstrate that this well-tolerated dipeptide may also have a significant impact in the 
treatment of the complications of diabetes. While it had been conceived that carnosine’s 
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anti-atherogenic action would be mediated by its well-characterised anti-glycative / 
glycoxidative activities, this study found carnosine-linked improvements in lipid 
parameters. Thus while hyperglycaemia is a key agent of atherogenesis and 
atherosclerotic progression in diabetes, it must be remembered that, at least in the case 
of Type 2 diabetes, hyperlipidaemia is also likely to have critical pathological role.  
 
5.6  Conclusion 
Prolonged carnosine supplementation has been shown to have a significant 
impact on the progression of the atherosclerosis in a well-established model of diabetes-
associated atherosclerosis. Diabetic mice had a greater extent of plaque formation in the 
brachiocephalic artery and aortic sinus compared with their non-diabetic littermates. 
There were no significant differences in the plaque area when carnosine-supplemented 
mice were compared with mice on plain water and matched for glycaemic status. 
However potential anti-atherosclerotic effects of carnosine were found when 
plaque composition was investigated. When compared to the other treatments there 
were significantly increased numbers of smooth muscle cells (as evidenced by the 
extent of α-actin staining) in the plaques of the carnosine treated diabetic mice. There 
was a significant decrease in macrophage cell numbers in the diabetic mice in the 
brachiocephalic and the aortic sinus. This can be potentially rationalised by the 
significantly higher extracellular lipid content in the same plaques with these lipid 
levels being the result of macrophage foam cell death and lysis. Conversely, carnosine 
supplementation resulted in greater levels of collagen in the plaque although this was 
not consistently linked to an increase in smooth muscle cell staining. It is clear that cell 
populations within the lesions of the carnosine treated animals and particularly these 
with diabetes are altered and this may result in greater lesion stability as judged by 
greater collagen and less extracellular lipid. 
The hypolipidaemic effect of carnosine did not affect plaque area in the diabetic 
mice. However, carnosine does seem to have played an important role in reducing 
extracellular lipid deposition possibly as a result of a decrease in macrophage apoptosis 
and / or necrosis which are known to result in extracellular lipid accumulation [50], 
slowing down atherosclerotic plaque progression by significantly modulating the 
composition of the plaques, engendering plaque stability. On the basis of this data it 
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would appear that supplementation with carnosine may be of benefit in the treatment of 
atherosclerosis including that associated with diabetes. 
These studies are extended in the following chapter where another anti-
lipidaemic agent was also examined using apo E
-/- 
mice but where atherosclerosis was 
driven by high fat-feeding. The focus of the following chapter concentrates on the 
hyperlipidaemic manifestations that were initially observed in the diabetic mice, in apo 
E
-/-
 and wild type C57BL/6 mice that were fed a high fed diet to induce obesity. The 
anti-oxidant and anti hyperlipidaemic properties of TEMPOL was investigated using 
this high fat obesity animal model to further examine whether TEMPOL reverses the 
atherosclerosis.  
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CHAPTER 6: 
INVESTIGATION OF THE IMPACT OF TEMPOL UPON 
ATHEROSCLEROSIS, LIPID PROFILE AND CYTOKINE 
EXPRESSION IN A MURINE OBESITY MODEL 
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6.1  Introduction 
Dyslipidaemia plays a major role in the majority of cardiovascular disorders 
including atherosclerosis [304,305,306]. Total blood cholesterol and LDL-cholesterol 
(LDL-C) are classified as independent risk and graded factors for cardiovascular disease 
(CVD) and meet the criteria for causality related to CVD risk [304]. The causality 
between saturated fat consumption, blood cholesterol levels, and CVD mortality has 
been identified from various genetic, animal study, experimental pathology and 
epidemiological investigations [304,305,307,308,309,310,311,312,313,314,315,316].  
There are several mechanisms postulated for the role of triglycerides in CVD, such as 
smooth muscle damage and impaired vascular repair, or that excess triglycerides in 
lipoproteins may result in abnormal transport, but the association between 
hypertriglyceridaemia and CVD remains controversial [317,318,319,320]. Elevated 
triglyceride levels may be a warning sign and indicate a need to investigate other 
metabolic manifestations such as central obesity, hypertension, low HDL-C and glucose 
intolerance [305,321,322].   
The prevalence and impact of dyslipidaemias and metabolic disorders has led to 
extensive investigations of therapies designed to prevent, inhibit or reverse 
cardiovascular related diseases [304]. Many studies have shown therapeutic reduction of 
these lipid fractions via pharmaceutical or surgical interventions are strongly associated 
with improved measures [323,324,325,326,327,328]. However, prevention of the 
development of obesity, through promotion of healthy eating practices and increased 
physical activity, remains critical to reducing the occurrence of dyslipidaemia and 
excess body weight gain in the community [5,309,329]. Treatments that arrest gain in 
body fat and / or promote body fat loss (including pharmaceuticals and surgical 
procedures) provide critical support where management of body mass remains 
refractory to behavioural modifications alone [327]. Pharmaceuticals also provide tools 
to investigate the mechanisms that underlie obesity, and one example of such a 
compound is TEMPOL which has known impacts upon body weight gain, sensitivity to 
radiation and tumourigenesis [330,331,332,333,334,335].  
TEMPOL (4-hydroxy-2,2,6,6-tetramethylpiperidine-N-oxyl; C9H18NO2) is a cell 
permeant nitroxide, whose structure is shown in Figure 6.1. It has a well characterised 
superoxide dismutase-mimetic activity (which is thought to be basis of its previously 
demonstrated hypotensive effects) and is capable of reacting, and thus detoxifying, a 
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number of free radicals and reactive oxygen species 
[336,337,338,339,340,341,342,343,344,345,346,347]. Previous work from James 
Mitchell (National Cancer Institute) has shown for C3H male and female mice, rendered 
obese by feeding with a Western-style high fat diet, that administration of TEMPOL (10 
mg/g of food) had a profound inhibitory effect upon weight gain. This compound also 
prevented obesity induced changes in leptin levels and decreased age-related 
spontaneous tumour incidence [330]. TEMPOL has been found to reduce irradiation 
induced salivary gland hypofunction (xerostomia) and alopecia in numerous brain, head 
and neck cancer murine models [331,332]. Phase I and II clinical trials for safety, 
pharmacokinetics and preliminary efficacy for the prevention of alopecia induced by 
whole brain radiotherapy have been reported, and this compound is under consideration 
for phase III trials [333,334,335].  
 
 
 
Figure 6.1: Chemical structure of TEMPOL. 
TEMPOL is also referred to as 4-Hydroxy-TEMPO, and 4-hydroxy-2,2,6,6-
tetramethylpiperidin-1-oxyl.  
 
 
The potential protective effects of TEMPOL have also been examined in the 
cardiovascular and diabetes area and research has shown that it can prevent the 
production of hepatic reactive oxygen species induced by diabetes [345]. 
Antihypertensive effects of TEMPOL have been revealed in cell signalling and animal 
models [336]. Several studies have shown TEMPOL lowers blood pressure of rodents 
that were made hypertensive [337,346,347]. Prolonged lowering of blood pressure by 
TEMPOL has been related to an enhancing effect of this compound on the production 
or the action of endogenous nitric oxide (NO˙) [336,338]. TEMPOL has also been 
reported to work as a vasodilator, and has been shown to exhibit protective effects upon 
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vessels and the endothelium in hypertensive rats [337,338,339,346,347] and also in 
small arteries from visceral fat of obese patients [348].  
Endothelial dysfunction is an early event in atherogenesis and further alterations 
occur to the endothelial layers of the arterial wall with the progression and severity of 
atherosclerosis [349,350,351,352,353]. In the previous chapter a model of diabetes-
associated atherosclerosis was investigated using apo E
-/-
 mice in which diabetes was 
induced using the pancreatic toxin streptozotocin. Induction of diabetes was associated 
with larger plaque volume as well as dramatic changes in artery wall composition with 
noticeable lipid accumulation and significantly lower collagen content. The impact of 
the anti-glycative / anti-oxidative agent carnosine upon plaque morphology was 
characterised as a shift to a more stable phenotype with an increased collagen content 
and decreased extracellular lipid. This was associated with a significant decrease in 
blood triglyceride levels. However, hyperglycaemic manifestations (elevated blood 
glucose and glycated Hb levels) in the diabetic mice were not arrested by carnosine.   
The current chapter focuses on the potential modulation of hyperlipidaemia and 
the vascular lipid accumulation of atherosclerosis, a critical component to the 
progression of this disease, in the absence of diabetes. Although there are many reported 
studies on the hypotensive and cardio-protective vascular functions of TEMPOL upon 
the endothelium, arteries and blood vessels, the potential anti-atherogenic action of 
TEMPOL remains poorly characterized.  Therefore the study reported in this chapter 
assesses the potential anti-atherogenic actions of TEMPOL in a murine model of high 
fat fed atherosclerosis and obesity.   
 
6.2  Aims 
The overall aims of this study were firstly to determine whether TEMPOL 
prevents or attenuates atherosclerotic plaque development in obesity-associated 
atherosclerosis, and secondly to examine if TEMPOL reverses or suppresses obesity-
associated hyperlipidaemia, and / or systemic inflammation. 
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6.3  Experimental methods 
6.3.1 Animal model design 
Heart and plasma samples were obtained from Prof. Jim Mitchell from the 
National Cancer Institute (United States) from apo E
-/-
 (n = 38) mice and the parent 
strain C57BL/6 (n= 28) as outlined in Section 2.10. For each strain (i.e. apo E
-/-
 and 
C57BL/6) there were four groups. The first two groups consisted of mice fed a regular 
chow diet with and without TEMPOL (10 mg/g) placed into the food whilst the third 
and fourth groups comprised of a high fat diet with and without TEMPOL included in 
the food as shown in Figure 6.2. Five animals were allocated in each group for the chow 
fed mice with or without TEMPOL supplementation for both animal types. For the apo 
E
-/-
 mice, 13 mice were dedicated to the HFD and 15 were allocated to the HFD with 
TEMPOL supplemented group. For the C57BL/6 parent strain, 8 mice were placed into 
the HFD and 10 were allocated to the HFD with TEMPOL supplemented group.  The 
composition of the chow and high fat diets are detailed in Table 2.1 under Section 2.10.  
 
6.3.2 Histology procedures 
The histological analysis of the aortic sinus was undertaken as detailed in 
Sections 2.7.5 to 2.7.7 and 2.10.1 to 2.10.3 from sample preparation, through to tissue 
sectioning and haematoxylin staining. Three slides (which contained 3 sections) were 
chosen for plaque analysis as described in Sections 2.10.2 and 2.10.3. The first triplicate 
section was taken at the first appearance of the three valve leaflets of the sinus. The 
third slide was taken from the first disappearance of all three valve leaflets. The second 
slide was taken between the first and third sections. The three chosen slides were 
stained with Haematoxylin and Eosin (H & E) as detailed in Section 2.7.7 and later 
photographed using the appropriate magnification as shown in Figure 2.6. The total 
surface area and plaque were determined using Adobe Photoshop as shown in Figure 
5.5. 
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Figure 6.2: Animal model for TEMPOL study. 
C57BL/6 wild type and the apo E
-/-
 mice were divided into four groups comprising of 
chow control mice with and without TEMPOL administered in the food, and high fat 
diet fed mice with and without TEMPOL inserted in the food.   
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6.3.2 Plasma analysis 
The mouse plasma samples were analysed as described in Sections 2.11 to 
2.11.2 for triglycerides, total cholesterol, HDL-cholesterol and LDL-cholesterol. 
Cytokine, inflammatory agents and adipokine measurements were also examined as 
detailed in Sections 2.11.3. Statistical analysis was carried out by using two-way 
ANOVA analyses followed by a Bonferroni’s posthoc test.  
 
6.4  Results  
6.4.1 Effects of TEMPOL upon body mass in apo E
-/-
 and parent strain C57BL/6 
mice 
The animal husbandry was carried out at the National Cancer Institute 
(Bethesda, MD, USA) as outlined in Section 2.10. The body masses of the mice were 
closely monitored for 20 weeks.  The body masses of the HFD fed mice increased 
considerably in comparison to the chow fed mice regardless of TEMPOL 
supplementation in both animal types. However treatment with TEMPOL resulted in 
significantly lower gain in mass for the HFD mice. Notably the body mass of the 
TEMPOL-treated HFD mice was similar to that of the non-HFD fed mice (Figure 6.3).  
 
 
173 
 
 
 
Figure 6.3: Average body mass of apo E
-/-
 (Panel A) and C57BL/6 (Panel B) mice 
during the intervention phase during which the mice were fed normal chow or 
HFD with or without TEMPOL supplementation.   
The mean body mass (g) of the mice from each group during the intervention period of 
7 weeks is displayed for apo E
-/-
 (Panel A) and 20 weeks for C57BL/6 (Panel B) mice.     
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6.4.2 Morphometry of atherosclerotic plaques in the aortic sinus  
The heart samples from the different experimental groups outlined above were 
supplied by the National Cancer Institute. As each of these was provided without an 
intact arterial tree, only the aortic sinus was available for plaque analysis. This was 
analysed in order to determine whether TEMPOL inhibited or delayed the progression 
of atherosclerosis. 
Three triplicate cross-sections were taken along the aortic sinus and 
morphometric measurements were performed for each mouse as described in Sections 
2.10.1 to 2.10.3. Atherosclerotic plaques were observed in the apo E
-/-
 mice however no 
atherosclerosis was detected in the aortic sinus in the parent strain mice regardless of 
their diet and body mass gain (Figure 6.4).  
The aortic sinuses from the HFD fed mice (10.8 ± 0.7 (x10³) μm²) contained less 
plaque than for the chow control mice (17.1 ± 2.9 (x10³) μm², p < 0.05). In contrast the 
HFD supplemented mice with TEMPOL (12.1 ± 1.2 (x10³) μm², p < 0.01) contained a 
lower plaque area than the chow fed animals supplemented with TEMPOL (20.5 ± 1.8 
(x10³) μm², p < 0.01) mice as shown in Figure 6.5 (Panel A).  
There were no statistical differences in the total cross-sectional areas of the 
aortic sinus as shown in Figure 6.5 (Panel B). When the plaque was examined over the 
total area as presented in Figure 6.5 (Panel C), there were no statistical differences in 
plaque percentage between the chow (16.5 ± 2.8%) and HFD (11.8 ± 0.8%) fed apo E
-/-
 
mice. A lower plaque percentage was seen in the HFD mice supplemented with 
TEMPOL (12.3 ± 1.1%, p < 0.01) than the chow with TEMPOL (20.6 ± 1.3%, p < 0.01) 
supplemented apo E
-/-
 mice.  
Although TEMPOL effectively suppressed HFD induced gain in body mass, in 
both apo E
-/-
 mice and the parent strain, it did not appear to suppress atherosclerotic 
development in the apo E
-/-
 mice. The plaques measured in the aortic sinuses in both 
groups of chow-fed mice (that is with or without TEMPOL) mice were significantly 
larger than for the HFD apo E
-/-
 mice, matched for TEMPOL treatment. No 
atherosclerosis was detected in the aortic sinuses taken from the parent strain C57BL/6 
mice. 
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Figure 6.4: Representative sections of the aortic sinus stained with H & E from 
chow and high fat diet (HFD) fed apo E
-/-
 mice with or without TEMPOL 
supplementation.  
Sections taken from the aortic sinus were stained with H & E and photographed using 
the 10x objective to determine the degree of plaque formation within the valve leaflets. 
The total plaque area was analysed over the total area and expressed as a percentage.  
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Figure 6.5: Plaque morphometry in the aortic sinus for plaque area (Panel A), total 
area (Panel B) and percentage of plaque on total area (Panel C) in apo E
-/-
 mice 
that were fed either a chow or HFD, with or without TEMPOL supplementation.  
Plaque and total cross sectional areas within the leaflets were determined in the aortic 
sinuses and expressed as (x10³) μm² in Panels A and B. Plaque is expressed as a 
percentage over the total area in Panel C. Statistical significance was achieved at * p < 
0.05 versus the chow control and ++ p < 0.01 versus the chow supplemented with 
TEMPOL mice using two-way ANOVA analysis followed by Bonferroni’s post hoc 
test. Values are expressed as mean ± SEM. 
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6.4.3 Effects of TEMPOL upon plasma triglyceride levels in the treatment 
groups 
Hypertriglyceridaemia is associated with an increased risk of cardiovascular 
disease and commonly seen in people with lipid abnormalities, visceral obesity, 
metabolic syndrome and type 2 diabetes [354].  Triglyceride levels were measured in 
plasma from all mice as described in Section 2.11.1 to determine whether TEMPOL had 
an effect upon the lipid profile in mice that became obese via consumption of a high fat 
fed diet. 
The measured plasma triglyceride levels were significantly higher for the HFD 
fed apo E
-/-
 mice (2 ± 0.1 mmol/L) than the chow control (0.8 mmol/L, p < 0.001). HFD 
fed TEMPOL mice (0.6 mmol/L, p < 0.001) showed lower triglyceride levels than the 
HFD fed mice as shown in Panel A of Figure 6.6.  
Triglyceride levels were significantly elevated in the high fat fed C57BL/6 mice 
(0.8 mmol/L) than the chow control animals (0.5 ± 0.1 mmol/L, p < 0.001). HFD fed 
mice that were supplemented with TEMPOL (0.5 mmol/L, p < 0.001) showed lower 
triglyceride levels than the HFD fed mice. Lower levels of triglycerides were also 
detected in the chow fed mice administered TEMPOL (0.3 mmol/L, p < 0.05) when 
compared to the HFD fed mice supplemented with TEMPOL mice as shown in Panel B 
of Figure 6.6.  
Overall, the HFD fed mice had higher triglyceride levels than the non-HFD fed 
mice in both animal types, and TEMPOL significantly attenuated this elevation. The 
triglyceride levels in the plasma of the HFD mice administered TEMPOL were similar 
to that of the non-HFD fed mice as shown in Figure 6.6.  
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Figure 6.6: Plasma triglyceride levels for apo E
-/-
 (Panel A) and C57BL/6 (Panel B) 
mice.  
Triglyceride levels (mmol/L) were measured in mice that were fed a chow or a high fat 
diet (HFD) with or without TEMPOL supplementation. Statistical significance is 
achieved at *** p < 0.001 versus chow control, + p < 0.05 versus chow with TEMPOL 
and ### p < 0.001 versus HFD fed mice using two-way ANOVA analysis followed by 
Bonferroni’s post-hoc test. Data are expressed as mean ± SEM. 
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6.4.4 Effects of TEMPOL upon plasma total cholesterol in apo E
-/-
 and parent 
strain C57BL/6 mice 
Hypercholesterolaemia is a major risk factor for CVD [310,311] and was 
assessed to determine whether TEMPOL treatment could also modulate cholesterol 
levels as seen with the triglyceride levels in the HFD mice. Total cholesterol levels were 
measured in the mouse plasma as described in Section 2.11.2.   
Total cholesterol levels were significantly elevated in the high fat fed apo E
-/-
 
mice (4.6 ± 0.2 mmol/L) when compared to the chow control mice (2.8 ± 0.1 mmol/L, p 
< 0.001) as shown in Panel A of Figure 6.7. The HFD fed TEMPOL mice (2.7 ± 0.1 
mmol/L, p < 0.001) had lower cholesterol levels than the HFD and the chow 
supplemented with TEMPOL (3.8 ± 0.5 mmol/L, p < 0.01) mice. The chow control 
mice had lower cholesterol levels than the chow supplemented with TEMPOL mice (p < 
0.05). 
HFD fed C57BL/6 mice had higher total cholesterol levels (4.2 ± 0.2 mmol/L) 
compared to the chow control (1.9 ± 0.1 mmol/L, p < 0.001). HFD fed mice 
supplemented with TEMPOL (2.7 ± 0.1 mmol/L, p < 0.001) exhibited lower cholesterol 
levels than the HFD fed mice. Total cholesterol levels were statistically higher in the 
HFD mice supplemented with TEMPOL than the chow mice supplemented with 
TEMPOL (1.5 ± 0.1 mmol/L, p < 0.001) as shown in Panel B of Figure 6.7. 
Overall, high fat-feeding resulted in a significant increase in total plasma 
cholesterol levels for both the apo E
-/-
 and parent strains, and TEMPOL significantly 
attenuated this elevation. The total cholesterol levels in the plasma of the HFD mice 
administered TEMPOL were similar to those of the chow-fed mice as shown in Figure 
6.7.  
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Figure 6.7: Plasma total cholesterol levels for apo E
-/-
 (Panel A) and C57BL/6 
(Panel B) mice.  
Total cholesterol levels (mmol/L) were measured in mice that were fed a chow or a high 
fat diet (HFD) with or without TEMPOL supplementation. Statistical significance was 
achieved at * p <0 .05, *** p < 0.001 versus chow, ++ p < 0.01, +++ p < 0.001, +++ p < 
0.001 versus chow administered TEMPOL mice, ### p < 0.001 versus HFD using two-
way ANOVA analysis followed by Bonferroni’s post-hoc test. Values are expressed as 
mean ± SEM. 
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6.4.5 Effects of TEMPOL upon plasma high density lipoprotein-cholesterol 
(HDL-C) levels in apo E
-/-
 and parent strain C57BL/6 mice 
High density lipoproteins are believed to have cardio-protective effects as they 
mediate cholesterol efflux and reverse cholesterol transport, which is critical in limiting 
the number of lipid-laden foam cells that contribute to atherosclerosis [355,356]. Many 
cohort and case-control studies have reported a negative correlation between HDL 
concentrations and the occurrence of atherosclerotic disease, and HDL-C is involved in 
protection against the pathogenesis of atherosclerosis [304,305,306]. HDL-C levels 
were therefore measured in the mouse plasma as described in Section 2.11.2 to 
determine whether TEMPOL could modulate HDL-C levels in obese mice that 
consumed a HFD.   
HFD fed apo E
-/-
 mice had higher HDL-C levels (0.4 mmol/L) than the chow 
control mice (0.1 mmol/L, p < 0.001). HFD mice supplemented with TEMPOL (0.1 
mmol/L, p < 0.001) had lower HDL-C levels than the HFD fed mice as shown in Panel 
A of Figure 6.8.  
HDL-C levels were significantly elevated in the HFD fed C57BL/6 mice (1.4 ± 
0.1 mmol/L) compared with the chow control fed mice (0.6 ± 0.1 mmol/L, p < 0.001). 
HFD mice supplemented with TEMPOL (0.9 mmol/L, p < 0.001) exhibited lower HDL-
C levels than the HFD fed mice. Lower levels of HDL-C (0.6 mmol/L, p < 0.001) were 
observed in the chow supplemented TEMPOL mice when compared to the HFD mice 
supplemented with TEMPOL as shown in Panel B of Figure 6.8.  
Overall high fat feeding was associated with elevated HDL-C in both mouse 
strains, and this elevation was attenuated by TEMPOL. The HDL-C levels in the plasma 
of the HFD administered TEMPOL mice were similar to that of the non-HFD fed apo E
-
/-
 mice.  
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Figure 6.8: Plasma HDL-C levels for apo E
-/-
 (Panel A) and C57BL/6 (Panel B) 
mice.  
HDL-C levels (mmol/L) were measured in mice that were fed a chow or a high fat diet 
(HFD) with or without TEMPOL supplementation. Statistical significance was achieved 
at *** p < 0.001 versus chow, +++ p < 0.001 versus chow administered TEMPOL and 
### p < 0.001 versus HFD fed mice using two-way ANOVA analysis followed by 
Bonferroni’s post-hoc test. Data are expressed as mean ± SEM. 
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6.4.6 Effects of TEMPOL upon plasma low density lipoprotein-cholesterol (LDL-
C) in apo E
-/-
 and parent strain C57BL/6 mice 
Total blood cholesterol and LDL-cholesterol (LDL-C) are classified as 
independent risk and graded factors for cardiovascular disease (CVD) and meet the 
criteria for causality related to CVD risk [304]. Increased levels of LDL-C are 
associated with the progression of atherosclerosis, metabolic dysfunction and obesity 
[357,358,359]. LDL-C levels were therefore measured in the mouse plasma as described 
in Section 2.11.2 to determine whether TEMPOL had an effect upon LDL-C levels in 
mice that consumed a HFD. 
LDL-C levels were significantly higher in the HFD fed apo E
-/-
 mice (4.3 ± 0.2  
mmol/L) when compared to the chow control (2.7 ± 0.1 mmol/L, p < 0.001) as shown in 
Panel A of Figure 6.9. The HFD mice supplemented with TEMPOL (2.6 ± 0.1 mmol/L, 
p < 0.001) had lower LDL-C levels than the HFD fed mice. Lower levels of LDL-C 
were observed in the chow fed mice than the chow supplemented with TEMPOL mice 
(2.7 ± 0.1 mmol/L, p < 0.05). There were statistically lower LDL-C levels in the HFD 
supplemented with TEMPOL than the chow supplemented with TEMPOL mice (p < 
0.01).   
The HFD fed C57BL/6 mice had higher LDL-C levels (2.8 ± 0.2 mmol/L) than 
the chow control (1.2 ± 0.1 mmol/L, p < 0.001) as shown in Panel B of Figure 6.9. HFD 
mice supplemented with TEMPOL (1.8 ± 0.1 mmol/L, p < 0.001) had lower LDL-C 
levels than the HFD fed mice.  Lower levels of LDL-C were also detected in the chow 
mice supplemented with TEMPOL (0.9 mmol/L, p < 0.001) than the HFD fed mice 
supplemented with TEMPOL.   
Overall high fat feeding was associated with elevated LDL-C levels in both 
strains of mice, and TEMPOL significantly attenuated this elevation. The LDL-C levels 
in the plasma of the HFD mice administered TEMPOL were similar to those of the non-
HFD fed apo E
-/-
 mice.  
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Figure 6.9: Plasma LDL levels for apo E
-/-
 (Panel A) and C57BL/6 (Panel B) 
mice.  
HDL levels (mmol/L) were measured in mice that were fed a chow or a high fat diet 
(HFD) with or without TEMPOL supplementation. Statistical significance was achieved 
at * p < 0.05, *** p < 0.001 versus chow, ++ p < 0.01, +++ p < 0.001 versus chow 
administered TEMPOL and ### p < 0.001 versus HFD fed mice using two-way 
ANOVA analysis followed by Bonferroni’s post-hoc test. Values are expressed as mean 
± SEM. 
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6.5 Effects of TEMPOL on cytokine levels in high fat diet (HFD) fed apo E
-/-
 
and wild type C57BL/6 mice 
6.5.1 Effects of TEMPOL on Tumour Necrosis Factor-α (TNF-α) levels  
TEMPOL had a dramatic effect in suppressing body weight gain and 
hyperlipidaemia in mice that consumed a HFD (see Sections 6.4.1, 6.4.3 - 6.4.6).  The 
consequences of obesity include the development of insulin-resistance and 
inflammation which may play central roles in atherosclerosis. A deficiency of the 
proinflammatory cytokine TNF-α has been shown previously to protect against insulin 
resistance induced by a HFD in TNF-α knockout mice [360]. The levels of the pro-
inflammatory cytokine TNF-α levels were therefore investigated to determine whether 
the profound effect of TEMPOL upon body mass gain suppressesed inflammation 
possibly induced by the HFD. TNF-α levels (pg/ mL) were measured in the mouse 
plasma as described in Section 2.11.3.  
Although HFD had a dramatic effect on obesity and hyperlipidaemia there were 
no significant differences observed in TNF-α levels between the chow and HFD fed 
mice.  There were also no statistical differences observed across all the groups for both 
the apo E
-/-
 and C57BL/6 strains as shown in Figure 6.10. Thus neither the high fat diet 
nor the supplementation with TEMPOL modulated the TNF-α levels in the mouse 
plasma.  
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Figure 6.10: Plasma TNF-α levels for apo E-/- (Panel A) and C57BL/6 (Panel B) 
mice.  
TNF-α levels (pg/mL) were measured in the plasma of mice that were fed a chow or a 
high fat diet (HFD) with or without TEMPOL supplementation. Values are expressed as 
mean ± SEM. No statistical differences were detected between the various groups using 
2-way ANOVA with Bonferroni’s post-hoc test. 
187 
 
6.5.2 Effects of TEMPOL on Monocyte Chemotactic Protein-1 (MCP-1) levels  
MCP-1 is an inflammatory marker commonly associated with atherosclerosis, 
obesity, diabetes, insulin resistance, metabolic dysfunction, adiposity and macrophage 
behaviour [312,361]. MCP-1 levels (pg/mL) were measured in the mouse plasma as 
described in Section 2.11.3.  
There were no statistical differences in MCP-1 levels detected between the apo 
E
-/-
 chow and HFD fed groups. However significantly lower MCP-1 levels were 
observed in the apo E
-/-
 HFD mice supplemented with TEMPOL (28.2 ± 4 pg/mL, p < 
0.01) when compared to HFD mice (43.8 ± 3.5 pg/mL). HFD mice supplemented with 
TEMPOL also contained lower MCP-1 levels than the chow apo E
-/-
 mice supplemented 
with TEMPOL (53.8 ± 4.1 mmol/L, p < 0.01) as shown in Figure 6.11 (Panel A).  
HFD fed C57BL/6 mice contained higher MCP-1 levels (36.6 ± 2.7 pg/mL) than 
the chow control (18.2 ± 4 pg/mL, p < 0.001) as shown in Panel B of Figure 6.11.  
Lower levels of MCP-1 were also detected in the HFD fed TEMPOL mice (23.4 ± 2.9 
pg/mL, p < 0.01) than the HFD fed mice.  
Overall HFD fed mice had higher MCP-1 levels than the non-HFD fed mice in 
C57BL/6 mice, and TEMPOL significantly attenuated this elevation. The MCP-1 levels 
in the plasma of the HFD mice administered TEMPOL were similar to that of the non-
HFD fed apo E
-/-
 mice, with the mean values not statistically different.  
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Figure 6.11: Plasma MCP-1 levels for apo E
-/-
 (Panel A) and C57BL/6 (Panel B) 
mice.  
MCP-1 levels (pg/mL) were measured in plasma of mice that were fed a chow or a high 
fat diet (HFD) with or without TEMPOL supplementation. Statistical significance was 
achieved at *** p < 0.001 versus chow, ++ p < 0.01 versus chow supplemented with 
TEMPOL and ## p < 0.01 versus HFD fed mice using two-way ANOVA analysis 
followed by Bonferroni’s post-hoc test. Values are expressed as mean ± SEM. 
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6.5.3 Effects of TEMPOL on interleukin-6 (IL-6) levels  
IL-6 is a biomarker of inflammation and is associated with the metabolic 
syndrome and obesity [313,362]. The levels of this species were therefore measured in 
the mouse plasma as described in Section 2.11.3.  
IL-6 levels were significantly higher in the HFD fed apo E
-/-
 mice (47 ± 2.7 
pg/mL) than the chow (10.4 ± 1.9 pg/mL, p < 0.001) control as presented in Panel A of 
Figure 6.12. Lower levels of IL-6 were observed in the HFD mice supplemented with 
TEMPOL (16.8 ± 1.5 pg/mL, p < 0.001) than the HFD fed mice.  
The IL-6 levels were greater in the HFD fed C57BL/6 mice (27.5 ± 2.2 pg/mL) 
than the chow control (4.9 ± 0.9 pg/mL, p < 0.001) as shown in Panel B of Figure 6.12. 
Lower IL-6 levels were detected in the HFD mice supplemented with TEMPOL (14.1 ± 
1.7 pg/mL, p < 0.001) than the HFD fed mice. The HFD supplemented mice with 
TEMPOL contained higher IL-6 levels than the chow supplemented mice with 
TEMPOL (4.8 ± 0.9 pg/mL, p < 0.01).  
Overall the HFD fed mice had higher levels of IL-6 than the non-HFD fed mice 
and TEMPOL significantly attenuated this elevation in both animal types. The IL-6 
values examined in the HFD mice supplemented with TEMPOL were similar to those of 
the non-HFD apo E
-/-
 mice with no statistical difference observed between these groups.  
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Figure 6.12: Plasma IL-6 levels for apo E
-/-
 (Panel A) and C57BL/6 (Panel B) mice. 
IL-6 levels (pg/mL) were measured in plasma of mice that were fed a chow or a high fat 
diet (HFD) with or without TEMPOL supplementation. Statistical significance was 
achieved at *** p < 0.001 versus chow and ++ p < 0.01 versus chow with TEMPOL 
supplementation and ### p < 0.001 versus HFD fed mice using two-way ANOVA 
analysis followed by Bonferroni’s post-hoc test. Values are expressed as mean ± SEM. 
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6.5.4 Effects of TEMPOL on serum amyloid-A (SAA) levels  
SAA is an acute-phase apolipoprotein predominantly produced by hepatocytes, 
the plasma levels of which have been positively correlated with the incidence of obesity, 
adiposity, diabetes and insulin resistance [363,364,365]. SAA levels were therefore 
measured in the mouse plasma as described in Section 2.11.3.  
SAA levels were significantly elevated in the HFD fed apo E
-/-
  mice (312.3 ± 
32.5 ng/mL) when compared to chow control mice (65.8 ± 15.4 ng/mL, p < 0.001) as 
presented in Panel A of Figure 6.13. The HFD mice supplemented with TEMPOL 
(127.3 ± 35.2 ng/mL, p < 0.001) had lower SAA levels than the HFD fed mice. 
HFD fed C57BL/6 mice exhibited higher SAA levels (294.4 ± 33.6 ng/mL) than 
the chow control (132 ± 9.6 ng/mL, p < 0.001) as shown in Panel B of Figure 6.13. 
HFD supplemented with TEMPOL mice (130.7 ± 9.4ng/mL, p < 0.001) showed lower 
SAA levels than the HFD fed mice.   
Overall the HFD mice had higher levels of SAA than the non-HFD fed mice and 
TEMPOL significantly attenuated this elevation in both the animal types. The SAA 
values examined in the HFD mice supplemented with TEMPOL were similar to that of 
the non-HFD fed mice in both animal types and there were no statistical differences 
observed between these groups.  
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Figure 6.13: Plasma SAA levels for apo E
-/-
 (Panel A) and C57BL/6 (Panel B) mice. 
SAA levels (ng/mL) were measured in plasma of mice that were fed a chow or a high 
fat diet (HFD) with or without TEMPOL supplementation. Statistical significance was 
achieved at *** p < 0.001 versus chow and ### p < 0.001 versus HFD fed mice using 
two-way ANOVA analysis followed by Bonferroni’s post-hoc test. Values are 
expressed as mean ± SEM. 
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6.5.5 Effects of TEMPOL on myeloperoxidase (MPO) levels  
MPO, a heme enzyme released by activated neutrophils and monocytes at sites 
of inflammation, catalyzes the oxidation of chloride ions to hypochlorous acid using 
hydrogen peroxide as a co-substrate [24]. Elevation of MPO levels have been reported 
to be an early biomarker of atherosclerosis and positively correlated with the incidence 
of obesity and cardiovascular disease in both children and adults [366,367]. MPO 
protein levels were therefore measured in the mouse plasma as described in Section 
2.11.3. 
MPO protein levels were significantly elevated in the HFD fed apo E
-/-
  mice 
(108.2 ± 7.1 ng/mL) when compared to chow control (39.8 ± 6 ng/mL, p < 0.001) as 
presented in Panel A of Figure 6.14. HFD mice supplemented with TEMPOL (28.8 ± 
2.2 ng/mL, p < 0.001) contained lower MPO levels than the HFD fed mice. Lower MPO 
levels were observed in the HFD supplemented with TEMPOL mice than the apo E
-/-
 
mice fed on chow supplemented with TEMPOL (57.6 ± 3.9 ng/mL, p < 0.01). 
HFD fed C57BL/6 mice had higher MPO levels (69.8 ± 5.3 ng/mL) than the 
chow control (23 ± 0.7 ng/mL, p < 0.001) as shown in Panel B of Figure 6.14. Lower 
levels of MPO were detected in the HFD mice supplemented with TEMPOL (43 ± 
4.1ng/mL, p < 0.001) than the HFD fed mice. Higher levels of MPO were present in the 
HFD mice supplemented with TEMPOL than the chow C57BL/6 mice supplemented 
with TEMPOL (22.7 ± 1.7 ng/mL, p < 0.01). 
Overall HFD fed mice of both strains had higher levels of MPO than the non-
HFD fed mice and TEMPOL significantly attenuated this elevation in both the animal 
types. The MPO levels detected in the HFD apo E
-/-
 mice supplemented with TEMPOL 
were the lowest of any of the apo E
-/-
 mouse groups examined. 
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Figure 6.14: Plasma MPO levels for apo E
-/-
 (Panel A) and C57BL/6 (Panel B) 
mice.  
MPO levels (ng/mL) were measured in plasma of mice that were fed a chow or a high 
fat diet (HFD) with or without TEMPOL supplementation. Statistical significance was 
achieved at *** p < 0.001 versus chow, ++ p < 0.01 versus chow with TEMPOL 
supplementation and ### p < 0.001 versus HFD fed mice using two-way ANOVA 
analysis followed by Bonferroni’s post-hoc test. Values are expressed as mean ± SEM. 
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6.5.6 Effects of TEMPOL on adiponectin levels  
Adipose tissue is a major energy reservoir in the body and a primary source of 
adipocytokines [368].  Adiponectin is a fat-derived hormone, secreted by adipocytes 
which exerts cardio-protective, anti-atherogenic, anti-inflammatory and anti-diabetic 
effects [369,370]. A reduction in adiponectin expression has been associated with 
obesity-related metabolic and cardiovascular diseases [368,370]. As a number of other 
cytokines and inflammatory agents were observed to be suppressed by TEMPOL in the 
obese and hyperlipidaemic high fat-fed mice examined in this project, it was of interest 
to determine whether adiponectin levels were also modulated in the mouse plasma. This 
adipokine was quantified as described in Section 2.11.3. 
Adiponectin levels were significantly decreased in the HFD fed apo E
-/-
 mice 
(9608 ± 592 ng/mL) compared to chow control (22091 ± 1202 ng/mL, p < 0.001). The 
HFD mice supplemented with TEMPOL (19103 ± 2035 ng/mL, p < 0.001) contained 
higher levels of adiponectin than the HFD fed mice, as presented in Panel A of Figure 
6.15. For the C57BL/6 mice there were no statistical differences in the levels of 
adiponectin amongst the groups as shown in Panel B of Figure 6.15.  
The HFD fed mice had the lowest levels of adiponectin, and TEMPOL 
significantly attenuated this decrease in adiponectin levels. The adiponectin values 
detected in the HFD mice supplemented with TEMPOL were similar to those of the 
non-HFD fed apo E
-/-
 mice and these data were not statistically different. Neither the 
HFD nor TEMPOL had any effect upon adiponectin levels in the C57BL/6 mice. 
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Figure 6.15: Plasma adiponectin levels for apo E
-/-
 (Panel A) and C57BL/6 (Panel 
B) mice.  
Adiponectin levels (ng/mL) were measured in plasma of mice that were fed a chow or a 
high fat diet (HFD) with or without TEMPOL supplementation. Statistical significance 
was achieved at *** p < 0.001 versus chow and ### p < 0.001 versus HFD fed mice 
using two-way ANOVA analysis followed by Bonferroni’s post-hoc test. Values are 
expressed as mean ± SEM. 
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6.5.7 Effects of TEMPOL on leptin levels 
Leptin is a hormone, secreted by adipocytes, that serves as a major negative 
regulator of food intake and engenders energy expenditure [368]. Dietary obesity is 
strongly correlated with hyperleptinaemia and hyperlipidaemia [78,312,330,371]. 
Leptin levels were therefore measured to confirm the inhibitory effects of TEMPOL 
upon inflammation, adiposity and body weight gain observed in the obese and 
hyperlipidaemic mice that were fed a HFD.   
The leptin levels were measured in the mouse plasma as described in Section 
2.11.3. The leptin levels were significantly elevated in the HFD fed apo E
-/-
 mice (95.2 
± 2.5 ng/mL) when compared to the chow control (4.3 ± 0.5 ng/mL, p < 0.001). HFD 
mice supplemented with TEMPOL (6.7 ± 0.6 ng/mL, p < 0.001) exhibited lower leptin 
levels than the HFD fed mice as presented in Panel A of Figure 6.16.  
HFD fed C57BL/6 mice produced higher leptin levels (112.5 ± 1.8 ng/mL) than 
the chow control (18.4 ± 0.4 ng/mL, p < 0.001) as shown in Panel B of Figure 6.16. The 
HFD mice supplemented with TEMPOL (15.1 ± 1.2 ng/mL, p < 0.001) contained lower 
leptin levels than the HFD fed mice.  Lower leptin values were also observed in the 
chow fed mice supplemented with TEMPOL (6.4 ± 0.5 ng/mL, p < 0.001) than the 
chow control.  Higher leptin levels were observed in the HFD supplemented with 
TEMPOL than the chow supplemented with TEMPOL mice (p < 0.001). 
Overall the HFD fed mice had higher levels of leptin than the non-HFD fed mice 
and TEMPOL significantly attenuated this elevation in both the animal types. The leptin 
values examined in the HFD mice supplemented with TEMPOL were similar to those of 
the chow control mice and these values were not statistically different in both animal 
types. For the apo E
-/-
 mice the leptin levels observed in the HFD supplemented with 
TEMPOL mice were similar to the non-HFD fed mice, and these values were not 
statistically different.  
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Figure 6.16: Plasma leptin levels for apo E
-/-
 (Panel A) and C57BL/6 (Panel B) 
mice.  
Leptin levels (ng/mL) were measured in plasma of mice that were fed a chow or a high 
fat diet (HFD) with or without TEMPOL supplementation. Statistical significance was 
achieved at *** p < 0.001 versus chow, +++ p < 0.001 versus chow with TEMPOL 
supplementation and ### p < 0.001 versus HFD fed mice using two-way ANOVA 
analysis followed by Bonferroni’s post-hoc test. Values are expressed as mean ± SEM. 
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6.5.8 Effects of TEMPOL on resistin levels  
As the data reported in the previous sections indicate that TEMPOL had an 
effect upon both adiponectin and leptin levels in the apo E
-/-
 obese and hyperlipidaemic 
mice that were on a HFD, resistin, an adipocyte secreted cytokine recently proposed to 
be associated with obesity and diabetes [78,372] was also quantified in the mouse 
plasma as described in Section 2.11.3.  
There were no statistical differences in resistin levels examined in the apo E
-/-
 
mice amongst the groups as shown in Panel A of Figure 6.17. There were also no 
statistical differences observed between the chow and HFD fed C57BL/6 mice as 
presented in Panel B of Figure 6.17. Resistin levels were however significantly higher 
in the HFD mice supplemented with TEMPOL C57BL/6  mice (52 ± 1.8 ng/mL) 
compared to chow fed mice supplemented with TEMPOL (26.2 ± 0.7 ng/mL, p < 0.001) 
and the HFD fed mice (23.7 ± 0.8 ng/mL, p < 0.001).  
Overall, there were no changes in resistin levels observed amongst the animals 
on the HFD, and TEMPOL did not have an effect upon resistin levels in the apo E
-/-
 
mice. However resistin values were greater in the HFD C57BL/6 mice supplemented 
with TEMPOL than the remaining groups of C57BL/6 mice.  
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Figure 6.17: Plasma resistin levels for apo E
-/-
 (Panel A) and C57BL/6 (Panel B) 
mice.  
Resistin levels (ng/mL) were measured in plasma of mice that were fed a chow or a high 
fat diet (HFD) with or without TEMPOL supplementation. Statistical significance was 
achieved at +++ p < 0.001 versus chow with TEMPOL supplementation and ### p < 
0.001 versus HFD fed mice using two-way ANOVA analysis followed by Bonferroni’s 
post-hoc test. Values are expressed as mean ± SEM. 
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6.6  Discussion 
The antioxidant activity and the antihypertensive effects of TEMPOL have been 
extensively studied with regard to inflammatory diseases including cancer 
[331,332,334,335], atherosclerosis [373,374,375,376], obesity [330,340,341,342] and 
diabetes [343,344,345] where oxidative damage is purported to contribute to 
pathogenesis and disease progression. In the present project, post mortem analyses was 
undertaken upon the aortic sinuses from atherosclerosis-prone mice (high fat-fed apo E
-
/-
 mice as well as the parent strain C57BL/6 strain) to elucidate the therapeutic potential 
of TEMPOL.  
Direct administration of TEMPOL has been shown to decrease blood pressure 
levels in many hypertensive rodent models [337,338,339,346,347]. TEMPOL and other 
nitroxides are considered safe to administer as no adverse effects appeared on cell 
growth and viability at concentrations of up to 1 mM [377]. Notably incubation with 
TEMPOL as high as 50 mM was shown to not provoke damage to chromosomal 
structures but instead was able to protect against radiation-induced chromosomal 
aberrations in cultured human peripheral blood lymphocytes [378]. Low loses of 
TEMPOL (0.4 mM/kg) given via intravenous injections have however been reported to 
cause restlessness and seizures [379,380]. However, TEMPOL concentrations as high as 
275 mg/kg were shown to be radioprotective in mice that were exposed to whole-body 
radiation [380].  TEMPO (2,2,6,6-tetramethylpiperidinoxyl radical; (CH2)3(CMe2)2NO˙
 
as shown in Figure 6.18) administration to mice was shown to result in rapid 
metabolism to produce the less toxic species TEMPOL [381]. Overall these studies 
imply that nitroxides are generally safe to administer except at exceptionally high 
dosages. Therefore we predicted that the 10 mg/g (equivalent to approx. 58 mM) 
TEMPOL that was utilised in these studies was likely to be well tolerated. Similar levels 
have been used in previous studies including long term feeding trials without any 
problems [330,331].   
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Figure 6.18: Chemical structure of TEMPO. 
TEMPO is also referred to as 2,2,6,6-tetramethylpiperidinoxidanyl, and 2,2,6,6-
tetramethylpiperidinoxyl radical. 
 
 
In this study, TEMPOL supplementation via food had a profound inhibitory 
effect, in both apo E
-/-
 and the parent C57BL/6 mice, upon the typical body mass gain 
that is the result of a high fat diet. Adult male apo E
-/-
 (or the parent C57BL/6) mice 
were fed for 7 weeks either on a standard chow diet or a high-fat diet (HFD) with the 
high fat feeding resulting in a substantial increase in body mass in both strains. 
TEMPOL feeding resulted in marked reduction in body mass gain. These findings 
confirm a previous study carried out by Mitchell et al. where TEMPOL administration 
via drinking water (2.9 - 58 mM) or food (10 mg/g food: 58 mM as used here) was also 
reported to result in significantly reduced body mass gain in C3H mice that were fed a 
bacon-flavoured mouse chow [330].  There seemed to be a dose dependent response as 
the degree of  inhibition of body weight gain increased with increasing dosages of 
TEMPOL, with 29 mM and above giving statistically significantly differences 
compared to both control groups (sucrose or ad lib). TEMPOL treated animals 
consumed approximately 20 to 30% less food than the non-TEMPOL administered 
mice.  
Although TEMPOL suppressed high fat feeding-induced body mass gain in both 
these previous studies [330,331] and the current investigation, the effect of this 
treatment on atherosclerosis remains under characterised. This was therefore further 
examined in the two animal models. Atherosclerotic plaque was assessed at one 
location, the aortic sinus. Regardless of diet, no plaque was observed in the aortic 
sinuses collected from the C57BL/6 parent strain. In contrast to this, plaques of 
substantial size were detected in the apo E
-/-
 mice. However, the plaque areas in the 
aortic sinuses from chow fed mice were significantly larger than those determined for 
the high fat-fed mice. This is a major limitation to the study as more plaque area should 
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be observed in the high fat-fed mice across all well-established atherosclerotic animal 
models. This may be due to fact that the animals may have been kept for too long before 
analysis as all animals possessed large plaques regardless of diet. Where plaque area 
could be determined for the purpose of comparison, TEMPOL was observed to have no 
impact upon plaque size. However, failure to develop a good model of atherosclerotic 
plaque induced by a high fat diet is a potential reason for the lack of reduction in plaque 
size detected with the TEMPOL treatment. An earlier time point would have been a 
more suitable approach to address this issue, before both the chow and high fat-fed apo 
E
-/-
 mice produced highly advanced atherosclerotic lesions. Although, in this pilot study, 
TEMPOL supplementation did not significantly modulate plaque area, refined 
experiments with a larger cohort kept for shorter periods and an assessment of 
atherosclerotic plaque development at more than one site may help elucidate the effect 
of TEMPOL upon atherosclerosis.  
The C57BL/6 wild type mice under the conditions employed do not appear to be 
suitable for examining atherosclerosis as no plaque was detected; this observation is in 
line with a study on hypercholesterolaemia induced by HFD diet in wild type and apo E
-
/-
 mice. Oil red O staining of the aortic arch, thoracic and abdominal  aorta did not give 
rise to significant plaques in the wild type C57BL/6 mice despite the high cholesterol 
diet; in contrast visible macroscopic plaques were detected in all three regions of the 
aorta in the apo E
-/-
 mice [382].  
TEMPOL supplementation was observed to have a marked effect upon the 
hyperlipidaemia induced by high fat feeding in both animal types, with supplementation 
significantly reducing plasma triglycerides, total cholesterol, HDL-C and LDL-C levels. 
These results are similar to those detected in both lean Zucker rats (LZR) and obsese 
Zucker rats (OZR) that were fed a HFD which invoked hyperlipidaemia with 
significantly elevated total cholesterol, very low-density lipoprotein-cholesterol and 
triglyceride levels. This hyperlipidaemia  was attenuated by TEMPOL (1 mM in 
drinking water for 10 weeks) [340]. In this previous study HDL-C levels were 
significantly lower in the HFD fed animals, and TEMPOL restored HDL-C to near 
control levels in both the OZR and LZR animal types [340].   
TEMPOL supplementation (1 mM in drinking water for four weeks in old 
Fischer 344 rats) has been shown previously to significantly decrease plasma glucose, 
insulin and triglycerides compared to non-TEMPOL supplemented rats [343]. Another 
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study also measured plasma metabolic parameters, where TEMPOL supplementation (1 
mM in drinking water for four weeks) in diabetic KK/Ta-Akita mice did not alter blood 
glucose, HbA1c, bodyweight or total cholesterol levels. Despite the unaltered metabolic 
parameters, TEMPOL treatment had an impact on renal function as it effectively 
decreased albuminuria and inhibited elevation of glomerular filtration rate (GFR) and 
renal hypertropy [344]. Furthermore although TEMPOL supplementation (29-58 mM) 
inhibited body weight gain in C3H mice [330], it did not affect plasma triglycerides, 
cholesterol and HDL levels, where all the mice, including controls were fed a high fat 
diet with or without various concentrations of TEMPOL. These differences compared to 
the current study may be due to the different mouse strains utilised. In the two animal 
models used in the current study, high fat feeding resulted in a substantial elevation of 
lipid levels, and TEMPOL treatment resulted in a marked reduction in these parameters. 
The effects of TEMPOL on weight gain as well as hyperlipidaemia were 
associated with a decrease in several pro-inflammatory cytokines and agents including 
MCP-1, IL-6, SAA and MPO levels, elevations in which are commonly seen in obesity-
related metabolic complications. Higher plasma levels and protein expression of TNF-α 
has been reported in obese patients than lean control subjects [383,384] and animal 
models [385,386]. The elevation of TNF-α levels and iNOS expression resulted in 
endothelial dysfunction in the small arteries observed  from visceral fat of obese 
patients [348]. Vascular superoxide radical generation which was also elevated in obese 
patients was attenuated by TEMPOL [348]. TNF-α levels were shown to be also 
elevated in Zucker obese fatty (ZOF) rats, a model for prediabetic metabolic syndrome 
in comparison to lean control rats [340,386]. TEMPOL was shown to significantly 
decrease the elevation of TNF-α levels [340] in the cortical tissues of the lean Zucker rat 
(LZR) and ZOF animals that were fed a HFD. However in the current study there were 
no differences detected between plasma TNF-α levels detected between the chow (non-
obese) and HFD (obese) fed mice in both animal strains; this may be due to differences 
in animal type as well as the use of the high fat diet in the current study.  
MCP-1 levels were significantly elevated in the C57BL/6 wild type mice fed a 
HFD in comparison to the chow. MCP-1 expression was also found to be significantly 
elevated by high fat feeding in Wistar-Kyoto (WKY) rats and spontaneous hypertensive 
rats (SHR) [341]. TEMPOL supplementation (1 mM in the drinking water) was shown 
to prevent the increase in MCP-1 levels, along with an inhibition of renal oxidative 
stress by suppressing an elevation of 8-isoprostane levels and elevation in macrophage 
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infiltration in both WKY and SHR animal types [341]. TEMPOL was shown to inhibit 
MCP-1 and IL-6 levels in endothelial cells that were incubated with TNF-α, IL-1 and 
IFN-γ cytokines in order to stimulate the ROS production which resulted in an elevation 
of MCP-1 and IL-6 [387].  
In the current study IL-6 and MPO plasma levels were showed to be suppressed 
by TEMPOL in the HFD fed obese mice of both animal strains.  A reduction in serum 
IL-6 has been reported previously, together with an inhibition of colonic MPO levels, in 
dextran sulfate sodium (DSS) induced colitis in male BABL/cA mice that were treated 
with TEMPOL (5 - 15 mg/kg/day) [388]. TEMPOL has been shown previously to 
inhibit  MPO mediated inflammation and tissue damage in multiple inflammatory 
pathologies such as renal disease [389], respiratory syndrome [390] and edema [391] 
and this was also seen in the current study, with TEMPOL shown to effectively 
suppress MPO levels in the  hyperlipidaemic obese mice. TEMPOL has been shown 
previously to attenuate carrageenan-induced inflammation arising from MPO mediated 
damage in rat paws and also was shown to inhibit rat neutrophil migration in vitro 
[391]. Renal dysfunction and injury induced by ischaemia / reperfusion has also been 
shown to be reduced by TEMPOL with MPO activity significantly inhibited in the rat 
kidneys, along with cell infiltration and lipid peroxidation as measured by 
malondialdehyde (MDA) [389]. Treatment with TEMPOL has also been reported to 
significantly ameliorate MPO activity in LPS (1 mg/kg) induced acute lung injury 
where MPO, MDA and NO levels were elevated in lung tissues of male albino mice 
[390]. Elevation of the cytokines, TNF-α, IL-1β and IFN-γ were also significantly 
reduced after the administration of TEMPOL in both bronchoalveolar lavage fluid and 
lung tissue homogenates [390].   
Plasma SAA levels have been shown to be increased in disorders linked with 
chronic inflammation such as rheumatic diseases, atherosclerosis, diabetes and obesity 
[392,393,394,395,396]. It has been reported previously that SAA is expressed at the 
highest concentrations by large adipocytes separated from adipose tissue from obese 
patients [397]. This is consistent with the data obtained from the two animal strains 
examined in the current study, where the obese hyperlipidaemic mice had very high 
levels of plasma SAA. Although there are no previous studies on the effects of 
TEMPOL upon SAA expression, TEMPOL was observed in the current study to have a 
significant effect upon plasma SAA levels in the HFD fed mice of both animal strains 
suggesting that TEMPOL may target adipose tissue in hyperlipidaemic obese mice.  
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The inhibitory effects of TEMPOL upon obesity, hyperlipidaemia and pro-
inflammatory agents and markers were also associated with changes in the levels of the 
adipocytokines adiponectin, leptin and resistin. Adiponectin exerts strong anti-
inflammatory and athero-protective effects on vascular tissue, and has an insulin-
sensitising effect on tissues associated with glucose and lipid metabolism [398,399]. A 
significant reduction in plasma adiponectin levels was detected in the high fat fed mice 
that became obese and hyperlipidaemic, when compared to the lean control apo E
-/- 
mice. Similar findings have been reported in other animal models 
[314,315,398,400,401,402] of obesity, diabetes and coronary artery disease. Lower 
adiponectin levels have been reported in various human cohort studies in subjects with 
obesity, diabetes and coronary artery disease [403,404,405,406,407,408].  In contrast, 
TEMPOL prevented the decrease in adiponectin levels that was induced by high fat 
feeding and obesity. TEMPOL has been reported to inhibit the expression of 
adipogenesis markers, adipose differentiation and lipid storage in mouse pre-adipocytes 
(3T3-L1) and human mesenchymal stem cells [342], which may be the underlying cause 
of the effects of TEMPOL on body weight gain, and the protective effects upon 
adiponectin levels seen in vivo.   
Resistin, another adipokine associated with obesity and metabolic disorders 
[78,372,409] was reported to be positively correlated with serum lipid levels and 
negatively associated with HDL-C levels in Indian male subjects [410]. However in the 
current study no differences were detected in plasma resistin levels between the lean 
and obese mice that were fed a high fat diet in both animal strains.  Although elevated 
plasma levels of fat-derived signalling molecules are correlated with obesity and 
vascular endothelial dysfunction and coronary heart disease, little is known about their 
specific roles, and the relationship with obesity remains controversial [411,412]. This 
species may therefore not be a suitable adipokine marker to elucidate the potential 
inhibitory mechanism of TEMPOL in obesity-related vascular and metabolic 
complications. 
High fat feeding in mice has been shown previously to result in 
hyperleptinaemia, a phenomena commonly seen in obesity as higher leptin levels are 
indicative of greater adipose tissue reservoirs and excess secretion causing leptin 
resistance [78,312,316,371]. TEMPOL was shown to prevent elevation of plasma leptin 
levels in the current study; this is consistent with the data of Mitchell et al. with similar 
TEMPOL dosages, where the mice were also shown to consume less food  [330]. 
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TEMPOL (2 mM in drinking water) has also been shown to be effective in controlling 
blood pressure in leptin-induced hypertensive male Wistar rats [413].    
Given the increasing incidence and economic burden of obesity, vascular and 
metabolic disorders, there is a pressing need to develop new therapeutic treatments to 
improve, delay and prevent these complications [5]. TEMPOL and its analogues have 
been shown to possess anti-hypertensive, anti-cancer, anti-inflammatory, anti-
hyperlipidaemic, cardio and renal protective actions. This present study is the first to 
demonstrate that this well tolerated nitroxide administered at relatively high 
concentrations also may be of importance in inhibiting or decreasing several cytokines 
and inflammatory factors associated with obesity and hyperlipidaemia resulting from 
high fat feeding in two animal strains. 
  
6.7  Conclusion 
Short term TEMPOL supplementation has been shown to have a significant 
impact upon body mass gain and hyperlipidaemia in a well-established model of obesity 
induced by high fat feeding. High fat fed mice had elevated levels of plasma 
triglycerides, total cholesterol, LDL and HDL compared animals fed a normal chow 
diet. However the progression and severity of atherosclerosis did not appear to be 
directly correlated with obesity in the apo E
-/-
 mice and there were no observable 
plaques in the C57BL/6 parent strain. Thus it is hard to discern whether TEMPOL had a 
significant effect upon atherosclerosis in this pilot study. Further studies are therefore 
necessary to elucidate the effect of TEMPOL on atherosclerotic lesions.  
However potential anti-hyperlipidaemic and anti-atherosclerotic effects of 
TEMPOL were detected when various systemic inflammatory responses were 
quantified. High fat feeding was observed to induce profound inflammatory responses 
with elevated levels of MCP-1, IL-6, SAA and MPO plasma levels detected when 
compared to the chow fed mice, for both the apo E
-/-
 and C57BL/6 strains, and these 
have been reported to be early biomarkers or correlate positively with atherosclerosis, 
obesity and cardiovascular diseases.  
TEMPOL was shown to decrease plasma levels of cholesterol and triglycerides, 
inflammatory responses and prevent body weight gain in the HFD fed mice. This was 
associated with changes in adipocytokines that are secreted by adipose tissue, as high 
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fat feeding induced hyperleptinaemia in both animal types and hypoadiponectinaemia in 
the apo E
-/- 
mice only. Dietary obesity is strongly correlated with hyperlipidaemia, 
hyperleptinaemia and hypoadiponectinaemia [78,312,330,368,370,371]. The elevated 
leptin levels were considerably suppressed by TEMPOL in both animal types and the 
lower adiponectin levels observed in the HFD fed apo E
-/- 
mice was reversed with 
TEMPOL. Therefore TEMPOL may exert cardio-protective, anti-atherogenic, anti-
inflammatory and anti-diabetic effects.  
The present chapter focused on the hyperlipidaemic effect of TEMPOL upon 
vascular manifestations in vivo. TEMPOL was shown to block weight gain, and also the 
systemic inflammatory response, in these fat-fed animals. The next chapter describes a 
follow up study to examine potential effects of TEMPOL against the deleterious 
manifestations of high glucose levels in human monocyte-derived macrophages 
(HMDM) in which elevated glucose levels engendered lysosomal dysfunction (see 
Chapters 3 and 4).  It also addresses whether TEMPOL has an effect upon inflammatory 
responses induced by high glucose.  
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CHAPTER 7: 
EFFECTS OF TEMPOL UPON CYTOKINE PRODUCTION AND 
LYSOSOMAL FUNCTION OF HUMAN MONOCYTE-DERIVED 
MACROPHAGES EXPOSED TO NORMAL AND HIGH GLUCOSE 
CONCENTRATIONS 
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7.1   Introduction 
Dysfunction of macrophages is a common feature of diabetic complications, 
manifested as inflammation, augmented susceptibility to infection, atherosclerotic 
progression and impaired wound healing after tissue damage [50,94,317,414,415], as 
such dysfunction would lead to defects or down regulation of non-specific immunity, 
inflammation and the adaptive immune response.  Several studies have investigated 
defence mechanisms against infectious disease in people with diabetes [416,417,418]. 
Monocytes from patients with diabetes have been reported to possess impaired 
chemostatic responses [419], and suppressed phagocytic activity [420]. This may be due 
to the inhibition of chemotactic, phagocytic and bactericidal functions in people with 
diabetes [420]. Finally many investigations have associated the severity of diabetes with 
an increased risk of cardiovascular disease attributable to the chronic hyperglycaemia in 
addition to other well-defined cardiovascular risk factors [114,236].  
Macrophages are believed to be involved in every phase of atherogenesis from 
early stage through to late-stage atherosclerotic lesions [266], most noted as lipid-laden 
foam cells which are critical to cholesterol accumulation in the vessel well and lesion 
development [421]. The main pathway of cholesterol accumulation in macrophage cells 
is via endocytic uptake of modified forms of (lipo) protein particles [422]. Macrophage 
lysosomal cholesterol accumulation is a major factor in the development of late-stage 
atherosclerotic lesions [423]. The presence of cholesterol and cholesteryl esters in foam 
cells is indicative of impaired cholesteryl ester hydrolysis and free cholesterol clearance 
[239,422]. Cholesterol accumulation in lysosomes and associated lysosomal 
dysfunction may therefore be critical in plaque progression.  
Functional changes in lysosomes induced by high glucose levels may affect the 
capacity of monocytes and macrophages, to catabolise modified (lipo) proteins 
specifically, and more generally impact upon macrophage function and survival. 
Lysosomal dysfunction induced by elevated glucose levels is evident in monocytes and 
macrophages exposed to high glucose in vitro [244] as reported in Chapters 3 and 4. 
The impact of hyperglycaemia upon atherosclerotic development is consistent with the 
data presented in Chapter 5 where diabetic mice plaques were larger in size with greater 
amounts of extracellular lipid and lower collagen content; characteristics of plaques 
with a higher risk of rupture. The beneficial effects of carnosine in this model were 
associated with reduced blood triglyceride levels as well as a greater portion of the 
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plaque being occupied by collagen in place of extracellular lipid, though this was 
without any impact on the chronic hyperglycaemia.  
For most subjects with diabetes the increased prevalence and rate of progression 
of atherosclerosis is likely to be the result of a combination of hyperglycaemia (and the 
associated oxidative and glycative stress), insulin resistance, a pro-inflammatory state 
and obesity. TEMPOL, a cell-permeable nitroxide is known to be capable of reacting, 
and detoxifying a number of free radicals and reactive oxygen species [336], and has 
reported impacts upon hypertension [336,337,339,346,347], diabetes [345,424,425], 
obesity [330,374], and cancer [331,332,426].  
The studies reported in the previous chapter indicated that exposure of fat-fed 
mice to TEMPOL had a profound inhibitory effect upon body weight gain, prevented 
obesity and attenuated hyperlipidaemia. The hypolipidaemic effect of TEMPOL was 
also associated with an inhibition of several pro-inflammatory cytokines and 
inflammatory agents, where these levels increased with obesity. Notably the source of 
these cytokines is not fully characterised in that both local adipocytes as well as 
infiltrating macrophages are implicated.  
This was the driver for the studies reported on this chapter whereby the effects 
of TEMPOL upon human monocyte-derived macrophages were examined. Further as 
chronic exposure of HMDM to high glucose levels has been shown to cause lysosomal 
dysfunction [244] and induce various innate and inflammatory responses, the impact of 
TEMPOL upon cytokine production as well as lysosomal function was examined for 
HMDM under normal and high glucose levels.  
 
7.2   Aims 
Firstly, to see if TEMPOL reverses the effect of lysosomal dysfunction seen in 
HMDM exposed to elevated glucose concentrations and in particular the detrimental 
impact upon the lysosomal enzymes studied in Chapters 3 and 4, and secondly to 
determine whether TEMPOL also has an effect upon cytokine production in the same 
macrophages in the light of the effects of TEMPOL on cytokine expression in vivo 
presented in Chapter 6. 
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7.3 Methods 
Human monocytes isolated from buffer coats of healthy donors were matured 
into macrophages over 10 days as described in Section 2.2.4 in RPMI media that 
contained normal (5.5 mM) or high (20 mM) glucose concentration and with or without 
supplementation with TEMPOL (100 μM). Cell pellets were obtained as detailed in 
Sections 2.2.5 to determine the lysosomal activities of cathepsins B, L and LAL as 
outlined in Sections 2.3 to 2.3.2 and 2.3.6. 
 
7.3.1 Secretion of cytokines by lipopolysaccharide (LPS) treatment 
Human monocytes were matured over 10 days in normal (5.5 mM) or high (20 
mM) glucose with or without TEMPOL added into the RPMI media. The pilot studies 
were conducted where the cells were initially stimulated with 0, 50 and 200 ng/mL of 
LPS on day 10. The cell culture supernatants were collected after 24 and 48 hrs of 
incubation and the levels of protein, interleukin-6 (IL-6), monocyte / macrophage 
chemotactic protein-1 (MCP-1), C-reactive protein (CRP), macrophage migration 
inhibitory factor (MIF), macrophage inflammatory protein-1α (MIP-1α) and tumour 
necrosis factor-α (TNF-α) were determined as previously described in Sections 2.11.3 - 
2.12.2. Based on these pilot studies, the cells were stimulated with 0, 25 and 50 ng/mL 
of LPS for 24 hrs before collection of the supernatants for analysis of the levels of 
protein,  CRP, MIP-1α and TNF-α.  
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7.4  Results 
7.4.1 The effect of TEMPOL upon lysosomal activities of cathepsin B, L and LAL 
in HMDM 
The lysosomal activities of human monocytes matured under normal (5.5 mM) 
and high (20 mM) glucose concentrations with and without TEMPOL supplementation 
(100 μM) were examined to determine whether TEMPOL counteracts the inhibition of 
lysosomal activity induced by high glucose.  
In agreement with studies present in Chapters 3 and 4, maturation of human 
monocytes in high glucose concentrations for 10 days modulated the activities of the 
three lysosomal activities as shown in Figure 7.1. In cells incubated in the high glucose 
concentrations the measured cathepsin B (64.5 ± 5.1%, p < 0.001), L (64.5 ± 5.1, p < 
0.001) and LAL (68.5 ± 6, p < 0.001) activities were significantly lower than the cells 
that were incubated in the normal 5.5 mM glucose (activity taken as 100%). However 
the presence of TEMPOL in either condition did not result in any significant 
differences. Thus addition of TEMPOL did not modulate the inhibition of lysosomal 
activities observed between the different concentrations of glucose as there were no 
statistical differences observed within the equivalent glucose treatment groups. 
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Figure 7.1: Lysosomal enzymatic activities in human monocytes matured under 
normal 5.5 mM or high 20 mM glucose concentrations with or without 100 μM 
TEMPOL supplementation for 10 days.  
Lysates of human monocytes that had been exposed to the normal 5.5 mM (blue) or 20 
mM (orange) glucose with or without TEMPOL (100 μM) were examined for the 
activities of lysosomal cathepsin B (Panel A), L (Panel B) and LAL (Panel C). Data 
(mean ± SEM) are the linear change in fluorescence intensity with time from 5 
independent donors. Statistical significant inhibition of lysosomal activities were 
examined at *** p < 0.001 against the normal 5.5 mM glucose conditions, and ### p < 
0.001 versus the normal glucose with TEMPOL supplementation. No statistical 
differences were detected between the samples with the same glucose treatment.  
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7.4.2  Protein content of human monocyte cells matured in varying glucose and 
LPS concentrations 
Initially the human monocytes from a single donor were incubated with the 
normal 5.5 mM and high 20 mM glucose concentrations for 10 days with this followed 
by 24 or 48 hr treatment with LPS (0, 50 and 200 ng/mL). This was to determine 
whether different times or concentrations of LPS affected cell confluence and total 
concentration of protein in HMDM that were matured in the presence of normal or high 
glucose.  The protein levels of the cells from various conditions were determined by the 
BCA protein assay by use of a standard curve generated using BSA as discussed in 
Section 2.4.1. The protein concentration in the zero LPS and zero time condition was 
0.6 μg/μL and there were no statistical differences observed in the protein content in the 
normal and high glucose treated HMDM that were subsequently stimulated for 24 or 48 
hr incubations with 0, 50 and 200 ng/mL of LPS as shown in Figure 7.2.  
 
 
Figure 7.2: Protein levels for HMDM cells subject to LPS stimulation (0, 50 and 
200 ng/mL) for 24 or 48 hrs after maturation for 10 days in normal 5.5 mM (blue) 
and high 20 mM (orange) glucose concentrations.   
BCA protein levels were determined for HMDM that had been matured in normal 5.5 
mM or high 20 mM glucose levels for 10 days followed by LPS stimulation at 0, 50 and 
200 ng/mL for 24 or 48 hrs. Values (µg/µL) are expressed as a mean of triplicate 
experiments from one monocyte donor.  
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7.4.3  MCP-1, IL-6, MIF, CRP, TNF-α and MIP- 1α expression by normal and 
hyperglycaemic HMDM after LPS stimulation 
Macrophages play a key role in the chronic inflammatory response in part by 
generating cytokines such as MCP-1, IL-6, MIF, CRP, TNF-α and MIP- 1α. MCP-1 is 
part of the chemostatic family and therefore also referred to as chemokine (C-C motif) 
ligand 2 (CCL2) and small inducible cytokine A2. MCP-1 is over secreted by many cell 
types including monocytes and macrophages at sites of inflammation triggered by either 
tissue injury or infection, which are commonly encountered with atherosclerosis, 
obesity, diabetes, insulin resistance, metabolic dysfunction and adiposity [312,361]. IL-
6 is a biomarker of inflammation that is secreted by T cells and macrophages to 
stimulate the immune response in particularly after tissue injury leading to 
inflammation, and elevated levels have been associated with the metabolic syndrome 
and obesity [313,362]. MIF (also known as glycosylation-inhibiting factor, GIF), is an 
important regulatory protein of the innate immune response released by the anterior 
pituitary gland. Elevated levels of MIF have been associated with diabetes, 
atherosclerosis and obesity [427,428,429,430,431,432,433,434,435,436], and lower 
levels of MIF protect against pancreatic beta-cell apoptosis and dysfunction [428]. 
CRP is a circulating plasma protein, which is secreted by the liver in response to 
inflammatory processes [437] and has been associated with the metabolic syndrome, 
insulin resistance and hyperglycaemia [438,439,440,441,442]. CRP has been shown to 
be a sensitive biomarker for cardiovascular disease (CVD) and CRP-inhibitors have 
been investigated as a treatment for cardiovascular disease [440,443,444,445,446].  
TNF-α is a cytokine produced by multiple cell types, primarily monocytes and 
macrophages, which are key inflammatory cells heavily involved in systemic 
inflammation and innate immunity [440]. Various studies have correlated elevated 
levels of TNF-α with diabetes [414,416,447,448,449,450], obesity 
[385,386,451,452,453] and cardiovascular disease [440,454,455,456,457,458,459].  
MIP-1α belongs to the chemokine family, and is also known as chemokine (C-C 
motif) ligand 3 (CCL3). This chemokine is secreted by many cell types, but particularly 
monocytes, macrophages, dendritic cells and lymphocytes and it is important for 
immune responses in infection and inflammation [460]. Higher levels of MIP-1α have 
been implicated in a number of studies of hyperglycaemia, obesity and atherosclerosis 
[449,460,461,462,463,464,465,466,467].  
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These cytokines which are associated with inflammation and tissue injury have 
been shown to be enhanced with hyperglycaemia, accelerated atherosclerosis and 
altered vascular wall function [387,414,447,448,449,450,468]. Therefore the 
concentrations of these cytokines were determined to examine the effect of high glucose 
and TEMPOL upon these potential pro-inflammatory factors.  
As normal and hyperglycaemic HMDM that were exposed to high 
concentrations of LPS for 24 or 48 hrs did not have significantly different levels of cell 
protein, the levels of cytokines were further examined at both time points. The levels of 
MCP-1, IL-6, MIF, CRP, TNF-α and MIP-1α were determined in the supernatants from 
cells that were stimulated with 0, 50 and 200 ng/mL of LPS as described in Sections 
2.12.1 and 2.12.2.  
Levels of MCP-1, IL-6, TNF-α and MIP-1α were increased with LPS 
stimulation, however there were no significant differences observed in MCP-1 and IL-6 
levels in HMDM that were stimulated with 50 or 200 ng/mL of LPS for either 24 or 48 
hr incubation periods as shown in Figure 7.4. 
A dose dependent increase in TNF-α and MIP-1α expression was seen with 
increasing concentrations of LPS as shown in Panels E and F in Figure 7.4. There was a 
marked up-regulation of TNF-α and MIP-1α levels in the hyperglycaemic HMDM when 
compared to the normal glucose cells that were stimulated with LPS at 50 and 200 
ng/mL for either 24 or 48 hrs. The differences between the two glucose treatment 
groups were more evident in the cells that were stimulated with 50 or 200 ng/mL LPS 
for 24 hrs. 
MIF was detected in the supernatants however there were no differences 
between the two incubation periods and no differences were observed between the 
different glucose concentrations and LPS levels. CRP was also detected in the 
supernatants that were not stimulated with LPS. There was a decrease in CRP levels in 
hyperglycaemic HMDM when compared to the normal glucose condition, with the 
reduction observed with high glucose more noticeable with LPS stimulation.   
Overall there was also an elevation in TNF-α and MIP-1α expression and a 
reduction in CRP levels in HMDM that were incubated with high glucose (20 mM). The 
largest differences between the normal and high glucose conditions occurred between 0 
and 50 ng/mL LPS at 24 hrs. This was followed by smaller changes between 50 and 200 
218 
 
ng/mL LPS, with even fewer differences observed for the 48 hr incubation periods. 
Hence lower concentrations of LPS of 0, 25 and 50 ng/mL and a 24 hr incubation period 
were used for subsequent experiments, as the differences in TNF-α, MIP-1α and CRP 
levels between the two glucose treatments were greatest with 50 ng/mL LPS for 24 hrs. 
These three cytokines were therefore investigated in depth for five donors to see if the 
up regulation of TNF-α and MIP-1α, and down regulation of CRP levels were 
reproducible for the two glucose concentrations in macrophages with lower levels of 
LPS stimulation for 24 hrs.  Simultaneously the effect of TEMPOL upon both normal 
and hyperglycaemic HMDM was investigated. 
 
7.4.4 Protein content of human monocyte cells matured in varying glucose, 
TEMPOL and LPS concentrations 
In these follow up experiments lower LPS levels of 0, 25 and 50 ng/mL were 
used as the optimal changes were observed to occur between 0 and 50 ng/mL of LPS at 
24 hrs (refer to Figure 7.3).  Differences in TNF-α, MIP-1α and CRP levels between the 
two (5.5 mM and 20 mM) glucose treatments were then assessed after 24 hrs in the 
absence and presence of (100 μM) TEMPOL.  Data was obtained from cells from five 
different donors.  BCA protein contents were determined for the cells at 0 and 24 hrs 
and LPS concentrations of  0, 25 and 50 ng/mL with and without TEMPOL (100 μM) 
for normal and high glucose treated HMDM cells. A protein concentration of 0.6 μg/μL 
was determined for the control cells and there were no statistical differences observed in 
the protein content in the HMDM that were stimulated with 0, 25 and 50 ng/mL of LPS 
with normal and high glucose concentrations with or without TEMPOL 
supplementation as shown in Figure 7.4.  
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Figure 7.3: Fold increase in MCP-1 (Panel A), IL-6 (B), MIF (C), CRP (D), TNF-α 
(E) and MIP-1α (F) expression compared to control (5.5 mM glucose) for 24 (clear 
bars) and 48 hrs (hatched bars) of LPS stimulation (0, 50 and 200 ng/mL) in 
HMDM that were matured for 10 days in normal 5.5 mM (blue) and high 20 mM 
(orange) glucose concentrations.   
Measurement of fold increase in MCP-1, IL-6, MIF, CRP, TNF-α and MIP- 1α  
expression compared to the normal 5.5 mM glucose (used as control) HMDM were 
incubated with normal (5.5 mM) or high (20 mM) glucose levels for 10 days followed 
by LPS stimulation with 0, 50 and 200 ng/mL for 24 or 48 hrs. Values in μg/μL are 
expressed as a mean of triplicate experiments from one monocyte donor.  
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Figure 7.4: Protein levels for HMDM cells after LPS stimulation (0, 25 and 50 ng/ 
mL) for 24 hrs after maturation for 10 days in normal 5.5 mM (blue) and high 20 
mM (orange) glucose concentrations with and without 100 μM TEMPOL 
supplementation.   
BCA protein levels (in μg/μL) were measured for HMDM that were matured in the 
normal 5.5 mM and high 20 mM glucose levels supplemented with and without 
TEMPOL for 10 days followed by LPS stimulation at 0, 25 and 50 ng/mL for 24 hrs. 
Data (mean ± SEM) are from five independent donors. No statistical differences were 
detected between any of the conditions. 
 
 
7.4.5 Effects of TEMPOL on C-Reactive Protein (CRP) levels from LPS induced 
normal and hyperglycaemic HMDM 
CRP levels were shown to be reduced with high glucose conditions in the pilot 
study, as shown in Figure 7.5, and this was further examined with multiple donors. The 
CRP levels were also determined in HMDM to examine the potential effects of 
TEMPOL upon CRP levels secreted by HMDM that were matured in normal (5.5 mM) 
and high (20 mM) glucose concentrations supplemented with and without TEMPOL. 
There were no statistical differences in CRP levels in the HMDMs that were incubated 
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in the normal 5.5 mM and high 20 mM glucose concentrations with 0, 25 or 50 ng/mL 
of LPS stimulation. There were no statistical changes observed in the normal and high 
glucose treated HMDM with or without TEMPOL supplemented in the media.  
Overall these results showed that there were no changes in CRP levels when the 
cells were exposed to 100 μM compared to 0 μM TEMPOL at either concentration of 
glucose or the different concentrations of LPS as shown in Figure 7.5.  
 
 
 
 
Figure 7.5: Fold increase in CRP expression compared to control (5.5 mM glucose) 
after 24 hrs of LPS stimulation (0, 25 and 50 ng/mL) for HMDM that had been 
matured for 10 days in normal 5.5 mM (blue) or high 20 mM (orange) glucose 
concentrations with and without 100 μM TEMPOL supplementation.   
Measurement of fold increase in CRP expression compared to the normal (5.5 mM) 
glucose (used as control) HMDM that were incubated with normal (5.5 mM) or high (20 
mM) glucose levels supplemented with and without TEMPOL for 10 days followed by 
LPS stimulation at 0, 25 and 50 ng/mL for 24 hrs. Data (mean ± SEM) are expressed in 
μg/μL from five independent donors.  
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7.4.6 Effects of TEMPOL on Tumour Necrosis Factor-α (TNF-α) levels from LPS 
induced normal and hyperglycaemic HMDM 
As enhanced secretion of TNF-α was detected with high glucose compared to 
the normal glucose treated HMDM in the initial experiments, this was investigated 
further with multiple donors. TEMPOL was investigated to determine whether it 
counteracts the increased secretion of TNF-α induced by high glucose levels. Therefore 
TNF-α levels were assessed in media from HMDM to examine the effect of TEMPOL 
upon TNF-α levels for cells matured in normal 5.5 mM and high 20 mM glucose 
concentrations with and without TEMPOL supplementation.  
Cells were exposed to 0, 25 and 50 ng/mL of LPS for 24 hrs after the maturation 
of monocytes to macrophages over 10 days. There was a dose dependent increase in 
TNF-α levels with increasing concentrations of LPS, as shown in Figure 7.6. There 
were no statistical differences in TNF-α levels across the groups when HMDM were not 
stimulated with LPS. 
For the cells that were exposed to 25 ng/mL of LPS for 24 hrs, TNF-α levels 
were significantly upregulated in HMDM that were incubated with high glucose (360.3 
± 161.9 fold increase over control) when compared to the normal glucose condition 
(131.4 ± 55.6 fold increase over control, p < 0.01), normal glucose with TEMPOL 
(132.3 ± 64.2 fold increase over control, p < 0.01) and high glucose with TEMPOL 
(124.6 ± 58.8 fold increase over control, p < 0.01).  
 Similarly when identical groups of cells were exposed to 50 ng/mL of LPS there 
was a significant elevation of TNF-α levels in HMDM that were incubated with high 
glucose (485.6 ± 197.8 fold increase over control) when compared to normal glucose 
(188.5 ± 80 fold increase over control, p < 0.001), normal glucose with TEMPOL 
(202.6 ± 96.5 fold increase over control, p < 0.001) and high glucose with TEMPOL 
(157.3 ± 69.8 fold increase over control, p < 0.001). 
HMDM incubated in high glucose levels (20 mM) had significantly elevated 
TNF-α levels when compared to both the HMDM groups that were incubated with 
normal glucose regardless of TEMPOL supplementation. TEMPOL significantly 
attenuated the elevation of TNF-α expression that was induced by high glucose. The 
TNF-α levels determined for the cells incubated in high glucose with TEMPOL were 
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similar to those of the normal glucose treated cells with no statistical differences 
observed.  
 
 
Figure 7.6: Fold increase in TNF-α expression compared to control (5.5 mM 
glucose) after 24 hrs of LPS stimulation (0, 25 and 50 ng/mL) for HMDM that 
were matured for 10 days in normal 5.5 mM (blue) and high 20 mM (orange) 
glucose concentrations with and without 100 μM TEMPOL supplementation.   
Measurement of fold increase in TNF-α expression compared to the normal (5.5 mM) 
glucose (used as control) HMDM that were incubated with normal (5.5 mM) or high (20 
mM) glucose levels supplemented with and without TEMPOL for 10 days followed by 
LPS stimulation at 0, 25 and 50 ng/mL for 24 hrs. Data (mean ± SEM) are expressed as 
μg/μL from five independent donors. Statistical significance is achieved at ** p < 0.01 
and *** p < 0.001 versus the remaining groups; 5.5 mM glucose, 5.5 mM glucose with 
TEMPOL and 20 mM glucose with TEMPOL by two-way ANOVA followed by 
Bonferroni’s post-hoc test.   
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7.4.7 Effects of TEMPOL on Macrophage Inhibitory Protein-1α (MIP-1α) 
secretion by LPS induced normal and hyperglycaemic HMDM 
As elevation of MIP-1α levels was observed with high glucose compared to the 
normal glucose treated HMDM cells in the pilot studies, this was subsequently 
examined for multiple donors. TEMPOL was also investigated to observe whether it 
suppresses the MIP-1α levels induced by high glucose levels. MIP-1α levels were 
assessed in HMDM to examine the effect of TEMPOL upon MIP-1α levels secreted by 
HMDM that were matured in normal 5.5 mM and high 20 mM glucose concentrations 
supplemented with and without TEMPOL. 
Cells were exposed to 0, 25 and 50 ng/mL of LPS for 24 hrs after the maturation 
of monocytes to macrophages. There was a dose dependent increase in MIP-1α levels 
when cells were exposed to 0, 25 and 50 ng/mL of LPS, as shown in Figure 7.7. There 
were no statistical differences in MIP-1α levels across the groups when HMDM were 
not stimulated with LPS. 
For the cells that were exposed to 25 ng/mL of LPS for 24 hrs, MIP-1α levels 
were significantly increased in HMDM that were matured in high glucose (46.1 ± 7.7 
fold increase over control) when compared to the normal glucose (16.9 ± 3 fold increase 
over control, p < 0.001), normal glucose with TEMPOL (18.2 ± 1.7 fold increase over 
control, p < 0.001) and high glucose with TEMPOL (17 ± 2.7 fold increase over control, 
p < 0.001).  
Similarly when identical groups of cells were exposed to 50 ng/mL of LPS there 
was a significant elevation of MIP-1α levels in HMDM that were incubated with high 
glucose (49 ± 10.2 fold increase over control) when compared to normal glucose (28.4 ± 
1.8 fold increase over control, p < 0.001), normal glucose with TEMPOL (29 ± 3.8 fold 
increase over control, p < 0.001) and high glucose with TEMPOL (28.2 ± 5.6 fold 
increase over control, p < 0.001). 
HMDM matured in high glucose (20 mM) had significantly higher MIP-1α 
levels than both the HMDM groups that were incubated with normal glucose regardless 
of TEMPOL supplementation. TEMPOL significantly attenuated the elevation of MIP-
1α expression that was induced by high glucose. The MIP-1α levels detected form the 
cells exposed to high glucose with TEMPOL were similar to those of the normal 
glucose treated cells, with no statistical differences detected.  
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Figure 7.7: Fold increase in MIP-1α expression compared to control (5.5 mM 
glucose) after 24 hrs of LPS stimulation (0, 25 and 50 ng/mL) for HMDM that 
were matured for 10 days in normal 5.5 mM (blue) and high 20 mM (orange) 
glucose concentrations with and without 100 μM TEMPOL supplementation.   
Measurement of fold increase in MIP-1α expression compared to the normal (5.5 mM) 
glucose (used as control) HMDM that were incubated with normal (5.5 mM) or high (20 
mM) glucose levels supplemented with and without TEMPOL for 10 days followed by 
LPS stimulation at 0, 25 and 50 ng/mL for 24 hrs. Data (mean ± SEM) are expressed as 
μg/μL from five independent donors. Statistical significance is achieved at *** p < 
0.001 versus the remaining groups; 5.5 mM glucose, 5.5 mM glucose with TEMPOL 
and 20 mM glucose with TEMPOL by two-way ANOVA followed by Bonferroni’s 
post-hoc test.  
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7.5  Discussions 
TEMPOL has been studied extensively as it has been reported to have potent 
anti-inflammatory activity which may therefore have therapeutic benefits in addition to 
reducing oxidative and / or glycative damage that initiates and accelerates progression 
of a number of inflammatory diseases [330,336,340,341,342,343,344,345,373,375,424]. 
Therefore compounds like TEMPOL may be valuable as novel therapies for the 
treatment of diabetes [343,344,345,424], obesity [330,340,341,342] and atherosclerosis 
[373,375]. Monocytes and macrophages are heavily involved in inflammatory diseases 
such as atherosclerosis, and the current studies demonstrated that their functions are 
influenced by hyperglycaemia [228,317]. Human monocyte-derived macrophages 
provide an ideal in vitro model to assess lysosomal function, and potential anti-
inflammatory and other immune-modulatory effects [244].  
Dosages of 5 mM TEMPOL have been reported as being relatively safe, as no 
adverse effects emerged on cell growth and viability in various in vitro studies 
[377,447,469,470].  Therefore it was assumed that TEMPOL supplementation at 100 
μM was likely to be well tolerated at both test levels for glucose. Indeed a previous 
study has examined human monocytes that were exposed to 30 mM glucose with 100 
μM TEMPOL [447]. In the present study TEMPOL at 100 μM did not affect the cellular 
protein levels significantly for the various glucose conditions or LPS treatments. 
 Glucose levels ranging from 10 to 30 mM are commonly used in in vitro studies 
of diabetes [244,471,472,473]. Potential defects in lysosomal degradation induced by 
exposure to high glucose have been investigated in monocytes and macrophages that 
were incubated with 10 to 30 mM glucose [244] and the extent of these changes have 
been examined in Chapters 3 and 4. For maturing monocytes and developed 
macrophages the inhibition of lysosomal activities, and the reductions detected in 
protein expression and lysosomal number were seen at 20 mM glucose and higher. 
Likewise, in the current study, reductions in cathepsins B, L and LAL enzymatic 
activities were detected in macrophages that were exposed to equivalent glucose 
conditions. This impairment of lysosomal activities may result in poor clearance of both 
native and modified proteins, including those internalised by endocytosis, or trafficked 
intracellularly and may help account for the lipid accumulation detected in macrophages 
causing foam cells. 
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TEMPOL (100 μM) supplementation did not arrest the inhibition of lysosomal 
activity induced by high glucose in HMDM cells. Therefore TEMPOL may not have an 
effect upon the lysosomal dysfunction induced by high glucose, or a higher dosage of 
TEMPOL may be required to observe any distinctive changes. Notably, TEMPOL 
appears to have an effect upon protein degradation system via a different mechanistic 
pathway, possibly via activating the protein kinase RNA-like endoplasmic reticulum 
kinase (PERK) [474].  Activation of the unfolding protein response (UPR) caused by 
endoplasmic reticulum- and oxidative-stress may stimulate c-jun N-terminal kinase 
(JNK). ROS generated from this activation can result in an accumulation of misfolded 
proteins, beta cell dysfunction, apoptosis and altered protein secretion [475,476]. Rats 
infused with TEMPOL (2.41 μM/kg/min) and high glucose (15 - 22 mM) were shown 
to have preserved endoplasmic reticulum function and reduced oxidative stress and beta 
cell dysfunction in isolated islets compared to the high glucose alone condition 
[474,477]. Butylated hydroxyanisole (BHA), a lipid-soluble antioxidant was also shown 
to suppress endoplasmic reticulum stress and protein secretion in chop
-/-
 C57BL/6 mice 
[475].   
Although TEMPOL (100 μM) did not arrest the decrease in lysosomal 
enzymatic activities induced by high glucose, further studies were carried to investigate 
the anti-inflammatory potential of TEMPOL. Macrophages play a critical role in innate 
immunity and inflammatory processes by synthesising and releasing particular 
cytokines, and elevated levels of MCP-1, IL-6, MIF, CRP, TNF-α, MIP-1α have been 
associated with hyperglycaemia, accelerated atherosclerosis  and altered vascular wall 
function [387,414,447,448,449,450,468]. A range of pro-inflammatory cytokines and 
agents were significantly reduced by TEMPOL (58 mM) in hyperlipidaemic and obese 
mice resulting from feeding with a HFD as reported in Chapter 6. Up-regulation of 
inflammatory pro-cytokines has been reported in various studies of diabetes 
[317,414,416,418,438,439,447,448,449,450,468], atherosclerosis 
[50,415,440,454,462,463] and obesity-related metabolic dysfunction 
[94,385,386,442,451,452,453,461] and cardiovascular diseases 
[443,445,455,456,457,458,459]. Therefore the potential inhibitory action of TEMPOL 
upon inflammatory cytokine release was investigated in HMDM exposed to high 
glucose and LPS.  
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Hyperglycaemia is a well known risk factor for both micro- and macrovascular 
disease and a number of studies have implicated changes in the inflammatory response 
in the early stages of diabetes and obesity [478,479]. People with diabetes with 
microvascular complications have been reported to have augmented production of 
inflammatory biomarkers, such as pro-inflammatory cytokines, over and above the 
levels detected in Type 1 diabetic (T1D) patients without microvascular complications 
and healthy control subjects [480,481,482,483]. Higher MIF have been detected in 
pregnant women with gestational diabetes [427] and a deficiency in MIF was shown to be 
protective from palmitic acid-induced apoptosis in pancreatic islets [428]. Although up-
regulation of pro-inflammatory cytokines is commonly encountered in people with 
hyperglycaemia, the pilot study carried out here with cells from one healthy donor 
showed that high glucose did not affect LPS-induced MCP-1, IL-6 and MIF levels. 
However TNF-α and MIP-1α levels were notably raised, and CRP levels were 
decreased, in macrophages that were matured in high glucose.  
Subsequent studies were carried out with human monocytes from five 
independent healthy donors that were matured to HMDM cells to confirm the elevation 
of TNF-α and MIP-1α and the reduction of CRP levels detected in the pilot studies. 
Further studies confirmed that high glucose (20 mM) matured in HMDM cells elevated 
the secretion of TNF-α and MIP-1α levels in response to LPS.  
High glucose did not affect CRP levels, despite the increasing levels of LPS and 
glucose concentrations to which the HMDM were exposed. CRP levels have been 
reported to be higher in Type 2 diabetes and diabetic nephropathy patients compared to 
healthy subjects and IL-6 levels were positively associated with severity of the disease 
[468]. Furthermore higher levels of CRP have been detected in the plasma of diabetic 
patients [438,439,440,441,442] and this has been reported to be a sensitive biomarker 
for CVD and atherosclerosis [440,443,444,445,446]. However this was not shown for 
human macrophages in in vitro studies. CRP is predominantly produced and released by 
the liver [437] which may be another reason as to why no differences were observed 
despite the varying levels of LPS (0 - 200 ng/mL) used to treat the human macrophages. 
This may suggest that only low levels of CRP are available in HMDM for secretion 
when induced by LPS. Testing for CRP levels in a different cell types may be 
worthwhile, in particularly in hepatocytes where CRP is primarily synthesised, and 
where the effect of TEMPOL upon CRP levels induced by high glucose may be more 
obvious. In contrast, the levels of TNF-α and MIP-1α were extremely responsive to 
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higher glucose concentrations for the same HMDM donors used to assess CRP levels 
suggesting that there were no problems with the cells in the experiments used.  
High glucose elevated the secretion of TNF-α and MIP-1α in response to LPS. 
Elevation of pro-inflammatory cytokines induced by high glucose has been reported in 
both in vitro and in vivo studies. Thus human monocytes that were incubated with 30 
mM glucose and treated with LPS (500 ng/mL; 24 hrs) increased secretion of MIP-1α 
levels, and higher levels of IL-6, IL-8, and MIP-1β were observed when compared to 
normal 5.6 mM glucose from U-937 monocytes [449]. Increases in TNF-α expression 
along with IL-1β, IL-6, IL-12, IL-18 were detected and found to be stimulated by 
hyperglycaemia in vivo from mouse peritoneal macrophages from STZ-induced diabetic 
C57BL/6 mice [414]. Macrophages from mice with diabetes (16.8 - 28 mM glucose) 
were also found to produce significantly more TNF-α, IL-6 and reactive oxygen 
intermediates than cells from normoglycaemic control CBA/J mice [450]. 
TEMPOL has been reported to alleviate high glucose induced oxidative stress 
[424,425,447,474]. In the current study, TEMPOL (100 μM) significantly attenuated the 
elevation of TNF-α and MIP-1α levels released from human macrophages induced by 
20 mM glucose, where many studies have reported an increase in these cytokines 
[414,447,448,449,450,460,461,462,463,464,465,466,467]. Given that TEMPOL at the 
same concentration also inhibited TNF-α levels in human monocytes exposed to a 
glucose concentration of 30 mM, and this was associated with inhibited ROS 
production, the probable mechanism in the current study would be the antioxidant 
activity of TEMPOL [447]. Interestingly TEMPOL was shown to block MCP-1 and IL-
6 release from endothelial cells that were stimulated with TNF-α, IL-1 and IFN-γ 
cytokines in order to engender the production of ROS [387]. TEMPOL (1 mM in 
drinking water) has also been shown to exert protective antioxidative effects against 
renal dysfunction in streptozotocin-induced diabetic rats, as malondialdehyde levels 
were significantly reduced, and this was coupled with a decrease in activity of 
superoxide dismutase and glutathione peroxidase [424]. In another animal model the 
same dose of TEMPOL (1 mM in drinking water) did not prevent early renal injury 
(proteinuria) induced by caffeine, but was found to suppress late stage renal 
inflammatory, proliferative and fibrotic changes that were inflicted by chronic caffeine 
consumption in obese ZSF1 rats [484]. Further to this, hypertension and insulin 
resistance were found to be associated with greater secretion of MCP-1 and TNF-α 
levels in the soleus rat muscle, with these changes being attenuated by TEMPOL [485]. 
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These findings suggest that TEMPOL ameliorates inflammation and oxidative stress 
caused by conditions that include high blood glucose levels. However, it cannot be 
excluded that the inhibition by TEMPOL of TNF-α and MIP-1α secretion induced by 
high glucose treatment may also indicate that other pathways may contribute to the 
inhibition of the inflammatory responses seen in diabetes and cardiovascular disorders 
such as atherosclerosis. Chemokine receptors have been shown to influence lipoprotein 
metabolism and atherosclerosis in mice [486,487,488,489,490]. Thus MIP-1α (CCL3) 
levels have been found to play a crucial role in lipid metabolism in hyperlipidaemic fat-
fed mice and to be positively associated with disease in various mouse models of 
atherosclerosis [462,491], and in human carotid endarterectomy samples [492]. Plasma 
lipids, leptin and insulin concentrations, atherosclerotic lesion area, the presence of 
lesional T lymphocytes, body adiposity, hepatic triglycerides and TNF-α levels in the 
adipose tissue were also significantly lower in CCL3
-/- 
 hyperlipidaemic mice [462].  
MIP-1α levels have also been shown to be elevated on incubation of mouse 
peritoneal macrophages with VLDL [493], however the effect of TEMPOL upon MIP-
1α secretion engendered by lipid remains unknown. The current study is the first to 
reveal that enhanced generation of TNF-α and MIP-1α levels by human macrophages 
induced by high glucose can be significantly inhibited by TEMPOL. These anti-
inflammatory effects strongly suggest that TEMPOL may have a significant role to play 
in diabetes-associated atherosclerosis which deserves further studies. In the previous 
chapter, TEMPOL was shown to prevent body weight gain and decrease the levels of 
several cytokines and inflammatory factors in hyperlipidaemic and obese mice. In the 
current study, TEMPOL was found to have a profound inhibitory impact upon the 
secretion of some of these species by human macrophages that had been previously 
exposed to high glucose.  
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7.6  Conclusion 
Lysosomal dysfunction is evident in HMDM exposed to hyperglycaemic (20 
mM) conditions as shown by a decrease in lysosomal cathepsin B, L and acid lipase 
activities. However, TEMPOL was unable to arrest these detrimental effects on 
lysosomal function induced by high glucose.  
High glucose induced an inflammatory response in HMDM as the levels of 
TNF-α and MIP-1α levels were significantly elevated.  TEMPOL (100 μM) 
supplementation of these cells exposed to high glucose significantly attenuated the 
elevation of TNF-α and MIP-1α levels induced by LPS. These are early biomarkers of 
inflammation and are known to be positively associated with hyperglycaemia, obesity 
and atherosclerosis. However, the effects of high glucose did not appear to be directly 
correlated with CRP secretion as there were no notable differences in CRP levels 
between normal and high glucose concentrations. Therefore it is hard to determine 
whether TEMPOL had a significant effect upon CRP levels and further studies are 
required to elucidate the effect of TEMPOL on CRP levels which are elevated in people 
with diabetes, obesity and related cardiovascular diseases [440,443,444,445,446]. 
Overall the anti-inflammatory effects exerted by TEMPOL observed in the 
present and previous chapters, strongly suggest that TEMPOL may have a potential 
protective role to play in diabetes-associated atherosclerosis.  
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CHAPTER 8: 
DISCUSSION AND FUTURE DIRECTIONS 
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8.1  Overview 
The research undertaken in this project sought to provide molecular insights into 
the links between diabetes and atherosclerosis, as well as exploring potential anti-
glycative and anti-oxidant compounds which may alleviate cardiovascular related 
diseases induced by hyperglycaemia and hyperlipidaemia.  
Hyperglycaemia, which may lead to chronically elevated levels of AGE and 
glycated proteins, is an independent risk factor for the diabetic complications of 
atherosclerosis [317].  In atherosclerosis, modified lipoproteins and lipid-laden 
macrophage-derived foam cells accumulate within lesions and formation of the latter 
may be partially due to an increased uptake of lipoproteins, decreased or altered 
intracellular metabolism and / or decreased cholesterol efflux. Modified (lipo) proteins 
in particular appear to accumulate in cells as a result of the impairment of the endo-
lysosomal system, which is responsible for the degradation or turnover of native or 
modified LDL particles. The potential role of hyperglycaemia in macrophage lysosomal 
dysfunction has not been fully elucidated, and the impact that high glucose 
concentrations may have on lysosomes was therefore investigated in both murine and 
human macrophages (Chapter 3), and monocytes during their maturation to 
macrophages (Chapter 4).  
These studies were subsequently extended to a diabetes-associated 
atherosclerotic animal model, where diabetes was induced by streptozotocin. This 
model was then used to investigate the potential anti-glycative, anti-lipidaemic and anti-
atherogenic properties of carnosine (Chapter 5).  
Hyperlipidaemia, a dominant feature of the metabolic syndrome, is also 
commonly seen in people with diabetes and cardiovascular diseases. Potential anti-
obesity, anti-lipidaemic and anti-inflammatory effects of TEMPOL (Chapter 6) were 
therefore examined in an animal model where mice were fed a high fat diet or normal 
chow with or without added TEMPOL. The potent anti-inflammatory effects of 
TEMPOL that were observed in these hyperlipidaemic obese mice were further 
investigated in human macrophages exposed to hyperglycaemia-like conditions 
(Chapter 7). The results obtained in each of these systems are discussed in further detail 
below.  
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8.2 Lysosomal dysfunction caused by high glucose in maturing monocytes and 
macrophages 
Lysosomes, are major sub-cellular organelles in macrophages and play a major 
role in degradation and the removal of a range of biomacromolecules [494]. 
Dysfunction of lysosomes may be responsible for the accumulation of 
damaged/glycated proteins and decreased or altered turnover of native or modified low 
density lipoprotein particles in macrophage foam cells [240,495]. Understanding the 
factors that influence lipid accumulation in macrophages is therefore an important line 
of study in diabetes-associated atherosclerosis.  
In the initial stages of atherosclerosis, excess sterol is primarily located within 
lipid droplets of the cell cytoplasm [496]. However, as lesions progress a significant 
amount of sterol is accumulated within the lysosomes of foam cells [423]. Furthermore 
an accumulation of oxidised lipids and proteins is known to occur in human 
atherosclerotic lesions [496,497,498,499], and previous studies have reported an 
enhanced accumulation of modified proteins and lipids during the development of 
diabetes-associated atherosclerosis [151,240,495,500].  
A possible mechanism for this accumulation is that modified proteins (e.g. 
glycated, oxidised or chemically modified) LDL are endocytosed via interaction with 
macrophage scavenger receptors. The endocytosed LDL is transported to the lysosomes 
to be degraded, with the free cholesterol released into the cytosol.  The free cholesterol 
is then available for efflux from the cell to lipid-free or lipid-poor apolipoprotein A1 
and HDL [501,502,503].  
Hyperglycaemia may have an impact on a number of these steps such as 
increased scavenger receptor expression and thus uptake of lipoprotein particles, 
impeded efflux of cytosolic cholesterol and impaired apolipoprotein A1 and HDL 
transport [272,504,505]. Macrophage scavenger receptor mRNA and protein levels have 
been shown to be modulated in HMDM by high glucose, with elevation of LOX1 
mRNA and decreased expression of SR-A1, SRB1, LDL-R and CD36 mRNA, however 
this did not impact the accumulation of cholesteryl esters in the HMDM [272]. This 
suggests that macrophage scavenger receptor levels may not be the key or sole 
determining factor in lipid accumulation in human macrophages. 
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Exposure of macrophages, but not smooth muscle and endothelial cells to 
glycated LDLs in the absence of high glucose has been shown to result in cholesterol 
and cholesterol ester accumulation. [151,500]. Furthermore lipid and cholesterol ester 
accumulation was observed in HMDM that were exposed to LDL glycated with 
methyglyoxal and glycoaldehyde [240]. This lipid accumulation was accompanied by 
greater endocytosis, degradation, and intracellular accumulation of modified apo B 
protein from glycoaldehyde-modified LDL [240]. Inhibition of LDL glycation by 
hydrazine compounds has been reported to inhibit and reduce lipid loading and foam 
cell formation in murine macrophage cells [506]. However extensive modification of 
the LDL was required to see intracellular accumulation of cholesteryl esters, and this 
may not reflect the situation in people with diabetes. It remains to be established 
whether high glucose levels alone drives this lipid or protein accumulation and to what 
degree hyperglycaemia impairs the metabolism and turnover rate of endogenous levels 
of glycated and oxidised lipoproteins, as these previous studies reported used high 
amounts of modified and glycated proteins and / or cells with unimpaired lysosomal 
metabolism. 
Cholesterol efflux from cells to apoA-1 and HDL metabolism may be affected 
by hyperglycaemia with this leading to lipid accumulation and contributing to the 
progression of atherosclerosis [507,508]. It has been shown that increasing glycation of 
apo A-1 is associated with a decreased activity of LCAT, a key enzyme in the 
metabolism of HDL [507]. A deficiency in LCAT activity has been reported for 
glycated apoA-1 isolated from people with Type 2 diabetes [429,431] and 
cardiovascular disease [430]. This reduction in enzyme reactivity may result in a 
decreased or impeded cholesterol efflux, as LCAT drives reverse cholesterol transport 
by esterifying cellular cholesterol and therefore allowing removal by HDL. Although 
glycation of apoA-1 may adversely affect reverse cholesterol and HDL function, this 
pathway alone may be insufficient to be the main driving factor of intracellular 
cholesterol accumulation in atherosclerosis.  
The studies reported in this thesis initially examined the potential impact of high 
glucose concentrations upon lysosomal enzymatic activities and number of lysosomes 
in murine J774A.1 macrophage-like cells that were incubated with normal (5.5 mM) or 
elevated concentrations of glucose (10 - 30 mM). The activities of three lysosomal 
cysteine proteases (cathepsins B, L and S), the aspartic acid protease cathepsin D and 
lysosomal acid lipase (all of which are highly expressed in normal macrophage 
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lysosomes), were found to be inhibited in cells exposed to high glucose concentrations. 
This decrease in multiple lysosomal activities may be due to a number of factors 
including; direct inactivation of these enzymes by glucose or materials derived from it, 
altered lysosomal pH, decreased protein levels or altered lysosome numbers. An acidic 
lysosomal environment must be achieved in order for the lysosomal enzymes to be fully 
activated; a higher pH may decrease the activity of these lysosomal enzymes. 
Alternatively a decrease in enzyme activity may also be due to a reduction in lysosomal 
protein levels or number. In the current study it has been shown that lysosomal 
cathepsin S protein levels were reduced by high glucose (30 mM) in HMDM cells 
[244]. Multiple lysosomal cathepsin activities along with acid lipase enzymatic 
activities were also decreased with high but lower concentrations of glucose (10 and 20 
mM) [244]. A deficiency in the activity of these enzymes may result in inadequate 
degradation of the ingested materials, further slowing down the breakdown and removal 
process of these particles. Lysosomal deficiency or lysosomal defects from 
hyperglycaemia may therefore lead to the accumulation of lipids in lysosomes.   
In order to provide a more suitable model of the situation in people with 
diabetes, these experiments were subsequently extended to human monocyte-derived 
macrophages (HMDM) that were collected from healthy donors. Long term exposure of 
these monocyte/ macrophage cells to elevated glucose levels resulted in a depression of 
lysosomal proteolytic and lipase activities.  
Lysosomal numbers were assessed in the murine J774A.1 and HMDM cells by 
LAMP-1 levels, aryl sulfatase activity and Lysotracker Red dye accumulation.  There 
was also less aryl sulfatase activity and LysoTracker Red staining, which are indicative 
of decreased lysosomal populations in the HMDM and J774A.1 cells that were exposed 
to 30 mM glucose [244]. High glucose modulated the levels of LAMP-1 protein, which 
is used as a general indicator for the presence of lysosomes [269]. LAMP-1 has been 
shown to play a key role in the generation of lysosomes, their translocation and the 
subsequent fusion of phagosomes with lysosomes [432]. Hyperglycaemia was also 
shown to decrease aryl sulfatase activity, Lysotracker dye accumulation and cathepsin 
protein levels supporting the LAMP-1 results with regard to the impact upon lysosomal 
number [244].   
As lysosomal enzymes and lipases were shown to be inhibited by 
hyperglycaemia, this may cause lysosomal dysfunction and a reduced capacity to 
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degrade and hydrolyse proteins, triglycerides and cholesterol esters, thereby 
contributing to lipid accumulation.  LAL is the only lysosomal hydrolase, available for 
the cleavage of cholesteryl esters and triglycerides delivered to the lysosomes [509]. A 
significant decrease in atherosclerotic plaques by LAL administration was observed in 
mice with LDL receptor deficiency with a HFD. Repeated dosages of additional LAL 
have also been reported to almost completely eradicate early stage lesions, and there 
were considerable improvement in the quality and quantity of advanced lesions [510].   
Intravenous injections of LAL into LAL-deficient mice corrected macrophage lipid 
storage disorders and decreased cholesterol and triglyceride content in multiple tissues 
[511,512].  
Lysosomal impairment in the murine J774A.1 and HMDM cells were seen with 
elevated glucose concentrations. However, whether the lysosomal dysfunction that was 
detected in these cellular studies can also be seen in vivo remains unanswered. This 
could be addressed by examining a standard diabetes atherosclerosis model to examine 
whether high glucose alone causes an accumulation of LDL particles within the 
lysosomes in vivo. This can be determined by lysosomal cathepsin and acid lipase 
markers in atherosclerotic lesions via immunohistology [510,511,513]. If lower levels 
of lysosomal markers are detected in the diabetic mice, this may confirm that lysosomal 
dysfunction or reduction of lysosomes within plaque macrophages can be potentially 
exacerbated by hyperglycaemia leading to plaque growth and instability. This would 
further define the roles of lysosomes and the magnitude of lysosomal damage that is 
inflicted by hyperglycaemia and the effect of this on plaque composition. Such studies 
would therefore provide key mechanistic data linking diabetes and atherosclerosis as 
postulated in Figure 8.1.  
Additional studies on the mechanisms of modified and oxidised lipid 
accumulation in cells as a result of hyperglycaemia could be carried out to examine the 
turnover and degradation rates of LDL in macrophages that are exposed to high glucose 
and which are known to be susceptible to LDL accumulation. The endocytosis, 
degradation rates, turnover of exogenous protein and net intracellular accumulation of 
native and glycated LDL could be examined by using 
125
I- of labeling LDL particles and 
radioactive counting. Lipid and cholesterol ester accumulation has been previously 
shown to be associated with greater endocytosis, degradation and intracellular 
accumulation of modified apo B lipoproteins in HMDM cells that were exposed to high 
amounts of glycoaldehyde-modified LDLs [240].  In such studies it would be of interest 
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to see whether high levels of glucose alone affects endocytosis and degradation of 
125
I-
BSA and 
125
I-LDL relative to the normal glucose conditions and whether high glucose-
exposed cells accumulate native and glycated LDLs. A possible reduction in endocytic 
and degradative activity may explain the diminished proteolytic capacity of lysosomal 
cathepsins and acid lipases in cells that are exposed to high glucose.  
Further mechanistic studies could be carried out to investigate possible 
detrimental effects of hyperglycaemia on various lysosomal gene expression pathways. 
The effect of high glucose concentrations on lysosomal cathepsin and lipase mRNA 
expression can be further examined by RT-PCR techniques. Structural changes to 
lysosomes can be viewed under routine electron microscopy and changes in lysosomal 
markers in hyperglycaemic macrophages in atherosclerotic lesions from diabetic mice 
or humans can be examined via immunohistochemistry [513]. This would provide a 
more solid understanding of the causes of lysosomal dysfunction induced by 
hyperglycaemia. 
Early endosome antigen 1 (EEA1) is responsible for translocation and fusion of 
early endosomes along with Arf and Rab GTPases, which are important in the 
regulation of fusion of transport vesicles [514,515]. The CD63/68 antigen is a 
glycoprotein of the LAMP family which binds to LDL and plays an important role in 
phagocytotic activity and intracellular lysosomal metabolism in late endosomes 
[516,517,518,519] and protein p62 mRNA is responsible for delivery of ubiquitin-
tagged proteins into autophagosomes [520,521,522]. Electron microscopic 
immunocytochemistry has revealed that fatty streaks of human aortas contained 
diminished amounts of EEA1 and Rab5a mRNAs, whilst the levels of CD68 and p62 
mRNAS were elevated in comparison to normal intima [513]. These data indicate that 
both early and late endo-lysosomal systems are affected in atherogenesis. Further 
investigations on the impairment that may be occurring in the early or late endo-
lysosomal systems, along with lysosomal structural changes arising from 
hyperglycaemia may determine whether alterations in lysosomal enzyme levels and 
activity result in a reduced capacity to clear native and modified lipoprotein particles, 
and hence whether this contributes to lipid accumulation within lysosomes.  
The studies in Chapter 4 were carried out to determine at which time point high 
glucose levels begin to impede lysosomal function. High glucose concentrations were 
shown to have an inhibitory effect on lysosomal cathepsin activity in monocytes within 
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two days of exposure in vitro. The magnitude of the glucose-induced changes in 
lysosomal cathepsin activities increased as the cells matured into macrophages. A 
similar but less marked trend was seen in lysosomal acid lipase activity.  
The reduced activities of lysosomal cysteine proteases observed in the 
monocytes and macrophages exposed to high glucose concentrations may be due to 
modification of the active site cysteine residues by reactive aldehydes and glycated 
proteins that may form intracellularly [243]. The loss of these active site residues in the 
lysosomal cysteine proteases could be quantified in further studies by use of an assay 
(e.g. Thio Glo) that measures thiol levels. Cathepsin D and L activity have been 
previously reported to reduce the toxicity of AGE [269].  Greater amounts of 
endosomes and lysosomes, as well as increased cathepsin D and L activity has been 
associated with endocytosis of AGEs and the phagocytic function of macrophages 
[269].  Cathepsin D activity has been shown to be essential for the degradation or 
modification of age-related proteins [523], and this enzyme has been demonstrated to be 
capable of degrading AGEs [274]. Excessive intracellular AGE accumulation within 
lysosomes and a reduction in AGE modified protein degradation were observed in 
fibroblasts isolated from cathepsin D knockout mice in comparison to the wild type 
animals [274].   
The results obtained in the current study demonstrate that lysosomal cathepsin 
enzymes and numbers are affected by high glucose during monocyte maturation to 
macrophages. Further investigations are required to determine whether this lysosomal 
inhibition also occurs in other cell types that are known to be capable of accelerating the 
oxidation and accumulation of LDL in vitro, such as endothelial cells, smooth muscle 
cells and lymphocytes. However whether hyperglycaemia causes lysosomal damage in 
vivo and to what degree lysosomal dysfunction influences the metabolism and turnover 
rate of glycated and oxidised proteins in humans remains to be determined. Therefore 
further research is necessary to verify the extent and mechanism of lysosomal 
impairment in vivo / clinical samples and whether this occurs in the same way as seen in 
the current cell studies.  
 Examination of monocytes and macrophages from people with and without 
Type 1 and 2 diabetes would provide a more tangible insight into whether the roles of 
cathepsins and lysosomal dysfunction are associated with hyperlipidaemia, and the 
severity of cardiovascular diseases. However one of the major limitations of this type of 
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study is that human tissue macrophages are difficult to obtain. Monocytes may be 
obtained from elutriation of human blood and matured into macrophages. However, the 
key issue to overcome is incubating the monocytes with the same (fluctuating) glucose 
concentrations that may be present in vivo in the donor.   
People with diabetes have varying levels of glucose throughout the day, which 
will produce inconsistency for sample collection and analysis. This glucose reading at 
the time of collection may not accurately reflect the patient’s overall glucose history and 
hence the glucose levels to which the cells have been exposed.  
Therefore further research on in vivo samples may be necessary to verify the 
extent and mechanism of lysosomal impairment before translation into clinical studies. 
Resident peritoneal macrophages could be obtained from normal and diabetic mice, and 
lysosomal enzymes, number and protein expression measured. Lysosomal number (as 
measured by LAMP-1 protein levels), multiple cathepsins, and acid lipase are known to 
be detectable in atherosclerotic lesions via immunohistochemistry techniques. The 
effect of high glucose concentrations on lysosomal cathepsin and lipase mRNA 
expression could be further assessed by RT-PCR techniques in aortic samples from 
healthy donors and these with established cardiovascular disease. Such studies may 
provide a deeper understanding of the molecular mechanisms behind lysosomal 
dysfunction induced by hyperglycaemia in vivo. 
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Figure 8.1: Proposed mechanisms for macrophage lysosomal dysfunction caused 
by high glucose in monocytes and macrophages.  
In normal blood glucose conditions as shown in the top panel, modified proteins (e.g. 
glycated, oxidised or chemically modified) LDL are taken up by the macrophage 
scavenger receptors and endocytosed and transported to the lysosomes. A diversity of 
lysosomal enzymes such as cathepsins and lipases work actively to degrade the 
internalised particles. The current studies indicate that additionally hyperglycaemia may 
modify scavenger receptor expression such that the rate of modified protein uptake is 
increased to a point where it is a burden upon the lysosomal system. Hyperglycaemia 
may affect the activity of lysosomal enzymes such as cathepsins and lipases, and thus 
alter intracellular protein and lipid metabolism as shown in the bottom panel. Finally 
hyperglycaemia has been shown to impair reverse cholesterol transport. Together, these 
could lead to impaired removal of modified proteins, LDL and excess cellular 
cholesterol accumulation generating macrophage foam cells and thus accelerate plaque 
development under conditions of hyperglycaemia.  
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8.3 Effects of carnosine on atherosclerotic plaque development in diabetic apo 
E
-/-
 mice 
As protein glycation and glycoxidation appear to contribute to the development 
of diabetic complications such as atherosclerosis, agents which block or reverse protein 
glycation / glycoxidation may have therapeutic potential in the treatment of these 
complications. Carnosine is an endogenous dipeptide that has been shown to; a) block 
and detoxify glycated proteins; b) act as an antioxidant; c) act as a buffer; and d) act as a 
sensitiser for Ca
2+ 
[524]. Carnosine has been shown to modulate triglycerides and 
glycation levels in both cell [169] and whole animal systems [282,499]. The studies 
reported in Chapter 5 were therefore carried out to examine whether prolonged 
supplementation with carnosine inhibits atherosclerosis in hyperglycaemic and 
hyperlipidaemic mice.  
Diabetes was confirmed in the experimental system chosen (streptozotocin was 
used to induce Type 1 diabetes in apo E
-/-
 mice) by significant increases in blood 
glucose, glycated haemoglobin and a significantly lower body mass. In these mice were 
also hyperlipidaemic as evidenced by increased plasma triglycerides and total 
cholesterol levels. The brachiocephalic artery and aortic sinus plaque area were 
significant greater in the diabetic mice. Plasma carnosine levels were elevated in mice 
that were supplemented with carnosine in both the non-diabetic and diabetic groups. 
Whilst carnosine supplementation had no effect upon the diabetes-induced 
hyperglycaemia or hypercholesterolaemia of the diabetic mice, supplementation 
significantly reduced plasma triglyceride levels by 23%. Thus, carnosine may have anti-
lipogenic actions as this compound, notably it has been shown to significantly reduce 
triglyceride and cholesterol levels in the heart and livers of diabetic Balb/cA mice [525]. 
Plasma and hepatic triglycerides and cholesterol levels have also been reported to be 
lowered by carnosine supplementation  in high fat fed non-diabetic C67BL/6 mice that 
were hyperlipidaemic and obese with hepatic steatosis [283].  
In the diabetic mice, increases in plaque areas were observed at both aortic sites, 
however this was not significantly reduced by carnosine.  Further histochemical studies 
were carried out to elucidate whether the observed hypolipidaemic action of carnosine 
modulated plaque composition by assessing the presence and number of smooth muscle 
cells and macrophages and the levels of lipid and collagen in the atherosclerotic 
plaques.  
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The major finding of this study is that carnosine can alter plaque composition 
potentially increasing plaque stability in diabetes-associated atherosclerosis. This was 
evidenced by an approximate 60% reduction in the area occupied by extracellular lipid 
and an increase in both the number of macrophages by 70% and collagen content by 
50% within the plaques assessed. Carnosine has been previously shown to inhibit 
glucose-induced oxidation and glycation of human LDL [525] and effectively block 
pro-atherosclerotic AGE formation by preventing glycation of LDL that promotes foam 
cell formation in human macrophages [169]. An anti-atherosclerotic activity of this type 
of compound has also been demonstrated in fat-fed apo E
-/-
 mice that were 
supplemented with D-carnosine octyl ester [282,499]. In addition significantly smaller 
atherosclerotic lesions has been reported in carnosine-supplemented mice compared to 
controls, and a lower extent of macrophage apoptosis, in animals exposed to 4-hydroxy-
2-nonenal (4-HNE) [499]. A more stable plaque phenotype with less accumulation of 
lipid and foam cells, reduced inflammation, apoptosis and necrotic core formation has 
also been observed in the aortic sinus in apo E null mice that were fed a pro-atherogenic 
diet with D-carnosine octylester compared to the untreated controls [282].  
The anti-atherogenic activities of carnosine detected in the current study (and its 
derivatives in other studies [169,282,499]) may be due to these agents scavenging 
species that modify LDL (either radicals or reactive aldehydes), thereby impeding 
oxidation and glycation processes. The results obtained in this study indicate that in a 
well-established model of diabetes-associated atherosclerosis, prolonged carnosine 
supplementation had a significant impact on markers of atherosclerotic plaque stability. 
Interestingly there was no effect of carnosine on either blood glucose or glycated 
haemoglobin levels, so whether the carnosine levels achieved in the plasma are 
sufficient to cause substantive anti-glycative / oxidative activity in these mice remain 
unresolved. It is however clear that significant changes are induced in the artery wall.  
Further studies are required to confirm whether there was a greater accumulation 
of glycation and lipid peroxidation products within the plaques of the diabetic mice used 
in this study. Various markers of oxidative stress including protein and lipid oxidation 
products have been associated with the initiation and progression of atherosclerosis 
[526,527]. AGE products have also been shown to accumulate in the plaques of diabetic 
and atherogenic mice [528,529]. Reactive aldehydes / lipid peroxidation products such 
as malondialdehyde (MDA) [530,531], 4-hydroxy-2-nonenal (4-HNE) [282,532], N-
epsilon-carboxymethyl-lysine (CML) [528,533], methylgloxal and AGE products 
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[534,535,536] can be detected in atherosclerotic lesions by immunohistochemical 
techniques. Quantification of some of these markers in the lesions of the carnosine-
treated and control mice would therefore allow conclusions to be drawn as to whether 
the levels of plasma carnosine achieved by supplementation in this study were also 
sufficient to prevent and / or reverse glycative and glycoxidative modifications within 
the atherosclerotic plaques.  
Further mechanistic studies on the hypolipidaemic effect of carnosine could be 
carried out in other organ systems such as the liver, muscles and adipose tissues of these 
mice. This would allow a clearer and deeper understanding of the hypolipidaemic and 
other potential pathways by which carnosine lowers plasma triglyceride and lipid 
content in this model. In this regard carnosine has been previously demonstrated to 
block increases in plasma and hepatic triglycerides and cholesterol in high fat diet fed 
C67BL/6 mice [283], and mechanistic studies showed that carnosine supplementation 
significantly decreased mRNA expression of lipogenic enzymes (malic enzyme, fatty 
acid synthase, HMG-CoA reductase) and the sterol regulatory element-binding proteins, 
SREBP-1c and SREBP-2, which have been shown to be elevated in high fat fed mice 
[283].  In the study reported in this thesis carnosine supplementation was not only 
shown to lower plasma triglycerides, but plaque lipid levels were also significantly 
reduced. This hypolipidaemic action may also have an impact upon hepatic, adipose and 
skeletal muscle triglyceride content, but this remains unknown. Examining liver 
morphology may be a good indicator of whether sterols or triglycerides have 
accumulated in the hepatocytes. Excessive fat accumulation in hepatocytes gives rise to 
non- alcoholic fatty liver disease and steatosis in its severe form, and carnosine has been 
previously reported to have protective effects against hepatic steatosis and to lower 
epidydymal fat in high fat fed mice [283]. A more quantitative approach would be 
directly measure the triglyceride and cholesterol levels of homogenised liver samples 
by, for example, HPLC / UPLC.  Similarly triglyceride measurements could also be 
made on adipose tissue (visceral, epididymal and inguinal fat) and skeletal muscles 
from the leg, such as the gastrocnemius, quadriceps and soleus. Quantification of lipids 
from these tissues may allow conclusions to be reached as to whether the intake of 
carnosine ameliorates systemic, adipocytic and hepatic inflammation in diabetes-
associated atherosclerosis.  
The hypolipidaemic and protective effect of carnosine upon plaque composition 
may also provide a clearer insight into the involvement of lysosomes in the 
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accumulation of damaged / glycated proteins and turnover of oxidised low density 
lipoprotein particles. It would also be interesting to determine whether the 
hypolipidaemic action of carnosine has a protective effect upon macrophage lysosomes 
in atherosclerotic plaques.  A higher content of F4/80-positive macrophages were 
detected in the lesions of the carnosine-treated mice regardless of their glycaemic status, 
and it would be of interest to determine whether lysosomal acid lipase activity (i.e. lipid 
hydrolysis) was enhanced by supplementation with carnosine. An enhanced rate of 
hydrolysis of cholesterol esters and triglycerides may explain why there was 
considerably less extracellular lipid accumulation observed in the diabetic mice that 
were supplemented with carnosine compared to the non-supplemented mice.   
Further clinical trials of carnosine, a well tolerated dipeptide in diabetic and 
hyperlipidaemic subjects may be of significant value in the treatment of the vascular 
complications of diabetes. However plasma levels of carnosine levels in humans are low 
due to rapid hydrolysis by carnosinase in plasma and a corresponding short half life 
making it hard to achieve therapeutic doses of carnosine [524,537]. Synthetic derivates 
have been shown to be less susceptible to such hydrolysis, and may therefore have 
therapeutic potential [287].  The use of these novel derivatives may provide a promising 
preventive and therapeutic strategy for diabetic vascular complications in humans and 
as such would appear to warrant further investigations.  
 
8.4 Impact of TEMPOL on lipid profiles and cytokine expression in 
hyperlipidaemic obese mice 
TEMPOL has been shown to have hypotensive and cardio-protective actions in 
rodents however the potential anti-atherogenic action of TEMPOL remains inadequately 
characterised. Administration of TEMPOL has also been shown to effectively suppress 
body weight gain in obese C3H male and female mice that were fed a high fat diet. In 
the light of this previous data, the studies reported in Chapter 6 attempted to investigate 
whether TEMPOL supplementation inhibited atherosclerosis and obesity in high fat fed 
mice. Hyperlipidaemia was confirmed by significant increases in blood cholesterol, 
triglycerides, LDL-C levels and excess body mass gain; however this was not reflected 
in the plaque areas of the aortic sinus. Although the results of this study showed that 
plaque areas were not attenuated by TEMPOL, this compound effectively suppressed 
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hyperlipidaemia, blocked fat accumulation and inflammatory responses in both mouse 
strains when these were fed a high fat diet (HFD).  
Although TEMPOL suppressed high fat feeding-induced body mass gain and 
hyperlipidaemia in both the C57BL/6 wild type and the apo E
-/-
 mice the plaque areas in 
the aortic sinuses from chow fed mice were significantly larger than those determined 
for the high fat-fed apo E
-/-
 mice. This may be due to the presence of highly advanced 
disease in the high fat feeding, leading to lesion remodelling and contraction. This 
suggests an earlier time point should have been chosen for examination of this 
parameter. In the apo E
-/-
 mice, TEMPOL inhibited the elevation of MCP-1, IL-6, SAA, 
MPO and leptin levels that were observed in the hyperlipidaemic mice. No changes 
were seen in resistin levels, however a significant decrease in adiponectin levels were 
observed between the chow and HFD fed mice, and TEMPOL was shown to reverse 
these changes. A similar scenario was seen for the C57BL/6 mice, with MCP-1, IL-6, 
SAA, MPO and leptin levels reduced in the high fat fed mice that were supplemented 
with TEMPOL. No changes were however seen in the adiponectin levels in these mice; 
however an increase in resistin levels was observed in the HFD fed mice that were 
supplemented with TEMPOL.  Unlike the apo E
-/-
 strain, the C57BL/6 mice did not 
produce any observable atherosclerotic plaques and therefore this does not appear to be 
a sensible model to assess whether TEMPOL can inhibit atherosclerosis. However the 
veracity of this conclusion needs to be tempered by the fact that only one location was 
examined and more plaque may have existed in other regions of the vasculature, in 
particularly the brachiocephalic artery, as it is a key site for atherosclerotic progression. 
However other regions were not available for analysis. An assessment of atherosclerotic 
plaque development at other sites may rationalise the observed differences between 
atherosclerotic progression between the chow and HFD fed groups for the two mouse 
strains.  
Examination of the plaque composition between the supplemented and control 
chow and HFD mice may allow differences in atherosclerotic lesion structure to be 
determined. TEMPOL supplementation was shown to have an impact upon obesity, 
preventing body weight gain, hyperlipidaemia, and decreasing a range of plasma lipids 
and inflammatory markers; these changes were also associated with striking differences 
in plaque compositional changes between the HFD, and HFD supplemented with 
TEMPOL, mice. This could be determined by staining the lesions for α-actin for smooth 
muscle cells, F4/80 for macrophages, picrosirius red for collagen content and 
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calculating extracellular lipid content.  The results in the previous carnosine study 
showed significant hypolipidaemic effects on plaque composition (using these staining 
procedures) although there were no statistical differences in the atherosclerotic plaque 
size. Further experiments with a larger cohort of apo E
-/-
 mice fed for shorter periods 
would be beneficial with regard to assessing possible changes in lesion extent induced 
by TEMPOL.   
The results obtained in this study indicate that in a well-established model of 
obesity related-hyperlipidaemia, prolonged TEMPOL supplementation had a significant 
impact on various inflammatory and cytokine levels. Elevation of MCP-1, IL-6, SAA 
and MPO levels as seen in the HFD fed mice in both animal types have been reported to 
be early biomarkers of, or correlate positively with, atherosclerosis, obesity and 
cardiovascular diseases [312,313,361,362,363,364,365,366,367,538] and TEMPOL was 
shown to inhibit the elevation of these cytokines. Inflammatory cells that infiltrate 
adipose tissue are known to contribute substantially to the increased cytokine release of 
this tissue [539]. Obesity, with greater body mass and adipose tissue, is also known to 
induce changes in the secretion of adipose-specific cytokines (i.e. adipokines) 
[538,539]. Hence the potential inhibitory effects of TEMPOL on these adipokines were 
examined and significant changes in the levels of adiponectin and leptin were detected. 
HFD induced obesity led to hyperleptinaemia in both animal strains and decreased 
adiponectin secretion in the apo E
-/-
 mice. The elevated leptin levels were suppressed by 
TEMPOL in both animal types and the lower adiponectin levels observed in the HFD 
fed apo E
-/-
 mice were reversed with TEMPOL. Further mechanistic studies on the 
hypolipidaemic effect of TEMPOL could be carried out on other organ systems such as 
the liver, muscle and adipose tissue, as previously discussed in Section 8.3. This would 
provide a clearer and deeper understanding of the hypolipidaemic roles and other 
potential systemic inflammatory mechanisms by which TEMPOL lowers plasma lipid 
content in obesity related metabolic syndrome complications.   
Although TEMPOL was shown to lower plasma lipid levels, and also the 
systemic inflammatory response, in these fat-fed animals, the mechanisms that underlie 
these changes remain unknown. Further work needs to be carried out in order to 
understand the anti-obesity and anti-inflammatory actions of TEMPOL using an in vitro 
model of adipocyte proliferation and differentiation to elucidate whether TEMPOL 
inhibits production of adipokines by decreasing adipocyte size and / or number. That is 
whether: (i) the inhibition of gain in mass represents a TEMPOL-mediated inhibition of 
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adipocyte proliferation or differentiation; (ii) the changes in the pattern of cytokine and 
adipokine secretion are a consequence of the effects of TEMPOL upon adipocyte 
proliferation / differentiation; and / or (iii) whether the action of TEMPOL is mediated 
by its antioxidant activities.  
The murine preadipocyte cell line 3T3-L1 is a commonly used model for 
preadipocyte proliferation and adipocyte differentiation in vitro. Cell proliferation of 
pre-adipocytes in the absence or presence of TEMPOL could be determined using the 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenltetrazolium bromide (MTT) assay, and the degree 
of adipocyte hypertrophy could be digitally imaged and quantified. Comparison of 
adipocyte differentiation, and lipid accumulation, between TEMPOL treated and 
untreated cells could be quantified by staining lipid droplets via Oil-Red staining, or by 
HPLC/ UPLC quantification of triglycerides and fatty acids in cell lysates.  
 High fat intake has been proposed to induce a degree of endotoxaemia [540] and 
recently Lassenius and colleagues [541] have demonstrated an elevated serum 
lipopolysaccharide (LPS) / HDL ratio in people with Type 1 diabetes particularly those 
diagnosed with features of the metabolic syndrome. Adipocytes express receptors for 
LPS [542] and activation of adipocytes by LPS, via Toll-like receptors, induces fatty 
acid release [543]. Thus the capacity of TEMPOL to inhibit fatty acid release could be 
compared between TEMPOL treated and untreated cultures in the presence of LPS. A 
number of cytokines which are secreted by adipocytes are known to be induced by LPS 
stimulation [342,363,364]. The secreted levels of adipokines (e.g. leptin and 
adiponectin) and cytokines (TNF-α, IL-6, IL-8, serum amyloid A and CCL-2 and -5) 
from pre and matured adipocytes could be determined using immunoassay kits to assess 
whether TEMPOL inhibits cytokine production and secretion from these cells. 
The inhibitory effect of TEMPOL upon adipocyte proliferation, differentiation 
and / or pro-inflammatory responses may be influenced by its superoxide dismutase-
mimetic activity [336,346,544]. Quantification of superoxide levels in TEMPOL-treated 
and untreated cells may therefore be worth assessing, and this could be measured by 
using the dihydroethidine / 2-hyxdroxy ethidium fluorimetric assay [545].  
Such work on adipocytes from 3T3-L1 cells would pave the way for future 
projects. 3T3-L1 cells could provide a standard model system to screen novel 
compounds e.g. structural analogues of TEMPOL before use in expensive animal 
models. Investigations on primary adipocytes obtained from fat-fed obese mice and 
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obese subjects (e.g. those who have undergone liposuction) would also provide a more 
complete systematic understanding of the anti-obesity and anti-inflammatory actions of 
TEMPOL. 
The results obtained in these studies suggest that TEMPOL supplementation 
may be beneficial in lowering plasma lipid levels and suppressing obesity and 
hyperlipidaemia. Thus TEMPOL may be of significant value in arresting body fat 
accumulation and promoting body fat loss where management of body mass is resistant 
to behavioural modifications alone. Although TEMPOL is well known for its potent 
hypotensive effects, the anti-atherogenic properties of TEMPOL remain unestablished, 
and deserve further study. 
 
8.5 Effects of TEMPOL upon lysosomal function and cytokine expression in 
HMDM cells incubated with high glucose 
In the light of the above data which shows that TEMPOL can down regulate 
inflammation and lower cytokine levels, further studies were carried out to determine 
whether this compound affected lysosomal function and cytokine expression in HMDM 
exposed to high glucose. The studies carried out to assess the potential anti-
inflammatory effects of TEMPOL against the deleterious effects of high glucose levels 
in HMDM on lysosomal dysfunction (Chapters 3 and 4), showed that TEMPOL was not 
able to reverse or arrest this inhibition.  
The studies reported in Chapter 7 examined the potential impact of high glucose 
concentrations on a range of cytokine factors produced by HMDM upon stimulation 
with LPS, in order to establish a suitable model to assess the potential anti-
inflammatory action of TEMPOL. This was of interest because the antioxidant 
TEMPOL has been shown to protect against renal dysfunction and inhibit the 
production of hepatic reactive oxygen species induced by streptozotocin in vivo 
[345,424]. TEMPOL has also been demonstrated to inhibit AGE induced TNF-α and 
ROS production in vitro [425].  
In the studies reported in Chapter 7 high glucose was found to significantly 
elevate secretions of TNF-α and MIP-1α and lower CRP expression in macrophages 
when compared to normal glucose conditions. Subsequent experiments with multiple 
donors confirmed the significant elevation in TNF-α and MIP-1α induced by high 
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glucose, and TEMPOL was shown to significantly attenuate the elevation of TNF-α and 
MIP-1α expression across all donors. This may be due to TEMPOL having a protective 
effect against the oxidative stress and damage inflicted by high glucose, and further 
studies would be required to determine and elucidate the potential protective effects of 
TEMPOL in human macrophages against oxidative and glycative damage. This could 
be achieved by the generation of various reactive oxygen species or the inclusion of 
advanced glycation end products markers by LPS stimulation in the media to examine 
whether TEMPOL inhibits or reverses potential elevations in ROS and AGE markers. 
The potential induction of inflammatory markers by high glucose and its modulation by 
TEMPOL could also be examined in other cell types such as monocytes, neutrophils, 
dendritic cells, lymphocytes and other leukocytes which act as key communicators 
between the innate and immune response. Studies on mouse peritoneal macrophages 
obtained from mice with diabetes (with and without TEMPOL supplementation) would 
also be potentially worthwhile to examine whether TEMPOL, which has been shown to 
inhibit TNF-α and MIP-1α elevations induced by high glucose at a cellular level, also 
has such actions in animals suffering from diabetes. Examination of the effects of 
TEMPOL on monocytes elutriated from the blood of people with Type 1 or 2 diabetes 
may further elucidate the roles of TEMPOL in humans.   
CRP secretion was not found to be affected by stimulation with LPS or exposure 
to high glucose; therefore it is difficult to conclude whether high glucose or TEMPOL 
supplementation had an effect upon these levels. Plasma CRP levels have been reported 
to be higher in people with diabetes, cardiovascular diseases and atherosclerosis, 
however this was not reflected in the human monocyte-derived macrophages examined 
in these studies. This may be due to the absence or only levels of low concentrations of 
CRP generated by HMDM. Further investigations would therefore be beneficial in other 
cell types, such as hepatocytes where CRP is primarily synthesised [437]. CRP levels 
are a sensitive marker for cardiovascular diseases and particularly atherosclerosis, and 
therefore further investigations in diabetic and hyperlipidaemic subjects may be 
warranted to elucidate potential beneficial effects of TEMPOL.  
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8.6  Concluding remarks 
The chronic elevated blood glucose levels detected in people with diabetes may 
have a detrimental impact upon macrophage lysosomal function that could promote 
atherosclerosis. The studies in this thesis attempted to demonstrate for the first time, 
some of the deleterious effects of high glucose upon lysosomes, and it has been shown 
that this includes inhibition of lysosomal enzymes and reduced lysosomal number in 
murine and human monocytes / macrophages.  Lysosomal dysfunction may therefore be 
an underlying cause for the increased incidence, and rate of development of 
atherosclerosis in people with diabetes.  
The endogenous agent carnosine was examined in a murine model of diabetes-
induced atherosclerosis. Carnosine supplementation was shown to have anti-
hyperlipidaemic effects and properties that may enhance plaque stability which may be 
of therapeutic value in the treatment of diabetes-accelerated atherosclerosis.  
The nitroxide TEMPOL was investigated in two well-established murine models 
of obesity induced by high fat feeding. TEMPOL was shown to effectively block weight 
gain in mice and relieve the associated hyperlipidaemia induced by a high fat diet. 
Further mechanistic studies showed that TEMPOL was able to reduce systemic 
inflammation and reverse the changed adipokine profile of obesity. Furthermore 
TEMPOL was shown to have an impact upon inflammation induced by high glucose in 
human macrophages. The anti-hyperlipidaemic, anti-obesity and anti-diabetic actions of 
TEMPOL may therefore be of therapeutic value in the treatment of many complications 
that arise from metabolic dysfunction.  
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